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PREFACE
This third edition of the Centre for Reviews and Dissemination (CRD) guidance for 
undertaking systematic reviews builds on previous editions published in 1996 and 2001. 
Our guidance continues to be recommended as a source of good practice by agencies 
such as the National Institute for Health Research Health Technology Assessment (NIHR 
HTA) programme, and the National Institute for Health and Clinical Excellence (NICE), 
and has been used widely both nationally and internationally. Our aim is to promote 
high standards in commissioning and conduct, by providing practical guidance for 
undertaking systematic reviews evaluating the effects of health interventions.
WHY SYSTEMATIC REVIEWS ARE NEEDED
Health care decisions for individual patients and for public policy should be informed 
by the best available research evidence. Practitioners and decision-makers are 
encouraged to make use of the latest research and information about best practice, and 
to ensure that decisions are demonstrably rooted in this knowledge.1, 2 However, this 
can be diffi cult given the large amounts of information generated by individual studies 
which may be biased, methodologically fl awed, time and context dependent, and can 
be misinterpreted and misrepresented.3 Furthermore, individual studies can reach 
confl icting conclusions. This disparity may be because of biases or differences in the way 
the studies were designed or conducted, or simply due to the play of chance. In such 
situations, it is not always clear which results are the most reliable, or which should be 
used as the basis for practice and policy decisions.4
Systematic reviews aim to identify, evaluate and summarise the fi ndings of all relevant 
individual studies, thereby making the available evidence more accessible to decision-
makers. When appropriate, combining the results of several studies gives a more 
reliable and precise estimate of an intervention’s effectiveness than one study alone.5-8 
Systematic reviews adhere to a strict scientifi c design based on explicit, pre-specifi ed 
and reproducible methods. Because of this, when carried out well, they provide reliable 
estimates about the effects of interventions so that conclusions are defensible. As well 
as setting out what we know about a particular intervention, systematic reviews can 
also demonstrate where knowledge is lacking.4, 9 This can then be used to guide future 
research.10
WHAT IS COVERED IN THE GUIDANCE
The methods and steps necessary to conduct a systematic review are presented in a 
core chapter (Chapter 1). Additional issues specifi c to reviews in more specialised topic 
areas, such as clinical tests (diagnostic, screening and prognostic), and public health 
are addressed in separate, complementary chapters (Chapters 2-3). We also consider 
questions relating to harm (Chapter 4) costs (Chapter 5) and how and why interventions 
work (Chapter 6).
v
CRD Systematic Reviews.indd   287 8/1/09   09:29:57
Systematic Reviews
This guide focuses on the methods relating to use of aggregate study level data. 
Although discussed briefl y in relevant sections, individual patient data (IPD) meta-
analysis, which is a specifi c method of systematic review, is not described in detail. The 
basic principles are outlined in Appendix 1 and more detailed guidance can be found 
in the Cochrane Handbook11 and specialist texts.12, 13 Similarly, other forms of evidence 
synthesis including prospective meta-analysis, reviews of reviews, and scoping reviews 
are beyond the scope of this guidance but are described briefl y in Appendix 1.
WHO SHOULD USE THIS GUIDE
The guidance has been written for those with an understanding of health research but 
who are new to systematic reviews; those with some experience but who want to learn 
more; and for commissioners. We hope that experienced systematic reviewers will 
also fi nd this guidance of value; for example when planning a review in an area that is 
unfamiliar or with an expanded scope. This guidance might also be useful to those who 
need to evaluate the quality of systematic reviews, including, for example, anyone with 
responsibility for implementing systematic review fi ndings.
Given the purpose of the guidance, the audience it is designed for, and the aim to 
remain concise, it has been necessary to strike a balance between the wide scope 
covered and the level of detail and discussion included. In addition to providing 
references to support statements and discussions, recommended reading of more 
specialist works such as the Cochrane Handbook,14 Systematic Reviews in the Social 
Sciences,4 and Systematic Reviews in Health Care15 have been given throughout the 
text.
HOW TO USE THIS GUIDE
The core methods for carrying out any systematic review are given in Chapter 1 which 
can be read from start to fi nish as an introduction to the review process, followed step 
by step while undertaking a review, or specifi c sections can be referred to individually. 
In view of this, and the sometimes iterative nature of the review process, occasional 
repetition and cross referencing between sections has been necessary.
Chapters 2-5 provide supplementary information relevant to conducting reviews 
in more specialised topic areas. To minimize repetition, they simply highlight the 
differences or additional considerations pertinent to their speciality and should be used 
in conjunction with the core principles set out in Chapter 1. Chapter 6 provides guidance 
on the identifi cation, assessment and synthesis of qualitative studies to help explain, 
interpret and implement the fi ndings from effectiveness reviews. This refl ects the 
growing recognition of the contribution that qualitative research can make to reviews of 
effectiveness.
vi
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For the purposes of space and readability:
The term ‘review’ is used throughout this guidance and should be taken as a short form 
for ‘systematic review’, except where it is explicitly stated that non-systematic reviews 
are being discussed.
‘Review question’ is used in the singular even though frequently there may be more 
than one question or objective set. The same process applies to each and every 
question.
A glossary of terms has been provided to ensure a clear understanding of the use of 
those terms in the context of this guidance and to facilitate ease of reference for the 
reader.
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3Core principles and methods for conducting a systematic review of health interventions
1.1 GETTING STARTED
There are a number of reasons why a new review may be considered. Commissioned 
calls for evidence synthesis are usually on topics where a gap in knowledge has been 
identifi ed, prioritised and a question posed. Alternatively the idea for a review may be 
investigator led, with a topic identifi ed from an area of practice or research interest; 
such approaches may or may not be funded. Whatever the motivation for undertaking a 
review the preparation and conduct should be rigorous.
1.1.1 Is a review required?
Before undertaking a systematic review it is necessary to check whether there are 
already existing or ongoing reviews, and whether a new review is justifi ed. This 
process should begin by searching the Database of Abstracts of Reviews of Effects 
(DARE),1 and the Cochrane Database of Systematic Reviews (CDSR).2 DARE contains 
critical appraisals of systematic reviews of the effects of health interventions. CDSR 
contains the full text of regularly updated systematic reviews of the effects of health 
care interventions carried out by the Cochrane Collaboration. Other sites to consider 
searching include, the National Institute for Health and Clinical Excellence (NICE) 
and the NIHR Health Technology Assessment (NIHR HTA) programme websites. The 
Campbell Collaboration website3 contains the Campbell Library of Systematic Reviews 
giving full details of completed and ongoing systematic reviews in education, crime 
and justice, and social welfare; and the Evidence for Policy and Practice Information 
(EPPI) Centre,4 whose review fi elds include education, health promotion, social care and 
welfare, and public health, has a database of systematic and non systematic reviews 
of public health interventions (DoPHER). It may also be worth looking at sites such as 
the National Guidelines Clearinghouse (NGC)5 or the Scottish Intercollegiate Guidelines 
Network (SIGN),6 as many guidelines are based on systematic review evidence. 
Searching the previous year of MEDLINE or other appropriate bibliographic databases 
may be helpful in identifying recently published reviews.
If an existing review is identifi ed which addresses the question of interest, then the 
review should be assessed to determine whether it is of suffi cient quality to guide policy 
and practice. In general, a good review should focus on a well-defi ned question and 
use appropriate methods. A comprehensive search should have been carried out, clear 
and appropriate criteria used to select or reject studies, and the process of assessing 
study quality, extracting and synthesising data should have been unbiased, reproducible 
and transparent. If these processes are not well-documented, confi dence in results and 
inferences is weakened. The review should report the results of all included studies 
clearly, highlighting any similarities or differences between studies, and exploring the 
reasons for any variations.
Critical appraisal can be undertaken with the aid of a checklist7-10 such as the example 
outlined in Box 1.1. Such checklists focus on identifying fl aws in reviews that might bias 
the results.8 Quality assessment is important because the effectiveness of interventions 
may be masked or exaggerated by reviews that are not rigorously conducted. 
Structured abstracts included in the DARE database1 provide worked examples of how a 
checklist can be used to appraise and summarise reviews.
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If a high quality review is located, but was completed some time ago, then an 
update of the review may be justifi ed. Current relevance will need to be assessed 
and is particularly important in fi elds where the research is rapidly evolving. Where 
appropriate, collaboration with the original research team may assist in the update 
process by providing access to the data they used. However, little research has been 
conducted on when and how to update systematic reviews and the feasibility and 
effi ciency of the identifi ed approaches is uncertain.11 If a review is of adequate quality 
and still relevant, there may be no need to undertake another systematic review.
Where a new systematic review or an update is required, the next step is to establish a 
review team and possibly an advisory group, to develop the review protocol.
Box 1.1: Critically appraising review articles
• Was the review question clearly defi ned in terms of population, interventions, 
comparators, outcomes and study designs (PICOS)?
• Was the search strategy adequate and appropriate? Were there any 
restrictions on language, publication status or publication date?
• Were preventative steps taken to minimize bias and errors in the study 
selection process?
• Were appropriate criteria used to assess the quality of the primary studies, 
and were preventative steps taken to minimize bias and errors in the quality 
assessment process?
• Were preventative steps taken to minimize bias and errors in the data 
extraction process?
• Were adequate details presented for each of the primary studies?
• Were appropriate methods used for data synthesis? Were differences between 
studies assessed? Were the studies pooled, and if so was it appropriate and 
meaningful to do so?
• Do the authors’ conclusions accurately refl ect the evidence that was reviewed?
1.1.2 The review team
The review team will manage and conduct the review and should have a range of 
skills. Ideally these should include expertise in systematic review methods, information 
retrieval, the relevant clinical/topic area, statistics, health economics and/or qualitative 
research methods where appropriate. It is good practice to have a minimum of two 
researchers involved so that measures to minimize bias and error can be implemented 
at all stages of the review. Any confl icts of interest should be explicitly noted early in 
the process, and steps taken to ensure that these do not impact on the review process.
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1.1.3 The advisory group
In addition to the team who will undertake the review there may be a number of 
individuals or groups who are consulted at various stages, including for example health 
care professionals, patient representatives, service users and experts in research 
methods. Some funding bodies require the establishment of an advisory group who will 
comment on the protocol and fi nal report and provide input to ensure that the review 
has practical relevance to likely end users. Even if this is not the case, and even where 
the review team is knowledgeable about the area, it is still valuable to have an advisory 
group whose members can be consulted at key stages.
Engaging with stakeholders who are likely to be involved in implementing the 
recommendations of the review can help to ensure that the review is relevant to their 
needs. The particular form of user involvement will be determined by the purpose of the 
consultation. For example, when considering relevant outcomes for the review, users 
may suggest particular aspects of quality of life which it would be appropriate to assess. 
An example of a review which incorporated the views of users to considerable effect is 
one evaluating interventions to promote smoking cessation in pregnancy, which included 
outcomes more relevant to users as a result of their involvement.12 However, consultation 
is time consuming, and needs to be taken into account in the project timetable. Where 
reviews have strict time constraints, wide consultation may not be possible.
At an early stage, members of the advisory group should discuss the audiences for 
whom the review fi ndings are likely to be relevant, helping to start the planning of a 
dissemination strategy from the beginning of the project.
The review team may also wish to seek more informal advice from other clinical or 
methodological experts who are not members of the advisory group. Likewise, where 
an advisory group has not been established, the review team may still seek advice from 
relevant sources.
Summary: Getting started
• Whatever the motivation for undertaking a review the preparation and conduct 
should be rigorous.
• A search of resources such as the DARE database should be undertaken to 
check for existing or ongoing reviews, to ensure a new review is justifi ed.
• A review team should be established to manage and conduct the review. The 
membership should provide a range of skills, including expertise in systematic 
review methods, information retrieval, the relevant clinical/topic area, statistics, 
health economics and/or qualitative research methods where appropriate.
• Formation of an advisory group including, for example, health care 
professionals, patient representatives, services users and experts in research 
methods may be a requirement of some funding bodies. In any event, it may 
be valuable to have an advisory group, whose members can be consulted at 
key stages.
• The review team may wish to seek advice from a variety of clinical or 
methodological experts, whether or not an advisory group is convened.
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1.2 THE REVIEW PROTOCOL
1.2.1 Introduction
The review protocol sets out the methods to be used in the review. Decisions about the 
review question, inclusion criteria, search strategy, study selection, data extraction, 
quality assessment, data synthesis and plans for dissemination should be addressed. 
Specifying the methods in advance reduces the risk of introducing bias into the review. 
For example, clear inclusion criteria avoids selecting studies according to whether their 
results refl ect a favoured conclusion.
If modifi cations to the protocol are required, these should be clearly documented and 
justifi ed. Modifi cations may arise from a clearer understanding of the review question, 
and should not be made because of an awareness of the results of individual studies. 
Further information is given in Section 1.2.4 How to deal with protocol amendments 
during the review.
Protocol development is often an iterative process that requires communication within 
the review team and advisory group and sometimes with the funder.
1.2.2 Key areas to cover in a review protocol
This section covers the development of the protocol and the information it should 
contain. The formulation of the review objectives from the review question and the 
setting of inclusion criteria are covered in detail here as these must be agreed before 
starting a review. The search strategy, study selection, data extraction, quality 
assessment, synthesis and dissemination are also mentioned briefl y as they are 
essential parts of the review protocol. However, to avoid repetition, full details of the 
issues related to both protocol requirements and carrying out the review are provided in 
Section 1.3 Undertaking the review.
1.2.2.1 Background
The background section should communicate the key contextual factors and conceptual 
issues relevant to the review question. It should explain why the review is required and 
provide the rationale underpinning the inclusion criteria and the focus of the review 
question, for example justifying the choice of interventions to be considered in the review.
1.2.2.2 Review question and inclusion criteria
Systematic reviews should set clear questions, the answers to which will provide 
meaningful information that can be used to guide decision-making. These should be 
stated clearly and precisely in the protocol. Questions may be extremely specifi c or very 
broad, although if broad, it may be more appropriate to break this down into a series 
of related more specifi c questions. For example a review to ‘assess the evidence on the 
positive and negative effects of population-wide drinking water fl uoridation strategies to 
prevent caries’,13 was undertaken by addressing fi ve objectives:
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Objective 1: What are the effects of fl uoridation of drinking water supplies on the 
incidence of caries?
Objective 2: If water fl uoridation is shown to have benefi cial effects, what is the 
effect over and above that offered by the use of alternative interventions and 
strategies?
Objective 3: Does water fl uoridation result in a reduction of caries across social 
groups and between geographical locations, bringing equity?
Objective 4: Does water fl uoridation have negative effects?
Objective 5: Are there differences in the effects of natural and artifi cial water 
fl uoridation?
Where there are several objectives it may be necessary to prioritise by importance and 
likelihood of being able to answer the question. It may even be necessary to restrict the 
scope of the question to a level that is manageable within set resources. For clarity, the 
singular term ‘review question’ is used throughout the guidance.
Box 1.2: Example review objective and PICOS elements for a review 
protocol
Review objective
The objective of this review is to assess the clinical effectiveness of treatments for 
childhood retinoblastoma.14
Participants
Studies of participants diagnosed with retinoblastoma at the age of 18 years or under.
Studies of adults where childhood retinoblastoma was followed up into adulthood.
Studies of mixed diagnoses if outcomes were reported separately for children with 
retinoblastoma.
Interventions
Any intervention or combination of interventions given for the treatment of retinoblastoma, 
including (but not restricted to) enucleation, external beam radiotherapy, chemotherapy, 
brachytherapy, cryotherapy, thermotherapy and photocoagulation.
Outcomes
Any clinical outcome, including (but not restricted to) survival, progression-free 
survival, tumour response, preservation of the eye, visual acuity, disease remission 
and adverse effects.
Study design
Randomised controlled trials (RCTs) and controlled trials. However, it is not 
anticipated that many studies of these designs will be available. Therefore, if 
information from controlled trials is not available, cohort studies are eligible for 
inclusion provided that data from a comparison group are reported.
Case series and case reports are excluded from the review owing to the high 
potential for bias in these study designs. Case–control studies (except where 
nested as part of a cohort study) and economic evaluations are also excluded.
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The review question can be framed in terms of the population, 
intervention(s), comparator(s) and outcomes of the studies that will 
be included in the review. These elements of the review question, 
together with study design, will then be refi ned in order to determine 
the specifi c inclusion criteria that will be used when selecting 
studies for the review. Although both the acronyms PICO or PICOS 
are commonly used, here the term PICOS will be used throughout 
for consistency. In some situations, not all the elements will be relevant, for example 
not every review question will specify type of study design to be included. The use of 
PICOS in the context of reviews incorporating different study designs is discussed in the 
relevant chapters.
The review question may be presented in general terms, for example, ‘What is the best 
treatment option for retinoblastoma?’ More often the actual question is discussed by 
the review team and an objective, or series of objectives, framed by the population, 
the intervention and the outcome(s) of interest agreed. For example, ‘The objective 
of this review is to assess the clinical effectiveness of treatments for childhood 
retinoblastoma.’14 The PICOS elements for this example are shown in Box 1.2.
Population
The included population should be relevant to the population to which the review 
fi ndings will be applied, and explicit inclusion criteria should be defi ned in terms of the 
disease or condition of interest. Any specifi ed restrictions should be clinically justifi able 
and relevant. Eligibility must usually be applied to the whole study and consideration of 
how to deal with studies that include a mixed population, some of whom are relevant 
to the review and some of whom are not, is required. If the inclusion criteria are broad, 
it may be informative to investigate effectiveness across subgroups of participants. 
However, in the absence of individual patient data (IPD), or very detailed reporting 
of data, broken down by participant characteristics, it is unlikely that inclusion can be 
restricted to particular types of participant or that detailed subgroup analyses will be 
possible. Where analysis of participant subgroups is planned, this should be specifi ed in 
the protocol. Examples of factors that may be investigated include participants’ gender, 
age, disease severity, the presence of any co-morbidities, socio-economic status, 
ethnicity and geographical area.
Interventions and comparators
The nature of the interventions explored in the review may be framed in very broad 
terms like ‘psychosocial interventions’ or may be more specifi c such as ‘cognitive 
behavioural therapy’. Factors usually specifi ed include the precise nature of the 
intervention (e.g. the method of administration of a drug), the person delivering the 
intervention (e.g. a community psychiatric nurse versus a non-professional carer) or 
setting in which the intervention is delivered (e.g. inpatient or outpatient).
Where comparative studies are to be included, the protocol should also specify which 
comparators are eligible. As with the interventions, comparators should be carefully 
defi ned, so that the scope of a term such as ‘palliative care’ or ‘usual care’ is clear. 
The protocol should also specify whether any co-interventions carried out at the same 
time affect eligibility for inclusion; this applies to both the intervention(s) and the 
comparator(s).
Population
Interventions
Comparators
Outcomes
Study design
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Outcomes
The success or failure of a therapeutic intervention will usually be assessed in terms 
of differences in mortality or morbidity in the populations treated. Primary outcomes 
are likely to include measures of mortality and morbidity but other outcomes may also 
be of importance, for example measures of quality of life and participants’ subjective 
experiences of pain or physical functioning.
A review should explore a clearly defi ned set of relevant outcomes and it is important 
to justify each outcome included. Input from the advisory group and the fi ndings from 
initial scoping searches and qualitative research may be helpful in deciding which 
outcomes to include.
The use of surrogate outcomes may be misleading, giving an over or underestimate of 
the true clinical outcome.15 Decisions about whether to consider surrogate outcomes 
should therefore be informed by available evidence about associations between the 
surrogate (e.g. blood pressure) and the outcome of interest (e.g. stroke). Often, 
surrogate outcomes are included only where a study also reports a relevant clinical 
outcome.
The review may also consider the timing of outcome assessment and possible adverse 
effects of the intervention. If the review is considering cost-effectiveness or economic 
issues as well as clinical effectiveness, the relevant economic outcomes should also be 
specifi ed.
Although the review may aim to consider a series of outcomes, it is rare that inclusion 
would be restricted to only those studies that report all the outcomes of interest. More 
usually inclusion criteria will require that included studies report the main outcome.
Study design
The types of study included in the review will play a major role in determining the 
reliability of the results and the validity of estimates of effect is linked to the study 
design. While some study designs are clearly more robust than others, this should not 
be the only factor in determining which types of study are eligible for inclusion.16
Scoping searches may reveal that there are likely to be only a limited number of 
relevant randomised studies. In this case researchers have the option of justifying a 
decision to limit study design, bearing in mind that the identifi cation of gaps in the 
current evidence base may in itself be a signifi cant fi nding of the review. Alternatively, 
they can include quasi-experimental or observational studies. For reviews in some 
topic areas, these may be the only types of study available. The study design inclusion 
criteria given as an example in Box 1.2 have been set to take account of the paucity of 
experimental studies, as indicated by the scoping searches.
In some cases a range of study designs may be needed to address different questions 
within the same review. For example, a review seeking to include information on 
adverse events will often include case-control and/or case-series (see Chapter 4) whilst 
a review incorporating participants’ experiences of an intervention is likely to include 
qualitative studies (see Chapter 6). The potential biases from the inclusion of a range of 
study designs are discussed in Section 1.3.4 Quality assessment.
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1.2.2.3 Defi ning inclusion criteria
The inclusion criteria should be set out in the protocol, to ensure that the boundaries of 
the review question are clearly defi ned. In the example in Box 1.2, the population to be 
studied was specifi ed in the review question as those with ‘childhood’ retinoblastoma. 
In addition to qualifying ‘childhood’ as under 18, appropriate timeframes for disease 
progression and treatment and the possibilities of concurrent disease processes have 
been taken into account. In reviews of interventions relating to other diseases it may be 
necessary to be more specifi c about how the disease of interest will be verifi ed, and to 
specify the disease stage and severity. In the simple example given in Box 1.2 the key 
interventions and outcomes of interest are listed.
The nature of the intervention(s) and comparator(s) should be specifi ed in detail. Whilst 
this may be more straightforward for drug interventions, more complex interventions 
may require detailed consideration of terms. For example, interventions such as ‘stress 
management’ or ‘relaxation’ may be defi ned differently by different study authors. 
Therefore researchers need to be clear about their own defi nitions and what elements 
are acceptable. An operational defi nition describing the content and delivery of the 
intervention will usually be helpful.
The inclusion criteria should capture all studies of interest. If the criteria are too 
narrowly defi ned there is a risk of missing potentially relevant studies and the 
generalisability of the results may be reduced. On the other hand, if the criteria are too 
broad the review may contain information which is hard to compare and synthesise.17,18 
Inclusion criteria also need to be practical to apply; if they are too detailed, screening 
may become overly complicated and time consuming.
Methodological quality
As previously stated, a review should be based on the best quality evidence available 
(see Box 1.3). Whatever the study design(s) included, it should not be assumed that 
all studies of the same basic design (e.g. RCT) are equally well-conducted. The quality 
of the included studies should be formally assessed as this will impact on the reliability 
of the results and therefore on the conclusions drawn. Although quality assessment 
can sometimes be used to exclude studies that do not meet certain criteria, this is not 
standard practice and differential quality is more usually assessed at the synthesis 
stage through sensitivity analysis. For further information see Section 1.3.4 Quality 
assessment and Section 1.3.5 Data synthesis.
(Continued)
Box 1.3: Hierarchy of study designs to assess the effects of 
interventions
This list is not exhaustive, but covers the main study designs. Refer to the 
glossary for defi nitions of other study designs. Names and defi nitions may differ 
(e.g. randomised controlled trial is often called randomised clinical trial).
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Randomised controlled trials
The simplest form of RCT is known as the parallel group trial which randomises 
eligible participants to two or more groups, treats according to assignment, and 
compares the groups with respect to outcomes of interest. Participants are allocated 
to groups using both randomisation (allocation involves the play of chance) and 
concealment (ensures that the intervention that will be allocated cannot be known 
in advance). There are different types of randomised study designs, such as:
Randomised cross-over trials
Where all participants receive all the interventions; for example in a two 
arm cross-over trial, one group receives intervention A before intervention 
B, and the other group receive intervention B before intervention A. It is the 
sequence of interventions that is randomised.
Cluster randomised trials
A cluster randomised trial is a trial where clusters of people rather than single 
individuals are randomised to different interventions. For example, whole 
clinics or geographical locations may be randomised to receive particular 
interventions, rather than individuals.
Quasi-experimental studies
The main distinction between randomised and quasi-experimental studies is 
the way in which participants are allocated to the intervention and control 
groups; quasi-experimental studies do not use random assignment to create the 
comparison groups.
Non-randomised controlled studies
Individuals are allocated to a concurrent comparison group, using methods 
other than randomisation. The lack of concealed randomised allocation 
increases the risk of selection bias.
Before-and-after study
Comparison of outcomes in study participants before and after the 
introduction of an intervention. The before-and-after comparisons may be in 
the same sample of participants or in different samples.
Interrupted time series
Interrupted time series designs are multiple observations over time that are 
‘interrupted’, usually by an intervention or treatment.
Observational studies
A study in which natural variation in interventions or exposure among participants 
(i.e. not allocated by an investigator) is investigated to explore the effect of the 
interventions or exposure on health outcomes.
Cohort study
A defi ned group of participants is followed over time and comparison is made 
between those who did and did not receive an intervention.
Case-control study
Groups from the same population with (cases) and without (controls) a 
specifi c outcome of interest, are compared to evaluate the association 
between exposure to an intervention and the outcome.
Case series
Description of a number of cases of an intervention and the outcome (without 
comparison with a control group). These are not comparative studies.
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Language
The ideal for most systematic reviews is to include all available relevant evidence. In 
principle, this includes studies written in any language to avoid the introduction of 
language bias into the review. Language bias arises because studies with statistically 
signifi cant results that have been conducted in non-English speaking countries may be 
more likely to be published in English language journals than those with nonsignifi cant 
results.19 In addition, trials originating in certain countries have been found to have 
unusually high proportions of positive results.20
Thus, if reviews include only studies reported in English, their results and inferences 
may be biased.19-21 Even if language bias does not infl uence summary effect estimates, 
it is likely to affect precision, because analysis will be based on fewer data.22 Whenever 
feasible, all relevant studies should be included regardless of language. However, 
realistically this is not always possible due to a lack of time, resources and facilities 
for translation. It is advisable therefore, to identify all non-English language papers, 
document their existence, but record ‘language’ as the reason for exclusion in cases 
where they cannot be dealt with. Although titles and abstracts are translated in many 
databases, full papers are usually only available in their primary language.
When a decision is made to include non-English language studies, the review question 
should inform the decision about which languages are chosen, as studies of particular 
interventions and/or settings are more likely than others to be published in certain 
languages. An investigation of the inclusion of non-English language reports of RCTs 
in systematic reviews concluded that language restrictions do not appear to bias 
the estimates in reviews of conventional interventions, but may bias the results of 
complementary or alternative medicines.23 Researchers need to give careful thought 
as to whether imposing language restrictions may potentially bias the results of their 
individual review. When non-English language literature is included in a review, its 
infl uence on the estimation and precision of effect may be explored in a sensitivity 
analysis.
Publication type/status
Studies are not always published as full papers in peer-reviewed journals; they may 
be published as reports, book chapters, conference abstracts, theses or they may be 
informally reported or remain unpublished. Ideally a review should aim to include all 
relevant studies, regardless of publication status, in order to avoid publication bias. 
Publication bias occurs when the publication of a study is infl uenced by its results, hence 
inclusion of only published studies may overestimate the intervention effect.24
There are practical issues that limit the inclusion of all studies regardless of publication 
type/status. Unpublished studies are likely to be harder to source, and more diffi cult 
to obtain, than published studies. The inclusion of conference abstracts and interim 
results should be considered, bearing in mind that contact with the study authors 
may be required to obtain full study details.25 The effects of including any data from 
abstracts alone should be carefully considered, since differences often occur between 
data reported in conference abstracts and their corresponding full reports, although 
differences in results are seldom large.26, 27 Also, it can be diffi cult to appraise study 
quality from minimal details provided in an abstract. Sensitivity analyses may be carried 
out to examine the effect of including data from conference abstracts.28
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The identifi cation of ongoing studies is important for a number of reasons. They may 
provide a useful starting point for subsequent reviews and updates; they may also 
improve the quality of conclusions about future research by indicating where new 
research has already commenced. Information about ongoing studies may be available 
as ‘partially published research’ like conference abstracts – these can be classifi ed as 
ongoing studies which may contribute to future reviews.29
1.2.2.4 Identifying research evidence
A preliminary search strategy for identifying relevant research should be included in 
the protocol. This should specify the databases and additional sources that will be 
searched, and also the likely search terms to be used. The search strategy should be 
constructed to take into account PICOS, although the outcome(s) of studies and/or 
study design are not always used. Incorporating decisions about publication status and 
language restrictions also needs to be made at this stage. In reviews of one year or 
more duration, or reviews in rapidly evolving fi elds, provision for repeating the searches 
towards the end of the review process should also be considered. In addition it may 
be useful to carry out current awareness searches to identify relevant papers as they 
are published. The approach taken will depend on the question and the topic, and also 
on the available time and resources. It is usual to include in the protocol details of the 
software that will be used to manage references. Further information is given in Section 
1.3.1 Identifying research evidence for systematic reviews.
1.2.2.5 Study selection
Study selection is usually conducted in two stages: an initial screening of titles and 
abstracts against the inclusion criteria to identify potentially relevant papers followed 
by screening of the full papers identifi ed as possibly relevant in the initial screening. 
The protocol should specify the process by which decisions on the selection of studies 
will be made. This should include the number of researchers who will screen titles and 
abstracts and then full papers, and the method for resolving disagreements about study 
eligibility. Section 1.3.2 Study selection contains more information.
1.2.2.6 Data extraction
The protocol should outline the information that will be extracted from studies 
identifi ed for inclusion in the review and provide details of any software to be used for 
recording the data. As with study selection the protocol should state the procedure 
for data extraction including the number of researchers who will extract the data 
and how discrepancies will be resolved. The protocol should also specify whether 
authors of primary studies will be contacted to provide missing or additional data. If 
foreign language papers are to be included, it may be necessary to specify translation 
arrangements. Further information is given in Section 1.3.3 Data extraction.
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1.2.2.7 Quality assessment
The protocol should provide details of the method of study appraisal to be used, 
including examples of the specifi c quality criteria. Details of how the study appraisal is 
to be used should be specifi ed, for example whether the results will inform sensitivity 
analyses. The protocol should also specify the process for conducting the appraisal 
of study quality, the number of researchers involved, and how disagreements will be 
resolved. For a detailed discussion of these issues see Section 1.3.4 Quality assessment.
1.2.2.8 Data synthesis
As far as possible, the protocol should specify the strategy for data synthesis. It should 
state whether a meta-analysis is planned, although whether a planned meta-analysis 
will ultimately prove possible will depend on the studies and data that are available. As 
analyses will depend on what data are available, and because it is diffi cult to anticipate 
all of the statistical issues that may arise, it can be diffi cult to pre-specify full details of 
the planned synthesis. However, the protocol should outline how heterogeneity will be 
explored and quantifi ed, under what circumstances a meta-analysis would be considered 
appropriate and whether a fi xed or random-effects model or both would be used. Where 
appropriate, the approach to narrative synthesis should also be outlined. The protocol 
should also specify the outcomes of interest and what effect measures will be used. Any 
planned subgroup or sensitivity analyses or investigation of publication bias should also 
be described. Further information is given in Section 1.3.5 Data synthesis.
1.2.2.9 Dissemination
Dissemination of fi ndings is an integral part of the review process and fundamental to 
ensuring that the essential messages from the review reach the appropriate audiences. 
It is helpful to consider how the review fi ndings will be disseminated from as early a 
stage as possible to allow adequate time for planning and development and to ensure 
that the proposed activities are properly resourced. Details are given in Section 1.3.8 
Disseminating the fi ndings of systematic reviews.
1.2.3 Approval of the draft protocol
Some commissioning or funding bodies may require that they formally approve 
the protocol, and will provide input to the draft protocol, in addition to the other 
stakeholders, such as clinical and methodological experts, patient groups and service 
users, who may be consulted. For commissioned reviews, even where it is not a specifi c 
requirement, it can be useful to communicate with the commissioner at the protocol 
development stage. This will help to ensure that the protocol meets the commissioning 
brief or where the review question or the scope of the project has been altered, that this 
is agreed before work commences.
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1.2.4 How to deal with protocol amendments during the review
Sticking rigidly to a protocol when it becomes apparent that a change of direction 
is required, can result in a review that is not useful to end users. It is possible that 
consideration of the primary research may raise questions which were not anticipated 
at the protocol stage. Where this results from a clearer understanding of the review 
question, it can be appropriate to carry out documented and justifi ed amendments to 
the protocol. In the report of the review fi ndings it is helpful to distinguish between 
the initial review question and any subsequent amendments. It is never appropriate to 
modify the protocol because of awareness of the results of individual studies, as this is 
likely to introduce bias and affect the validity of the review’s conclusions.
Many reviews undergo protocol modifi cation.30 Where modifi cations are a possibility, 
the implications for the review process and workload should be considered carefully. 
In particular, the likely impact on the literature search should be assessed, as it may 
require modifi cation and running again. Data extraction forms may also need to be 
amended, and any data that have already been extracted might require some re-
working. Protocol amendments should be documented in a protocol addendum and in 
the fi nal report of the review.
Summary: The review protocol
• The protocol sets out in advance the methods to be used in the review with 
the aim of minimizing bias.
• The background section of the protocol should communicate the key 
contextual and conceptual factors relevant to the review question and provide 
the justifi cation for the review.
• The protocol should specify the review question.
• Study inclusion and exclusion criteria should be clearly defi ned using the 
relevant PICOS elements.
• The protocol should also specify the methods which will be used to:
• Identify research evidence
• Select studies for inclusion
• Data extract included studies
• Quality assess included studies
• Synthesise results
• Disseminate the review fi ndings
• In cases when it becomes apparent that a modifi cation to the protocol is 
required, protocol amendments should be clearly documented and justifi ed.
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1.3 UNDERTAKING THE REVIEW
1.3.1 Identifying research evidence for systematic reviews
This section describes how to undertake a systematic search using a range of methods 
to identify studies, manage the references retrieved by the searches, obtain documents 
and write up the search process. Practical examples of constructing search strategies 
are given in Appendix 2, and Appendix 3 provides examples of how the search should 
be documented. Issues around the identifi cation of research evidence that are specifi c 
to review type such as adverse effects or clinical tests are discussed in the relevant 
chapters.
Conducting a thorough search to identify relevant studies is a key factor in minimizing 
bias in the review process. The search process should be as transparent as possible and 
documented in a way that enables it to be evaluated and reproduced.
Studies can be located using a combination of the following approaches:
• Searching electronic databases
• Visually scanning reference lists from relevant studies
• Handsearching key journals and conference proceedings
• Contacting study authors, experts, manufacturers, and other organisations
• Searching relevant Internet resources
• Citation searching
• Using a project Internet site to canvas for studies
1.3.1.1 Minimizing publication and language biases
Decisions about where and how to search could unintentionally introduce bias into 
the review, so the team needs to consider, and try to minimize, the possible impact 
of search limitations. For example, restricting the searching to the use of electronic 
databases, which consist mainly of references to published journal articles, could result 
in the review being subject to publication bias as this approach is unlikely to identify 
studies that have not been published in peer reviewed journals. Wider searching is 
needed to identify research results circulated as reports or discussion papers. The 
identifi cation of grey literature, such as unpublished papers, is diffi cult, but some are 
included on databases such as NTIS (National Technical Information Service) and 
HMIC (Health Management Information Consortium). Libraries of specialist research 
organisations and professional societies may also provide access to collections of grey 
literature.
Searching databases and registers that include unpublished studies, such as records 
of ongoing research, conference proceedings and theses, can reduce the impact of 
publication bias. Conference proceedings provide information on both research in 
progress and completed research. Conference abstracts are recorded in some major 
bibliographic databases such as BIOSIS Previews, as well as in dedicated databases 
such as Index to Scientifi c and Technical proceedings, ZETOC, and the Conference 
Papers Index.31-34 It is also worth consulting catalogues from major libraries, for 
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example the British Library and the US National Library of Medicine. The abstracts in 
conference proceedings may only give limited information, and there can be differences 
between data presented in an abstract and that included in a fi nal report.35, 36 For 
these reasons, researchers should try to acquire the full report, if there is one, before 
considering whether to include the results in a systematic review.
As already discussed, limiting searches to English language papers can introduce 
language bias. Large bibliographic databases, such as MEDLINE and EMBASE, do include 
a small number of non-English language journals.37 Using additional databases such 
as LILACS (Latin American and Caribbean Health Sciences Literature) that contain 
collections of non-English language research can minimize potential language bias.
1.3.1.2 Searching electronic databases
The selection of electronic databases to search will depend upon the review topic. 
Lists of databases are available from libraries and from database providers, such as 
Dialog and Wolters Kluwer, while subject experts will be familiar with the bibliographic 
databases in their fi eld.
For reviews of health care interventions, MEDLINE and EMBASE are the databases most 
commonly used to identify studies. The Cochrane Central Register of Controlled Trials 
(CENTRAL) includes details of published articles taken from bibliographic databases and 
other published and unpublished sources.38 There are other databases with a narrower 
focus that could be equally appropriate. These include PsycINFO (psychology and 
psychiatry), AMED (complementary medicine), MANTIS (osteopathy and chiropractic) 
and CINAHL (nursing and allied health professions). If the topic includes social care 
there are a range of databases available including ASSIA (Applied Social Sciences 
Index and Abstracts), CSA Sociological Abstracts, and CSA Social Services Abstracts, 
that could be used. The databases referred to above are all subject-based but there 
are others, such as AgeInfo, Ageline and ChildData, that focus on a specifi c population 
group that could be relevant to the review topic.
Due to the diversity of questions addressed by systematic reviews, there can be no 
agreed standard for what constitutes an acceptable search in terms of the number of 
databases searched. For example, if the review is on a cross-cutting public health topic 
such as housing and health it is advisable to search a wider range of databases than if 
the review is of a pharmaceutical intervention for a known health condition (see 
Chapter 3, Section 3.3 Identifying research evidence).
1.3.1.3 Searching other sources
In addition to searching electronic databases, published and unpublished research may 
also be obtained by using one or more of the following methods.
Scanning reference lists of relevant studies
Browsing the reference lists of papers (both primary studies and reviews) that have 
been identifi ed by the database searches may identify further studies of interest.
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Handsearching key journals
Handsearching involves scanning the content of journals, conference proceedings and 
abstracts, page by page. It is an important way of identifying very recent publications 
that have not yet been included and indexed by electronic databases or of including 
articles from journals that are not indexed by electronic databases.39 Handsearching 
can also ensure complete coverage of journal issues, including letters or commentaries, 
which may not be indexed by databases. It can also compensate for poor or inaccurate 
database indexing that can result in even the most carefully constructed strategy failing 
to identify relevant studies. Selecting which journals to handsearch can be done by 
analysing the results of the database searches to identify the journals that contain the 
largest number of relevant studies.
Searching trials registers
Trials can be identifi ed by searching one or more of the many trials registers that exist. 
It can be a particularly useful approach to identifying unpublished or ongoing trials. 
Many of the registers are available on the Internet and some of the larger ones, such 
as www.ClinicalTrials.gov and www.who.int/trialsearch/, include the facility to search 
by drug name or by condition. While some registers are disease specifi c, others collect 
together trials from a specifi c country or region. Pharmaceutical companies may also 
make information about trials they have conducted available from their websites.
Contacting experts and manufacturers
Research groups and other experts as well as manufacturers may be useful sources 
of research not identifi ed by the electronic searches, and may also be able to supply 
information about unpublished or ongoing research. Contacting relevant research 
centres or specialist libraries is another way of identifying potential studies. While these 
methods can all be useful, they are also time consuming and offer no guarantee of 
obtaining relevant information.
After a thorough and systematic search has been conducted, and relevant studies 
have been identifi ed, topic experts can be asked to check the list to identify any known 
missing studies.
Searching relevant Internet resources
Internet searching can be a useful means of retrieving grey literature, such as 
unpublished papers, reports and conference abstracts. Identifying and scanning specifi c 
relevant websites will usually be more practical than using a general search engine such 
as ‘Google’.
Reviews of transport and ‘welfare to work’ programmes have reported how Internet 
searching of potentially relevant websites was effective in identifying additional studies 
to those retrieved from databases.40, 41 It is worth considering using the Internet when 
investigating a topic area where it is likely that studies have been published informally 
rather than in a journal indexed in a bibliographic database.
Internet searching should be carried out in as structured a way as possible and the 
procedure documented (see Appendix 3).
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Citation searching
Citation searching involves selecting a number of key papers already identifi ed for 
inclusion in the review and then searching for articles that have cited these papers. This 
approach should identify a cluster of related, and therefore highly relevant, papers. 
As this is in effect a search forward through time, citation searching is not suitable for 
identifying recent papers as they cannot have been referenced by other older papers.
Citation searching used to be limited to using the indexes Science Citation Index 
Expanded, Social Sciences Citation Index, and Arts & Humanities Citation Index,. but 
other resources (including CINAHL, PsycINFO and Google Scholar) now include cited 
references in their records so these are also available for citation searching. Using 
similar services offered by journals such as the BMJ can also be helpful.
Using a project Internet site to canvas for studies
Where it has been agreed that a dedicated website should be set up for the review, 
for example as part of the overall dissemination strategy, this can be used to canvas 
for unpublished data/grey literature. Inclusion of an email contact address allows 
interested parties to submit information about relevant research. Posting the inclusion 
and exclusion criteria on the website may help to ensure submissions are appropriate. 
Throughout the review process the website should be continually updated with 
information about the studies identifi ed. Personal responses should be sent to all 
respondents and where appropriate submitted material should be included in the library 
of references. Further details about dedicated project websites can be found in Section 
1.3.8 Disseminating the fi ndings of systematic reviews.
This approach should probably only be considered for ‘high profi le’ reviews and then it 
should be as an adjunct to active canvassing for unpublished/grey literature.
1.3.1.4 Constructing the search strategy for electronic databases
Search strategies are explicitly designed to be highly sensitive so as many potentially 
relevant studies as possible are retrieved. Consequently the searches tend to retrieve 
a large number of records that do not meet the inclusion criteria. While it is possible 
to increase the precision of a search strategy, and so reduce the number of irrelevant 
papers retrieved, this may lead to relevant studies being missed.42
Constructing an effective combination of search terms involves breaking down the 
review question into ‘concepts’. Using the Population, Intervention, Comparator, and 
Outcomes elements from PICOS can help to structure the search, but it is not essential 
that every element is used. For example it may be better not to use terms for the 
outcomes since inclusion might mean that the database being searched fails to show 
relevant studies simply because the outcome is not mentioned prominently enough in 
the record, even though the study measured it. For each of the elements used, it is 
important to consider all the possible alternative terms. For example a drug intervention 
may be known by a generic name and one or more proprietary names. Advice should be 
sought from the topic experts on the review team and advisory group.
For a detailed discussion of how to structure a search from a review question, including 
the use of search fi lters for study design, see Appendix 2.
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1.3.1.5 Text mining
Text mining is a rapidly developing approach to utilizing the large amount of published 
text now available. Its potential use in systematic reviews is currently being explored 
and it may in future be an additional useful way of identifying relevant studies.43, 44 
The aim of text mining is to identify connections between seemingly unrelated facts 
to generate new ideas or hypotheses. A number of processes are involved in the 
technique: a) Information Retrieval identifi es documents to match a user’s query; b) 
Natural Language Processing provides linguistic data needed to perform c) Information 
Extraction, the process of automatically obtaining structured data from an unstructured 
natural language document; and d) Data Mining, the process of identifying patterns in 
large sets of data.45, 46 In future this approach may be helpful in automatically screening 
and ranking large numbers of potentially eligible studies prior to assessment by the 
researchers.
There are a variety of text mining tools available, for example TerMine and Acromine47 
are tools dealing with term extraction and variation. Also of interest are KLEIO,48 
which provides advanced searching facilities across MEDLINE and FACTA, which fi nds 
associated concepts using text analysis.49 Further information about text mining and 
the use of these tools can be found on the National Centre for Text Mining website 
(www.nactem.ac.uk/).
1.3.1.6 Updating literature searches
Depending on the scope and timescale of the review, an update of the literature 
searches towards the end of the project may be required. If the initial searches were 
carried out some time before the fi nal analysis is undertaken (e.g. six months) it may 
be necessary to re-run the searches to ensure that no recent papers are missed. To do 
this successfully the date the original search was conducted and the years covered by 
the search must have been recorded.
When doing update searches the update date fi eld should be used rather than the 
actual date. This ensures that anything added to the database since the original search 
was conducted will be identifi ed. If the database has added a lot of older material (e.g. 
from 1967) this will be removed by using the original date limits (e.g. 1990-2008) in 
combination with the update date fi eld. For databases that do not include an update 
date fi eld it may be better to run the whole search again and then use reference 
management software to remove those records that have already been identifi ed and 
assessed.
1.3.1.7 Current awareness
If a review is covering an area where there is rapid change or if a major study is 
expected to report its fi ndings in the near future, setting up current awareness alerts 
can ensure that new papers are identifi ed as soon as they become available. Options for 
current awareness include e-mail alerts from journals and RSS feeds from databases or 
websites.
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1.3.1.8 Managing references
To ensure the retrieved records are managed effi ciently the team should agree working 
practices. For example, who will screen the references and record decisions about 
which documents to obtain and how to code these decisions; whether decisions about 
rejecting or obtaining documents should be made blind to others’ decisions; and how to 
store documents received. In addition, one member of the team should be responsible 
for identifying and removing duplicate references, ordering inter-library loans, recording 
the receipt of documents, and following up non-arrivals.
Using bibliographic software such as EndNote, Reference Manager or ProCite to record 
and manage references will help in documenting the process, streamline document 
management and make the production of reference lists for reports and journal papers 
easier. EPPI-Reviewer, a web-based review management programme, also incorporates 
reference management functions.4, 50 Alternatively it is possible to construct a database 
of references using a database package such as Microsoft Access or a word processing 
package. By creating a ‘library’ (database) of references, information can be shared 
by the whole review team, duplicated references can be identifi ed and deleted more 
easily, and customised fi elds can be created where ordering decisions can be recorded.42 
Specialised bibliographic management software packages have the facility to import 
references from electronic databases into the library and interact with word processing 
packages so bibliographies can be created in a variety of styles.
When an electronic library of references is used, it is important to establish in advance 
clear rules about which team members can add or amend records in the library, and 
that consistent terminology is used to record decisions. It is usually preferable to have 
one person from the team responsible for the library of references.
1.3.1.9 Obtaining documents
Obtaining a large number of papers in a short space of time can be very labour 
intensive. The procedure for acquiring documents will vary according to organisational 
arrangements and will depend on issues such as cost, what resources are available, 
and whether access to an inter-library loan network is available. Most libraries in the 
United Kingdom will be able to obtain articles from the British Library Document Supply 
Centre’s collection although membership is required and there is a charge per article. 
Many journals are available in full text on the Internet, although a subscription may 
be required before articles can be downloaded. It may be cost-effective to travel to a 
particular library to obtain material if a large number of references are required and are 
available. The information specialist on the team is likely to know about networks of 
associated libraries and electronic resources that can be used for obtaining documents.51
1.3.1.10 Documenting the search
The search process should be reported in suffi cient detail so that it could be re-run at 
a later date. The easiest way to document the search is to record the process and the 
results contemporaneously. The decisions reached during development and any changes 
or amendments made should be recorded and explained. It is important to record all 
searches, including Internet searches, handsearching and contact with experts.
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Providing the full detail of searches helps future researchers to re-run or update the 
searches and enables readers to evaluate the thoroughness of searching. The write up 
of the search should include information about the databases and interfaces searched 
(including the dates covered), full detailed search strategies (including any justifi cations 
for date or language restrictions) and the number of records retrieved.
When systematic reviews are reported in journal articles, limits on the word count 
may make it impossible to provide full details of the searches. In these circumstances 
as much information as possible should be provided within the available space. For 
example, ‘We searched MEDLINE, EMBASE and CINAHL’ is more helpful to the reader 
than ‘We conducted computer searches’. Many journals now have an electronic 
version of the publication where the full search details can be provided. Alternatively, 
the published report can include the review team’s contact details so full details of 
the search strategies can be requested. If a detailed report is being written for the 
commissioners of the review, the full search details should be included.
The use of fl ow charts to demonstrate how relevant papers are identifi ed is detailed in 
Section 1.3.2 Study selection. Guidance on documenting the different aspects of the 
searching process is given in Appendix 3.
Summary: Identifying research evidence for systematic reviews
• The search for studies should be comprehensive.
• The extent of searching is determined by the research question and the 
resources available to the research team.
• Thorough searching is best achieved by using a variety of search methods 
(electronic and manual) and by searching multiple, possibly overlapping 
resources.
• Most of the searching is likely to take place at the beginning of the review with 
an update search towards the end.
• Using bibliographic software to record and manage references will help in 
documenting the process, streamline document management and make the 
production of reference lists for reports and journal papers easier.
• The search process should be documented in full or details provided of where 
the strategy can be obtained.
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1.3.2 Study selection
Literature searching may result in a large number of potentially eligible records that 
need to be assessed for inclusion against predetermined criteria, only a small proportion 
of which may eventually be included in the review. The process for selecting studies 
should be explicit and conducted in such a way as to minimize the risk of errors and 
bias. This section explains the steps involved and the issues to be considered when 
planning and conducting study selection.
1.3.2.1 Process for study selection
The process by which decisions on the selection of studies will be made should be 
specifi ed in the protocol, including who will carry out each stage and how it will be 
performed. The aim of selection is to ensure that all relevant studies are included in the 
review.
It is important that the selection process should minimize biases, which can occur 
when the decision to include or exclude certain studies may be affected by pre-formed 
opinions.52-56 The process for study selection therefore needs to be explicit, objective 
and minimize the potential for errors of judgement. It should be documented clearly 
to ensure it is reproducible (see Figure 1.1). The selection of studies from electronic 
databases is usually conducted in two stages:
Stage 1: a fi rst decision is made based on titles and, where available, abstracts. These 
should be assessed against the predetermined inclusion criteria. If it can be determined 
that an article does not meet the inclusion criteria then it can be rejected straightaway. 
It is important to err on the side of over-inclusion during this fi rst stage. The review 
question and the subsequent specifi cation of the inclusion and exclusion criteria are 
likely to determine ease of rejection in this fi rst stage. Where the question and criteria 
are tightly focused then it is usually easier to be confi dent that the rejected studies are 
not relevant. Rejected citations fall into two main categories; those that are clearly not 
relevant and those that address the topic of interest but fail on one or more criteria 
such as population. For those in the fi rst category it is usually adequate to record as 
an irrelevant study, without a reason why. For those in the second category it is useful 
to record why the study failed to meet the inclusion criteria, as this increases the 
transparency of the selection process. Where abstracts are available the amount and 
usefulness of the information to the decision-making process often varies according 
to database and journal. Structured abstracts such as those produced by the BMJ are 
particularly useful at this stage of the review process.
Stage 2: for studies that appear to meet the inclusion criteria, or in cases when a 
defi nite decision cannot be made based on the title and/or abstract alone, the full paper 
should be obtained for detailed assessment against the inclusion criteria.
Some searching methods provide access to full papers directly, for example 
handsearching journals and contact with research groups, in which case assessment for 
inclusion is a one stage process.
Even when explicit inclusion criteria are specifi ed, decisions concerning the inclusion 
of individual studies can remain subjective. Familiarity with the topic area and an 
understanding of the defi nitions being used are usually important.
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The reliability of the decision process is increased if all papers are independently 
assessed by more than one researcher, and the decisions shown to be reproducible. One 
study found that on average a single researcher is likely to miss 8% of eligible studies, 
whereas a pair of researchers working independently would capture all eligible studies.57 
Assessment of agreement is particularly important during the pilot phase (described 
later in this section), when evidence of poor agreement should lead to a revision of 
the selection criteria or an improvement of their coding. Agreement between assessors 
(inter-assessor reliability) may be formally assessed mathematically using a Kappa 
statistic (a measure of chance-corrected agreement).58
The process for resolving disagreements between assessors should be specifi ed in the 
protocol. Many disagreements may be simple oversights, whilst others may be matters 
of interpretation. These disagreements should be discussed and, where possible, 
resolved by consensus after referring to the protocol; if necessary a third person may 
be consulted.
If resources and time allow, the lists of included and excluded studies may be discussed 
with the advisory group. In addition, these lists can be posted on a dedicated website 
with a request for feedback on any missing studies, an approach used in a review of 
water fl uoridation.59 For further information see Section 1.3.8 Disseminating the fi ndings 
of systematic reviews.
Piloting the study selection process
The selection process should be piloted by applying the inclusion criteria to a sample 
of papers in order to check that they can be reliably interpreted and that they classify 
the studies appropriately. The pilot phase can be used to refi ne and clarify the inclusion 
criteria and ensure that the criteria can be applied consistently by more than one 
person. Piloting may also give an indication of the likely time needed for the full 
selection process.
Masking/blinding
Judgements about inclusion may be affected by knowledge of the authorship, 
institutions, journal titles and year of publication, or the results and conclusions of 
articles.60 Blind assessment may be possible by removing such identifying information, 
but the gain should be offset against the time and effort required to disguise the source 
of each article. Several studies have found that masking author, institution, journal 
name and study results is of limited value in study selection.61, 62 Therefore, the general 
opinion is that unmasked assessment by two independent researchers is acceptable.
Dealing with lack of information
Sometimes the amount of information reported about a study is insuffi cient to make a 
decision about inclusion, and it can be helpful to contact study authors to ask for more 
details. However, this requires time and resources, and the authors may not reply, 
particularly if the study is old. If authors are to be contacted it may be advisable to 
decide in advance how much time will be given to allow them to reply. If contacting 
authors is not practical then the studies in question could be excluded and listed as 
‘potentially relevant studies’. If a decision is made to include such studies, the infl uence 
on the results of the review can be checked in a sensitivity analysis.
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Dealing with duplication
It is important to look for duplicate publications of research results to ensure they are 
not treated as separate studies in the review. Multiple papers may be published for 
a number of reasons including: translations; results at different follow-up periods or 
reporting of different outcomes. However, it is not always easy to identify duplicates as 
they are often covert (i.e. not cross referenced to one another) and neither authorship 
nor sample size are reliable criteria for identifi cation of duplication.63 Estimates of 
prevalence of duplicate publication range from 1.4% to 28%,64 and studies have been 
found to have up to fi ve duplicate reports.63 Multiple reports from the same study may 
include identical samples with different outcomes reported or increasing samples with 
the same outcomes reported.
Multiple reporting can lead to biased results, as studies with signifi cant results are 
more likely to be published or presented more frequently, leading to an overestimation 
of treatment effects when fi ndings are combined.65 When multiple reports of a 
study are identifi ed these should be treated as a single study but reference made 
to all the publications. It may be worthwhile comparing multiple publications for 
any discrepancies, which could be highlighted and the study authors contacted for 
clarifi cation.
Documenting decisions
It is important to have a record of decisions made for each article. This may be in paper 
form, attached to paper copies of the articles, or the selection process may be partially 
or wholly computerised. If the search results are provided in electronic format, they 
can be imported into a reference management program such as EndNote, Reference 
Manager or ProCite which stores, displays and enables organisation of the records, 
and allows basic inclusion decisions to be made and recorded (in custom fi elds). For 
more complex selection procedures, where several decisions and comments need to be 
recorded, a database program such as Microsoft Access may be of use. There are also 
programs specifi cally designed for carrying out systematic reviews which include aids for 
the selection process, such as TrialStat SRS and EPPI-Reviewer.
Reporting study selection
A fl ow chart showing the number of studies/papers remaining at each stage is a simple 
and useful way of documenting the study selection process. Recommendations for 
reporting and presentation of a fl ow chart when reporting systematic reviews with 
or without a meta-analysis have been developed by the PRISMA group, formerly the 
QUOROM group. Publication of these guidelines is forthcoming.66, 67 In the meantime, the 
existing QUOROM guidelines for the reporting meta-analysis of RCTs,9 provide guidance 
that is equally applicable to all systematic reviews. Figure 1.1 is an example of a fl ow 
chart from a systematic review of treatments for childhood retinoblastoma.14
A list of studies excluded from the review should also be reported where possible, 
giving the reasons for exclusion. This list may be included in the report of the review as 
an appendix. In general, this list is most informative if it is restricted to ‘near misses’ 
(i.e. those studies that only narrowly failed to meet inclusion criteria and that readers 
might have expected to see included) rather than all the research evidence identifi ed. 
Decisions to exclude studies may be reached at the title and abstract stage or at the full 
paper stage.
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Figure 1.1: Flow chart of study selection process14
Titles and abstracts
identified and screened
n = 3114
Full copies retrieved and
assessed for eligibility
n = 760
Excluded n = 2342
Unable to obtain/further
information required to make
assessment n = 14
Excluded n = 665
Not relevant design n = 401
Background discussion n = 209
No outcome/intervention or
treatment n = 27
No patients with
retinoblastoma n = 21
Duplicate publication n = 7
Publications meeting
inclusion criteria
n = 77
Publications included in
the review n = 42
Number of studies
included in the review
n = 31
Excluded n = 35
No clear comparison group
n = 33
Outcomes not reported
separately for each treatment
n = 1
No actual data available on
treatment outcome n = 1
Foreign language n = 16
Studies identified from
contact with experts
n = 1
Studies identified from
searching in reference list
n = 1
Publications providing
additional information to
located published studies
n = 3
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Summary: Study selection
• In order to minimize bias, studies should be assessed for inclusion using 
selection criteria that fl ow directly from the review question and that have 
been piloted to check that they can be reliably applied.
• Study selection is a staged process involving sifting through the citations 
located by the search, retrieving full reports of potentially relevant citations 
and, from their assessment, identifying those studies that fulfi l the inclusion 
criteria.
• Parallel independent assessments should be conducted to minimize the risk 
of errors. If disagreements occur between assessors, they should be resolved 
according to a predefi ned strategy using consensus and arbitration as 
appropriate.
• The study selection process should be documented, detailing reasons for 
exclusion of studies that are ‘near-misses’.
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1.3.3 Data extraction
Data extraction is the process by which researchers obtain the necessary information 
about study characteristics and fi ndings from the included studies. Data extraction 
requirements will vary from review to review, and the extraction forms should be 
tailored to the review question. The fi rst stage of any data extraction is to plan the 
type of analyses and list the tables that will be included in the report. This will help to 
identify which data should be extracted. General guidance on the process is given here, 
but the specifi c details will clearly depend on the individual review topic.
A sample data extraction form and details of the data extraction process should be 
included in the review protocol. A common problem at the protocol stage is that 
there may be limited familiarity with the topic area. This can lead to uncertainties, for 
example, about comparators and outcome measures. As a result, time can be wasted 
extracting unnecessary data and diffi culties can arise when attempting to utilise and 
synthesise the data. Suffi cient time early in the project should therefore be allocated to 
developing, piloting and refi ning the data extraction form.
The extraction of data is linked to assessment of study quality in that both processes 
are often undertaken at the same time.
Standardised data extraction forms can provide consistency in a systematic review, 
whilst reducing bias and improving validity and reliability.68 Use of an electronic form 
has the added advantage of being able to combine data extraction and data entry into 
one step, and to facilitate data analysis and the production of results tables for the fi nal 
report.
1.3.3.1 Design
Integral to the design of the form is the category of data to be extracted. It may be 
numerical, fi xed text such as yes/no, a ‘pick list’, or free text. However, the number of 
free text fi elds should be limited as much as possible to simplify the analysis of data. 
The form should be unambiguous and easy to use in order to minimize discrepancies. 
Instructions for completion should be provided and each fi eld should have decision 
rules about coding data in order to avoid ambiguity and to aid consistent completion. 
Piloting the form is essential. Paper forms should only be used where access to 
direct completion of electronic forms is impossible, to reduce risks of error in data 
transcription.
1.3.3.2 Content
The nature of the data extracted will depend on the type of question being addressed 
and the types of study available. Box 1.4 gives an example of some of the information 
that might be extracted for a comparative study.
The results to be extracted from each individual study may be reported in a variety 
of ways, and it is often necessary for a researcher to manipulate the available data 
into a common format. Manipulations of the reported fi ndings are discussed in further 
detail in Section 1.3.5 Data synthesis, but can include using confi dence intervals to 
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determine standard errors or estimating the hazard ratio from a survival curve. Data 
can be categorised at this stage; however, it is advisable to extract as much of the 
reported data as is likely to be needed, and categorise at a later stage, so that detailed 
information is not lost during data extraction.
1.3.3.3 Software
EPPI-Reviewer is a web application that enables researchers to manage all stages of 
a review in a single location. RevMan and TrialStat SRS are other software packages 
that can be used in data extraction for systematic reviews. Other tools commonly used 
include general word processing packages, spreadsheets and databases.
Whichever software package is used, ideally it should have the ability to provide 
different types of question coding. Some software will also allow researchers to develop 
quality control mechanisms for minimizing data entry errors, for example, by specifying 
ranges of valid values.
1.3.3.4 Piloting data extraction
Data extraction forms should be piloted on a sample of included studies to ensure that 
all the relevant information is captured and that resources are not wasted on extracting 
data not required. The consistency of the data extracted should be assessed to make 
sure that those extracting the data are interpreting the forms, and the draft instructions 
and decision rules about coding data, in the same way. This will help to reduce data 
extraction errors. The exporting, analysis and outputs of the data extraction forms 
should also be pilot tested where appropriate, on a small sample of included studies. 
This will ensure that the exporting of data works correctly and the outputs provide the 
information required for data analysis and synthesis.
When using databases, piloting is particularly important as it becomes increasingly 
diffi cult to make changes once the template has been created and information has been 
entered into the database. Early production of the expected output is also the best way 
to check that the correct data structure has been set up.
1.3.3.5 Process of data extraction
Data extraction needs to be as unbiased and reliable as possible, however it is 
prone to human error and often subjective decisions are required. The number of 
researchers that will perform data extraction is likely to be infl uenced by constraints 
on time and resources. Ideally two researchers should independently perform the 
data extraction (the level of inter-rater agreement is often measured using a Kappa 
statistic58). As an accepted minimum, one researcher can extract the data with a 
second researcher independently checking the data extraction forms for accuracy and 
completeness. This method may result in signifi cantly more errors than two researchers 
independently performing data extraction but may also take signifi cantly less time.69 
Any disagreements should be noted and resolved by consensus among researchers 
or by arbitration by an additional independent researcher. A record of corrections or 
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Box 1.4  Example information requirements for data extraction
General information
Researcher performing data extraction
Date of data extraction
Identifi cation features of the study:
Record number (to uniquely identify study)
Author
Article title
Citation
Type of publication (e.g. journal article, conference abstract)
Country of origin
Source of funding
Study characteristics
Aim/objectives of the study
Study design
Study inclusion and exclusion criteria
Recruitment procedures used (e.g. details of randomisation, blinding)
Unit of allocation (e.g. participant, GP practice, etc.)
Participant characteristics
Characteristics of participants at the beginning of the study e.g.
Age
Gender
Ethnicity
Socio-economic status
Disease characteristics
Co-morbidities
Number of participants in each characteristic category for intervention and control 
group(s) or mean/median characteristic values (record whether it is the number 
eligible, enrolled, or randomised that is reported in the study)
amendments to data extraction forms should be kept for future reference, particularly 
where there is genuine ambiguity (internal inconsistency) which cannot be resolved 
after discussion with the study authors. If using an electronic data extraction form 
that does not keep a record of amendments, completed forms can be printed and 
amendments recorded manually, before correcting the electronic version.
As with screening studies for inclusion, blinding researchers to the journal and author 
details has been recommended.70, 71 However, this is a time-consuming operation, may 
not alter the results of a review and is likely to be of limited value.61
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Intervention and setting
Setting in which the intervention is delivered
Description of the intervention(s) and control(s) (e.g. dose, route of 
administration, number of cycles, duration of cycle, care provider, how the 
intervention was developed, theoretical basis (where relevant))
Description of co-interventions
Outcome data/results
Unit of assessment/analysis
Statistical techniques used
For each pre-specifi ed outcome:
Whether reported
Defi nition used in study
Measurement tool or method used
Unit of measurement (if appropriate)
Length of follow-up, number and/or times of follow-up measurements
For all intervention group(s) and control group(s):
Number of participants enrolled
Number of participants included in analysis
Number of withdrawals, exclusions, lost to follow-up
Summary outcome data e.g.
Dichotomous: number of events, number of participants
Continuous: mean and standard deviation
Type of analysis used in study (e.g. intention to treat, per protocol)
Results of study analysis e.g.
Dichotomous: odds ratio, risk ratio and confi dence intervals, p-value
Continuous: mean difference, confi dence intervals
If subgroup analysis is planned the above information on outcome data or results 
will need to be extracted for each patient subgroup
Additional outcomes
Record details of any additional relevant outcomes reported
Costs
Resource use
Adverse events
NB: Notes fi elds can be useful for occasional pieces of additional information or 
important comments that do not easily fi t into the format of other fi elds.
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Reviews that include only published studies may be at risk of overestimating the 
treatment effect. Including data from unpublished studies (or unpublished outcomes) 
is therefore important in minimizing bias. However, this can be time-consuming and 
the original data may no longer be available. Although those performing IPD meta-
analyses,72 have generally been successful in obtaining data from the authors of 
unpublished studies, the same may not be true of other types of review. The practical 
diffi culties of locating and obtaining information from unpublished studies may, for 
example, make the ideal of including relevant unpublished studies unachievable in 
the timescales available for many commissioned reviews. When information from 
unpublished studies is obtained, the published and unpublished material should be 
subjected to the same methodological evaluation.
Summary: Data extraction
• Standardised data extraction forms provide consistency in a systematic 
review, thereby potentially reducing bias, improving validity and reliability.
• Data extraction forms should be designed and developed with both the review 
question and subsequent analysis in mind. Suffi cient time should be allocated 
early in the project for developing and piloting the data extraction forms.
• The data extraction forms should contain only information required 
for descriptive purposes or for analyses later in the systematic review. 
Information on study characteristics should be suffi ciently detailed to allow 
readers to assess the applicability of the fi ndings to their area of interest.
• Data extraction needs to be unbiased and reliable, however it is prone to 
human error and often subjective decisions are required. Clear instructions 
and decision rules about coding data should be used.
• As a minimum, one researcher should extract the data with a second 
researcher independently checking the data extraction forms for accuracy and 
detail. If disagreements occur between assessors, they should be resolved 
according to a predefi ned strategy using consensus and arbitration as 
appropriate.
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1.3.4 Quality assessment
1.3.4.1 Introduction
Research can vary considerably in methodological rigour. Flaws in the design or conduct 
of a study can result in bias, and in some cases this can have as much infl uence on 
observed effects as that of treatment. Important intervention effects, or lack of effect, 
can therefore be obscured by bias.
Recording the strengths and weaknesses of included studies provides an indication of 
whether the results have been unduly infl uenced by aspects of study design or conduct 
(essentially the extent to which the study results can be ‘believed’). Assessment of 
study quality gives an indication of the strength of evidence provided by the review 
and can also inform the standards required for future research. Ultimately, quality 
assessment helps answer the question of whether the studies are robust enough to 
guide treatment, prevention, diagnostic or policy decisions.
Many useful books discuss the sources of bias in different study designs in detail, or 
provide an in-depth guide to critical appraisal.73-75 No single approach to assessing 
methodological quality is appropriate to all systematic reviews. The best approach will 
be determined by contextual, pragmatic and methodological considerations. However, 
the following sections describe the underlying principles of quality assessment and the 
key issues to consider.
1.3.4.2 Defi ning quality
Quality is a complex concept and the term is used in different ways. For example, 
a project using the Delphi consensus method with experts in the fi eld of quality 
assessment of RCTs was unable to generate a defi nition of quality acceptable to all 
participants.76
Taking a broad view, the aim of assessing study quality is to establish how near the 
‘truth’ its fi ndings are likely to be and whether the fi ndings are of relevance in the 
particular setting or patient group of interest. Quality assessment of any study is likely 
to consider the following:
• Appropriateness of study design to the research objective
• Risk of bias
• Other issues related to study quality
• Choice of outcome measure
• Statistical issues
• Quality of reporting
• Quality of the intervention
• Generalisability
The importance of each of these aspects of quality will depend on the focus and nature 
of the review. For example, issues around statistical analysis are less important if 
the study data are to be re-analysed in a meta-analysis, and the quality of reporting 
is irrelevant where data (either individual patient or aggregate) and information are 
obtained directly from those responsible for the study.
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Appropriateness of study design
As discussed previously, types of study used to assess the effects of interventions can 
be arranged into a hierarchy, based broadly on their susceptibility to bias (Box 1.3). 
Although the RCT is considered the best study design to evaluate the effect of an 
intervention, in cases where it is unworkable or unethical to randomise participants (e.g. 
when evaluating the effects of smoking on health), researchers may instead have to 
use a quasi-experimental or an observational design. Simply grading studies using this 
hierarchy does not provide an adequate assessment of study quality, because it does 
not take into account variations in quality among studies of the same design. Even RCTs 
can be implemented in such a way that fi ndings are likely to be seriously biased and 
therefore of little value in decision-making.
It should be noted that the terminology used to describe study designs (e.g. cohort, 
prospective, retrospective, historical controls, etc.) can be ambiguous and used in 
different ways by different researchers. Therefore it is important to consider the 
individual aspects of the study design that may introduce bias rather than focussing 
on the descriptive label used. This is particularly important for the description of non-
randomised studies.
Risk of bias
Bias refers to systematic deviations from the true underlying effect brought about by 
poor study design or conduct in the collection, analysis, interpretation, publication or 
review of data. Bias can easily obscure intervention effects, and differences in the risk 
of bias between studies can help explain differences in fi ndings.
Internal validity is the extent to which an observed effect can be truly attributed to the 
intervention being evaluated, rather than to fl aws in the design or conduct of the study. 
Any such fl aws can increase the risk of bias.
The types of bias, and the ways in which they can be minimized by each type of study 
design, are described below.
Randomised controlled trials
The RCT is generally considered to be the most appropriate study design for evaluating 
the effects of an intervention. This is because, when properly conducted, it limits 
the risk of bias. The simplest form of RCT is known as the parallel group trial which 
randomises eligible participants to two or more groups, treats according to assignment, 
and compares the groups with respect to outcomes of interest.
Participants are allocated to groups using both randomisation (allocation involves the 
play of chance) and concealment (ensures that the intervention that will be allocated 
cannot be known in advance of assignment). When appropriately implemented, these 
aspects of design should ensure that the groups being compared are similar in all 
respects other than the intervention. The groups should be balanced for both known 
and unknown factors that might infl uence outcome, such that any observed differences 
should be attributable to the effect of the intervention rather than to intrinsic differences 
between the groups.
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Allocation in this way avoids the infl uence of confounding, where an additional factor is 
associated both with receiving the intervention and with the outcome of interest. For 
example, babies who are breast fed are less likely to have gastrointestinal illnesses than 
those who are bottle fed. Though this might suggest evidence for the protective effect of 
breastfeeding, mothers who breast feed also tend to be of higher socio-economic status, 
which in itself is associated with a range of health benefi ts to the baby. Therefore, 
when evaluating any possible protective effects of breastfeeding socio-economic status 
should be considered as a potential confounding factor. In some cases, the possible 
confounding factor(s) may not be known or measurable. In an RCT, so long as a 
suffi cient number of participants are assigned then the groups should be balanced with 
respect to both known and unknown potential confounding factors.
Selection bias or allocation bias occurs where there are systematic differences between 
comparison groups in terms of prognosis or responsiveness to treatment. Concealed 
assignment prevents investigators being able to predict which intervention will be 
allocated next and using that information to select which participant receives which 
treatment. For example, clinicians may want to ’try out‘ the new intervention in patients 
with a poorer prognosis. If they succeed in doing this by knowing or correctly ‘guessing’ 
the order of allocation, the intervention group will eventually contain more seriously ill 
participants than the comparison group, such that the intervention will probably appear 
less effective than if the two groups had been properly balanced.
The most robust method for concealing the sequence of treatment allocation is a central 
telephone randomisation service, in which the care provider calls an independent trial 
service, registers the participant’s details and then discovers which intervention they 
are to be given. Similarly, an on-site computer-based randomisation system that is not 
readable until the time of allocation might be used. Envelope methods of randomisation, 
where allocation details are stored in pre-prepared envelopes, are less robust and 
more easily subverted than centralised methods. Where this method is adopted, sealed 
opaque sequentially numbered envelopes that are only opened in front of the participant 
being randomised should be used. Unfortunately, the methods which are used to ensure 
that the randomisation sequence remains concealed during implementation (frequently 
referred to as concealment of allocation) are often poorly reported making it diffi cult to 
discern whether the methods were susceptible to bias.
Some studies, which may describe themselves as randomised, may allocate participants 
to groups on an alternating basis, or based on whether their date of birth is an odd or 
even number. Allocation in these studies is neither random nor concealed.
Performance bias refers to systematic differences (apart from the intervention of 
interest) in the treatment or care given to comparison groups during the study and 
detection bias refers to systematic differences between groups in the way that outcomes 
are ascertained. The risk of these biases can be minimized by ensuring that people 
involved in the study are unaware of which groups participants have been assigned 
to (i.e. they are blinded or masked). Ideally, the participants, those administering the 
intervention, those assessing outcomes and those analysing the data should all be 
blinded. If not, the knowledge of which comparison group is which may consciously 
or unconsciously infl uence the behaviour of any of these people. The feasibility and/
or success of blinding will partly depend on the intervention in question. There are 
situations where blinding is not possible owing to the nature of the intervention, for 
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example where a particular intervention has an obvious physiological effect whereas the 
comparator does not, and others where it may be unethical (e.g. sham surgery carries 
risks with no intended benefi t). Methods of blinding for studies of drugs involve the use 
of pills and containers of identical size, shape and number (placebos). Sham devices 
can be used for many device interventions and for some procedural interventions sham 
procedures can be used (e.g. sham acupuncture). Blinding of outcome assessors is 
particularly important for more subjective outcome measures such as pain, but less 
important for objective measures such as mortality. Implementation of a blinding 
process does not however guarantee successful blinding in practice. In study reports, 
terms such as double-blind, triple-blind or single-blind can be used inconsistently77 and 
explicit reporting of blinding is often missing.78 It is important to clarify the exact details 
of the blinding process.
A well-conducted RCT should have processes in place to achieve complete and good 
quality data,79 in order to avoid attrition bias. Attrition bias refers to systematic 
differences between the comparison groups in terms of participants withdrawing or 
being excluded from the study. Participants may withdraw or drop-out from a study 
because the treatment has intolerable adverse effects, or on the other hand, they may 
recover and leave for that reason. They may simply be lost to follow-up, or they may be 
withdrawn due to a lack of data on outcome measures. Other reasons that participants 
may be excluded include mistaken randomisation of participants who, on review, did not 
meet the study inclusion criteria, and participants receiving the wrong intervention due 
to protocol violation. The likely impact of such withdrawals and exclusions needs to be 
considered carefully; if the exclusion is related to the intervention and outcome then it 
can bias the results (for example, not accounting for high numbers of withdrawals due 
to adverse effects in one intervention arm will unduly favour that intervention). Serious 
bias can arise as a result of participants being withdrawn for apparently ad hoc reasons 
that are related to the success or failure of an intervention. There is evidence from the 
fi eld of cancer research that exclusion of patients from the analysis may bias results,80 
though how this may apply to other fi elds is unclear. An intention to treat (ITT) analysis 
is generally recommended in order to reduce the risk of bias.
An ITT analysis includes outcome data on all trial participants and analyses them 
according to the intervention to which they were randomised, regardless of the 
intervention(s) they actually received. Complete outcome data are often unavailable 
for participants who drop-out before the end of the trial, so in order to include all 
participants, assumptions need to be made about their missing outcome data (for 
example by imputation of missing values). ITT analysis generally provides a more 
conservative, and potentially less biased, estimate in trials of effectiveness (see Section 
1.3.5.2 Quantitative synthesis of comparative studies). However, ITT analyses are often 
poorly described and applied81 and if assessing methodological quality associated with 
statistical analysis, care needs to be taken in judging whether the use of ITT analysis 
has minimized the risk of attrition bias and whether it was appropriately applied. If 
an ITT analysis is not used, then the study should at least report the proportion of 
participants excluded from the analysis to allow a researcher to judge whether this is 
likely to have led to bias.
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The minimum criteria for assessment of risk of bias in RCTs are set out in Box 1.5. While 
all these criteria are relevant to assessing risk of bias, their relative importance can 
be context specifi c. For example, the importance of blinded outcome assessment will 
vary depending on whether the outcomes involve subjective judgement (this may vary 
between different outcomes measured within the same trial). Therefore, when planning 
which criteria to use it is important to think carefully about what characteristics would 
realistically be considered ideal. The Cochrane handbook provides a detailed assessment 
tool for use when assessing risk of bias in an RCT.82
Box 1.5: Criteria for assessment of risk of bias in RCTs
• Was the method used to generate random allocations adequate?
• Was the allocation adequately concealed?
• Were the groups similar at the outset of the study in terms of prognostic 
factors, e.g. severity of disease?
• Were the care providers, participants and outcome assessors blind to 
treatment allocation? If any of these people were not blinded, what might be 
the likely impact on the risk of bias (for each outcome)?
• Were there any unexpected imbalances in drop-outs between groups? If so, 
were they explained or adjusted for?
• Is there any evidence to suggest that the authors measured more outcomes 
than they reported?
• Did the analysis include an intention to treat analysis? If so, was this 
appropriate and were appropriate methods used to account for missing data?
Other randomised study designs
In addition to parallel group RCTs, there are other randomised designs where further 
quality criteria may need to be considered. These are described below.
Randomised cross-over trials
In randomised cross-over trials all participants receive all the interventions. For example 
in a two arm cross-over trial, one group receives intervention A before intervention B, 
and the other group receives intervention B before intervention A. It is the sequence 
of interventions that is randomised. The advantage of cross-over trials is that they are 
potentially more effi cient than parallel trials of a similar size, in which each participant 
receives only one of the interventions. The criteria for assessing risk of bias in RCTs also 
apply to cross-over trials, but there are some additional factors that need to be taken 
into consideration.
The cross-over design is inappropriate for conditions where the intervention may 
provide a cure or remission, where there is a risk of spontaneous improvement or 
resolution of the condition, where there is a risk of deterioration over the period of the 
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trial (e.g. degenerative conditions) or where there is a risk that patients may die.83 
This is because these outcomes lead either to the participant being unable to enter 
the second period or, on entering the second period, their condition is systematically 
different from that in the fi rst period.
The possibility of a ‘carryover’ of the effect of the intervention provided in the fi rst 
period into the second intervention period is an important concern in this study design.83 
This risk is dealt with by building in a treatment-free or placebo ‘washout period’ 
between the intervention periods.83 The adequacy of the washout period length will need 
to be considered as part of the assessment of risk of bias.
The statistical analysis appropriate to cross-over trials are discussed in the synthesis 
section and statistical advice is likely to be required (see Section 1.3.5 Data synthesis).
Cluster randomised trials
A cluster randomised trial is a trial where clusters of people rather than single 
individuals are randomised to different interventions.84 For example, whole clinics or 
geographical locations may be randomised to receive particular interventions, rather 
than individuals.
The distinctive feature of cluster trials is that the outcome for each participant within a 
cluster may not be independent, since individuals within the cluster are likely to respond 
in a similar way to the intervention. Underlying reasons for this intra-cluster correlation 
include individuals in a cluster being affected in a similar manner due to shared 
exposure to a common environment such as specifi c hospital policies on discharge 
times; or personal interactions between cluster members and sharing of attitudes, 
behaviours and norms that may lead to similar responses.84 This has implications for 
estimating the sample size required (i.e. the sample needs to be larger than for an 
individually randomised trial) and the statistical analysis.
When assessing the risk of selection bias in cluster randomised trials there are 
two factors that need to be considered: the randomisation of the clusters and how 
participants within clusters are selected into the study.85 The fi rst can be dealt with 
by using an appropriate randomisation method with concealed allocation (clusters are 
often allocated at the outset). However, where the trial design then requires selection 
of participants from within a cluster, the risk of selection bias should also be assessed. 
There is a clear risk of selection bias when the person recruiting participants knows 
in advance the clinical characteristics of a participant and which intervention they will 
receive. Also, potential participants may know in advance which intervention their 
cluster will receive, leading to different participation rates in the comparison groups.85 
Two key methods for reducing bias in the selection of individuals within clusters have 
been identifi ed: recruitment of individuals prior to the random allocation of clusters and, 
where this is not possible, use of an impartial individual to recruit participants following 
randomisation of the clusters.86
The statistical analyses appropriate to cluster randomised trials are discussed in Section 
1.3.5 Data synthesis and statistical advice is likely to be required.
Wider reading is recommended prior to conducting a quality assessment of cluster 
randomised trials. Several texts discuss the design, analysis and reporting of this trial 
design.75, 84, 87, 88
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Quasi-experimental studies
The main distinction between randomised and quasi-experimental studies is the way 
in which participants are allocated to the intervention and control groups; quasi-
experimental studies do not use random assignment to create the comparison groups.
In non-randomised controlled studies, individuals are allocated to concurrent 
comparison groups, using methods other than randomisation. The lack of concealed 
randomised allocation increases the risk of selection bias.
Before-and-after studies evaluate participants before and after the introduction of an 
intervention. The comparison is usually made in the same group of participants, thus 
avoiding selection bias, although a different group can be used. In this type of design 
however, it can be diffi cult to account for confounding factors, secular trends, regression 
to the mean, and differences in the care of the participants apart from the intervention 
of interest.
An alternative to this is a ‘time series’ design. Interrupted time series studies are 
multiple observations over time that are ‘interrupted’, usually by an intervention or 
treatment and thus permit separating real intervention effects from other long-term 
trends. It is a study design used where others, such as RCTs, are not feasible, for 
example in the evaluation of a screening service or a mass media campaign. It is also 
frequently used in policy evaluation, for example to measure the effect of a smoking 
ban.
The circumstances in which, and extent to which, studies without randomisation are 
at risk of bias are not fully understood.89 A key infl uencing factor may be the extent to 
which prognosis infl uences selection for a particular intervention as well as eventual 
outcome.89 Because of the risk of bias, careful consideration should be given to the 
inclusion of quasi-experimental studies in a review to assess the effectiveness of an 
intervention. If included, researchers should think carefully about the strength of this 
evidence and how it should be interpreted.
A review of quality assessment tools designed for or used to assess studies without 
randomisation identifi ed key aspects of quality as being particularly pertinent:89
• How the treatment groups were created (how allocation occurred; and whether 
the study was designed to generate groups that are comparable on key 
prognostic factors e.g. by ‘matching’ participants in each group).
• The comparability of intervention and comparison groups at the analysis stage. 
For example, whether prognostic factors were identifi ed; and whether case-mix 
adjustment was used to account for any between group differences.
Other quality issues identifi ed were similar to those for assessing performance, 
detection and attrition bias in RCTs: blinding of participants and investigators; the 
level of confi dence that the participants received the intervention to which they were 
assigned and experienced the reported outcome as a result of that intervention; the 
adequacy of the follow-up; and appropriateness of the analysis.
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Observational studies
In observational studies the intervention(s) that individuals receive are determined by 
usual practice or ‘real-world’ choices, as opposed to being actively allocated as part of 
the study protocol.
Observational studies are usually more susceptible to bias than experimental studies, 
and the conclusions that can be drawn from them are necessarily more tentative and 
are often hypothesis generating, highlighting areas for further research.
Observational designs such as cohort studies, case-control studies and case series 
are often considered to form a hierarchy of increasing risk of bias. However, such a 
hierarchy is not always helpful because, as noted before, the same label can be used 
to describe studies with different design features and there is not always agreement on 
the defi nitions of such studies. Attention should focus on specifi c features of the studies 
(e.g. participant allocation, outcome assessment) and the extent to which they are 
susceptible to bias.
In a cohort study design, a defi ned group of participants is followed over time and 
comparison is made between those who did and did not receive an intervention (e.g. 
a study may follow a cohort of women who choose to use oral contraceptives and 
compare them over time with women who choose other forms of contraception). 
Prospective cohort studies are planned in advance and defi ne their participants before 
the intervention of interest and follow them into the future. These are less likely to be 
susceptible to bias than retrospective cohort studies, which identify participants from 
past records and follow them from the time of that record.
Case-control studies compare groups from the same population with (cases) and 
without (controls) a specifi c outcome of interest, to evaluate the association between 
exposure to an intervention and the outcome. The risk of selection bias in such studies 
will be dependent on how the control group was selected. Groups may be matched 
to make them comparable for potential confounding factors. However, since analysis 
cannot be performed on matched variables, the matching criteria must be selected 
carefully, as this can give rise to ‘over-matching’ when the factors are related to 
allocation to the intervention.
Case series are observations made on a number of individuals (with no control group) 
and are not comparative. They can, however, provide useful information, for example 
about the unintentional effects of an intervention (see Chapter 4) and in such situations 
it is important to assess their quality.
Other issues related to study quality
Choice of outcome measure
As well as using blinding to minimize bias when assessing outcomes, it is usually 
necessary to consider the reliability or validity of the actual outcome measure being 
used (e.g. several different scales can be used to measure quality of life or psychological 
outcomes). It is important that the scales are fully understood to enable comparison, 
(e.g. a high score implies a favourable outcome in some scales and an unfavourable one 
in others).
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The outcome should also be relevant and meaningful to both the intervention and the 
evaluation (i.e. a treatment intended to reduce mortality should measure mortality, not 
merely a range of biochemical indicators).
Statistical issues
Although issues around statistical analysis are less important if the study data are 
to be combined in a meta-analysis, when studies are not being quantitatively pooled 
it is also important to assess statistical issues around design and analysis. For 
example, assessing whether a study is adequately powered to detect an effect of the 
intervention.90 The assessment of statistical power may involve relying on the sample 
size calculation in the primary study, where reported. However, defi ning population 
parameters for sample size calculations is a subjective judgement which may vary 
between investigators;91 for some review topics it may be appropriate to defi ne a priori 
an adequate sample size for the purposes of the review.
Quality of reporting
Inadequate reporting of important aspects of methodological quality such as allocation 
concealment, blinding and statistical analysis is common,92 as is failure to report detail 
about the intervention and its implementation. Quality of reporting does not necessarily 
refl ect the quality of the underlying methods or data, but when planning quality 
assessment it is important to decide how to deal with poor reporting. One approach is 
to assume that if an item is not reported then the criterion has not been met. While 
this may often be justifi able,93, 94 there is evidence to suggest that failure to report a 
method does not necessarily mean it has not been used.95-97 Therefore it is important 
to be accurate and distinguish between failure to report a criterion and failure to meet 
a criterion. For example, a criterion can be described as being met, not met, or unclear 
due to inadequate reporting.
There have been a number of initiatives aimed at improving the quality of reporting 
of primary research. The CONSORT statement contains a set of recommendations for 
the reporting of RCTs,98 the TREND statement provides guidelines for the reporting of 
non-randomised evaluations of behavioural and public health interventions,99 and the 
STROBE statement is an initiative to improve reporting of observational studies.100 The 
EQUATOR network promotes the transparent and accurate reporting of health research 
in a number of ways, including the use of these consensus reporting guidelines.101 It is 
anticipated that implementation of these guidelines will help improve the standard of 
reporting, which should make quality assessment more straightforward.
Quality of the intervention
In addition to study design, it is often helpful to assess the quality of the intervention and 
its implementation. At its most simplistic, the quality of an intervention refers to whether 
it has been used appropriately. This is a fairly straightforward assessment where, for 
example drug titration studies have been conducted. It is more problematic where there 
is no preliminary research suggesting that an intervention should be administered in a 
particular way,102 or where the intervention requires a technical skill such as surgery or 
physiotherapy.103 It is important to establish to what extent these are standardised, as this 
will affect how the results should be interpreted.
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The quality of the intervention is particularly relevant to complex interventions made up 
from a number of components, which act independently and inter-dependently.104, 203, 204 
These include clinical interventions such as physiotherapy as well as public health 
interventions such as community-based programmes. The quality of an intervention can 
be conceptualised as having two main aspects: (i) whether the intervention has been 
appropriately defi ned and (ii) whether it has been delivered as planned (the integrity or 
fi delity of the intervention).
If the quality of the intervention is relevant, the review should assess whether the 
intervention was implemented as planned in the individual studies (i.e. how many 
participants received the intervention as planned, whether consistency of implementation 
was measured, and whether it is likely that participants received an unintended 
intervention/contamination of the intervention that may infl uence the results). In some 
topic areas, for example when a sham device or procedure is being used, it may also be 
relevant to assess the quality of the comparator. When an intervention relies on the skill of 
the care provider it may be useful to assess whether the performance of those providing 
the intervention was measured. For more detailed information on complex interventions 
see Chapter 3.
Generalisability
Generalisability, also known as applicability or external validity, is not considered 
in detail in this section. In addition to assessing the risk of bias (internal validity), 
researchers may also consider how closely a study refl ects routine practice or the usual 
setting where the intervention would be implemented. However, this is not an inherent 
characteristic of a study as the extent to which a study is ‘generalisable’ depends 
also on the situation to which the fi ndings are being applied.105 Therefore the issue 
of generalisability is also raised in Section 1.2 The review protocol in the context of 
defi ning inclusion criteria for the review, Section 1.3.3 Data extraction and in Section 
1.3.6 Report writing.
1.3.4.3 The impact of study quality on the estimate of effect
Several empirical studies have explored how quality can infl uence the results of 
clinical trials (and therefore the results of reviews of trials). Trials with double-blinding 
and adequate concealment of allocation have been found to indicate less benefi cial 
treatment effects than trials without these features.106 Similarly, exclusion of lower 
quality studies has led to less benefi cial effects in meta-analyses.106 In meta-analyses of 
subjectively assessed outcomes (e.g. patient reported outcomes), inadequate allocation 
concealment and lack of blinding have been associated with substantially more 
benefi cial treatment effects, whereas for objective outcomes (e.g. mortality) there was 
a modest effect of inadequate allocation concealment and no effect of lack of blinding.107 
There is some evidence about the relationship between study quality and the estimate 
of effect that is contradictory to the above,108, 109 though this may be due to the data 
sets used and how specifi c quality criteria were defi ned.
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1.3.4.4 The process of quality assessment in systematic reviews
There are two main approaches towards assessing quality. One involves the use of 
checklists of quality items and the other of scales which provide an overall numerical 
quality score for each study.110
Tools for assessing quality
Checklists can be a reliable means of ensuring that all the studies assessed are critically 
appraised in a standardised way. There are many different checklists and scales readily 
available, 75, 111-116 which can be modifi ed to meet the requirements of the review, or a 
new detailed checklist, specifi c to the review, may be developed.
Because some items included may require a degree of subjective judgement, it is 
important to pilot the use of the checklist and to ensure that the quality assessment is 
undertaken independently by two researchers.
The use of scales with summary scores to distinguish high and low quality studies is 
questionable and not recommended.117, 118 Very few scales have been developed using 
standard techniques to establish their validity and reliability.113 The weighting assigned 
to methodological items varies considerably between scales,117 and does not usually take 
into account the direction of bias.119 An investigation comparing low-molecular-weight 
heparin (LMWH) with standard heparin for thromboprophylaxis in general surgery found 
that trials identifi ed as ‘high quality’ by some of the 25 scales investigated indicated that 
LMWH was not superior to standard heparin, whereas trials identifi ed as ‘high quality’ by 
other scales led to the opposite conclusion, that LMWH was benefi cial.117 It is therefore 
preferable that aspects of quality such as blinding and treatment allocation (and their 
potential impact on study results) should be considered individually.117
Checklists by type of study design
In general checklists tend to be specifi c to particular study designs, and where reviews 
include more than one type of study design, separate lists can be used or a combined 
list selected or developed. Checklists have also been developed for use with both 
randomised and non-randomised studies such as that by Downs and Black.111
There are multiple systems available for the evaluation of RCTs,112, 113 in addition to the 
Cochrane handbook assessment tool for assessing risk of bias.82 In a review of checklists 
for the assessment of non-randomised studies, nearly 200 tools were identifi ed. From 
these, six were recommended as being suitable for use in systematic reviews including 
non-randomised studies.89 The Cochrane Effective Practice and Organisation of Care 
Group (EPOC) have developed guidelines to assist researchers in making decisions 
about when to include studies that use interrupted time series designs and how to 
assess their methodological quality.115, 116 A useful checklist for observational studies 
was published as part of the US Agency for Healthcare Research and Quality’s (AHRQ) 
‘Systems to Rate the Strength of Scientifi c Evidence’.112 The most recent version of the 
Cochrane Handbook also contains guidance on dealing with non-randomised studies in 
systematic reviews of interventions, from the protocol to synthesis stages.75
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How will the quality assessment information be used?
Simply reporting which quality criteria were met by studies included in a systematic 
review is not suffi cient. The implications of the quality assessment for interpreting 
results need to be explicitly considered.
Study quality can be incorporated into the synthesis either quantitatively through 
subgroup or sensitivity analyses (see Section 1.3.5.2: Quantitative synthesis), or in a 
narrative synthesis. In the latter, the quality assessment can be used to help interpret 
and explain differences in results across studies (e.g. unblinded studies with subjective 
outcomes may have consistently larger effects than blinded studies) and inform a 
qualitative interpretation of the risk of bias (see Section 1.3.5.1 Narrative synthesis).
Summary: Quality assessment
• An important part of the systematic review process is to assess the risk of 
bias in included studies caused by inadequacies in study design, conduct 
or analysis that may have led to the treatment effect being over or 
underestimated.
• Various tools are available but there is no single tool that is suitable for use in 
all reviews. Choice should be guided by:
• Study design
• The level of detail required in the assessment
• The ability to distinguish between internal validity (risk of bias) and external 
validity (generalisability)
• Using quality scores is problematic; it is preferable to consider individual 
aspects of methodological quality in the quality assessment and synthesis.
• Where appropriate, the potential impact that methodological quality had on 
the fi ndings of the included studies should be considered.
• Detailed quality assessment can be time consuming if a review includes a 
large number of studies and may require considerable expertise in critical 
appraisal. If resources are limited, priority should be given to assessment of 
the key sources of bias.
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1.3.5 Data synthesis
Synthesis involves the collation, combination and summary of the fi ndings of individual 
studies included in the systematic review. Synthesis can be done quantitatively using 
formal statistical techniques such as meta-analysis, or if formal pooling of results 
is inappropriate, through a narrative approach. As well as drawing results together, 
synthesis should consider the strength of evidence, explore whether any observed effects 
are consistent across studies, and investigate possible reasons for any inconsistencies. 
This enables reliable conclusions to be drawn from the assembled body of evidence.
Deciding what type of synthesis is appropriate
Many systematic reviews evaluating the effects of health interventions focus on 
evidence from RCTs, the results of which, generally, can be combined quantitatively. 
However, not all health care questions can be addressed by RCTs, and systematic 
reviews do not automatically involve statistical pooling. Meta-analysis is not always 
possible or sensible. For example, pooling results obtained from diverse non-randomised 
study types is not recommended.120 Similarly, meta-analysis of poor quality studies 
could be seriously misleading as errors or biases in individual studies would be 
compounded and the very act of synthesis may give credence to poor quality studies. 
However, when used appropriately, meta-analysis has the advantage of being explicit 
in the way that data from individual studies are combined, and is a powerful tool for 
combining study fi ndings, helping avoid misinterpretation and allowing meaningful 
conclusions to be drawn across studies.
The planned approach should be decided at the outset of the review, depending on the 
type of question posed and the type of studies that are likely to be available. There may 
be topics where it can be decided a priori that a narrative approach is appropriate. For 
example, in a systematic review of interventions for people bereaved by suicide, it was 
anticipated there would be such diversity in the included studies, in terms of settings, 
interventions and outcome measures, that a narrative synthesis alone was proposed in 
the protocol.121
Narrative and quantitative approaches are not mutually exclusive. Components 
of narrative synthesis can be usefully incorporated into a review that is primarily 
quantitative in focus and those that take a primarily narrative approach can incorporate 
some statistical analyses such as calculating a common outcome statistic for each study.
Initial descriptive synthesis
Both quantitative and narrative synthesis should begin by constructing a clear 
descriptive summary of the included studies. This is usually done by tabulating details 
about study type, interventions, numbers of participants, a summary of participant 
characteristics, outcomes and outcome measures. An indication of study quality or risk 
of bias may also be given in this or a separate table (see Section 1.3.2 Study selection 
and Section 1.3.4 Quality assessment). An example is given in Table 1.1. If the review 
will not involve re-calculating summary statistics, but will rather rely on the reported 
results of the author’s analyses, these may also be included in the table. The descriptive 
process should be both explicit and rigorous and decisions about how to group and 
tabulate data should be based on the review question and what has been planned in the 
protocol. This initial phase will also be helpful in confi rming that studies are similar and 
reliable enough to synthesise, and that it is appropriate to pool results.
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Table 1.1: Example table describing studies included in a systematic review of 
the effectiveness of drug treatments for attention defi cit hyperactivity disorder in 
children and adolescents. 122
Study Design Intervention – N Age  Duration Core outcomes
   (years) (weeks) 
Administered once C (5x) MPH (5 mg/day,   5–12 5 Core: no hyp; Abbreviated
daily   o.d.) – 45   CTRS: total score
Rapport, 1989  MPH (10 mg/day,    QoL: not reported
  o.d.) – 45   AE: not reported
  MPH (15 mg/day,    
  o.d.) – 45
DuPaul, 1993 C (5x) MPH (5 mg/day,  6–11 6 Core: No hyp; Abbreviated
  o.d.) – 31   CTRS: total score
  MPH (10 mg/day,    QoL: not reported
  o.d.) – 31   AE: not reported
  MPH (15 mg/day,    
  o.d.) – 31
Werry, 1980 C (3x) MPH (0.40 mg/kg,  5.5–12.5 4 Core: Conners’ Teacher
  o.d.) – 30   Questionnaire: hyperactivity; 
     Conners’ Parent 
     Questionnaire: hyperactivity
     QoL: CGI (physician)
     AE: weight
Administered two  C (4x) MPH (8.76 mg/  13–15 8 Core: CPRS: Hyperactivity
or more times daily  day, b.d.) – 11   Index; Conners’ Teacher
Brown, 1988     Hyperactivity Index; 
     ACTeRS: hyperactivity
     QoL: not reported
     AE: SERS (parents); weight
Fischer, 1991 C (3x) MPH (0.40 mg/ 2.4–17.2 3 Core: CPRS-R: Hyperactivity
  kg/day, b.d.) – 161   Index; CTRS-R: 
     hyperactivity index; 
     CTRS-R: hyperactivity
     QoL: not reported
     AE: CPRS-R: psychosomatic; 
     SERS (parents, teachers): 
     number of side-effects, 
     mean severity rating
Fitzpatrick, 1992 C (4x) MPH (10–15 mg/ 6.9–11.5 8 Core: Conners’ Hyperactivity
  day, b.d.) – 19   Index (parents and teacher); 
     TOTS: hyperactivity (parents 
     and teachers)
     QoL: no CGI; comments 
     ratings (parent/teacher)
     AE: STESS (parents); weight
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Study Design Intervention – N Age  Duration Core outcomes
   (years) (weeks) 
Fine, 1993 C (3x) MPH [0.30 mg/ 6–10 3 Core: not reported
  kg/day (unclear),    QoL: not reported
  b.d.] – 12   AE: side-effects 
     questionnaire
Hoeppner, 1997 C (3x) MPH (0.30 mg/ 6.1–18.2 4 Core: CPRS: Hyperactivity
  kg/day, b.d.) – 50   Index; CTRS: Hyperactivity 
     Index
     QoL: not reported
     AE: not reported
Handen, 1999 C (3x) MPH (12–15 mg/ 4–5.1 3 Core: CTRS: Hyperactivity
  day, max. 3x) – 11   Index; CTRS: hyperactivity
     QoL: not reported
     AE: Side Effects Checklist 
     (teachers, parents); mean 
     severity rating 0–6
Manos, 1999 C (4x) MPH (10 mg/  5–17 4 Core: no hyp; ASQ (parents
  day, b.d.) – 42   and teachers); ARS (parent)
     QoL: no CGI; composite 
     ratings (clinician)
     AE: Side Effects Behaviour 
     Monitoring Scale (parents)
Barkley, 2000 C (5x) MPH (10 mg/day,  12–17 5 Core: no hyp; ADHD Total
  b.d.) – 38   Parent/Teacher rating
     QoL: not reported
     AE: number and severity of 
     side-effects (teachers, 
     parents, self)
Tervo, 2002 C (3x) MPH (0.10 mg/ M=9.9 3 Core: no hyp; CBCL (parent)
  kg/day, b.d.) – 41 (2.9)  QoL: not reported
     AE: not reported
ACTeRS, ADD-H Comprehensive Teachers’ Rating Scale; AE, adverse effects; ARS, ADHD Rating Scale; 
ASQ, Abbreviated Symptoms Questionnaire; b.d., twice daily; C, cross-over trial (number of cross-
overs); CBCL, Child Behaviour Checklist; CGI, Clinical Global Impression; CPRS, Conners’ Parent Rating 
Scale; CTRS, Conners’ Teacher Rating Scale; MPH, methylphenidate hydrochloride; N, number of 
participants; o.d., once daily; P, parallel trial; hyp, hyperactivity; PACS, Parental Account of Childhood 
Symptoms; SERS, Side Effects Rating Scale.
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1.3.5.1 Narrative synthesis
All systematic reviews should contain text and tables to provide an initial descriptive 
summary and explanation of the characteristics and fi ndings of the included studies. 
However simply describing the studies is not suffi cient for a synthesis. The defi ning 
characteristic of narrative synthesis is the adoption of a textual approach that provides 
an analysis of the relationships within and between studies and an overall assessment of 
the robustness of the evidence.
A narrative synthesis of studies may be undertaken where studies are too diverse 
(either clinically or methodologically) to combine in a meta-analysis, but even where a 
meta-analysis is possible, aspects of narrative synthesis will usually be required in order 
to fully interpret the collected evidence.
Narrative synthesis is inherently a more subjective process than meta-analysis; 
therefore, the approach used should be rigorous and transparent to reduce the potential 
for bias. The idea of narrative synthesis within a systematic review should not be 
confused with broader terms like ‘narrative review’, which are sometimes used to 
describe reviews that are not systematic.
A general framework for narrative synthesis
How narrative syntheses are carried out varies widely, and historically there has been a 
lack of consensus as to the constituent elements of the approach or the conditions for 
establishing credibility. A project for the Economic and Social Research Council (ESRC) 
Methods Programme has developed guidance on the conduct of narrative synthesis in 
systematic reviews.123-126 The guidance offers both a general framework and specifi c 
tools and techniques that help to increase the transparency and trustworthiness of 
narrative synthesis.
The general framework consists of four elements:
• Developing a theory of how the intervention works, why and for whom
• Developing a preliminary synthesis of fi ndings of included studies
• Exploring relationships within and between studies
• Assessing the robustness of the synthesis
Though the framework is divided into these four elements, the elements themselves 
do not have to be undertaken in a strictly sequential manner, nor are they totally 
independent of one another. A researcher is likely to move iteratively among the 
activities that make up these four elements.
For each element of the framework, this guidance presents a range of practical tools and 
techniques. It is not mandatory (or indeed appropriate) to employ each one of these 
for every narrative synthesis, but the appropriate tools/techniques should be selected 
depending upon the nature of the evidence being synthesised. The reason for the choice 
of tool or technique should be specifi ed in the methods section of the review.
A fuller description of these tools and techniques and narrative synthesis in general can 
be found in the ESRC guidance report.125, 126 It should be noted that the list given here 
is not comprehensive and other tools and techniques may be appropriate in certain 
circumstances.
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The four elements of the narrative synthesis framework (and some of their related tools 
and techniques) are described below (Figure 1.2).126
Figure 1.2: Example of applying the narrative synthesis framework
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Developing a theory of how the intervention works, why and for whom
The extent to which theory will play a role will partly depend upon the type of 
intervention(s) being evaluated. For example, theory may only play a minor role in 
a systematic review looking at the effects of a single therapeutic drug on patient 
outcomes because many aspects of the ‘mechanism of action’ will have been established 
in early studies investigating pharmacodynamics, dose-fi nding etc. Alternatively, in a 
systematic review evaluating the effects of a psychosocial or educational programme, 
theories about the causal chain linking the intervention to the outcomes of interest will 
be of crucial importance and might be presented descriptively or in diagrammatic form, 
as displayed in Figure 1.3.
Figure 1.3: Interventions to increase use and function of smoke alarms: implicit 
theory of change model
Reduction in smoke/fire related deaths/injuries
Removes cost
barrier
Alarm acquisition
Alarm use and function
Removes
‘effort’ barrier
Increases
knowledge
Changes perception
of risks
Discounted/free alarms
and safety equipment
Safety education
Developing a preliminary synthesis of fi ndings of included studies
Once the relevant studies have been data extracted, the fi rst step is to bring together, 
organise and describe their fi ndings. The direction and size of the reported effects may 
be the starting point. Or, for example, a collection of studies evaluating one kind of 
intervention might be divided into subgroups of studies with distinct populations, such 
as children and adults. It is important to remember that this is only the fi rst step of 
the synthesis. The remaining elements of the framework need to be taken into account 
before it can be considered adequate as a narrative synthesis.
Table 1.2 describes a range of tools and techniques that might be employed at this 
stage of the synthesis.
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Table 1.2: Developing a preliminary synthesis of fi ndings of included studies
Textual descriptions of studies A descriptive paragraph on each included study. These 
 descriptions should be produced in a systematic way, including 
 the same type of information for all studies if possible and in the 
 same order. It may be useful for recording purposes to do this 
 for all excluded studies as well.
Groupings and clusters The included studies might be grouped at an early stage of the 
 review, though it may be necessary to refi ne these initial groups 
 as the synthesis develops. This can also be a useful way of 
 aiding the process of description and analysis and looking 
 for patterns within and across groups. It is important to use the 
 review question(s) to inform decisions about how to group the 
 included studies.
Tabulation A common approach, used to represent data visually. The way 
 in which data are tabulated may affect readers’ impressions of 
 the relationships between studies, emphasising the importance 
 of a narrative interpretation to supplement the tabulated data.
Transforming data into a  In both narrative and quantitative synthesis it is important to
common measure ensure that data are presented in a common measure to allow 
 an accurate description of the range of effects.
Vote-counting as a descriptive  Simple vote-counting might involve the tabulation of fi ndings
tool according to direction of effect. More complex approaches
 can be developed both in terms of the categories used and by 
 assigning different weights or scores to different categories. 
 However, vote-counting can disregard sample size and be 
 misleading. So, the interpretation of the results must be 
 approached with caution and subjected to further scrutiny.
Translating data: thematic  A technique used in the analysis of qualitative data in primary
analysis research can be used to systematically identify the main, 
 recurrent and/or most important (based on the review question) 
 themes and/or concepts across multiple studies.127
Translating data: content  A technique for compressing many words of text into fewer
analysis content categories based on explicit rules of coding.128 Unlike 
 thematic analysis, it is essentially a quantitative method, since 
 all the data are eventually converted into frequencies.
Exploring relationships within and between studies
Patterns emerging from the data during the preliminary synthesis need to be rigorously 
scrutinised in order to identify factors that might explain variations in the size/direction 
of effects. At this stage there is a clear attempt to explore relationships between: (a) 
characteristics of individual studies and their reported fi ndings; and (b) the fi ndings of 
different studies.
However, when exploring heterogeneity in this way, it is necessary to be wary of 
uncovering associations between characteristics and results that are based on 
comparisons of many subgroups – some of these may simply have occurred by chance. 
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Subgroup comparisons which are specifi ed in advance (i.e. as part of the review 
protocol) are more likely to be plausible than those which are not.129, 130
The extent to which these factors can be explored in the review depends on how clearly 
they are reported in the primary research studies. The amount of detail may depend on 
the type of publication and the nature of the intervention being reviewed (e.g. highly 
standardised interventions may not be described as fully as more unusual ones).
Tools and techniques that might be employed at this stage of the synthesis are 
described in Table 1.3.
Table 1.3: Exploring relationships within and between studies
Graphs, frequency  There are several visual or graphical tools that can help
distributions, funnel plots,  reviewers explore relationships within and between studies. 
forest plots and L’Abbe plots These include: presenting results in graphical form; plotting 
 fi ndings (e.g. effect size) against study quality; plotting 
 confi dence intervals; and/or plotting outcome measures.
Moderator variables and  This refers to the analysis of variables which can be expected to 
subgroup analyses  moderate the main effects being examined in the review. This 
 can be done at the study level, by examining characteristics 
 that vary between studies (such as study quality, study design 
 or study setting) or by analysing characteristics of the sample 
 (such as subgroups of participants).
Idea webbing and conceptual  Involves using visual methods to help to construct groupings 
mapping and relationships. The basic idea underpinning these approaches 
 is (i) to group fi ndings that are empirically and/or conceptually 
 similar and (ii) to identify (again on the basis of empirical 
 evidence and/or conceptual/theoretical arguments) relationships 
 between these groupings.
Qualitative case descriptions Any process in which descriptive data from studies included in 
 the systematic review are used to try to explain differences 
 in statistical fi ndings. For example why one intervention 
 outperforms another apparently similar intervention or why 
 some studies are statistical outliers.
Investigator/methodological/  Triangulation makes use of a combination of different 
conceptual triangulation perspectives and/or assessment methods to study a particular 
 phenomenon. This could apply to the methodological and 
 theoretical approaches adopted by the researchers undertaking 
 primary studies included in a systematic review, e.g. 
 investigator triangulation explores the extent to which 
 heterogeneity in study results may be attributable to the diverse 
 approaches taken by different researchers. Triangulation 
 involves analysing the data in relation to the context in which 
 they were produced, notably the disciplinary perspectives and 
 expertise of the researchers producing the data.
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Assessing the robustness of the synthesis
Towards the end of the synthesis process, the analysis of relationships as described 
above should lead into an overall assessment of the strength of the evidence. This is 
essential when drawing conclusions based on the narrative synthesis.
Robustness can relate to the methodological quality of the included studies (such as 
risk of bias), and/or the credibility of the product of the synthesis process. Obviously, 
these are related. The credibility of a synthesis will depend on both the quality and 
the quantity of the evidence base it is built on, and the method of synthesis and the 
clarity/transparency of its description. If primary studies of poor methodological quality 
are included in the review in an uncritical manner then this will affect the integrity of 
the synthesis. Attempts to minimize the introduction of bias might include ‘weighting’ 
the fi ndings of studies according to technical quality (i.e. giving greater credence to the 
fi ndings of more methodologically sound studies) and providing a clear justifi cation for 
this. Similarly, a clear description of the potential sources of bias within the synthesis 
process itself helps establish credibility with the reader.
Table 1.4 describes the tools and techniques that might be employed at this stage of the 
synthesis.
Table 1.4: Assessing the robustness of the synthesis
Use of validity assessment Use of specifi c rules to defi ne weak, moderate or good evidence. 
 An example is the approach used by the US Centers for Disease 
 Control and Prevention131 although there are many other 
 evidence grading systems available. Decisions about the 
 strength of evidence are explicit although the criteria used are 
 often debated.
Refl ecting critically on the  Use of a critical discussion to address methodology of the
synthesis process synthesis used132 (especially focusing on its limitations and 
 their potential infl uence on the results); evidence used (quality, 
 validity, generalisability) – with emphasis on the possible 
 sources of bias and their potential infl uence on results of the 
 synthesis; assumptions made; discrepancies and uncertainties 
 identifi ed; expected changes in technology or evidence 
 (e.g. identifi ed ongoing studies); aspects that may have an 
 infl uence on implementation and effectiveness in real settings. 
 Such a discussion would provide information on both the 
 robustness and generalisability of the synthesis.
Checking the synthesis with  It is possible to consult with the authors of included primary 
authors of primary studies studies in order to test the validity of the interpretations 
 developed during the synthesis and the extent to which they are 
 supported by the primary data.133 The authors of the primary 
 studies may have useful insights into the possible accuracy 
 and generalisability of the synthesis; this is most likely to be 
 useful when the number of primary studies is small. This is a 
 technique that has been used with qualitative evidence.
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1.3.5.2 Quantitative synthesis of comparative studies
As with narrative synthesis, quantitative synthesis should be embedded in a review 
framework that is based on a clear hypothesis, should consider the direction and size 
of any observed intervention effects in relation to the strength of evidence, and should 
explore relationships within and between studies. The requirements for a careful and 
thoughtful approach, the need to assess the robustness of syntheses, and to refl ect 
critically on the synthesis process, apply equally but are not repeated here.
This section aims to outline the rationale for quantitative synthesis of comparative 
studies and to focus on describing commonly used methods of combining study results 
and exploring heterogeneity. A more detailed overview of quantitative synthesis for 
systematic review is given in the Cochrane Handbook.75 Comprehensive accounts 
are also given by Whitehead134 and Cooper and Hedges,135 and a discussion of recent 
developments and more experimental approaches is given in a paper by Sutton and 
Higgins.136
Decisions about which comparisons to make, and which outcomes and summary effect 
measures to use, should have been addressed as part of the protocol development. 
However, as synthesis depends partly on what results are actually reported, some 
planned analyses may not be possible, and others may have to be adapted or 
developed. Any departures from the analyses planned in the protocol should be clearly 
justifi ed and reported.
Decisions about what studies should and should not be combined are inevitably 
subjective and require careful discussion and judgement. As far as possible a priori 
consideration at the time of writing the protocol is desirable. There will always be 
differences between studies that address a common question. Reserving meta-
analyses for only those studies that evaluate exactly the same interventions in near 
identical participant populations would be severely limiting and seldom achievable in 
practice. For example, whilst it may not be sensible to average the results of studies 
using different classes of experimental drugs or comparators, it may be reasonable 
to combine results of studies that use analogues or drugs with similar mechanisms of 
action. Likewise, it will often be reasonable to combine results of studies that have used 
similar but not identical comparators (e.g. placebo and no treatment). Where there are 
substantial differences between studies addressing a broadly similar question, although 
combining their results to give an estimate of an average effect may be meaningless, 
a test of whether an overall effect is present might be informative. It can be useful to 
calculate summary statistics for each individual study to show the variability in results 
across studies. It may also be helpful to use meta-analysis methods to quantify this 
heterogeneity, even when combined estimates of effect are not produced.
Reasons for meta-analysis
Combining the results of individual studies in a meta-analysis increases power and 
precision in estimating intervention effects. In most areas of health care, ‘breakthroughs’ 
are rare and we may reasonably expect that new interventions will lead to only modest 
improvements in outcome; such improvements can of course be extremely important 
to individuals and of signifi cant benefi t in terms of population health. Large numbers 
of events are required to detect modest effects, which are easily obscured by the play 
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of chance, and studies are often too small to do so reliably. Thus, in any group of small 
trials addressing similar questions, although a few may have demonstrated statistically 
signifi cant results by chance alone, most are likely to be inconclusive. However, 
combining the results of studies in a meta-analysis provides increased numbers of 
participants, reduces random error, narrows confi dence intervals, and provides a greater 
chance of detecting a real effect as statistically signifi cant (i.e. increases statistical 
power). Meta-analysis also allows observation and statistical exploration of the pattern 
of results across studies and quantifi cation and exploration of any differences.
Combining comparative study results in a meta-analysis
Most meta-analyses take a two-step approach in that they fi rst analyse the outcome of 
interest and calculate summary statistics for each individual study. In the second stage, 
these individual study statistics are combined to give an overall summary estimate. 
This is usually calculated as a weighted average of the individual study estimates. The 
greater the weight awarded to a study, the more it infl uences the overall estimate. 
Studies are usually, at least in part, weighted in inverse proportion to their variance (or 
standard error squared), a method which essentially gives more weight to larger studies 
and less weight to smaller studies. It is also possible to weight studies according to 
other factors such as trial quality, but such methods are very seldom implemented and 
not recommended.
Two main statistical models are used. Fixed-effect models weight the contribution 
of each study proportional to the amount of information observed in the study. This 
considers only variability in results within studies and no allowance is made for variation 
between studies. Random-effects models allow for between-study variability in results 
by weighting studies using a combination of their own variance and the between-study 
variance. Where there is little between-study variability, the within-study variance will 
dominate and the random-effects weighting will tend towards that of the fi xed-effect 
weighting. If there is substantial between-study variability, this dominates the weighting 
factor and within-study variability contributes little to the analysis. In this way, all trials 
will tend towards contributing equally towards the overall estimate and it can be argued 
that small studies will unduly infl uence the estimate. Those in favour of random-effects 
argue that it formally allows for between-study variability and that the fi xed-effect 
approach unrealistically assumes a single effect across trials and gives over-precise 
estimates. In practice, with well-defi ned questions, the results of both approaches 
are often very similar and it is common to run both to test robustness of the choice of 
statistical model.
Generic inverse variance method of combining study results
The generic inverse variance method is a widely used and easy to implement method 
of combining study results that underlies many of the approaches that are described 
later. It is very fl exible and can be used to combine any type of effect measure provided 
that an effect estimate and its standard error is available from each study. Effect 
estimates may include adjusted estimates, estimates corrected for clustering and repeat 
measurements, or other summaries derived from more complex statistical methods.
A fi xed-effect meta-analysis using the generic inverse variance method calculates 
a weighted average of study effect estimates (EEIV) by summing individual effect 
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estimates (EEi), for example, the log odds ratio or the mean difference, and weighting 
these by the reciprocal of their squared standard errors (SEi) as follows:
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A random-effects approach involves adjusting the study specifi c standard errors to 
incorporate between-study variation, which can be estimated from the effects and 
standard errors associated with the included studies.138
Types of data
Other ways to combine studies of effectiveness are available, some of which are specifi c 
to the nature of the data that have been collected, analysed and presented in the 
included studies.
Box 1.6: Illustration of how to calculate risk ratio, relative and 
absolute risk reduction, and odds ratios and their standard errors
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Dichotomous/binary outcomes
Dichotomous outcomes are those that either happen or do not happen and an individual 
can be in one of only two states, for example having an acute myocardial infarction or 
not having an infarction. Dichotomous outcomes are most commonly expressed in terms 
of risks or odds. Although, in everyday use, the terms risk and odds are often used to 
mean the same thing, in the context of statistical evaluation they have quite specifi c 
meanings.
Risk describes the probability with which a health outcome will occur and is often 
expressed as a decimal number between 0.0 and 1.0, where 0.0 indicates that there is 
no risk of the event occurring, and 1.0 indicating certainty that the event will take place. 
A risk of 0.4 indicates that about four in ten people will experience the event. Odds 
describe the ratio of the probability that an event will happen to the probability that it 
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will not happen and can take any value between zero and infi nity. Odds are sometimes 
expressed as the ratio of two integers such that 0.001 can be written 1:1000 indicating 
that for every one individual who will experience the event, one thousand will not.
Risk ratios (RR), also known as relative risks, indicate the change in risk brought about 
by an intervention and are calculated as the probability of an event in the intervention 
group divided by the probability of an event in the control group (where the probability 
of an event is estimated by the total number of events observed in the group divided 
by the total number of individuals in that group). A risk ratio of 2.0 indicates that the 
intervention leads to the risk becoming twice that of the comparator. A risk ratio of 0.75 
indicates that the risk has been reduced to three quarters of that of the comparator. 
This can also be expressed in terms of a reduction in risk whereby the relative risk 
reduction (RRR) is given as one minus the risk ratio multiplied by 100. For example, a 
risk ratio of 2.0 corresponds to a relative risk reduction of –100% (a 100% increase), 
while a risk ratio of 0.75 corresponds to a relative risk reduction of 25%. Box 1.6 
illustrates the calculation of these measures and further details of the formulae can be 
found elsewhere.137
Risk ratios can be combined using the generic inverse variance method applied to the 
log risk ratio and its standard error (either in a fi xed effect or a random-effects model). 
Odds ratios (OR) describe the ratio of the odds of events occurring on treatment to the 
odds of events occurring on control, and therefore describes the multiplication of the 
odds of the outcome that occur with use of the intervention. Box 1.6 illustrates how 
to calculate the odds ratio for a single study. Odds ratios can be combined using the 
generic inverse variance method applied to the log odds ratio and its standard error as 
described above.
The Mantel-Haenszel method for combining risk ratios or odds ratios, which uses a 
different weighting scheme, is more robust when data are sparse, but assumes a fi xed 
effect model.137
The Peto odds ratio139 (ORPeto) is an alternative estimate of a combined odds ratio in a 
fi xed effect model, and is based on the difference between the observed number of events 
and the number of events that would be expected (O – E) if there was no difference 
between experimental and control interventions (see Box 1.6). Combining studies using 
the Peto method is straightforward, and it may be particularly useful for meta-analysis of 
dichotomous data when event rates are very low, and where other methods fail. 
PetoCombined
sum of ( ) across studies
OR exp
sum of ( ) across studies
O E
v
⎛ ⎞−
= ⎜ ⎟
⎝ ⎠
This approach works well when the effect is small (that is when the odds ratio is 
close to 1.0), events are relatively uncommon, and there are similar numbers in the 
experimental and control groups. The approach is commonly used to combine data from 
cancer trials which generally conform to these expectations. Correction for zero cells is 
not necessary (see below) and the method appears to perform better than alternative 
approaches when events are very rare. It can also be used to combine time-to-event 
data by pooling log rank observed minus expected (O – E) events and associated 
variance. However, the Peto method does give biased answers in some circumstances, 
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especially when treatment effects are very large, or where there is a lack of balance in 
treatment allocation within the individual studies.140 Such conditions will not usually apply 
to RCTs but may be particularly important when combining the results of observational 
studies which are often unbalanced.
Although both risk ratios and odds ratios are perfectly valid ways of describing a 
treatment effect, it is important to note that they are not the same measure, cannot 
be used interchangeably and should not be confused. When events are relatively rare, 
say less than 10%,141 differences between the two will be small, but where the event 
rate is high, differences will be large. For treatments that increase the chance of events, 
the odds ratio will be larger than the risk ratio and for interventions that reduce the 
chance of events, the odds ratio will be smaller than the risk ratio. Thus if an odds 
ratio is misinterpreted as a risk ratio it will lead to an overestimation of the effect of 
intervention. Unfortunately, this error in interpretation is quite common in published 
reports of individual studies and systematic reviews. Although some statisticians 
prefer odds ratios owing to their mathematical properties (they do not have inherent 
range limitations associated with high baseline rates and naturally arise as the antilog 
of coeffi cients in mathematical modelling, making them more suitable for statistical 
manipulation), they have been criticised for not being well understood by clinicians and 
patients.142, 143 It may therefore be preferable, even when calculations have been based 
on odds ratios, to transform the fi ndings to describe results as changes in the more 
intuitively understandable concept of risk.
Neither the risk ratio nor the odds ratio can be calculated for a trial if there are no 
events in the control group (as calculation would involve division by zero), and so in 
this situation it is customary to add 0.5 to each cell of the 2x2 table.137 If there are no 
events (or all participants experience the event) in both groups, then the trial provides 
no information about relative probability and so it is omitted from the meta-analysis. 
These situations are likely to occur when the event of interest is rare, and in such 
situations the choice of effect measure requires careful thought. A simulation study has 
shown that when events are rare, most meta-analysis methods give biased estimates of 
effect,144 and that the Peto odds ratio (which does not require a 0.5 correction) may be 
the least biased.
Continuous outcomes
Continuous outcomes are those that take any value in a specifi ed range and can 
theoretically be measured to many decimal places of accuracy, for example, blood 
pressure or weight. Many other quantitative outcomes are typically treated as continuous 
data in meta-analysis, including measurement scales. Continuous data are usually 
summarized as means and presented with an indication of the variation around the mean 
using the standard deviation (SD) or standard error (SE). The effect of an intervention on 
a continuous outcome is measured by the absolute difference between the mean outcome 
observed for the experimental intervention and control, termed the mean difference (MD). 
This estimates the amount by which the treatment changes the outcome on average and 
is expressed:
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Study mean differences and their associated standard errors can be combined using the 
generic inverse variance method.
Where studies assess the same outcome but measure it using different scales (for 
example, different quality of life scales), the individual study results must be 
standardised before they can be combined. This is done using the standardised mean 
difference (SMD), which considers the effect size in each study relative to the variability 
in the study and is calculated as the mean difference divided by the standard deviation 
among all participants. Where scales differ in direction of effect (i.e. some increase with 
increasing severity of outcome whilst others decrease with increasing severity), this 
needs to be accounted for by assigning negative values to the mean of one set of studies 
thereby giving all scales the same direction of measurement. There are three commonly 
used methods of recording the effect size in the standardised mean difference method, 
Cohen’s d,145 Hedges adjusted g,145 and Glass’ delta.146 The fi rst two differ in whether the 
standard deviation is adjusted for small sample bias. The third differs from the other two 
by standardizing by the control group standard deviation rather than an average standard 
deviation across both groups. The standardised mean difference assumes that differences 
in the standard deviation between studies refl ect differences in the measurement scale 
and not differences between the study populations. The summary intervention effect can 
be diffi cult to interpret as it is presented in abstract units of standard deviation rather than 
any particular scale.
Note that in social science meta-analyses, the term ‘effect size’ usually refers to versions 
of the standardised mean difference.
Time-to-event outcomes
Time-to-event analysis takes account not only of whether an event happens but when 
it happens. This is especially important in chronic diseases where even although we 
may not be able to ultimately stop an event from happening, slowing its occurrence 
can be benefi cial. For example, in cancer studies in adult patients we rarely anticipate 
cure, but hope that we can signifi cantly prolong survival. Time-to-event data are often 
referred to as ‘survival’ data since death is often the event of interest, but can be used 
for many different types of event such as time free of seizures, time to healing or time 
to conception. Each study participant has data capturing the event status and the time 
of that status. An individual may be recorded with a particular elapsed time-to-event, or 
they may be recorded as not having experienced the event by a particular elapsed time 
or period of follow-up. When the event has not (yet) been observed, the individual is 
described as censored, and their event-free time contributes information to the analysis 
up until the point of censoring.
The most appropriate way to analyse time-to-event data is usually to use Kaplan Meier 
analysis and express results as a hazard ratio (HR). The HR summarises the entire 
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survival experience and describes the overall likelihood of a participant experiencing an 
event on the experimental intervention compared to control. Meta-analyses that collect 
individual participant data are able to carry out such analysis for each included study 
and then pool these using a variant of the Peto method described above. Alternatively a 
modelling approach can be used.
Meta-analyses of aggregate data often treat time-to-event data as dichotomous and 
carry out analyses using the numbers of individuals who did or did not experience 
an event by a particular point in time. However, using such dichotomous measures 
in a meta-analysis of time-to-event outcomes is discarding information and can pose 
additional problems. If the total number of events reported for each study is used to 
calculate an odds ratio or risk ratio, this can involve combining studies reported at 
different stages of maturity, with variable follow-up, resulting in an estimate that is both 
unreliable and diffi cult to interpret. This approach is not recommended. Alternatively, 
ORs or RRs can be calculated at specifi c points in time. Although this makes estimates 
comparable, interpretation can still be diffi cult, particularly if individual studies 
contribute data at different time points. In this case it is unclear whether any observed 
difference in effect between time points is attributable to the timing or to the analyses 
being based on different sets of contributing studies. Furthermore, bias could arise if 
the time points are subjectively chosen by the researcher or selectively reported by the 
study author at times of maximal or minimal difference between intervention groups.
A preferable approach is to estimate HRs by using and manipulating published or other 
summary statistical data or survival curves.147, 148 This approach has also been described 
in non-technical step-by-step terms.149 Currently, such methods are under-used in 
meta-analyses,149 which may refl ect unfamiliarity with the methods and that study 
reports do not always include the necessary statistical information150, 151 to allow the 
methods to be used.
Ordinal outcomes
Outcomes may be presented as ordinal scales, such as pain scales (where individuals’ 
rate their pain as none, mild moderate or severe). These are sometimes analysed as 
continuous data, with each category being assigned a numerical value (for example, 
0 for none, 1 for mild, 2 for moderate and 3 for severe). This is usual when there are 
many categories, as is the case for many psychometric scales such as the Hamilton 
depression scale or the Mini-Mental State Examination for measuring cognition. 
However, a mean value may not be meaningful. Thus, an alternative way to analyse 
ordinal data is to dichotomise them (e.g. none or mild versus moderate or severe) to 
produce a standard 2×2 table. Methods are available for analysing ordinal data directly, 
but these typically require expert input.
Counts and rates
When outcomes can be experienced repeatedly they are usually expressed as event 
counts, for example, the number of asthma attacks. When these represent common 
events, they are often treated and analysed as continuous data (for example, number of 
days in hospital) and where they represent uncommon events they are often dichotomised 
(for example, whether or not each individual had at least one stroke).
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When events are rare, analyses usually focus on rates expressed at the group level, such 
as the number of asthma attacks per person, per month. Although these can be combined 
as rate ratios using the generic inverse variance method, this is not always appropriate 
as it assumes a constant risk over time and over individuals, and is not often done in 
practice. It is important not to treat rate data as dichotomous data because more than 
one event may have arisen from the same individual.
Presentation of quantitative results
Results should be expressed in formats that are easily understood, and in both relative 
and absolute terms.
Where possible, results should be shown graphically. The most commonly used graphic 
is the forest plot (see Box 1.7), which illustrates the effect estimates from individual 
studies and the overall summary estimate. It also gives a good visual summary of the 
review fi ndings, allowing researchers and readers to get a sense of the data. Forest 
plots provide a simple representation of the precision of individual and overall results 
and of the variation between-study results. They give an ‘at a glance’ identifi cation of 
any studies with outlying or unusual results and can also indicate whether particular 
studies are driving the overall results. Forest plots can be used to illustrate results for 
dichotomous, continuous and time-to-event outcomes.152
Individual study results are shown as boxes centred on their estimate of effect, with 
extending horizontal lines indicating their confi dence intervals. The confi dence interval 
expresses the uncertainty around the point estimate, describing a range of values within 
which it is reasonably certain that the true effect lies; wider confi dence intervals refl ect 
greater uncertainty. Although intervals can be reported for any level of confi dence, 
in most systematic reviews of health interventions, the 95% confi dence interval is 
used. Thus, on the forest plot, studies with wide horizontal lines represent studies with 
more uncertain results. Different sized boxes may be plotted for each of the individual 
studies, the area of the box representing the weight that the study takes in the analysis 
providing a visual representation of the relative contribution that each study makes to 
the overall effect.
The plot shows a vertical line of equivalence indicating the value where there is no 
difference between groups. For odds ratios, risk ratios or hazard ratios this line will 
be drawn at an odds ratio/risk ratio/hazard ratio value of 1.0, while for risk difference 
and mean difference it will be drawn through zero. Studies reach conventional levels 
of statistical signifi cance where their confi dence intervals do not cross the vertical line. 
Summary (meta-analytic) results are usually presented as diamonds whose extremities 
show the confi dence interval for the summary estimate. A summary estimate reaches 
conventional levels of statistical signifi cance if these extremities do not cross the line 
of no effect. If individual studies are too dissimilar to calculate an overall summary 
estimate of effect, a forest plot that omits the summary value and diamond can be 
produced.
Odds ratios, risk ratios and hazard ratios can be plotted on a log-scale to introduce 
symmetry to the plot. The plot should also incorporate the extracted numerical data 
for the groups for each study, e.g. the number of events and number of individuals for 
odds ratios, the mean and standard deviation for continuous outcomes. Other forms of 
graphical displays have also been proposed.153
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Box 1.7: Effects of four trials included in a systematic review
a) Presented without meta-analysis
Review: EVAR meta-analysis
Comparison: 01 EVAR vs. open repair                                                                                       
Outcome: 01 30-day mortality                                                                                           
Study  EVAR  Open repair  OR (fixed)  OR (fixed)
or sub-category  n/N  n/N  95% CI  95% CI
 Cuypers 2001               1/57               1/19             0.32 [0.02, 5.40]        
 DREAM 2004                 2/171              8/174            0.25 [0.05, 1.17]        
 EVAR I 2004                9/531             24/516            0.35 [0.16, 0.77]        
 Soulez 2005                0/20               0/20                Not estimable         
 0.1  0.2  0.5  1  2  5  10
 Favours treatment  Favours control
b) Presented with meta-analysis (fi xed effect model)
c) Presented with meta-analysis (random-effects model)
Example forest plots taken from a systematic review of endovascular stents for 
abdominal aortic aneurism (EVAR).154
Review: EVAR meta-analysis
Comparison: 01 EVAR vs. open repair                                                                                       
Outcome: 01 30-day mortality                                                                                           
Study  EVAR  Open repair  OR (fixed)  OR (fixed)
or sub-category  n/N  n/N  95% CI  95% CI
 Cuypers 2001               1/57               1/19             0.32 [0.02, 5.40]        
 DREAM 2004                 2/171              8/174            0.25 [0.05, 1.17]        
 EVAR I 2004                9/531             24/516            0.35 [0.16, 0.77]        
 Soulez 2005                0/20               0/20                Not estimable         
Total (95% CI) 779                729      0.33 [0.17, 0.64]
Total events: 12 (EVAR), 33 (Open repair)
Test for heterogeneity: Chi? = 0.17, df = 2 (P = 0.92), I? = 0%
Test for overall effect: Z = 3.25 (P = 0.001)
 0.1  0.2  0.5  1  2  5  10
 Favours treatment  Favours control
Review: EVAR meta-analysis
Comparison: 01 EVAR vs. open repair                                                                                       
Outcome: 01 30-day mortality                                                                                           
Study  EVAR  Open repair  OR (random)  OR (random)
or sub-category  n/N  n/N  95% CI  95% CI
 Cuypers 2001               1/57               1/19             0.32 [0.02, 5.40]        
 DREAM 2004                 2/171              8/174            0.25 [0.05, 1.17]        
 EVAR I 2004                9/531             24/516            0.35 [0.16, 0.77]        
 Soulez 2005                0/20               0/20                Not estimable         
Total (95% CI) 779                729      0.33 [0.17, 0.65]
Total events: 12 (EVAR), 33 (Open repair)
Test for heterogeneity: Chi? = 0.17, df = 2 (P = 0.92), I? = 0%
Test for overall effect: Z = 3.23 (P = 0.001)
 0.1  0.2  0.5  1  2  5  10
 Favours treatment  Favours control
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Relative and absolute effects
Risk ratios, odds ratios and hazard ratios describe relative effects of one intervention 
versus another, providing a measure of the overall chance of the event occurring on the 
experimental intervention compared to control. These relative effects do not provide 
information on what this comparison means in absolute terms. Although there may 
be a large relative effect of an intervention, if the absolute risk is small, it may not be 
clinically signifi cant because the change in absolute terms is minimal (a big percentage 
of a small amount may still be a small amount). For example, a risk ratio of 0.8 may 
represent a 20% relative reduction in events from 50% to 40% or it could represent 
a 20% relative reduction from 5% to 4% corresponding to absolute differences of 
10% and 1% respectively. There may be situations where the former is judged to be 
clinically signifi cant whilst the latter is not. Meta-analysis should use ratio measures; for 
example, dichotomous data should be combined as risk ratios or odds ratios and pooling 
risk differences should be avoided. However, when reporting results it is generally 
useful to convert relative effects to absolute effects. This can be expressed as either an 
absolute difference or as a number needed to treat (NNT). Absolute change is usually 
expressed as an absolute risk reduction which can be calculated from the underlying risk 
of experiencing an event if no intervention were given and the observed relative effect 
as shown in Box 1.8.
Box 1.8: Calculation of absolute risk reduction and number needed to 
treat from relative risks, odds ratios and hazard ratios
Absolute risk reduction from relative risk
Absolute risk reduction from hazard ratio156
ARR = Scontrol 
HR – Scontrol at chosen time point
Number needed to treat
baselineRisk1)(RRARR −=
Absolute risk reduction from odds ratio155
baseline
baselinebaseline
baseline Risk
)Risk(1ORRisk
OR)(1)Risk(1
ARR ×
−+
−−
=
Where:
RR = relative risk ARR = absolute risk reduction
Scontrol = proportion event free on control treatment HR = hazard ratio
ARR
1
NNT =
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Consideration of absolute effects is particularly important when considering how results 
apply to different types of individuals who may have different underlying prognoses and 
associated risks. Even if there is no evidence that the relative effects of an intervention 
vary across different types of individual (see Subgroup analyses and Meta-regression 
below), if the underlying risks for different categories of individual differ, then the 
effect of intervention in absolute terms will be different. It is therefore important when 
reporting results to consider how the absolute effect of an intervention varies for 
different types of individual and a table expressing results in this way, as shown in Table 
1.5, can be useful. The underlying risk for different types of individual can be estimated 
from the studies included in the meta-analysis, or generally accepted standard 
estimates can be used. Confi dence intervals should be calculated around absolute 
effects.
Table 1.5: Example table expressing relative effects as absolute effects for 
individuals with differing underlying prognoses.
 2 year survival rate
HR = 0.84  Baseline Absolute increase Change
95% CI (0·78–0·92)   (95% CI) 
Age <=40 50% 5% (3% – 8%) From 50 to 55%
 41-59 14% 5% (2% – 8%) From 14 to 19%
 >=60 4% 2% (1% – 4%) From 4 to 6%
Histology AA 31% 6% (3% – 9%) From 31 to 37%
 GBM 9% 4% (2% – 6%) From 9 to 13%
 Other 52% 5% (3% – 8%) From 52 to 57%
Performance Good 22% 6% (3% – 9%) From 22 to 28%
Status Poor 9% 4% (2% – 6%) From 9 to 13%
Baseline survival and equivalent absolute increases in survival calculated from a meta-analysis of 
chemotherapy in high-grade glioma.157
AA = anaplastic astrocytoma, GBM = glioblastoma multiforme.
The NNT, which is derived from the absolute risk reduction as shown in Box 1.8, also 
depends on both relative effect and the underlying risk. The NNT represents the number 
of individuals who need to be treated to prevent one event that would be experienced 
on the control intervention. The lower the number needed to treat, the fewer the 
patients that need to be treated to prevent one event, and the greater the effi cacy of 
the treatment. For example a meta-analysis of antiplatelet agents for the prevention 
of pre-eclampsia found an RR of 0.90 (0.84 – 0.97) for pre-eclampsia.158 Plausible 
underlying risks of 2%, 6% and 18% had associated NNTs of 500 (313-1667), 167 
(104-556) and 56 (35-185) respectively.
Sensitivity analyses
Sensitivity analyses explore the robustness of the main meta-analysis results by 
repeating the analyses having made some changes to the data or methods.159 Analyses 
run with and without the inclusion of certain trials will assess the degree to which 
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particular studies (perhaps those with poorer methodology) affect the results. For 
example, analyses might be carried out on all eligible trials and a sensitivity analysis 
restricted to only those that used a placebo in the control group. If results differ 
substantially, the fi nal results will require careful interpretation. However care must be 
taken in attributing reasons for differences, especially when a single or small numbers 
of trials are included/excluded in the sensitivity analysis, as a study may differ in 
additional ways to the issue being explored in the sensitivity analysis. Some sensitivity 
analyses should be proposed in the protocol, but as many issues suitable for exploration 
in sensitivity analyses only come to light whilst the review is being done, and in 
response to decisions made or diffi culties encountered, these may have to change and/
or be supplemented.
Exploring heterogeneity
There will inevitably be variation in the observed estimates of effect from the 
studies included in a meta-analysis. Some of this variation arises by chance alone, 
refl ecting the fact that no study is so large that random error can be removed 
entirely. Statistical heterogeneity refers to variation other than that which arises by 
chance. It refl ects methodological or clinical differences between studies. Exploring 
statistical heterogeneity in a meta-analysis aims to tease out the factors contributing 
to differences, such that sources of heterogeneity can be accounted for and taken into 
consideration when interpreting results and drawing conclusions.
There is inevitably a degree of clinical diversity between the studies included in a 
review,160 for example because of differing patient characteristics and differences in 
interventions. If these factors infl uence the estimated intervention effect then there 
will be some statistical heterogeneity between studies. Methodological differences that 
infl uence the observed intervention effect will also lead to statistical heterogeneity. For 
example, combining results from blinded and unblinded studies may lead to statistical 
heterogeneity, indicating that they might best be analysed separately rather than in 
combination. Although it manifests itself in the same way, heterogeneity arising from 
clinical differences is likely to be because of differences in the true intervention effect, 
whereas heterogeneity arising from differences in methodology is more likely to be 
because of bias.
An idea of heterogeneity can be obtained straightforwardly by visually examining forest 
plots for variations in effects. If there is poor overlap between the study confi dence 
intervals, then this generally indicates statistical heterogeneity.
More formally a χ2 (chi-squared) test (see Box 1.9), often also referred to as Q-
statistic, can assess whether differences between results are compatible with chance 
alone. However, care must be taken in interpreting the chi-squared test as it has low 
power, consequently a larger P value (P<0.1) is sometimes used to designate statistical 
signifi cance. Although a statistically signifi cant test result may point to a problem with 
heterogeneity, a nonsignifi cant test result does not preclude important between-study 
differences, and cannot be taken as evidence of no heterogeneity. Conversely, if there 
are many studies in a meta-analysis, the test has high power to detect a small amount 
of heterogeneity that, although statistically signifi cant, may not be clinically important.
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Accepting that diversity is likely to be inherent in any review, methods have also been 
developed to quantify the degree of inconsistency across studies, shifting the focus 
from signifi cance testing to quantifying heterogeneity. The I2 statistic160, 161 describes the 
percentage of variability in the effect estimates that can be attributed to heterogeneity 
rather than chance (see Box 1.9).
Box 1.9: Chi-squared test (or Q-statistic) and test for interaction
Chi-squared test: 
( )∑ −= 221 pooledi
i
EEEE
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Q
100%
Q
dfQ
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⎤
⎢
⎣
⎡ −
=
Where Q is the chi-squared statistic, and df its degrees of freedom.
To examine differences across subgroups, either Q or I2 can be applied to meta-
analytic results from each subgroup rather than to individual studies (i.e. the sum in 
Q is across subgroups rather than across studies).
Although the I2 statistic often has wide confi dence intervals and it is diffi cult to provide 
hard and fast rules on what level of inconsistency is reasonable in a meta-analysis, as 
a rough guide it has been suggested that I2 values of up to 40% might be unimportant, 
30% to 60% might be moderate, 50 to 90% may be substantial and 75% to 100% 
considerable.75
If statistical heterogeneity is observed, then the possible reasons for differences should 
be explored162 and a decision made about if and how it is appropriate to combine 
studies. A systematic review does not always need to include a meta-analysis and, if 
there are substantial differences between study estimates of effect, particularly if they 
are in opposing directions, combining results in a meta-analysis can be misleading. 
One way of addressing this is to split studies into less heterogeneous groups according 
to particular study level characteristics (e.g. by type of drug), and perform separate 
analyses for each group. Forest plots can be produced to show subsets of studies on 
the same plot. Each subset of studies can have its own summary estimate, and if 
appropriate an overall estimate combined across all studies can also be shown. Showing 
these groupings alongside each other in this way provides a good visual summary of 
how they compare. This approach allows the consistency and inconsistency between 
subsets of studies to be examined. Differences can be summarised narratively, but where 
possible they should also be evaluated formally. A χ2 test for differences across subgroups 
can be carried out (see Box 1.9).
2
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The infl uence of patient-level characteristics (e.g. age, gender) or issues related to 
equity (e.g. ethnicity, socioeconomic group) can also be explored through subgroup 
analyses, meta-regression or other modelling approaches. However, there is generally 
insuffi cient information in published study reports to allow full exploration of 
heterogeneity in this way and this can usually only be addressed satisfactorily when IPD 
are available. Such exploration of heterogeneity may enable additional questions to be 
addressed, such as which particular treatments perform best or which types of patient 
will benefi t most, but is unlikely to be helpful when there are few studies. Wherever 
possible, potential sources of heterogeneity should be considered when writing the 
review protocol and possible subgroup analyses pre-specifi ed rather than trying to 
explain statistical heterogeneity after the fact.
Subgroup analyses
Subgroup analyses divide studies (for study level characteristics) or participant data (for 
participant level characteristics) into subgroups and make indirect comparisons between 
them. These analyses may be carried out to explore heterogeneity (see above) as well 
as to try to answer particular questions about patient or study factors. For example a 
subgroup analysis for study level characteristics might examine whether the results of 
trials carried out in primary health care settings are the same as trials carried out in a 
hospital setting. A participant level subgroup analysis might examine whether the effect 
of the intervention is the same in men as in women.
In individual studies it is unusual to have suffi cient numbers and statistical power to 
permit reliable subgroup analyses of patient characteristics. However, provided that 
such data have been collected uniformly across studies, a meta-analysis may achieve 
suffi cient power in each subgroup to permit a more reliable exploration of whether 
the effect of an intervention is larger (or smaller) for any particular type of individual. 
Although, owing to the multiplicity of testing, these analyses are still potentially 
misleading, subgroup analysis within the context of a large meta-analysis may be the 
only reasonable way of performing such exploratory investigations. Not only do the 
greater numbers give increased statistical power, but consistency across trials can be 
investigated. Indeed, the possibility of undertaking such analyses is a major attraction 
of IPD meta-analyses as dividing participant data into groups for subgroup analysis is 
seldom possible in standard reviews of aggregate data.163 Subgroup analyses in most 
(non IPD) systematic reviews focus on grouping according to trial attributes.
The interpretation of the results of subgroup analyses must be treated with some caution. 
Even where the original data have come from RCTs, the investigation of between-study 
differences is indirect and equivalent to an observational study.164, 165 There may be 
explanations for the observed differences between groups, other than the attributes 
chosen to categorise groupings. Comparisons which are planned in advance on the basis 
of a plausible hypothesis and written into the protocol are more credible than fi ndings 
that are found through post hoc exploratory analyses. Furthermore, the likelihood of 
fi nding false negative and false positive signifi cance tests rises rapidly as more subgroup 
analyses are done. Subgroups should therefore be restricted to a few potentially 
important characteristics where it is reasonable to suspect that the characteristic will 
interact with or modify the effect of the intervention. Note that there is often confusion 
between prognostic factors and potential effect modifi ers; just because a characteristic is 
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prognostic does not mean that it will modify the effect of an intervention. For example, 
whilst gender is prognostic for survival (women live longer than men) it does not 
necessarily mean that women will benefi t more than men will from a drug to treat lung 
cancer.
Meta-regression
Meta-regression can be used to investigate the effects of differences in study 
characteristics on the estimates of the treatment effect,140 and can explore continuous as 
well as categorical characteristics. In principle it can allow for the simultaneous exploration 
of several characteristics and their interactions, though in practice this is seldom possible 
because of small numbers of studies.166 As in any simple regression analysis, meta-
regression aims to predict outcome according to explanatory variables or covariates of 
interest. The covariates may be constant for the entire trial, for example, the protocol 
dose of a drug, or a summary measure of attributes describing the patient population, 
for example, mean age or percentage of males. The regression is weighted by precision 
of study estimates such that larger studies have more infl uence than smaller studies. 
The regression coeffi cient is tested to establish whether there is an association between 
the intervention effect and the covariate of interest. Provided that enough data are 
available (at least 10 studies),82 the technique may be a useful exploratory tool. 
However, there are limitations. Not all publications will report on all the covariates of 
interest (and there could be potential bias associated with selective presentation of data 
that have shown a positive association within a primary study). If a study is missing 
a covariate it drops out of the regression, limiting the power and usefulness of the 
analysis, which is already likely to be based on relatively few data points.
Meta-regression is not a good way to explore differences in treatment effects 
between different types of individual as summary data may misrepresent individual 
participants.167 What is true of a study with a median participant age of 60 may not 
necessarily be true for a 60-year-old patient. Potentially all the benefi t could have 
been shown in the 50-year-olds and none in the 60 and 70-year-olds. Comparison of 
treatment effects between different types of individual, for example between men and 
women, should be done using subgroup analyses and not by using meta-regression 
incorporating the proportion of women in each trial. It should always be borne in mind 
that fi nding a signifi cant association in a meta-regression does not prove causality and 
should rather be regarded as hypothesis generating.
Assessing the possibility of publication bias
Although thorough searches should ensure that a systematic review captures as many 
relevant studies as possible, they cannot eliminate the risk of publication bias. As 
publication and associated biases can potentially infl uence profoundly the fi ndings of 
a review, the risk of such bias should be considered in the review’s conclusions and 
inferences.24 The book by Rothstein et al provides a comprehensive discussion of 
publication bias and associated issues.168
The obvious way to test for publication bias is to compare formally the results of 
published and unpublished studies. However, more often than not unpublished studies 
are hidden from the reviewer, and more ad hoc methods are required. A common 
technique to help assess potential publication bias is the funnel plot.
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This is a scatter plot based on the fact that precision in estimating effect increases with 
increasing sample size. Effect size is plotted against some measure of study precision 
– of which standard error is likely to be the best choice.169 A wide scatter in results of 
small studies, with the spread narrowing as the trial size increases, is expected. If there 
is no difference between the results of small and large studies, the shape of the plot 
should resemble an inverted funnel (see Box 1.10). If there are differences, the plot will 
be skewed and a gap where the small unfavourable studies ought to be is often cited 
as evidence of publication bias. However, the shape of a funnel plot can also depend on 
the measures selected for estimating effect and precision169, 170 and could be attributable 
to differences between small and large studies other than publication bias. These 
differences could be a result of other types of methodological bias, or genuine clinical 
differences. For example, small studies may have a more selected participant population 
where a larger treatment effect might be expected. Funnel plots are therefore more 
accurately described as a tool for investigating small study effects.
Box 1.10: Example funnel plots from a systematic review of dressings 
and topical agents used in the healing of chronic wounds183
 Symmetrical Asymmetrical
o Traditional vs. dressing/topical agent other than hydrocolloid
n Traditional vs. hydrocolloid dressing only
This funnel plot, of all the studies that 
compared traditional treatments with 
modern dressing or topical agents for the 
treatment of leg ulcers and pressure sores, 
showed little evidence of asymmetry.
This funnel plot, of trials that compared 
traditional treatments with hydrocolloid 
dressings for the treatment of leg 
ulcers and pressure sores, showed clear 
asymmetry. This was considered likely to 
be the result of publication bias.
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Although visual inspection of funnel plots has been shown to be unreliable,170, 171 this 
might be improved if contour zones illustrating conventional levels of signifi cance 
are overlaid on the plot to illustrate whether ‘missing’ studies are from zones of 
statistical signifi cance or not. If the ‘missing’ studies are from nonsignifi cant zones, 
this may support a publication bias. On the other hand if ‘missing’ studies are from 
statistically signifi cant zones, the asymmetry may be more likely to be attributable 
to other causes.172 Over time a range of statistical and modelling methods have been 
developed to test for asymmetry, the most frequently used of which are those based 
on rank correlation173 or linear regression174, 175 and complex modelling176 methods. 
Some methods (for example, the trim and fi ll method177, 178) attempt to adjust for 
any publication bias detected.176 However, all methods are by nature indirect and the 
appropriateness of many methods is based on some strict assumptions that can be 
diffi cult to justify in practice.
Although frequently used to help assess possible publication bias, funnel plots and 
associated statistical tests are often used and interpreted inappropriately,179, 180 
potentially giving false assurance where a symmetrical plot overlooks important 
bias or undermining important valid evidence because of an asymmetric plot.179 The 
methods are inappropriate where there is statistical heterogeneity; have low power 
and are of little use where there are few studies; and are meaningless where studies 
are of similar size. Consequently, situations where they are helpful are few and their 
use is not generally a good way of dealing with publication bias.181 Therefore use of 
these methods to identify or adjust for publication bias in a meta-analysis should be 
considered carefully and generally be restricted to sensitivity analyses. Results should 
be interpreted with caution. Statistical tests will not resolve bias and avoidance of 
publication bias is preferable. In time this may become easier with more widespread 
registration of clinical trials and other studies at inception.182
Dealing with special study designs and analysis issues
Intention to treat analyses
ITT is usually the preferred type of analysis as it is less likely to introduce bias than 
alternative approaches. True intention to treat analysis captures two criteria: (i) 
participants should be analysed irrespective of whether or not they received their 
allocated intervention and irrespective of what occurred subsequently, for example, 
participants with protocol violations or those subsequently judged ineligible should be 
included in the analysis; (ii) all participants should be included irrespective of whether 
outcomes were collected. Although the fi rst criterion is generally accepted, there is no 
clear consensus on the second81 as it involves including participants in the analyses 
whose outcomes are unknown, and therefore requires imputation of data. Many authors 
describe their analyses as ITT when only the fi rst criterion has been met. Alternative 
analysis of all participants for whom outcome data are available is termed available case 
analysis. Some studies present analysis of all participants who completed their allocated 
treatment, this is per protocol or treatment received analysis which may be seriously 
biased.
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Imputing missing data
Although statistical techniques are available to impute missing data, this cannot 
reliably compensate for missing data184 and in most situations imputation of data is 
not recommended. It is reasonable for most systematic reviews to aim for an available 
case analysis and include data from only those participants whose outcome is known. 
Achieving this may require making contact with the study author if individuals for whom 
outcome data were recorded have been excluded from the published analyses. The 
extent and implications of missing data should always be reported and discussed in 
the review. If the number of participants missing from the fi nal analysis is large it will be 
helpful to detail the reasons for their exclusion.
In some circumstances, it might be informative to impute data in sensitivity analyses 
to explore the impact of missing data.185 For missing dichotomous data the analysis 
can assume that either all participants with missing data experienced the event, or 
that they all did not experience the event. This generates the theoretical extremes of 
possible effect. Data could also be imputed using the rate of events observed in the 
control group, however this does not add information, gives infl ated precision and is 
not recommended. Where missing data are few, imputation will have little impact on 
the results. Where missing data are substantial, analysis of worst/best case scenarios 
will give a wide range of possible effect sizes and may not be particularly helpful. 
Approaches to imputing missing continuous data have received little attention. In some 
cases it may be possible to use last observation carried forward, or to assume that no 
change took place. However, this cannot be done from aggregate data and the value of 
such analysis is unclear. Any researcher contemplating imputing missing data should 
consult with an experienced statistician.
Cluster randomised trials
In cluster randomised trials, groups rather than individuals are randomised, for example 
clinical practices or geographical areas. Reasons for allocating interventions in this 
way include evaluating policy interventions or group effects such as in immunisation 
programmes, and avoiding cross-contamination, for example, health promotion 
information may be easily shared by members of the same clinic or community. In 
many instances clustering will be obvious, for example where primary care practices 
are allocated to receive a particular intervention. In other situations the clustering 
may be less obvious, for example where multiple body parts on the same individual 
are allocated treatments or where a pregnant woman has more than one fetus. It is 
important that any cluster randomised trials are identifi ed as such in the review.
As participants within any one cluster are likely to respond in a manner more similar 
to each other than to other individuals (owing to shared environmental exposure or 
personal interactions), their data cannot be assumed to be independent. It is therefore 
inappropriate to ignore the clustering and analyse as though allocation had been at 
the individual level. This unit of analysis error would result in overly narrow confi dence 
intervals and straightforward inclusion of trials analysed in this way would give undue 
weight to that study in a meta-analysis. Unfortunately, many primary studies have ignored 
clustering and analysed results as though from an individual randomised trial.186, 187 One 
way to avoid the problem of inappropriately analysed cluster trials is to carry out meta-
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analyses using a summary measure for each cluster as a single observation. The sample 
size becomes the number of clusters (not the number of individuals) and the analysis 
then proceeds as normal. However, depending on the size and number of clusters, this 
will reduce the statistical power of the analysis considerably and unnecessarily. Indeed the 
information required to do this is unlikely to be available in many study publications.
A better approach is to adjust the results of inappropriately analysed primary studies 
to take account of the clustering, by increasing the standard error of the estimate of 
effect.75 This may be achieved by multiplying the original standard error by the square 
root of the ‘design effect’. The design effect can be calculated from the intracluster 
correlation coeffi cient, which, although seldom reported, can use external values from 
similar studies such as those available from the University of Aberdeen Health Services 
Research Unit (www.abdn.ac.uk/hsru/epp/iccs-web.xls). A common design effect is 
usually adopted across the intervention groups.
( )
adjusted
DE 1 M 1 ICC
SE SE DE
= + − ×⎡ ⎤⎣ ⎦
=
where:
DE = design effect
M = mean cluster size
ICC = intracluster correlation coeffi cient
SE = standard error of the effect estimate
These values can then be used in a generic inverse variance meta-analysis alongside 
unadjusted values from appropriately analysed trials.
Cross-over trials
Cross-over trials allocate each individual to a sequence of interventions, for example 
one group may be allocated to receive treatment A followed by treatment B, and the 
other group allocated to receive B followed by A. This type of trial has the advantage 
that each participant acts as their own control, eliminating between participant 
variability such that fewer participants are required to obtain the same statistical 
power. They are suitable for evaluating interventions that have temporary effects in 
treating stable conditions. They are not appropriate where an intervention can have a 
lasting effect that compromises treatment in subsequent periods of the trial, or where 
a condition has rapid evolution, or the primary outcome is irreversible. The fi rst task of 
the researcher is to decide whether the cross-over design is appropriate in assessing the 
review question.
Appropriate analysis of cross-over trials involves paired analysis, for example using 
a paired t-test to analyse a study with two interventions and two periods (using 
experimental measurement – control measurement) for each participant, with standard 
errors calculated for these paired measurements. These values can then be combined in 
a generic inverse variance meta-analysis. Unfortunately, cross-over trials are frequently 
inappropriately analysed and reported.
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A common naive analysis of cross-over data is to treat all measurements on 
experimental and control interventions as if they were from a standard parallel group 
trial. This results in confi dence intervals that are too wide and the trial receives too little 
weight in the meta-analysis. However, as this is a conservative approach, it might not 
be unreasonable in some circumstances. Where the effect of the fi rst intervention is 
thought to have infl uenced the outcome in subsequent periods (carry-over), a common 
approach is to use only the data from the fi rst period for each individual. However, this 
will be biased if the decision to analyse in this way is based on a test of carry-over and 
studies analysed in this way may differ from those using paired analyses. One approach 
to combining studies with differing types of reported analyses is to carry out an analysis 
grouped by type of study i.e. grouped by cross-over trial paired analysis, cross-over trial 
with fi rst period analysis, parallel group trial, and explore whether their results differ 
(see Subgroup analyses above).
Alternatively, the researcher can carry out their own paired analysis for each trial if 
(i) the mean and standard deviation or standard error of participant differences are 
available; (ii) the mean difference plus a t-statistic, p-value or confi dence interval from 
a paired analysis is available; (iii) a graph from which individual matched measurements 
can be extracted; or (iv) if individual participant data are available.188 Another approach 
is to attempt to approximate a paired analysis by imputing missing standard errors by 
‘borrowing’ from other studies that have used the same measurement scale or by a 
correlation coeffi cient obtained from other studies or external sources.75 Researchers 
will need to decide whether excluding trials is preferable to inferring data. If imputation 
is thought to be reasonable, advice should be sought from an experienced statistician. 
Authors should state explicitly where studies have used a cross-over design and how 
this has been handled in the meta-analysis.
Mixed treatment comparisons
Mixed treatment comparisons (MTC), or network meta-analyses, are used to analyse 
studies with multiple intervention groups and to synthesise evidence across a series 
of studies in which different interventions were compared. These are used to rank 
or identify the optimal intervention. They build a network of evidence that includes 
both direct evidence from head to head studies and indirect comparisons whereby 
interventions that have not been compared directly are linked through common 
comparators. A framework has been described that outlines some of the circumstances 
in which such syntheses might be considered.189 Methods for conducting indirect 
comparisons190, 191 and more complex mixed treatment methods192, 193 require expert 
advice. Researchers wishing to undertake such analyses should consult with an 
appropriately experienced statistician.
Bayesian methods
Unlike standard analysis techniques, Bayesian analyses allow for the combination of 
existing information with new evidence using established rules of probability.194 A simple 
Bayesian analysis model includes three key elements:
1. Existing knowledge on the effect of an intervention can be retrieved from a 
variety of sources and summarised as a prior distribution
2. The data from the studies are used to form the likelihood function
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3. The prior distribution and the likelihood function are formally combined to 
provide a posterior distribution which represents the updated knowledge about 
the effect of the intervention
Bayesian approaches to meta-analysis may be useful when evidence comes from a 
diverse range of sources particularly when few data from RCTs exist.195, 196 They can 
also be used to account for the uncertainty introduced by estimating the between-study 
variance in the random-effects model, which can lead to reliable estimates and predictions 
of treatment effects.197 While there are several good texts available,198-200 if a Bayesian 
approach is to be used, the advice of a statistical expert is strongly recommended.
Describing results
When describing review fi ndings, the results of all analyses should be considered 
as a whole, and overall coherence discussed. Consistency across studies should be 
considered and results interpreted in relation to biological and clinical plausibility. 
Where there have been many analyses and tests, care should be taken in interpreting 
unexpected or implausible fi ndings as among a large number of tests the play of chance 
alone is likely to generate spurious statistically signifi cant results.
Quantitative results of meta-analyses should be expressed as point estimates together 
with associated confi dence intervals and exact p-values. They should not be presented 
or discussed only in terms of statistical signifi cance. This is particularly important where 
results are not statistically signifi cant as nonsignifi cance can arise both when estimates 
are close to no effect with narrow confi dence intervals, or when estimates of effect 
are large with wide confi dence intervals. Whilst in the former, we can be confi dent 
that there is little difference between the interventions compared, in the latter there is 
insuffi cient evidence to draw conclusions. Researchers should be aware that describing 
a result as ‘there is no statistical (or statistically signifi cant) difference between the two 
interventions’ can be (mis)read as there being no difference between interventions.
It is important that inconclusive results are not interpreted as indicating that an 
intervention is ineffective and estimates with wide confi dence intervals that span no 
effect should be described as showing no clear evidence of a benefi t or harm rather than 
as there being no difference between interventions. Demonstrating lack of suffi cient 
evidence to reach a clear conclusion is an important fi nding in its own right.
Similarly, care should be taken not to overplay results that are statistically signifi cant, 
as with large enough numbers, even very modest differences between interventions can 
be statistically signifi cant. The size of the estimated effect, and its confi dence intervals, 
should be considered in view of how this relates to current or future practice (see 
Section 1.3.6 Report writing).
It is usually helpful to present fi ndings in both relative and absolute terms and in 
particular to consider how relative effects may translate into different absolute effects 
for people with differing underlying prognoses (see Relative and absolute effects section 
above). Where a number of outcomes or subgroup analyses are included in a review it 
can be helpful to tabulate the main fi ndings in terms of effect, confi dence intervals and 
inconsistency or heterogeneity statistics.
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Summary: Data synthesis
• Synthesis involves bringing the results of individual studies together and 
summarising their fi ndings.
• This may be done quantitatively or, if formal pooling of results is inappropriate, 
through a narrative approach.
• Synthesis should also explore whether observed intervention effects 
are consistent across studies, and investigate possible reasons for any 
inconsistencies.
Initial descriptive synthesis
All syntheses should begin by constructing a clear descriptive summary of the 
included studies.
Narrative synthesis is frequently an essential part of a systematic review, and 
as with every other stage of the process, bias must be minimized.
Narrative synthesis has typically not followed a strict set of rules. However, a 
general framework can be applied in order to help maintain transparency and add 
credibility to the process. The four elements of this framework are:
• Developing a theory of how the intervention works, why and for whom
• Developing a preliminary synthesis of fi ndings of included studies
• Exploring relationships within and between studies
• Assessing the robustness of the synthesis
Each element contains a range of tools and techniques that can be applied. A 
researcher is likely to move iteratively among the four elements, choosing those 
tools and techniques that are appropriate to the data being synthesised and 
providing justifi cations for these choices.
Quantitative synthesis
• Meta-analysis increases power and precision in estimating intervention effects.
• Results of individual studies are combined statistically to give a pooled 
estimate of the ‘average’ intervention effect.
• Most meta-analysis methods are based on calculating a weighted average of 
the effect estimates from each study.
• The methods used to combine results will depend on the type of outcome 
assessed.
• Quantitative results should be expressed as point estimates together with 
associated confi dence intervals and exact p-values.
• Variation in results across studies should be investigated.
• Sensitivity analyses give an indication of the robustness of results to the type 
of study included and the methods used.
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1.3.6 Report writing
Report writing is an integral part of the systematic review process. This section 
deals with the primary scientifi c report of the review which often takes the form of 
a comprehensive report to the commissioning body. Many commissioners have their 
own guidance for production and submission of the report. Alternatively the primary 
report may take the form of a journal article, where space limitations may mean 
that important details of the review methods have to be omitted. These can be made 
available through the journal’s or the review team’s website. Whatever the format, it is 
important to take as much care over report preparation as over the review itself. The 
report should describe the review methods clearly and in suffi cient detail that others 
could, if they wished, repeat them. There is evidence that the quality of reporting in 
reports of primary studies may affect the readers’ interpretation of the results, and the 
same is likely to be true of systematic reviews.201 It has also been argued that trials and 
reviews often provide incomplete or omit the crucial ‘how to’ details about interventions, 
limiting a clinicians’ ability to implement fi ndings in practice.202-204
The QUOROM statement9 has set standards for how reviews incorporating meta-analysis 
should be reported, and many journals require articles submitted to adhere to these 
standards. The QUOROM checklist and fl ow chart are useful resources for all authors of 
systematic review reports. However, recognising that the quality of reporting of many 
systematic reviews is disappointing,205 the QUOROM group have broadened their remit, 
been renamed PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-
Analyses),206 and developed a fl ow chart and checklist for the reporting of systematic 
reviews with or without a meta-analysis.66, 67
1.3.6.1 General considerations
Resources for writers
There are many resources for writers available in both printed and electronic form. 
These include guides to technical writing and publishing,207-209 style manuals210, 211 and 
guides to use of English.212 The EQUATOR Network is an initiative that seeks to improve 
the quality of scientifi c publications by promoting transparent and accurate reporting of 
health research.101 It provides an introduction to reporting guidelines, and information 
for authors of research reports, editors and peer reviewers as well as those developing 
reporting guidelines.
Style and structure
Commissioning bodies and journals usually have specifi c requirements regarding 
presentation and layout that should be followed when preparing a report or article. 
Some organisations offer detailed guidance while others are less specifi c. In the 
absence of guidance, a layered approach such as a one page summary of the research 
‘actionable messages’, three-page executive summary and a 25-page report is 
advocated as the optimal way to present research evidence to health service managers 
and policy-makers.213 Box 1.11 presents a suggested outline structure for a typical 
report of a systematic review.
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Many journals publish papers electronically ahead of print publication and electronic 
publishing often allows additional material, such as large tables, or search strategies 
to be made available through the journal’s website. There is no specifi c word limit 
for reports published in electronic format only, for example in the Cochrane Library, 
although Cochrane reviews ‘should be as succinct as possible’.75
Box 1.11: Suggested structure of a systematic review report
Title
Contents list
Abbreviations/glossary
Executive summary or structured abstract
Background
Objectives
Methods (data sources, study selection, data extraction, quality assessment, data 
synthesis)
Results
Conclusions
Main text
Background/introduction
Review question(s)
Review methods
Identifi cation of studies
Study selection (inclusion and exclusion criteria; methods)
Data extraction
Quality assessment
Data synthesis
Results of the review
Details of included and excluded studies
Findings of the review
Secondary analyses (sensitivity analyses etc.)
Discussion (interpretation of the results)
Conclusions
Recommendations/implications for practice/policy
Recommendations/implications for further research
Acknowledgements or list of contributors and contributions
Funding
Confl icts of interest
References
Appendices
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Researchers should familiarise themselves with the conventions favoured by their 
commissioning body or ‘target’ journal. Many journals now prefer a clear and active 
style that is understandable to a general audience. Weaknesses in the use of grammar 
and spelling constitute obstacles to clear communication and should be eliminated as 
far as possible. The fi eld of scientifi c and technical communication predominantly uses 
English as its common language, so those who are unsure of their ability in written 
English may fi nd it helpful to have their report checked by an accomplished speaker/
writer who is familiar with the subject matter before submission.
Contents lists and headings are essential for guiding the reader through longer 
documents. Inclusion of an index may also be helpful. It is particularly important to 
adopt a consistent style (e.g. font, point size, font style) for different levels of main 
headings and sub-headings.
Planning
Time spent preparing a brief outline covering the main points to be included in the 
report can save time overall. The outline should focus on who the intended audience is 
and what they need to know. The review team will need to agree the outline and, if the 
report is to be written by multiple authors, allocate writers for each section. Dividing 
the work amongst a number of people reduces the burden on each individual but there 
is a risk of loss of consistency in style and terminology. In addition, completion of the 
report relies on all the team members working to the agreed schedule. It is essential for 
the lead author (corresponding author for journal articles) to monitor progress and take 
responsibility for accuracy and consistency.
Authorship and contributorship
The report of a systematic review will usually have a number of authors. According to 
the International Committee of Medical Journal Editors (ICMJE),214 authorship credit 
should be based on:
1. Substantial contributions to conception and design, or acquisition of data, or 
analysis and interpretation of data
2. Drafting the article or revising it critically for important intellectual content; and
3. Final approval of the version to be published
All authors should meet all of these conditions. The review team should agree amongst 
themselves who will be authors and the order of authorship. Order of authorship is often 
taken to refl ect an individual’s contribution to the report and methods are available 
for scoring contributions to determine authorship.215 Alternatively authors can simply 
be listed alphabetically. Contributions that do not meet the criteria for authorship (for 
example, data extraction or membership of an advisory group) should be included in the 
acknowledgements.
Some journals, for example the BMJ, favour a system of contributorship.216 In addition 
to the standard list of authors, there is a list of all those who contributed to the paper 
with details of their contributions. One contributor (occasionally more than one) is 
listed as guarantor and accepts overall responsibility for the work. This system gives 
some credit to those who do not meet the ICMJE criteria for authorship and provides 
accountability for each stage of the review.
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Peer review and feedback
Most systematic reviews have an expert advisory group assembled at the beginning of 
the project and members of this group should be asked to review the draft report and 
comment on its scientifi c quality and completeness. The commissioning body may also 
organise its own independent peer review of the draft report before publication.
Medical journals almost invariably seek external peer review of manuscripts submitted 
for publication. Draft manuscripts may also be posted on institutional websites or 
electronic preprint servers, allowing an opportunity for feedback from a wide range of 
interested parties, although for reports intended for journals it is important to ensure 
that such posting will not be considered as prior publication.
In addition to scientifi c peer review, end users may also be asked to assess the 
relevance and potential usefulness of the review. They may recommend changes that 
would help in identifying the main messages for dissemination and important target 
audiences as well as possible formats and approaches.
When feedback from external reviewers has been received, a fi nal report can be 
prepared. A record of the comments and the way in which they were dealt with should 
be kept with the archive of the review.
Confl ict of interests
The ICMJE state that a confl ict of interests exists if ‘an author (or the author’s 
institution), reviewer, or editor has fi nancial or personal relationships that 
inappropriately infl uence (bias) his or her actions’.214 Relationships that might constitute 
a confl ict of interests are common and there is nothing wrong with having such 
relationships. However, it is important that they are declared so that readers are aware 
of the possibility that authors’ judgements may have been infl uenced by other factors. 
Review authors need to be explicit about any potential confl ict of interests because such 
transparency is important in maintaining the readers’ confi dence.
1.3.6.2 Executive summary or abstract
The executive summary (for full-length reports) or abstract (for journal articles) is the 
most important part of the report because potentially it is the only section that many 
readers will actually read (perhaps in conjunction with the discussion and conclusions). 
It should present the fi ndings of the review clearly and concisely and allow readers to 
quickly judge the quality of the review and the generalisability of its fi ndings. Providing 
a good balance between detail of the intervention and how the review was conducted, 
and the results and conclusions is always a challenge, and may require several 
iterations across the whole review team. The summary is usually the last section to 
be written so that full consideration can be given to all relevant aspects of the project. 
However the process of summary writing may help in the further development of the 
recommendations by forcing review teams to identify the one or two most important 
fi ndings and the conclusions which fl ow from them. It should be remembered that 
revisions to the report or article following peer review may also need to be refl ected 
in the summary. Assistance from outside parties and medical writers may be helpful in 
developing a good summary.
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1.3.6.3 Formulating the discussion
The purpose of the discussion section of a report is to help readers to interpret the 
results of the review. This should be done by presenting an analysis of the fi ndings and 
outlining the strengths and weaknesses of the review. The discussion should also place 
the fi ndings in the context of the existing evidence base, particularly in relation to any 
existing relevant reviews. It has been suggested that more could and should be done in 
discussion sections to contextualise both the nature of the research and the fi ndings to 
the existing evidence base.217 There should be a balance between objectively describing 
the results, and subjectively speculating on their meaning.218 It is important to present a 
clear and logical train of thought and reasoning, supported by the fi ndings of the review 
and other existing knowledge. For example although statistically signifi cant results and 
clear evidence of effectiveness may have been demonstrated, without an exploration of 
the impact on clinical practice it may not be clear whether they are clinically signifi cant. 
Information on the interpretation of the analysis is given throughout Section 1.3.5 Data 
synthesis.
Some commissioners and most journals have a set format or structure for the report. 
This may require the discussion section to incorporate the conclusions and any 
implications or recommendations, or may require these as separate sections. In the 
absence of a structured format for the discussion section, the framework given in Box 
1.12 may be helpful.
Box 1.12: Framework for the discussion section of a review
Statement of principal fi ndings
Strengths and weaknesses of the review
Appraisal of methodological quality of the review
Relation to other reviews, in particular considering any differences
Meaning of the review’s fi ndings
Strengths and weaknesses of the evidence included in the review
Direction and magnitude of effects observed in the included studies
Applicability of the fi ndings of the review
Implications
Practical implications for clinicians and policy-makers
Unanswered questions and implications for further research
Based on Docherty and Smith (1999)219
1.3.6.4 Conclusions, implications, recommendations
Faced with the need to make decisions and limited time to read the whole report, many 
readers may go directly to the conclusions. Therefore, whether incorporated in the 
discussion section or presented separately, it is essential that the conclusions be clearly 
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worded and based solely on the evidence reviewed. The conclusions should summarise 
the evidence and draw out the implications for health care, and preferably be worded to 
show how they have been derived from the evidence.
Conclusions are generally a standard requirement, however, many commissioners and 
journals have their own conventions about implications and recommendations. For 
example, the NIHR HTA programme require the conclusions section of reports to include 
the implications for health care and specify recommendations for future research, 
in order of priority. They specifi cally exclude making recommendations for policy or 
clinical practice.220 Authors’ conclusions from Cochrane reviews are presented as the 
implications for practice and research; recommendations are not made.130
In the absence of guidance from the commissioner, it is generally advisable to avoid 
making recommendations about policy or practice, unless this is the focus of the review. 
The nature of the review question should therefore guide whether it is appropriate to 
include recommendations or focus on the implications for policy, practice and/or further 
research, and how these are best presented. Whether recommendations are made or 
implications drawn, it is important to ensure that these are supported by the evidence 
and to avoid making any statements that are outside the defi ned scope of the review. 
The way in which a recommendation or implication is phrased can considerably infl uence 
the way in which it is interpreted and implemented (or ignored). Hence, it is important 
to make all statements as precise as possible.221-223
Recommendations for practice are usually only made in guidelines, and are formulated 
from a variety of sources of information in addition to review fi ndings. There are a 
number of schemes available for grading practice recommendations according to the 
strength of the evidence that supports them.224-230 Systematic review reports should aim 
to provide the information required to implement any of these systems if used. It should 
be noted that not all the schemes take into account the generalisability of the fi ndings 
of the review to routine clinical practice. This should always be a consideration when 
drawing up the implications or if making recommendations.
A clear statement of the implications or recommendations for future research should 
be made; vague statements along the lines of ‘more research is needed’ are not 
helpful and should be avoided. Specifi c gaps in the evidence should be highlighted to 
identify the research questions that need answering. Where methodological issues 
have been identifi ed in existing studies, suggestions for future approaches may be 
made. Where possible, research recommendations should be listed in order of priority, 
and an indication of how rapidly the knowledge base in the area is developing should 
be included. This can assist in planning an update of the review and help guide 
commissioners when allocating funding.
The DUETs initiative (Database of Uncertainties about the Effects of Treatments; 
(www.duets.nhs.uk), recommends the presentation of research recommendations in 
a structured format represented by the acronym EPICOT (Evidence, Population(s), 
Intervention(s), Comparison(s), Outcome(s), Time stamp). Timeliness (duration of 
intervention/follow-up), disease burden and suggested study design are considered as 
optional additional elements of a structured research recommendation. Further details 
and an example of how to formulate research recommendations using the EPICOT 
format can be found in an article published by the DUETS Working Group.231 It is worth 
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noting that there is some debate about the applicability of the EPICOT format for some 
reviews, particularly those of complex interventions.232
Summary: Report writing
• Report writing is an integral part of the systematic review process.
• Reviews may be published as a report for the commissioner, as a journal 
article or both. Researchers should be aware of the requirements of 
commissioning bodies and journals and adhere to them.
• Readability is a key aspect of reporting; a review’s fi ndings will not be acted 
on if they are not clearly presented and understood.
• The executive summary (for full-length reports) or abstract (for journal 
articles) is the most important part of the report, because it is potentially the 
only section that many readers will actually read (perhaps in conjunction with 
the discussion and conclusions).
• A structured framework can be helpful for preparing the discussion section of 
the report.
• Implications for practice or policy and recommendations for further research 
should be based solely on the evidence contained in the review.
• The fi ndings from systematic reviews are frequently used to inform guideline 
development. Guideline recommendations are often formulated using a 
grading scheme. Systematic review reports should therefore aim to provide 
the information required for such grading schemes.
• A structured format for the presentation of research recommendations has 
been developed as a result of the DUETS initiative.
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1.3.7 Archiving the review
There are published guidelines relating to the retention of primary research data.233 
While these do not currently relate to systematic reviews, they do represent appropriate 
good practice. Where policies on retention, storage and protection are not specifi ed 
by a commissioner, researchers might consider including this information in research 
proposals so that it is clear from the outset what will be kept and for how long.
Decisions need to be made about which documents are vital to keep and which can 
be safely disposed of. Extracted data and quality assessment information should 
be preserved. In addition, records of decisions made during protocol development, 
inclusion screening and data extraction, are unique and should be kept. Minutes of 
meetings, correspondence as well as peer review comments and responses might also 
be held for a specifi c period of time as further records of the decision-making process. 
It is always advisable to permanently store a copy of the fi nal report, particularly if the 
only other copy in existence is the one submitted to the commissioners.
Some information used in the review such as conference abstracts, additional 
information from authors, and unpublished material may be particularly diffi cult to 
obtain at a later stage so hard copies should be archived. This also applies to material 
retrieved from the Internet, which should be printed for the archive, as links to web 
pages are not permanent.
Whilst it may be easy and space saving to archive material electronically, paper records 
are often preferable as the equipment used to access documents stored in electronic 
formats can become obsolete after a relatively short period of time.
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1.3.8 Disseminating the fi ndings of systematic reviews
In recent years, there has been substantial investment in the commissioning 
of systematic reviews assessing the effects of a range of different health care 
interventions. To improve the quality of health care, and ultimately health outcomes, 
the review fi ndings need to be effectively communicated to practitioners and policy-
makers. The transfer of knowledge obtained through research into practice has long 
been acknowledged as a complex process234-238 that is highly dependent on context and 
the interaction of a multitude of interconnected factors operating at the level of the 
individual, group, organisation and wider health system.
A number of conceptual frameworks have attempted to represent the complexity of 
knowledge translation processes.234, 236, 238-244 One recent framework,244 whilst recognising 
the importance of non-linear diffusion, highlights a pivotal role for the direct or planned 
dissemination of contextualised, actionable messages derived from systematic reviews 
to inform practice and policy decision-making processes.
CRD’s experience of direct dissemination has led to the development of a framework, 
which is supported by both theoretical and empirical research into the ways by 
which different audiences become aware of, receive, access, read and use research 
fi ndings (Figure 1.4). This involves targeting the right people with a clear and relevant 
message, communicating via appropriate and often multiple channels (any medium 
used to convey a message to an audience or audiences), whilst taking account of the 
environment in which the message will be received.
Detailed information about this framework is provided here; case studies showing the 
framework in use can be found on the CRD website (www.york.ac.uk/inst/crd). The 
framework provides a basic structure that enables researchers to consider carefully the 
appropriateness of their plans for dissemination, simple or complex, and could be used 
by anyone seeking to promote the fi ndings of a review.
1.3.8.1 What is dissemination?
As interest in enhancing the impact of health research has increased, so too has the 
terminology used to describe the approaches employed.241, 245 Terms like dissemination, 
diffusion, implementation, knowledge transfer, knowledge mobilisation, linkage and 
exchange and research into practice are all being used to describe overlapping and 
interrelated concepts and practices. Given this, it is helpful to explain how the term 
dissemination is used here.
Dissemination is a planned and active process that seeks to ensure that those who 
need to know about a piece of research get to know about it and can make sense of 
the fi ndings. As such it involves more than making research accessible through the 
traditional mediums of academic journals and conference presentations. It requires 
forethought about the groups who need to know the answer to the question a review is 
addressing, the best way of getting the message directly to that audience, and doing so 
by design rather than chance. Hence an active rather than passive process.
The term dissemination is often used interchangeably with implementation but it is more 
appropriate to see the terms as complementary. Dissemination and implementation are 
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part of a continuum.239, 246, 247 At one end are activities that focus on making research 
accessible, raising awareness of new fi ndings and encouraging consideration of practice 
alternatives and policy options. At the other end of the continuum are activities that 
seek to increase the adoption of research fi ndings into practice and policy and that 
facilitate, reinforce and maintain changes in practice.
CRD’s primary focus is very much at the awareness raising end of the continuum, 
though there is no clear cut off point, and there is evidence for the positive effects 
of planned dissemination on the implementation of research evidence in practice.237 
For example, there is some evidence that the centre’s Effective Health Care and 
Effectiveness Matters series of bulletins had a positive impact on the quality of health 
care delivered. Empirical studies have suggested that the dissemination of these 
bulletins contributed to reductions in the prophylactic extraction of wisdom teeth,248, 249 
in the use of surgical interventions for glue ear,250, 251 and impacted on the prescribing of 
selective serotonin reuptake inhibitors for depression.252, 253
Dissemination should not be viewed as an adjunct to the review process or as 
something to be considered at the end when thoughts turn to publication. Nor should 
it be seen as separate from the wider social context in which the review fi ndings 
are expected to be used. It is an integral part of the review process and should be 
considered from an early stage to allow adequate time for planning and development, 
for the allocation of responsibilities and to ensure that the proposed activities are 
properly resourced. The CRD framework (Figure 1.4) offers a sequential approach to 
considering, developing and implementing appropriate dissemination strategies for 
individual systematic reviews. The framework has been utilised for a wide range of 
topics and audiences for over a decade.
1.3.8.2 CRD’s approach to dissemination
Traditionally, research on dissemination and implementation has tended to focus on 
the use of research knowledge, rather than on the effects of dissemination activities. 
However, a number of conceptual frameworks have been put forward which consistently 
suggest that the effectiveness of dissemination activities is determined by careful 
consideration of a number of key attributes.234, 237, 254-258 These are:
• The characteristics of the research message
• The setting in which the message is received
• The characteristics of the target audience(s)
• The source of the research message
• The presentation of the research message
• The communication channel(s) used
Assuming that all research has an audience (but not that all research should be 
widely disseminated), whether the message provides an unequivocal answer or simply 
highlights the need for further research, our approach is structured around six key 
attributes which are interlinked and diffi cult to consider in isolation (see Figure 1.4). The 
key messages from the review are the starting point for determining the audience to be 
targeted.
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Figure 1.4: CRD Dissemination framework
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The literature on communication259 and diffusion239 (i.e. how, why, and at what rate 
ideas/innovations spread through social systems) highlights three types of messages 
that can impact on the knowledge and attitudes of target audiences: awareness, 
instruction (‘how to’) and persuasion (information that reduces uncertainty about 
expected consequences). Message characteristics to consider include the nature of the 
intervention, the strength of the evidence, its transferability, the degree of uncertainty 
and whether the fi ndings confi rm or reject existing predispositions or practices. 
Messages also have to be perceived as relevant and meaningful by the audiences being 
targeted. Knowledge about both the wider setting (economic, social, organisational 
and political environments) within which a target audience resides and the context 
(hostile or receptive) in which a message is to be received, should be used to inform the 
development of appropriate dissemination strategies.
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Characteristics of the target audience(s)
Deciding who to target usually involves an element of prioritisation (segmentation) as 
resource constraints can make it diffi cult to reach all possible audiences. In prioritising, 
relevance (who needs to know about this research) and receptivity (who is most likely 
to be infl uenced and to infl uence others) need to be considered. The question of how 
best to reach target audiences can in part be answered by drawing upon the theoretical 
literature on research utilisation (the ways by which different audiences become aware 
of, access, read and make use of research fi ndings).260, 261 This literature helps to 
inform the selection of the most appropriate or feasible communication channels for 
the audiences being targeted. Channels frequently used to promote review fi ndings 
include paper and electronic publishing, email alerting services, direct and relationship 
marketing, mass media campaigns as well as engaging directly with target audiences.
Presentation of the research message and communication channel(s) used
The literature on diffusion239 makes a distinction between mass media channels and 
interpersonal (face to face) channels. The former are generally regarded as being 
more important for dissemination purposes whereas interpersonal channels are more 
important for activity at the implementation end of the continuum. CRDs experience is 
that a combination of communication channels is helpful in increasing the likelihood that 
target audiences will encounter the review messages being promoted.
The selection of communication channels may also inform the presentation (tailoring) 
of the research message itself. When tailoring messages, consideration is given to the 
target audience, language used, the format, structure and style of presentation, the 
types of appeal and the amount of repetition. It is generally appropriate to try to write 
for an educated but non-research specialist health professional or decision-maker. Lay 
terms are used rather than technical language and statistics presented in as simple 
a form as possible. The aim is to make information accessible to a broad range of 
readers and anyone who would like more details can access the full report. It has been 
advocated that a layered structure such as the ‘1:3:25’ format (i.e. one page of the 
research ’bottom lines’ or ‘actionable messages’, three-page executive summary and 
a 25-page report) is the optimal way to present research evidence to health service 
managers and policy-makers.213 This type of structuring involving a front page of key 
messages has become common place and refl ects documented audience preferences for 
the ‘bottom line’ up front. There is some evidence that this order of presentation can 
increase overall understanding of the research fi ndings but may also in some instances 
alienate those who are less receptive to or in disagreement with the conclusions 
presented.262, 263
Source of the research message
How the source (i.e. the research team or organisation) is perceived by a target 
audience in terms of its credibility (trustworthiness), attractiveness (likemindedness) 
or power, is an important consideration. For example, where the evidence base is 
contested (clinically or politically), and/or where audiences are less familiar with 
systematic review methods generally, promoting source credibility can be crucial from 
the outset. An approach CRD has used when encountering these issues, has been to 
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create dedicated, publicly accessible websites that provide information about all aspects 
of the review. These websites enable external scrutiny of the review process, and 
include feedback facilities for interested parties to comment, ask questions or submit 
evidence for consideration. Our experience suggests it is important to make it clear 
that contributions of existing research evidence, including published/grey literature, are 
welcome, but that personal experience and anecdote, whilst important, does not usually 
form part of a systematic review. An example of a review dedicated website can be 
found at www.york.ac.uk/inst/crd/fl uorid.htm. Considerable effort is required to set up, 
monitor and maintain a dedicated website and our experience of the benefi t is varied. 
It is important therefore to consider the likely benefi t to the review and the target 
audience before setting up a site.
Dissemination strategies
It has been proposed that there are four dissemination models that can be employed to 
link ‘research to action’.262, 263 These are:
• Push strategies which are largely associated with supply (researcher) led 
distribution of new research fi ndings
• Pull strategies which facilitate demand (audience) led access to research
• Linkage and exchange264 efforts which involve two way communications and 
partnerships between producers and users of research
• Integrated approaches that incorporate aspects of all three
In reality, push, pull and exchange strategies are not mutually exclusive; facilitating 
user pull often requires the application of a promotional push strategy (e.g. utilising 
email alerting services or RSS feeds) to inform and remind target audiences about 
review fi ndings that are forthcoming or have been made available online for example. 
CRD favours the integrated approach that incorporates elements of all three strategies, 
but where the emphasis shifts according to the topic and the audiences to be targeted.
Evaluation of impact
There is an increasing requirement, particularly from funders, for the impact of research 
to be predicted in advance of the work and then assessed after completion.265, 266 There 
are a number of specialised research impact assessment approaches, but these usually 
require specialist skills and additional resources.267, 268 Taking the issue of whether 
academic quality or practical use and impact of research is most important, a pragmatic 
framework has been proposed which addresses both points.269 The framework is based 
on the assessment criteria used in UK universities. It provides a structure for a narrative 
description of the impact of the fi ndings from why the research question was fi rst posed 
and funded, to where the results were sent, discussed, and put into policy and/or 
practice.
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Summary: Dissemination
• Simply making research available does not ensure that those that need to 
know about it get to know about it or can make sense of the fi ndings.
• Dissemination is a planned and active process that can aid the transfer of 
research into practice.
• Dissemination should not be viewed as an adjunct but rather as an integral 
part of the review process and should be considered from the outset.
• CRD employs a topic-driven approach that involves targeting the right people 
with understandable and relevant messages, communicating via appropriate 
(often multiple) channels, whilst taking account of the environment in which 
the message will be received.
• The CRD framework provides a basic structure for developing appropriate 
dissemination strategies and could be used by anyone seeking to promote the 
fi ndings of a review.
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2.1 INTRODUCTION
Clinical tests are routinely used for diagnosis, confi rming or excluding the presence 
of a disease or condition (such as pregnancy). They are also used to monitor disease 
progression, assess prognosis, and screen asymptomatic populations for disease. Any 
process that yields information used to inform patient management can be regarded as 
a clinical test.1 This includes a wide range of processes from history taking and physical 
examination to complex imaging techniques. The test itself is an intervention and forms 
part of the continuum of patient care. New tests are adopted into clinical practice for 
a number of reasons, including replacement of an existing test (where the new test is 
expected to reduce the negative impact on the patient, provide better information, or 
equivalent information for less cost), triage (to decide whether a more expensive or 
invasive test is necessary), or as an addition to the existing testing protocol.
The ultimate aim of any research on clinical tests should be to determine impact upon 
patient management and outcome. An RCT comparing the effect of different diagnostic 
strategies on one or more clinical outcomes could be considered ideal, as it provides 
direct information on the benefi t to patients and can be modifi ed to address various 
types of diagnostic question.2 However, RCTs may not be appropriate for addressing all 
diagnostic questions3, 4 and to date much of the research on diagnostic tests is in the 
form of test accuracy studies. The basic aim of test accuracy studies is to assess how 
well a test can distinguish between people with and without the disease/condition of 
interest. The outcome measures used describe the probabilistic relationships between 
positive and negative test results, and the presence or absence of disease, as compared 
with the best currently available method (i.e. the clinical reference standard). As such, 
test accuracy studies do not directly measure the relative benefi ts and harms to patients 
of testing. Evidence on the accuracy of a test, combined with evidence of a prognostic 
link between the target condition and preventable morbidity/mortality, may be 
considered indicative of the likely effectiveness of the test.5 Where a new test is being 
evaluated, evidence for a prognostic link between the target disease/condition and 
long-term morbidity or mortality should be available as should an effective intervention. 
However, this is not always the case as tests can be established in clinical practice with 
limited supporting evidence.
When considering a systematic review of test accuracy studies, it is important to assess 
whether review fi ndings will be able to provide the information necessary to inform 
clinical practice. Any review of test accuracy is likely to be of limited value where 
evidence is lacking that the disease/condition is associated with long-term morbidity 
or mortality, or where no effective intervention is available. This is illustrated by the 
following examples:
• Magnetic Resonance Angiography (MRA) versus intra-arterial Digital Subtraction 
Angiography (DSA) for the detection of carotid artery stenosis.6 There is evidence 
from RCTs that carotid endarterectomy is an effective treatment for symptomatic 
carotid artery stenosis at thresholds defi ned by DSA. MRA is a less invasive test 
option. A review of test accuracy is therefore likely to be informative.
• Ultrasound versus Micturating Cystourethrography (MCUG) for the detection of 
vesicoureteric refl ux (VUR) in children with urinary tract infection (UTI).7 There 
is confl icting evidence of a link between VUR and long-term renal damage and 
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the effectiveness of treatment options, such as prophylactic antibiotics, is also 
uncertain. A review of test accuracy alone is therefore unlikely to be informative.
Although some study designs, such as those based upon multivariable prediction 
modelling, may better refl ect the true nature of the diagnostic workup and are 
potentially more informative than test accuracy studies,8, 9 they are rare. Consequently, 
systematic review methods for assessing clinical tests have largely focused upon test 
accuracy studies and this chapter discusses methods developed specifi cally to deal 
with such studies. Section 2.2 focuses on diagnostic accuracy studies, but the methods 
described also apply to test accuracy studies used to assess the performance of new 
screening tests, within established screening programmes. The clinical effectiveness 
of screening programmes is best evaluated using RCTs and systematic reviews of such 
studies should follow the principles outlined in Chapter 1. Section 2.3 describes methods 
for reviewing prognostic studies.
In light of the limitations described in relation to test accuracy studies, careful 
consideration should always be given to the likely informative value and any additional 
data requirements before undertaking a systematic review of test accuracy.
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2.2 DIAGNOSTIC TESTS
2.2.1 The review question
As with all systematic reviews, the development of a clear, well-defi ned question is 
essential to maintaining transparency of the review process and to the quality and 
relevance of the fi ndings. Some aspects of the question require particular consideration 
when planning a review of test accuracy.
2.2.1.1 Population
Diagnostic tests perform differently in different populations,10, 11 for example it would 
generally be inappropriate to evaluate the performance of a test in a secondary care 
population when the test is mainly used in primary care. Both frequency and severity of 
the target condition would be expected to be greater in secondary care. It is therefore 
important to clearly defi ne the population of interest. The ideal study sample for a test 
accuracy study is a consecutive or randomly selected series of patients in whom the 
target condition is suspected, or for screening studies, the target population. Because 
participant sampling methods are often poorly reported in test accuracy studies,12 
using the sampling method as an inclusion/exclusion criterion is likely to result in 
a substantial reduction in available data. It is likely to be more useful to consider 
the sampling method and/or its reporting as an aspect of study quality (see Section 
2.2.5 Quality assessment) and to base the inclusion criteria relating to the population 
upon participant characteristics. For example in a review comparing the accuracy of 
different imaging techniques, the inclusion criteria might state that only patients with a 
specifi ed level of symptoms, representative of those in whom the test would be used for 
intervention planning, are eligible.
2.2.1.2 Intervention (index test)
In reviews of test accuracy the ‘index test’ (the test whose performance is being 
evaluated) can be viewed as the intervention. As with any review, the scope of the 
question can be broad such as ‘what is the optimum testing pathway for the diagnosis 
and follow-up investigation of childhood urinary tract infection (UTI)?’13 or it can 
be narrow; for example ‘what is the diagnostic accuracy of magnetic resonance 
angiography (MRA) when compared with intra-arterial x-ray angiography, for the 
detection of carotid artery stenosis?’6 The former is likely to include a number of 
different technologies, addressing multiple target conditions, whereas the latter 
compares the performance of an alternative (replacement), less invasive or less 
costly diagnostic technology with that of the reference standard for the detection of a 
specifi ed target condition. The rate of technological development may be an important 
consideration; in this latter example inclusion of MRA techniques that are already 
obsolete in clinical practice, is unlikely to be useful.
Careful consideration should always be given to the equivalence of different analytical 
techniques when setting inclusion criteria. For example, a systematic review of faecal 
occult blood tests to screen for colorectal cancer14, 15 evaluated both immunochemical 
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and colourimetric methods for detecting blood in the faeces; though both methods 
target blood, they cannot be considered equivalent tests.
The traditional concept of test accuracy often implies the dichotomisation of data into 
test results which are classifi ed as positive (target condition present) or negative (target 
condition absent). Any systematic review of test accuracy will therefore need to consider 
diagnostic thresholds (points at which results are classifi ed as positive or negative) for 
each included index test.
2.2.1.3 Reference standard/comparator
The reference standard is usually the best test currently available, and is the standard 
against which the index test is compared. It need not be the test used routinely in 
practice (although it can be), and may include information which is not known for some 
time after the tests have been done (e.g. follow-up of test negatives in cancer).
The test accuracy study is based upon a one-sided comparison between the results of 
the index test and those of the reference standard. Any discrepancy is assumed to arise 
from error in the index test. Selection of the reference standard is therefore critical to 
the validity of a test accuracy study and the defi nition of the diagnostic threshold forms 
part of that reference standard.
It is important to note that the assumption of 100% accuracy for the reference standard 
rarely holds true in practice. This represents a fundamental fl aw in the test accuracy 
study design, since the index test can never be deemed to perform better than the 
reference standard, and its value may therefore be underestimated.16
Where several tests are available to diagnose the target condition, there is often 
no consensus about which test constitutes the reference standard. In such cases a 
composite reference standard, which combines the results of several available tests to 
produce a better indicator of true disease status may be used.17 A number of statistical 
methods have been proposed to estimate the performance of tests in the absence of a 
single accepted reference standard.18, 19
There may be instances when it is deemed unethical to use an invasive procedure as 
a reference standard in a study.20 In such cases, clinical follow-up and fi nal diagnosis 
may sometimes be used as a surrogate reference standard. There will also be occasions 
when clinical follow-up and fi nal diagnosis provides the most appropriate reference 
standard. The length of follow-up should ideally be defi ned in advance. Studies using 
follow-up and clinical outcome in this way may be viewed as prognostic studies in that 
they are measuring the accuracy with which the test is able to predict a future event, 
rather than the accuracy with which it is able to determine current status. Where such 
studies are included in a systematic review, it is important to defi ne, in advance, what 
constitutes appropriate follow-up and hence an adequate reference standard.
The comparator is an alternative test, usually that which is used in current practice, 
against which the index test must be evaluated in order to assess its potential role. 
Ideally, this should be done by comparing index test and comparator to the reference 
standard in the same population.
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Figure 2.1: The 2x2 contingency table
  Reference standard
  Positive Negative
Index test
 Positive TP FP
 Negative FN TN
From the 2 x 2 contingency table, the following commonly used measures of test 
performance can be calculated:
Sensitivity =
FNTP
TP
+
The proportion of people with the target condition who have a positive test result.
Specifi city =
FPTN
TN
+
The proportion of people without the target condition who have a negative test result.
Overall accuracy =
TNFPFNTP
TNTP
+++
+
The proportion of people correctly classifi ed by the test.
Positive predictive value =
FPTP
TP
+
The probability of disease among persons with a positive test result.
2.2.1.4 Outcome measures
The primary outcome of interest for any systematic review of test accuracy is the data 
required to populate 2 x 2 contingency tables. These describe the relationship between 
the results of the index test and the reference standard at a given diagnostic threshold 
(point at which results are classifi ed as positive or negative). The table includes the 
number of true positives (TP: those that have the disease and test positive), false 
positives (FP: those that do not have the disease and test positive), false negatives (FN: 
those that do have the disease and test negative) and true negatives (TN: those that do 
not have the disease and test negative). See Figure 2.1.
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Negative predictive value =
FNTN
TN
+
The probability of non-disease among persons with a negative test result.
Positive likelihood ratio =
 
⎟⎟⎠
⎞
⎜⎜⎝
⎛
+
⎟⎟⎠
⎞
⎜⎜⎝
⎛
+
TNFP
FP
FNTP
TP
 or 
Negative likelihood ratio =
 
⎟⎟⎠
⎞
⎜⎜⎝
⎛
+
⎟⎟⎠
⎞
⎜⎜⎝
⎛
+
FNTN
TN
FNTP
FN
 or 
Likelihood ratios (LR) describe how many times more likely it is that a person with 
the target condition will receive a particular test result than a person without. Positive 
likelihood ratios greater than 10 or negative likelihood ratios less than 0.1 are 
sometimes judged to provide convincing diagnostic evidence.21
Diagnostic odds ratio =
FNFP
TNTP
×
×
Used as an overall indicator of diagnostic performance and calculated as the odds of 
a positive test result among those with the target condition, divided by the odds of a 
positive test result among those without the condition.
Sensitivity
1– Specifi city
1– Sensitivity
Specifi city
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In primary studies, a receiver operating characteristic (ROC) curve describes the 
relationship between ‘true positive fraction’ (sensitivity) and ‘false positive fraction’ 
(1– specifi city) for different positivity thresholds. It is used to display the trade-offs 
between sensitivity and specifi city as a result of varying the diagnostic threshold.
Below is an example ROC analysis for serum thyroid stimulating hormone (TSH) as a 
diagnostic test for primary hypothyroidism:
Test results (Serum TSH) vs. reference standard (thyroid status)
Serum TSH (mIU/L) Number with primary  Number without primary 
 hypothyroidism hypothyroidism
<6 17 325
6-12 42 158
13-15 46 48
16-20 66 33
>20 284 5
Sensitivity and specifi city values for each diagnostic threshold (derived from the 2 x 2 contingency 
data and expressed as percentages)
Diagnostic threshold for a positive test 
result (mIU/L) Sensitivity Specifi city
≥6 96.2% 57.1%
>12 87.0% 84.9%
>15 76.9% 93.3%
>20 62.4% 99.1%
2 x 2 contingency data for serum TSH diagnostic threshold (derived by summing the numbers of 
participants, with and without primary hypothyroidism, on either side of the diagnostic threshold)
Diagnostic threshold for a 
positive test result (mIU/L) TP FP FN TN
≥6 438 244 17 325
>12 396 86 59 483
>15 350 38 105 531
>20 284 5 171 564
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Figure 2.2: Example ROC curve for thyroid stimulating hormone (TSH)
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‘Q*’, or maximal joint sensitivity and specifi city, is the point on the ROC curve that 
intersects with the line of symmetry. It is sometimes used as an indicator of overall 
test performance where there is no clinical preference for maximising either sensitivity 
(minimizing false negatives) or specifi city (minimizing false positives). However Q* is 
not useful if the thresholds at which tests have been evaluated do not lie close to the 
line of symmetry and can then give misleading results if used to compare performance 
between tests.
In some scenarios (e.g. tests used in population screening) a threshold which skews 
diagnostic performance may be preferable (e.g. minimizing the number of false 
negatives at the expense of some increase in the number of false positive results, 
in conditions/diseases where missing the presence of disease will lead to serious 
consequences). Overall diagnostic accuracy is summarised by the area under the curve 
(AUC); the closer the curve is to the upper left hand corner the better the diagnostic 
performance.22 The AUC ranges from 0 to 1, with 0.5 indicating a poor test where the 
accuracy is equivalent to chance.
As with other types of intervention, when assessing the clinical effectiveness of a 
diagnostic test, it is important to consider all outcome measures which may be relevant 
to the use of the test in practice. These might include adverse events (see Chapter 4) 
and the preferences of patients, although inclusion of such information is rare.
2.2.1.5 Study design
There are two basic types of test accuracy study: ’single-gate’ which are similar to 
consecutive series (and previously sometimes called diagnostic cohort studies) and 
’two-gate’ which are similar to case-control studies. The term ‘two-gate’ being used 
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where two sets of inclusion criteria or ‘gates’ are applied, one for participants who have 
the target condition and one for those who do not. These designs differ in structure 
from other cohort and case-control studies in that both are generally cross-sectional in 
nature.23
• The single-gate design includes participants in whom the disease status is 
unknown, and compares the results of the index test with those of the reference 
standard used to confi rm diagnosis, i.e. it is broadly representative of the 
scenario in which the test would be used in practice.
• The two-gate design compares the results of the index test in patients with 
an established diagnosis of the target condition with its results in healthy 
controls or controls with another diagnosis (known status, with respect to 
the target condition, is therefore treated as the reference standard); i.e. it is 
unrepresentative of practice and is unlikely to contain the full spectrum of health 
and disease over which the test would be used.
There are inherent problems with the two-gate design that may lead to bias. The 
selective inclusion of cases with more advanced disease is likely to lead to over 
estimations of sensitivity and inclusion of healthy controls is likely to lead to over 
estimations of specifi city. The recruitment of healthy controls from the general 
population has been associated with two- to three-fold increases in measures of test 
performance time-to-events derived from a diagnostic cohort design.11, 24, 25 This over 
estimation can be increased further when cases of severe disease are used alongside 
healthy controls.26 By contrast, where cases are derived from individuals with mild 
disease, underestimations of sensitivity can result.27 Where the control group is derived 
from patients with alternative diagnoses, specifi city may be under or overestimated, 
depending upon the alternative diagnosis.23 In theory, the two-gate study design could 
produce a valid estimate of test performance if the cases were sampled to match the 
reference standard positive patients in a single-gate study (in terms of the spectrum of 
disease severity) and controls were matched to the reference standard negative patients 
(in terms of the spectrum of alternative conditions). In practice however, this is diffi cult 
to achieve.23 Whilst two-gate studies are therefore of limited use in assessing how a test 
is likely to perform in clinical practice, they can be useful in the earlier phases of test 
development.28
Where systematic reviews include both single and two-gate study designs, careful 
consideration should be given to the methods of analysis and the impact of study design 
should be assessed in any meta-analyses.29
2.2.2 Identifying research evidence
2.2.2.1 Sources
The importance of searching a wide range of databases to avoid missing relevant 
diagnostic test accuracy studies has been demonstrated, with MEDLINE, EMBASE, 
BIOSIS, LILACS, Pascal and Science Citation Index all providing unique records.30 The 
reference lists of included studies can also be a useful resource.
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The Cochrane Diagnostic Test Accuracy Working Group31 is creating a database of 
test accuracy studies,32 similar to the non-topic specifi c Cochrane Central Register of 
Controlled Trials (CENTRAL) which includes details of published articles taken from 
bibliographic databases and other published and unpublished sources.33
2.2.2.2 Database searching
Many electronic databases do not have appropriate indexing terms to label test accuracy 
studies, and those that do tend not to apply them consistently.30, 34-36 They also vary in 
their design which adds to the diffi culty in identifi cation.34 The problem is compounded 
by the fact that the original authors are often poor at identifying their studies as being 
test accuracy.30
It has been reported that the use of fi lters to identify reports of diagnostic test accuracy 
studies in electronic databases may miss a considerable number of relevant articles 
and is therefore not generally considered appropriate.34, 36, 37 Database searching 
should concentrate on terms for index tests and target conditions. If further restriction 
is required, it can be achieved by means of topic specifi c terms, rather than using a 
fi lter.36, 38 It is hoped, however, that in time, as the issues of reporting and indexing 
diagnostic, screening and prognostic studies are more widely realised, the situation will 
improve allowing the development of more accurate fi lters.
2.2.3 Publication bias
As the data used in studies of test accuracy are often collected as part of routine clinical 
practice (and in the past have tended not to require formal registration) it has been 
argued that test accuracy studies are more easily conducted and abandoned than RCTs. 
They may therefore be particularly susceptible to publication bias.39 Simulation studies 
have, however, indicated that the effect of publication bias on meta-analytic estimates 
of the Diagnostic Odds Ratio (DOR) is not likely to be large.40
It has been demonstrated that the unique features of the test accuracy study make the 
application of the Begg, Egger, and Macaskill tests of funnel plot asymmetry potentially 
misleading.40 An alternative approach uses funnel plots of (natural logarithm (ln) DOR) 
vs. (1/√effective sample size) and tests for asymmetry using related regression or rank 
correlation tests.40 It should be noted that the power of all statistical tests for funnel 
plot asymmetry decreases with increasing heterogeneity of DOR. It should also be 
noted that factors other than publication bias, for example aspects of study quality and 
population characteristics, may be associated with sample size.
Given the limitations of current knowledge, to ignore the possibility of publication bias 
would seem unwise, however, its assessment in reviews of test accuracy is complex.
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2.2.4 Data extraction
The same precautions against reviewer bias and error should be employed whilst 
extracting data from test accuracy studies as would be applied in any other type of 
review. Independent checking of 2x2 data is particularly important, as test accuracy 
studies are often poorly reported,12, 41 and the production of a 2x2 table from these 
studies can be far from straightforward.
Some studies may provide the actual results for each test for individual patients. In 
this case the researcher may need to classify each patient according to the diagnostic 
thresholds defi ned in the review protocol.
Studies may provide categorical data, which may represent multiple categories or 
stages of disease (as shown in example 1). In this case data will need to be extracted 
for the numbers of index test positive and negative participants (using the threshold(s) 
defi ned in the review protocol, which may include all thresholds reported) with 
and without the target condition (as defi ned by the reference standard, using the 
threshold(s) defi ned in the review protocol).
Data extraction, example 1
 Reference standard
  0-19% 20-49% 50-79% 80-100%
 0–19% 5 8 4 1
 20–49% 6 4 5 1
 50–79% 1 9 15 4
 80–100% 2 5 6 10
Index test
If the threshold for a positive test in example 1 was 20% (for both index test and 
reference standard), then the 2x2 data would be extracted as in example 1a.
Data extraction, example 1a
  Reference standard
  Positive Negative
Index test
 Positive TP FP
 Negative FN TN
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The value for TP is derived by summing the number of participants, from the shaded 
cells, who have both reference standard and index test results at or above the 
diagnostic threshold (20%), i.e. 4+5+1+9+15+4+5+6+10=59.
The value for FP is derived by summing the number of participants who have a 
reference standard result below 20%, but an index test result above this threshold, i.e. 
6+1+2=9.
The value for FN is derived by summing the number of participants who have a 
reference standard result at or above 20%, but an index test result below this 
threshold, i.e. 8+4+1=13.
The value for TN corresponds to the single cell representing participants who have both 
a reference standard and index test result below 20%, i.e. 5.
  Reference standard
  Positive Negative
Index test
 Positive 59 9
 Negative 13 5
If the index test threshold was increased to 50%, with the reference standard remaining 
at 20% and the same procedure of summing relevant cells applied, then the 2x2 data 
would be extracted as in example 1b.
Data extraction, example 1b
  Reference standard
  Positive Negative
Index test
 Positive 49 3
 Negative 23 11
There may be instances when the raw data are not reported, but 2x2 data can be 
calculated from reported accuracy measures and total numbers of diseased or non-
diseased patients. In example 2, 100 patients underwent an index test and reference 
standard test. The study reports that the index test correctly identifi ed 20 diseased 
patients and had a sensitivity of 80% and a specifi city of 95%.
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Data extraction, example 2
Sensitivity = TP/(TP+FN) = 0.8
Therefore 20/(20+FN)=0.8
 20=0.8(20+FN)
 20=16 + 0.8FN
 0.8FN=20-16=4
 FN=4/0.8=5
This gives:
  Reference standard
  Positive Negative
Index test
 Positive 20
 Negative 5
Therefore, if there were 100 patients in total and 25 were reference standard positive, 
then 75 were reference standard negative.
Specifi city = TN/(TN+FP) = 0.95
 TN/75=0.95
 TN=75x0.95
 TN=71
As there are 100 patients, FP= 100-(20+5+71) = 4, so the fi nal 2x2 table is:
  Reference standard
  Positive Negative
Index test
 Positive 20 4
 Negative 5 71
Somewhat more problematic are cases when the data do not ‘fi t’ the 2x2 contingency 
table model. ‘Forcing’ data into a 2x2 contingency table, for example by classifying 
uncertain index test results as FP or FN, may be inappropriate. The contingency 
table can be extended to form a six cell table, which accommodates uncertain or 
indeterminate index test results,42 as shown in Figure 2.3.
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The informative value of an indeterminate test result can be assessed using an 
indeterminate likelihood ratio (or LR+/-), defi ned as the probability of an indeterminate 
test result in the presence of disease divided by the probability of an indeterminate test 
result in the absence of disease.42
When index test and reference standard give clear results (ie considered determinate), 
but there is incomplete concordance, the 2x2 table may be expanded to accommodate 
a more complete clinical picture. In example 3, taken from an analysis of imaging 
techniques for the localisation of epileptic foci, category E represents those patients 
for whom the index test and reference standard both detected disease, but differing 
numbers of foci. Category F represents those patients for whom the index test and 
reference standard both detected disease, but identifi ed foci in different areas of the 
brain.43
Figure 2.3: The 3x2 contingency table
  Reference standard
  Positive Negative
 Positive A B
Index test Indeterminate E F
 Negative C D
Data extraction, example 3
  Reference standard
  Positive Negative
 Positive A B
Index test
 Negative C D
 Partially correct E
 Incorrect F
2.2.5 Quality assessment
Structured appraisal of methodological quality is key to assessing the reliability of test 
accuracy studies included in a systematic review.44 Quality assessment should consider 
the association of individual elements of methodological quality with test accuracy; 
generating overall ‘quality scores’ is not recommended.45
There are many differences in the design and conduct of diagnostic accuracy studies 
that can affect the interpretation of their results. Some differences lead to systematic 
bias such that estimates of diagnostic performance will differ from their true values, 
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others give rise to variation in results between studies, which can limit applicability. 
The distinction between bias and variation is not always clear, and quality assessment 
checklists have tended to include items that are pertinent to both.46, 47 Sources of 
variation and bias that are potentially relevant when considering studies of test accuracy 
are described in Table 2.1. Whilst it is clear that variation (e.g. in the demographic 
characteristics or severity of disease in the study population) can affect the applicability 
of the results of both individual studies and systematic reviews, there is limited evidence 
on the effects of design-related biases in primary studies on the results of systematic 
reviews.11, 24, 26, 48 Research on the impact of design-related biases is largely a work in 
progress, being dependent upon the availability of adequate data sets and consistent 
methods of quality assessment.
Guidelines for assessing the methodological quality of test accuracy studies were 
fi rst developed in the 1980s.16, 46 A large number of quality assessment tools and 
checklists have since been published, often as part of individual systematic reviews. 
Methodological work has identifi ed 67 tools designed to assess the quality of test 
accuracy studies and 24 guides to the interpretation, conduct or reporting of test 
accuracy studies.49 Only six of the quality assessment tools specifi ed which aspects of 
quality they aimed to cover.50-55 One quality assessment tool46 and one guide to the 
reporting of diagnostic accuracy studies56 provided detailed information of how items 
had been selected for inclusion in the tool, and none reported systematic evaluation of 
the tool.
QUADAS was the fi rst attempt to develop an evidence-based, validated, quality 
assessment tool specifi cally for use in systematic reviews of test accuracy studies.47 
The items included in QUADAS were derived by combining empirical evidence from 
three systematic reviews, reported in two publications11, 49 with expert opinion, using a 
formal consensus method.47 The QUADAS criteria and the sources of bias and variation 
to which they relate are given in Table 2.2. Each item is scored as ‘Yes’, ‘No’ or ‘Unclear’ 
and generic guidance on scoring has been published.47, 57 It is, however, impossible 
to provide a universally applicable description of how some QUADAS items should be 
scored, e.g. the defi nition of ‘an appropriate patient spectrum’, or ‘a reference standard 
likely to correctly classify the target condition.’ It is therefore important that guidance 
on scoring be refi ned for individual reviews, with the defi nition of what should be scored 
as ‘Yes’, ‘No’ and ‘Unclear’ being specifi ed for each QUADAS item and agreed by the 
whole review team at the start of the review; this should be done in close consultation 
with clinical experts.57 Piloting of the quality assessment process on a small sample 
of included studies should be done in an attempt to eliminate any discrepancies in 
understanding between reviewers.
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Table 2.1: Sources of bias and variation in test accuracy studies11
Source Bias and/
 or variation Description
Population
Demographic 
characteristics Variation Test may perform differently in different populations.
Disease severity Variation Differences in disease severity may lead to different 
  estimates of diagnostic performance.
Disease prevalence Variation The prevalence of the target condition varies with
 Bias the setting and may affect estimates of diagnostic 
  performance. In settings of higher prevalence, 
  interpreters are more prone to classify test results as 
  abnormal (context bias).
Participant selection Variation A selection process that may not include a spectrum 
  of patients similar to that in which the test will be 
  used in practice may limit the applicability of study 
  fi ndings.
Test methods
Test execution Variation Differences in the execution of the index test and/or 
  reference standard can result in different estimates of 
  diagnostic performance; clear reporting of the 
  methods used is therefore important.
Technological  Variation Diagnostic performance of tests can change over time 
 development due to technological improvements.
Treatment paradox Bias Occurs when treatment is started, based upon the 
  results of one test prior to undertaking the other; 
  thus disease state is potentially altered between 
  tests.
Disease progression Bias Occurs when there is suffi cient time delay between 
  the application of the index test and the reference 
  standard to allow change in the disease state.
Application of the reference standard
Use of an inappropriate Bias The error in diagnoses derived from an imperfect 
reference standard  reference standard can result in underestimation of 
  the performance of the index test.
Differential verifi cation Bias Occurs when the diagnosis is verifi ed using different 
  reference standards, depending upon the result of the 
  index test.
Partial verifi cation Bias Occurs where only a selected sample of participants 
  undergoing the index test also receive the reference 
  standard.
(Continued)
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Source Bias and/
 or variation Description
Interpretation (reading process)
Test or diagnostic  Bias Where interpretation of either the index test or 
review  reference standard may be infl uenced by knowledge 
  of the results of the other test. Diagnostic review bias 
  may be present when the results of the index test 
  are known to those interpreting the reference 
  standard. Test review bias may be present when the 
  results of the reference standard are known to those 
  interpreting the index test.
Clinical review Bias The availability of other relevant clinical information 
  (e.g. symptoms, co-morbidities) may also affect 
  estimates of test performance.
Incorporation Bias Occurs when the result of the index test is used in 
  establishing the fi nal diagnosis (i.e. it forms part of 
  the reference standard).
Observer Variation The interpretation placed upon a test result may vary 
  between observers and this can affect estimates of 
  test accuracy. The reproducibility of a test within 
  (intra) and between (inter) observers affects its 
  applicability in practice.
Analysis
Handling of  Bias Diagnostic tests fail or produce un-interpretable 
un-interpretable  results with varying frequency. Study participants 
results  for whom a test result could not be obtained are 
  often removed from reported analyses. This may lead 
  to a biased assessment of test performance.
Arbitrary choice of  Variation The choice of a threshold value based upon that 
threshold value (the  which maximises sensitivity and specifi city for the 
diagnostic threshold is  study data may result in exaggerated estimates of 
derived from the same  test performance. The test may perform less well at 
data set in which test   the chosen threshold when evaluated in a new 
performance is evaluated)  independent patient set.
QUADAS is a generic tool, which may be adapted to optimise its usefulness for specifi c 
topic areas. Researchers should, therefore, also consider in advance whether all 
QUADAS items are relevant to their topic area, and whether there are any additional 
items that are not included in QUADAS.57 For example, disease progression bias may 
not be a relevant issue where the clinical course of the target condition is slow; when 
comparing the performance of imaging tests, or other tests which require subjective 
interpretation by the operator, the impact of observer variation may need to be 
considered as variation in test performance with individual operators of the same test 
(e.g. different individuals conducting and/or interpreting an ultrasound examination) can 
exceed, and therefore mask, a difference in performance between two different tests 
(e.g. ultrasound and magnetic resonance imaging).58, 59
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Table 2.2: The QUADAS items
QUADAS criterion Bias/variation assessed
Was the spectrum of patients representative of the  Population characteristics
patients who will receive the test in practice? (demographic, severity and 
 prevalence of disease)
Were the selection criteria clearly described? Participant selection
Is the reference standard likely to correctly classify the  Use of an inappropriate reference 
target condition? standard
Is the time period between reference standard and index 
test short enough to be reasonably sure that the target  Disease progression
condition did not change between the two tests? 
Did the whole sample or random selection of the sample  Partial verifi cation
receive verifi cation using a reference standard of diagnosis? 
Did the patients receive that same reference standard  Differential verifi cation
regardless of the index test results? 
Was the reference standard independent of the index test? Incorporation
Was the execution of the index test described in suffi cient  
detail to permit replication? Test execution
Was the execution of the reference standard described in 
suffi cient detail to permit replication?
Were the index test results interpreted without knowledge 
of the results of the reference standard? Test review
Were the reference standard results interpreted without  Diagnostic review
knowledge of the results of the index test? 
Were the same clinical data available when the test results 
were interpreted as would be available when the test is  Clinical review
used in practice? 
Were un-interpretable/intermediate test results reported? Handling of un-interpretable or 
 missing results
Were withdrawals from the study explained?
It is worth noting that the information that can be derived from the quality assessment 
of test accuracy studies is often limited by poor reporting. Where QUADAS items are 
scored ‘unclear’ the researcher cannot be certain whether this indicates poor methods 
with the attendant consequences for bias/variation, or simply poor reporting of a 
methodologically sound study. The STARD initiative60 has proposed standards for the 
reporting of diagnostic accuracy studies. If these standards are widely adopted and 
lead to a general improvement in the reporting of test accuracy studies, reviewers 
will increasingly be able to assess methodological quality rather than the quality of 
reporting.
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2.2.6 Data synthesis
A thorough investigation of heterogeneity should be undertaken before deciding if 
studies are suitable for combining in a meta-analysis and if so what method to use. 
Clinical and methodological differences such as patient populations, tests, study 
design and study conduct, should be considered in addition to statistical variation in 
the accuracy measures reported by studies. Where a meta-analysis is not considered 
clinically or statistically meaningful, a structured narrative synthesis can be carried 
out which can include the presentation of results in one or more graphical formats.61 
For example the results of individual studies can be plotted in ROC space, as in Figure 
2.4, whether or not a summary curve is included. As well as stratifi cation by index test 
characteristics, reviews which focus on determining the optimal diagnostic pathway for 
a condition, rather than the diagnostic performance of a single test, should consider 
structuring narrative reports to represent the order in which tests would be applied 
in clinical practice. Reviews which consider differential diagnosis from a common 
presenting symptom, such as a review of the performance tests to determine the cause 
of haematuria, should consider stratifying the narrative by target condition with the 
most common diagnosis addressed fi rst. These approaches aim to increase readability 
for practitioners and can equally be applied to the structure of reports which include 
meta-analyses.
2.2.6.1 Assessment of statistical heterogeneity
Threshold effect
A source of heterogeneity unique to test accuracy studies, which requires careful 
assessment, arises from the choice of the threshold used to defi ne a positive result.62 
Even when different thresholds are not explicitly defi ned, variation in interpretation 
by observers may result in implicit variation in threshold. This can be assessed 
visually using a ROC space plot and statistically by measuring the correlation between 
sensitivity and specifi city. However, statistical tests may be unreliable where studies 
in a systematic review have small sample sizes; threshold effect may be present but 
undetected by statistical tests. A ROC space plot is a plot of the ‘true positive rate’ 
(sensitivity) from each study against the ‘false positive rate’ (1 - specifi city). If a 
threshold effect exists then the plot will show a curve (as the threshold decreases 
the sensitivity will increase and the specifi city will decrease). This curve follows the 
operating characteristics of the test at varying thresholds.
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Figure 2.4: ROC space plot
Figure 2.4 clearly shows a curve in the top left hand corner of the plot, indicating 
the presence of a threshold effect. The presence of a threshold effect can also be 
investigated using a regression62 or a hierarchical summary ROC (HSROC) model63 which 
are described in more detail in the meta-analysis section below.
Heterogeneity of individual diagnostic accuracy measures
Variability amongst each of the individual measurements (sensitivity, specifi city, positive 
and negative likelihood ratio, and DOR) can be assessed using the same methods as 
for other study types. Forest plots can be used to visually assess differences between 
studies, although these will not show any threshold effects. Paired forest plots should be 
used when illustrating paired outcome measures such as sensitivity and specifi city. Use 
of statistical tests of heterogeneity does not reliably indicate absence of heterogeneity 
and it is generally advisable to assume the presence of heterogeneity and to fi t models 
which aim to describe and account for it.
2.2.6.2 Meta-analysis
The meta-analysis of diagnostic accuracy studies requires the use of some specifi c 
statistical methods which differ from standard methods. Meta-analysis has two main 
aims: to obtain a pooled measure of diagnostic accuracy and in the case of summary 
ROC (SROC) models, to explore the heterogeneity amongst studies. Diagnostic accuracy 
is usually represented by a pair of related measurements, for example: sensitivity and 
specifi city; positive and negative likelihood ratio; and this relationship needs to be 
incorporated into the analysis methods.
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Pooling individual diagnostic accuracy measures
A robust approach to combining data and estimating the underlying relationship 
between sensitivity and specifi city is the construction of an SROC curve. Methods that 
involve pooling sensitivities and specifi cities from individual studies, or combining 
positive and negative likelihood ratios fail to account for the paired nature of the 
parameters, and should generally be avoided. However, where only one parameter (e.g. 
sensitivity, but not specifi city) is presented, simple pooling of proportions is the only 
option. Assessment of single parameters is usually inappropriate, but is sometimes used 
when there is a specifi c clinical reason why only one parameter should be the focus of 
interest.
Diagnostic odds ratios can be pooled using standard fi xed or random-effects methods 
for pooling odds ratios. However, these methods do not help estimate average 
sensitivity and specifi city and may produce erroneous results where there is a 
relationship between DOR and threshold.64
Predictive values should not be pooled in meta-analyses as they are affected by the 
prevalence of disease in the populations of the studies. Overall predictive values are 
sometimes calculated using estimates of prevalence from the included studies and 
pooled estimates of likelihood ratios. However, the potentially misleading nature of such 
estimates should be considered carefully.
Simple methods of estimating summary ROC curves
The Moses-Littenburg regression based method,62 has been used as a simple method of 
pooling study results in the presence of a suspected threshold effect. It can be used in 
preliminary exploratory analyses and is helpful in understanding the data.65 However, it 
has limitations and should not be used to obtain summary estimates of sensitivity and 
specifi city. The usual regression model assumptions are not met.66, 67 It also assumes 
that there is only one result per study and so cannot deal adequately with studies which 
have multiple data sets per test (e.g. data for a number of different thresholds).
It is possible to pool ROC curves, or the AUC from individual studies although this is 
not recommended and would not be practical in the case where some studies reported 
data for a single threshold and others presented data (or a ROC curve) for a number of 
thresholds.21
Optimal methods of modelling SROC curves
Statistical models, including hierarchical and bivariate models, have been developed 
for the estimation of SROC curves in the meta-analysis of test accuracy results. The 
HSROC model63 accounts for both within- and between-study variation in true positive 
and false positive rates. The model estimates parameters for the threshold, log DOR 
and the shape of the underlying ROC curve. It has been shown that it is possible to fi t 
this model using statistical package SAS, and that this method provides results that 
agree with the more complex Bayesian methods.68 The HSROC model can be extended 
to deal with studies that provide results for more than one threshold, but programming 
is challenging. The bivariate model67 analyses sensitivity and specifi city jointly, therefore 
retaining the paired nature of the original data (a STATA command function has recently 
been produced for the bivariate model). The HSROC and bivariate models have been 
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shown to produce equivalent results in the absence of other study-level covariates.69 It 
is recommended that meta-analyses using these models should be undertaken with the 
assistance of a statistician.
Exploring heterogeneity
Sources of methodological and/or clinical heterogeneity can be explored using subgroup 
analyses. Ideally subgroups should be planned at the protocol stage. However, where 
this is dependent upon what data are available, and an adaptive process is needed, 
this should be stated clearly in the protocol. Results from different groups, for example 
different tests, or study designs, can be visually assessed by using a ROC space plot 
with different symbols. Figure 2.5 illustrates the divergent accuracy results between 
different study designs from a systematic review of faecal occult blood tests used in 
screening for colorectal cancer,15 which indicates that two-gate studies (white circles) 
overestimate test performance compared with single-gate studies (black circles).
Figure 2.5: ROC space plot using different symbols
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HSROC and bivariate models can be used to assess heterogeneity by including 
covariates. These models allow investigation of the effect of covariates on sensitivity 
and specifi city separately, rather than just the DOR (although this can still be obtained). 
Further research is needed to determine which SROC models are the most appropriate 
for the exploration of heterogeneity as the choice of model may depend on which 
accuracy measure (DOR, sensitivity, specifi city) is most affected.69 An overview of the 
different methods used to explore heterogeneity in systematic reviews of diagnostic test 
accuracy is available.70 It should be noted that, as for meta-regression analyses of other 
study designs, these analyses are exploratory, can only include covariates reported by 
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the studies and should not be conducted if there are only a small number of studies 
(a minimum of 10 studies per covariate is needed). Regardless of the approach used, 
study-level factors to be examined should be defi ned in the protocol and aspects of 
methodological quality, (e.g. QUADAS items) should be considered individually, rather 
than as overall quality scores.45, 48
2.2.6.3 Software
Methods for calculating outcome measures, assessing heterogeneity, producing plots 
(both with and without summary estimates) and undertaking exploratory analyses 
using the Moses model are available in a user-friendly form in the Meta-DiSc software 
(www.hrc.es/investigacion/metadisc_en.html).71 Systematic reviews of diagnostic 
accuracy studies have been incorporated in version 5.0 of the Cochrane Review 
Manager software. More specialist statistical software packages, such as STATA, SAS or 
WINBUGS, are needed to fi t HSROC/bivariate models and the support of a statistician 
with knowledge of the fi eld is generally recommended.
2.2.7 Presentation of results
When presenting the results of a systematic review of clinical tests it is important to 
consider how these results will be understood by clinicians and applied in practice. The 
understanding of and preferences for measures of test performance by clinicians has 
been the subject of much research and comment.72-74 The ‘best’ method remains elusive 
but some general points, which may improve clarity and aid interpretation, are given 
below.
The presentation of diagnostic measures should be similar for both narrative and meta-
analytic approaches, with graphical representation and/or tabulation of individual study 
results and additional results presented if meta-analysis was performed. Suffi cient detail 
of the tests, participants, study design and conduct should be presented in tables.75 
The 2 x 2 table results of TP, FP, FN and TN together with sensitivity and specifi city, 
as a minimum should be presented for each study. The choice of accuracy measures 
presented depends on the aims and anticipated users of the review. Sensitivity and 
specifi city and likelihood ratios are measures of test performance; likelihood ratios may 
be more useful in a clinical setting as they can be used to calculate the probability of 
disease given a particular test result, whereas DORs are diffi cult to interpret clinically.22 
Forest plots or ROC space plots provide useful visual summaries and can be easier 
to interpret than large tables of numbers. The ranges should be presented when 
summarising results which have not been subject to meta-analytic pooling. For paired 
results it may be useful to also present the corresponding measure for the studies at 
each end of the range, e.g. ‘sensitivity ranged from 48% (at a specifi city of 80%) to 
92% (at a specifi city of 70%)’.
If a meta-analysis was undertaken then the presentation of results depends on the 
methods used. If sensitivity or specifi city have been pooled as individual measures 
then the summary estimate together with the 95% confi dence intervals should be 
presented. If an SROC model has been used then the relevant SROC curve(s) should be 
presented. Where the performance of a number of index tests is being compared it may 
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be useful to present multiple SROC curves (or un-pooled data sets) on the same plot. 
Summary measures of overall diagnostic accuracy, such as AUC or the Q* point (the 
point on the curve where sensitivity and specifi city are equal) may also be presented. 
However, the relevance of the Q* point is debatable, as its use may lead to summary 
estimates of sensitivity and specifi city outside the values in the original studies.67 Pairs 
of sensitivity and specifi city values can also be read from the SROC curve and presented 
as a number of summary points in order to provide an overall description of the curve. 
The estimated SROC curves should also be presented if HSROC or bivariate models have 
been used. These models enable the calculation of summary estimates of sensitivity 
and specifi city, which should be reported along with their 95% confi dence intervals. 
Although the use of HSROC or bivariate models to generate summary likelihood ratios 
is not recommended,76 where likelihood ratios are considered helpful to interpretation, 
summary likelihood ratios can be calculated from the pooled estimates of sensitivity 
and specifi city generated by these models. For results from a HSROC or bivariate 
model, as these retain the paired nature of sensitivity and specifi city, a region can be 
plotted around the summary operating point which represents the 95% confi dence 
intervals of both measures.67 Confi dence interval regions can also be plotted for the 
results of individual studies, but care is required to ensure that these are not mistakenly 
interpreted as representations of study weighting. Both models can also be used to plot 
a prediction region; this is the region which has a particular probability of including the 
true sensitivity and specifi city of a future study.69
Summary: Diagnostic studies
• Researchers planning systematic reviews of test accuracy should give careful 
consideration to context (e.g. is there evidence of a prognostic link between 
the target condition and preventable morbidity/mortality).
• Diagnostic tests should be evaluated in patients who are representative 
of those in whom the test will be used in practice; ideally a consecutive or 
randomly selected series whose diagnosis is unknown at the time of testing. 
• Careful consideration should be given to what is the appropriate reference 
standard to establish diagnosis.
• Diffi culties in searching bibliographic databases for test accuracy studies and 
the lack of suitable methodological search fi lters mean that more specifi c 
searches carry a risk of missing studies. Searches based upon index test and 
target condition, which are designed to maximise sensitivity, are therefore 
recommended.
• Test accuracy studies are often poorly reported, hampering data extraction, 
quality assessment and synthesis.
• Though often unable to provide a defi nitive estimate of test accuracy, 
systematic reviews can highlight important gaps in the evidence base and aid 
in the design of future studies.
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2.3 PROGNOSTIC TESTS
Prognostic markers (biomarkers) are characteristics that help to identify or categorise 
people with different risks of specifi c future outcomes. They may be simple clinical 
measures such as body mass index, but are more often pathological, biochemical, 
molecular or genetic measures or attributes. Identifying those who are or who are not 
at risk can facilitate intervention choice, and aid patient counselling.
Prognostic research has to date received much less attention than research into 
therapeutic or diagnostic areas, and an evidence-based approach to the design, conduct 
and reporting of primary studies of prognostic markers is needed.77 Reviews have shown 
that primary prognostic studies are often of poor quality.78
Synthesis of prognostic studies is a relatively new and evolving area in which the 
methods are less well developed than for reviews of therapeutic interventions or of 
diagnostic accuracy, and available reviews have often been of poor quality.79-82
Although numbers of completed prognostic reviews are relatively few,83 they are 
becoming more common. Of 294 reviews of prognostic studies published since 1966, 
almost all have appeared since 1996, occurring most commonly in cancer (15%), 
musculoskeletal disorders and rheumatology (13%), cardiology (10%), neurology 
(10%), and obstetrics (10%).79 Available reviews often include large numbers of studies 
and patients. For example, some reviews in cancer and cardiovascular disease have 
reported data on over 10,000 patients for a single marker.84-87
This section focuses mainly on reviews of studies of potential prognostic markers and 
builds on previous work.88 Given that this is a developing area where methods and 
approaches will undoubtedly change rapidly, this section presents a discussion rather 
than fi rm guidance. Systematic reviews of studies which develop a prognostic model 
(risk score) are not considered here.
2.3.1 Defi ning the review question: setting inclusion criteria
Defi ning the review question and setting inclusion criteria should be approached in the 
same way as set out in Chapter 1, Section 1.2 The review protocol. However, some 
aspects of methodology require particular attention when planning a systematic review 
of prognostic studies, and should be considered at an early stage.
2.3.1.1 Population/study design
Patients included in a prognostic study are usually selected as an ‘inception’ cohort of 
patients identifi ed very early in the course of their disease, perhaps at diagnosis. Even 
if the cohort is identifi ed retrospectively, it should be followed forwards in time from 
a particular point, such as diagnosis or (if relevant) randomisation. The case-control 
design is liable to bias.89 Careful thought as to what study designs will be included in the 
review is needed.
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2.3.1.2 Intervention
Although often ignored in prognostic studies, if the intervention that patients receive 
varies on account of perceived prognosis, this precludes an unbiased assessment of the 
prognostic ability of a marker (unless alternative interventions are equally effective). 
Although the intervention effect may be small compared to the effect of important 
prognostic variables and consequently will have little impact on fi ndings, ideally, 
prognostic variables should be evaluated in a cohort of patients treated the same way, 
or that have been included in an RCT.90, 91 The intervention received is rarely reported in 
primary studies.
2.3.2 Defi ning the review question: other considerations
2.3.2.1 Publication bias and sample size
Evidence of publication and associated reporting biases is accumulating for prognostic 
studies.92, 93 For example, in a systematic review of studies of a marker Bcl2 in non-
small cell lung cancer, almost all the smaller studies showed a statistically signifi cant 
relationship between Bcl2 and risk of dying, with large hazard ratios, whereas the three 
large studies were all nonsignifi cant and showed a much smaller effect.94 A recent 
review of the prognostic importance of TP53 status in head and neck cancer showed 
clearly that published studies had larger effects than unpublished studies.80 This is in 
keeping with the belief that epidemiological studies are more prone to publication bias 
than randomised trials.80, 95 Publication bias may indeed be worse as many studies are 
based on retrospective analysis of existing clinical databases, and so in essence they do 
not really exist until published.
Adequate sample size is equally as important for prognostic studies as for clinical trials, 
but has received little attention. For example, three quarters of 47 papers reporting 
prognostic studies in osteosarcoma had fewer than 100 cases.96 The likely presence of 
publication bias means that small studies are unreliable and for prognostic reviews there 
is a good argument for omitting small studies from meta-analysis, for example those 
with fewer than 100 patients or even 100 events.
Selective reporting of outcomes is also a concern in prognostic studies. For example, in 
cancer studies the two principal outcomes are time to death (overall survival) and time 
to recurrence of disease (‘disease-free survival’). Many studies, such as in the case-
study in Section 2.3.7, report only one of these outcomes, which may have been chosen 
in relation to the fi ndings.
2.3.2.2 Cutpoints
Most markers are continuous measurements. However, it is very common in cancer, 
and occasionally in other fi elds, for continuous marker values to be converted to 
binary variables whereby each patient is characterised as having a high or low value. 
Dichotomisation is statistically ineffi cient,97, 98 but in some fi elds, notably cancer, it is 
ubiquitous. Dichotomising does not introduce bias if the split is made at the median or 
some other pre-specifi ed percentile. However, if the cutpoint is chosen based on analysis 
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of the data, in particular by splitting at the value which produced the largest difference 
in outcome between categories, then severe bias will be introduced.99 Signifi cant 
fi ndings associated with a data-derived cutpoint will be overoptimistic, perhaps by a 
large amount. Such studies may best be excluded from any meta-analysis.
Many reports do not state how cutpoints were chosen. When the numbers above and 
below the cutpoint differ or are not stated, and when the chosen cutpoint is unique to 
that study, it may be unwise to assume that the choice was made in a valid way.
2.3.2.3 IPD vs summary data
Several authors have noted the considerable advantages of obtaining individual patient 
data (IPD),100, 101 and it is clear that IPD could be especially valuable for systematic 
reviews of prognostic markers. In addition to the usual advantages of IPD over 
published summary statistics100 (see Appendix 1), there are some specifi c advantages. 
Firstly, it may allow inclusion of more studies as not all studies provide the necessary 
outcome data. Secondly, it allows all data sets to be analysed in a consistent way, 
which in this case means adjusting for the same variables and using the same analysis 
method. Thirdly, the marker values can be kept continuous, increasing statistical power 
and informativeness. Finally, it is possible to conduct analyses restricted to clinical 
subgroups, for example by stage of disease.
The natural extension of standard systematic reviews would be to try to collect IPD from 
all identifi ed studies, whether published or not. Although this has been attempted for 
prognostic studies it has been found to be very time consuming.102, 103 Concerns about 
publication bias and the overhead attached to identifying, obtaining and processing 
each data set have led to the suggestion that for a prognostic meta-analysis of IPD, 
restriction to only the larger studies or perhaps those carried out in one region104 would 
be preferable to one based on summary published data that included every published 
study.77
2.3.3 Identifying research evidence
Identifying prognostic studies is hampered by an absence of standard descriptors and 
indexing terms. In recent years search strategies have been developed to identify 
prognostic studies in MEDLINE105 (see Box 2.1) and EMBASE.106 An improved search 
strategy for MEDLINE, CINAHL and HealthStar has recently been presented107 but is as 
yet unpublished.
2.3.4 Data extraction
Aspects of particular relevance in prognostic studies include recording how the 
measurements were made (e.g. equipment or assay used), length of follow-up, 
distribution of the marker, any cutpoints used (with rationale), amount of missing data, 
methods of statistical analysis, including variables adjusted for, and the number of 
participants included in the fi nal model.
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A prognostic study with a dichotomous endpoint, such as 30 day mortality after surgery, 
is statistically no different from a diagnostic accuracy study and poses no additional 
diffi culties for extraction of results. Random-effects endpoints are desirable but there 
are often diffi culties in extracting the log hazard ratio and its standard error from 
published reports. Guidance on how to estimate these quantities when they are not 
given explicitly is available.108
2.3.5 Quality assessment
The assessment of the appropriateness of the methodology used in the primary studies 
is a key element of any systematic review, but has been performed in a minority of 
cases in prognostic systematic reviews.79, 109 This may refl ect the absence of widely 
agreed criteria for assessing the quality of prognostic studies. Although it is not good 
practice to use quality as an inclusion criterion, an evaluation of reviews79 found that 
this was done in 55/163 (34%) reviews.
Reviews of prognostic studies have demonstrated that generally the methodological 
quality of included studies is poor. For example, one review which assessed 104 
prognostic studies in kidney disease against eight criteria, found that three-quarters of 
the studies satisfi ed four or fewer of the eight criteria.78
As with other study designs, quality scores are problematic.48, 110, 111 For example, a 
quality score was developed which evaluated aspects of study methodology grouped into 
four main categories: the scientifi c design; laboratory methodology; the generalisability 
of the results; and the analysis of the study data.112 No details were provided of the 
development of this scoring system, and as it includes elements of both methodology 
Box 2.1: Effective MEDLINE searching strategies for studies of 
prognosis
Best single term
exp epidemiologic studies
The complex search strategy with the highest sensitivity
incidence.sh.
OR exp mortality
OR follow-up studies.sh.
OR prognos:.tw.
OR predict:.tw.
OR course:.tw.
Key
exp denotes exploding the succeeding indexing term
: is a truncation symbol in Ovid
sh denotes searching in the subject headings
tw denotes searching for a textword
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and reporting it is hard to interpret. Further, for many of the items (e.g. ‘source of 
samples’) there is no explanation of the coding scheme. It is preferable to consider 
specifi c aspects of methodology related to the risk of bias.
Despite the lack of empirical evidence to support the importance of particular study 
features affecting the reliability of study fi ndings, especially the risk of bias, theoretical 
considerations and common sense point to several methodological aspects that are 
likely to be important.
2.3.5.1 Generic criteria
Table 2.3 lists methodological features that are likely to be important for the internal 
validity of prognostic studies.88 The items are not phrased as questions but rather as 
domains of likely importance. Most authors have presented their checklists as questions. 
For example, ‘Was there a representative and well-defi ned sample of patients at a 
similar point in the course of the disease?’, taken from a checklist produced by the 
Evidence-Based Medicine Working Group,113 is a question that includes three elements 
from Table 2.3. This checklist is widely quoted, for example in a guide for clinicians,114 
but it omits several of the items in Table 2.3.
It is generally agreed that to be reliable (and clinically interpretable) a prognostic 
study requires a well-defi ned (‘inception’) cohort of patients at the same stage of their 
disease, preferably at diagnosis.115 This also illustrates the more general requirement 
that the cohort can be clearly described, which is necessary for the study to have 
external validity.
2.3.5.2 Context-specifi c criteria
There may also be context-related quality aspects that should be considered in 
individual reviews. For example, some studies may have used inferior laboratory 
methods to measure the marker. However, it is important to distinguish aspects of a 
study that might be a cause of bias, and hence be genuinely a matter of quality, and 
those that just refl ect variation in study conduct but where no bias is likely. Examples 
of the latter are patient inclusion criteria, length of follow-up, and choice of measuring 
device or assay kit. Such factors may well be a cause of heterogeneity and it may be 
prudent to perform separate (subgroup) analyses to investigate whether they are in fact 
of importance. There are several published checklists for assessing prognostic studies in 
cancer.116-118
2.3.5.3 Implementing quality assessment
Quality assessment in prognostic systematic reviews is often incomplete and there is 
wide variation in current practice. A review of reviews identifi ed 14 methodological 
domains grouped within six dimensions relating to the risk of bias of prognostic studies79 
as shown in Table 2.4.
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Table 2.3: A framework for assessing the internal validity of articles describing 
prognostic factor studies88
Study feature Qualities sought
Sample of patients Inclusion criteria defi ned
 Sample selection explained
 Adequate description of diagnostic criteria
 Clinical and demographic characteristics fully described
 Representative
 Assembled at a common (usually early) point in the course of their 
 disease
 Complete
Follow-up of patients Suffi ciently long
Outcome Objective
 Unbiased (e.g. assessment blinded to prognostic information)
 Fully defi ned
 Appropriate
 Known for all or a high proportion of patients
Prognostic variable Fully defi ned, including details of method of measurement if relevant
 Precisely measured
 Available for all or a high proportion of patients
 If relevant, cutpoint(s) defi ned and justifi ed
Analysis Continuous predictor variable analysed appropriately
 Statistical adjustment for all important prognostic factors
Intervention subsequent Fully described
to inclusion in cohort Intervention standardised or randomised
2.3.5.4 Quality of reporting
Assessment of study quality is often seriously hampered by poor reporting of 
methodological details,119, 120 as is well known for other types of research. The REporting 
recommendations for tumour MARKer prognostic studies (REMARK) initiative has 
proposed guidelines for reporting prognostic studies in cancer, most of which apply to 
any medical context.121 Adoption of the REMARK guidelines should lead to improved 
reporting of prognostic studies.
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Table 2.4: System for assessing quality of prognostic factor studies, with 
proportion of 153 prognostic systematic reviews meeting each item79
 % reviews   % reviews 
 adequately   assessing 
Potential bias assessing bias Domains addressed domain
1. Study participation 55 1. Source population clearly  50
The study sample represents    defi ned 21
the population of interest on   2. Study population described 50
key characteristics, suffi cient   3. Study population represents
to limit potential bias to the    source population or
results   population of interest
2. Study attrition 42 4. Completeness of follow-up 19
Loss to follow-up (from sample    described 42
to study population) is not   5. Completeness of follow-up
associated with key    adequate
characteristics, suffi cient to 
limit potential bias (i.e., the 
study data adequately 
represent the sample) 
3. Prognostic factor  59 6. Prognostic factors defi ned 31
measurement   in study participants to  59
The prognostic factor of    suffi ciently limit potential bias
interest is adequately  7. Prognostic factors measured 
measured   appropriately
4. Outcome measurement 51 8. Outcome defi ned 42
The outcomes of interest are   9. Outcome measured  51
adequately measured in study    appropriately
participants to suffi ciently limit 
potential bias
5. Confounding measurement  13 10. Confounders defi ned and 21
and account   measured
Important potential confounders   11. Confounding accounted for 53
are appropriately accounted for, 
limiting potential bias with 
respect to the prognostic factor 
of interest
6. Analysis 33 12. Analysis described 8
The statistical analysis is   13. Analysis appropriate 33
appropriate for the design of   14. Analysis provides suffi cient  32
the study, limiting potential for    presentation of data
presentation of invalid results
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2.3.6 Data synthesis
2.3.6.1 Outcome measures
In prognostic studies the focus of interest is what may happen in the future. It is 
natural, therefore, that most prognostic studies have outcomes that are the time to 
a specifi c event, such as death. However, some prognostic studies with dichotomous 
outcomes may inappropriately ignore the time element. For example, a study looking 
at death within three years may classify all patients as dead or alive, but those patients 
who are lost to follow-up before three years (i.e. have censored survival times) 
cannot be so classifi ed and may be excluded. One exception is studies of prognosis 
in pregnancy where outcomes often relate to the birth of the baby (e.g. predicting 
caesarean section or pre-term birth). Such outcomes are genuinely dichotomous and 
can be analysed in the same way as a study of diagnostic accuracy.
Meta-analysis of time-to event outcomes of aggregate data derived from publications 
is usually done using the generic inverse-variance approach and may use a fi xed effect 
or random-effects model (see Chapter 1, Section 1.3.5 Data synthesis). This type of 
analysis and extensions have been discussed, as has investigation of heterogeneity 
in such studies.122, 123 Although the preferred statistical summary is the hazard ratio 
(HR) (see Chapter 1, Section 1.3.5 Data synthesis) many publications do not report 
the HR or the information needed to calculate it. Consequently, some of the identifi ed 
studies cannot be included in the synthesis. Furthermore, non-reporting of appropriate 
statistical summary measures may be more likely if the marker was found not to be 
statistically signifi cantly related to outcome, leading to bias. Statistical methods for 
analysing IPD time-to-event data have been compared,124 and methods have been 
published for combining IPD with published summary data.125
When all studies have reported data as dichotomous or continuous, meta-analysis may 
be relatively straightforward. However, if there is a mixture of binary, multi-category, 
and continuous representation of the same marker, meta-analysis will be problematic 
and expert input will be advisable. Similar problems have been reported in meta-
analysis of epidemiological studies.126
In principle researchers may need to combine estimates of a marker that is kept 
continuous in some studies and dichotomised in others. It is important to note that the 
hazard ratios for those two cases are not comparable so they should not be combined. 
There is a related literature on combining data on dose-response relationships in 
epidemiology.127-129
2.3.6.2 Adjustment for other variables
In RCTs the groups being compared are expected to be very similar with regard to 
prognostic factors (baseline characteristics) through the use of a random sequence of 
intervention assignment. In non-randomised studies there is no such safeguard and 
we should expect the groups being compared to differ in various ways. In prognostic 
studies we are comparing individuals with different levels of a marker, whether binary 
or continuous. That comparison could easily be biased by other variables that are 
associated with both the marker and patient prognosis – in other words the comparison 
may be ‘confounded’.
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Furthermore, while it may be of interest to know if a marker considered alone is 
prognostic, in most cases the real aim of a prognostic marker study should be to 
ascertain if the marker adds useful clinical information to what is already known. In 
many clinical contexts much is already known about prognosis, and it is important 
to know whether the new marker offers additional prognostic value over and above 
that achieved with previously identifi ed prognostic variables. As an example, a study 
examined the ‘incremental usefulness’ of 10 biomarkers for predicting the risk of 
cardiovascular events, adjusted for age, sex, and conventional risk factors.130 That 
approach implies the addition of the marker to a statistical model that includes other 
known prognostic variables. As well as addressing the most sensible clinical question, 
adjustment should greatly reduce the risk of confounding.
Dealing with adjustment presents a problem for synthesis, as individual studies are 
likely to have used different statistical approaches for adjustment and adjusted for 
different selections of variables. Some syntheses avoid this methodological variation by 
using unadjusted estimates.131 While this approach is standard in systematic reviews 
of RCTs, in prognostic studies it replaces one problem with a worse one; unadjusted 
analyses are likely to be biased. Although the unadjusted estimate provides the 
maximum opportunity for comparison of consistent estimates across studies,131 it is 
important to adjust for other prognostic variables to get a valid picture of the relative 
prognosis for different values of the marker. Prognostic studies thus generally require 
analysis using multiple regression analysis, although stratifi cation may be useful in 
simpler situations. For outcomes which are dichotomous or time to a specifi c event, 
logistic or Cox proportional hazards regression models respectively are appropriate for 
examining the infl uence of several prognostic factors simultaneously. For this purpose, 
known prognostic factors should preferably not be subjected to a variable selection 
process. Even though such variables may not reach specifi ed levels of signifi cance in a 
particular study, they should be included in the models generated in order to compare 
results to other reported studies. Comparison of models with and without the marker 
of interest provides an estimate of its independent effect and a test of statistical 
signifi cance of whether the new marker contains additional prognostic information.
In practice, researchers will often fi nd a mixture of adjusted and unadjusted results. 
Only 47/129 (36%) of prognostic marker studies in cancer used multivariate modelling 
in which the marker was added to standard clinical variables.132 A recent review 
presented separate meta-analyses of adjusted and unadjusted results of BCL-2 as a 
protective prognostic marker in breast cancer.133 It demonstrated, as expected, that the 
adjusted hazard ratio was lower than the unadjusted value but these differences were 
small (disease free survival (DFS) HR 1.58 vs HR 1.66). This approach reduces the need 
for speculation about the value of adjustment, which seems a good strategy even if all 
studies are then combined.
2.3.6.3 Sensitivity analyses
General considerations of investigating the sensitivity of the review fi ndings to various 
choices apply equally to reviews of prognostic studies. In the specifi c context of 
prognosis, given the evidence about publication bias, it may be advisable to conduct a 
sensitivity analysis in which smaller studies are excluded.
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2.3.7 Case study
An example of a systematic review addressing a prognostic question is given in Box 
2.2.87
Box 2.2: Case study
Objective
This systematic review of aggregate data obtained from study publications 
aimed to obtain better quantifi cation of the prognostic importance of Ki-67/MIB-
1 expression as a marker of cell proliferation in early breast cancer. Ki-67 is 
present in all proliferating cells and there is great interest in its role as a marker 
of proliferation. MIB-1 is a monoclonal antibody against recombinant parts of the 
Ki-67 antigen.
Inclusion criteria
The review included studies evaluating the relationship between Ki-67/MIB-1 
status and prognosis in early breast cancer published by May 2006. Studies had to 
have been published as a full paper in English. No minimal sample size or minimal 
median duration of follow-up was defi ned.
Searching
PubMed was searched using the following keywords: ‘breast cancer’, ‘Ki-67’, 
‘MIB-1’, ‘proliferative index’, ‘proliferative marker’, ‘survival’ and ‘prognostic’. The 
authors also screened references from the relevant literature, including all the 
identifi ed studies and reviews. When the same patient population was reported in 
more than one publication, only the most recent or complete study was included.
Data extraction
The methods of Parmar et al134 were used to extract log HR and SE(log HR). Three 
people independently extracted information from survival curves.
Data availability
Sixty-eight eligible studies were identifi ed of which 46 studies (including 12,155 
patients) could be included in meta-analyses; 38 studies for disease free survival 
and 35 studies for overall survival.
Study characteristics
Table 2.5 shows that there was considerable variation in study characteristics, 
for example in patient characteristics, cutpoint used to defi ne high Ki-67, and 
prevalence of raised levels of the marker. All studies dichotomised Ki-67 values. 
Even studies with the same threshold had prevalence of high values ranging from 
11% to 88%. The studies also varied considerably in the interventions patients 
had received and in the antibody used in laboratory evaluations of Ki-67.
(Continued)
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Table 2.5: Systematic review of Ki-67 as a prognostic marker in early breast 
cancer: excerpt from table of study characteristics and results for disease-free 
survival (hazard ratios and 95% confi dence intervals) 87
  Follow-  
  up  
  (median   Preval- How
Study N months) Threshold ence chosen HR 95% CI
Bevilacqua, 1996 107 74 10% 88% arbitrary 2.75 1.02 – 7.39
Bos, 2003 150 106  10% 42% arbitrary 2.47 1.08 – 5.65
  (mean)     
Brown, 1996 674 72 5% 25% optimal  1.19 0.79 – 1.80
     cutoff  
Caly, 2004 244 72  32% 50% unclear 1.95 0.92 – 4.14
  (min)     
Domagala (N0), 1996 111 88 10% 60% median 3.04 1.03 – 8.99
Domagala (N+), 1996 75 88 10% 53% median 1.38 0.66 – 2.86
Erdem, 2005 47 73 10% 28% median 17.23 2.42 – 122.4
Fresno, 1997 146 75 10% 58% arbitrary 1.81 0.71 – 4.59
Gasparini, 1994 165 60 7.5% 50% mean 2.58 1.21 – 5.49
Gonzalez, 2003 221 103 30% NR arbitrary 3.18 1.52 – 6.65
Goodson, 2000 112 61 24% 50% mean 2.90 1.18 – 7.15
Heatley, 2002 59 60 10% 44% mean 0.81 0.36 – 1.81
Hlupic (N+), 2004 192 180 10% 61% arbitrary 1.30 0.80 – 2.11
Jacquemier, 1998 152 60 3.5% 49% median 3.29 1.49 – 7.22
Jansen, 1998 321 128 7% 48% median 1.35 1.01 – 1.80
Jensen, 1995 118 104 17% 46% median 3.41 1.44 – 8.06
Liu, 2001 773 196 17.8% 50% median 1.76 1.41 – 2.20
Locker, 1992 67 27 9% 34% tertile 4.19 1.19 – 14.7
Mottolese, 2000 157 60 10% 55% arbitrary 1.82 0.90 – 3.67
Pellikainen, 2003 414 57 20% 44% arbitrary 2.56 1.46 – 4.50
Pierga, 1996 136 70 8% 49% median 1.37 0.64 – 2.91
Pietilainen, 1996 188 103 20% 53% arbitrary 1.88 1.16 – 3.05
  (mean)     
Pinder, 1995 177 NR 34% 42% tertile 1.66 1.09 – 2.52
Pinto, 2001 295 39.6 10% 46% arbitrary 1.46 0.74 – 2.87
Querzoli, 1996 170 66.5 13% 25% tertile 2.05 1.11 – 3.77
Railo, 1993 326 32.4  10% 11% unclear 2.39 0.77 – 7.38 
  (mean)     
Etc
N: Number of participants; HR: Hazard ratio; CI: Confi dence interval
(Continued)
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Study results were combined using the Peto-Yusuf method. No studies were 
excluded because of methodological quality but some studies were excluded 
because suitable data were not available – those included studies which did not 
provide unadjusted results. Random-effects meta-analyses were used because 
there was considerable heterogeneity. Separate meta-analyses were performed 
for overall (OS) and DFS. Both showed a signifi cant association between raised 
Ki-67 and worse survival: HR 1.93 (95% CI: 1.74 – 2.14) and 1.95 (1.70 – 2.24) 
respectively. Table 2.5 shows the reported characteristics and the results (HR) for 
DFS for a subset of the studies.
The 17 omitted studies were included in a sensitivity analysis with no appreciable 
change to the fi ndings. The authors did not consider possible publication bias.
Conclusions
The authors concluded that ‘Despite some limitations, this meta-analysis supports 
the prognostic role of Ki-67 in early breast cancer, by showing a signifi cant 
association between its expression and the risk of recurrence and death in all 
populations considered and for both outcomes, DFS and OS.’ They also noted that 
the reporting of the individual studies was suboptimal and that they had assessed 
only the univariate prognostic value of Ki-67. They suggested that a prospective 
study to examine whether Ki-67 was of prognostic importance over and above 
known factors. Thus, in common with many reviewers of such studies, these 
authors did not feel that the existing literature was strong enough on which to 
base clinical decisions.
2.3.8 Systematic review as a driver for improved study quality
Systematic reviews can play a valuable role not just in summarising the fi ndings of 
published studies but also in drawing attention to the poor and inconsistent methods 
used. Good systematic reviews are needed to highlight the weaknesses of the evidence 
base behind prognostic markers and to provide guidance on how better quality studies 
can be carried out in the future. This is true of prognostic studies and it has been 
commented that ‘one has to question why it is acceptable for tumour marker studies to 
be performed with less scientifi c rigor than studies of new pharmaceutical agents.’135
As an example, a review of 26 published systematic reviews of prognostic markers in 
cancer found common defi ciencies in both conduct and reporting.109 Less than 75% of 
the systematic reviews stated clearly their aims and objectives, the literature search 
strategy, and the study eligibility criteria. Only 20% reported the fi nal number of 
primary studies used. Less than 50% of the systematic reviews reported elements 
of primary study description and analysis, such as sampling methods, cancer stage, 
cutpoint, and numeric results including CIs and P-values. The exception was the sample 
size, which was reported in 73% of the systematic reviews. About half of the systematic 
reviews had carried out a meta-analysis. Of those, some did not include a forest plot 
or numerical summary with confi dence intervals. Most had explored heterogeneity, 
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but only 66% investigated possible publication/small study bias. Surprisingly, only one 
group of systematic review investigators assessed the quality of the primary studies.
Summary: Prognostic studies
• Diffi culties in searching the literature for prognostic studies mean that there is 
a higher risk of missing studies than is the case for RCTs.
• Prognostic variables should be evaluated in a representative sample of 
patients assembled at a common point in the course of their disease. Ideally 
they should all have received the same medical treatment or have been 
included in an RCT.
• There is no standard approach for assessing methodological quality. Prognostic 
studies are frequently found to be methodologically poor.
• Meta-analysis based on published data is often hampered by poor reporting of 
methods and results and by variation in study and patient characteristics.
• Publication bias is a common problem in studies of prognosis.
• Meta-analysis of prognostic studies using individual patient data can overcome 
some of the diffi culties.
• Systematic reviews can inform the conduct of better primary studies in the 
future.
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Systematic reviews of public health interventions
3.1 INTRODUCTION
This chapter provides an overview of issues relevant to systematic reviews of public 
health interventions. Public health is a broadly defi ned set of activities that aim to 
protect, promote, and restore the health of all people. Their success is invariably 
dependent on health, social, and economic contexts that have a wide reaching and 
sustainable impact on peoples’ lives. Public health interventions are diverse, including 
those that seek to address change at the individual level (for example, targeting specifi c 
attitude or behaviour change), and those that operate with structural (or policy-
changing) intent to promote a wider population or community effect often focusing on 
the social, physical, economic, or legislative context.
Evaluation of public health interventions is usually complex, as multiple interventions, 
outcomes, participants, settings and stakeholders are often necessary components. 
Because of the complexity, no single evaluation method is likely to be appropriate and 
a range of different study designs are used. A framework for the design and evaluation 
of complex interventions has been proposed which offers guidance on the various phases, 
including establishing the theoretical basis (mechanisms of action) for the intervention.1, 2 
A sound theoretical base is considered vital to the design of complex interventions and 
in explaining likely mechanisms for success.3, 4 However, in practice many interventions 
and evaluations lack explicit theoretical underpinning.
The complexity of public health research may dictate a process that is far more iterative 
than in most other types of systematic review, although the use of a conceptual 
framework for guiding pathways within the systematic review process may offer a way 
forward (see Section 3.2, The review question, scope and planning). Because of the 
complexity, traditional criteria for producing systematic reviews have been criticised 
for being too tightly defi ned, and only partially fulfi lling requirements for reviews 
addressing public health questions.5-9 As a result, existing guidelines are being updated 
and expanded.10
The aim of this chapter is to identify key issues and challenges specifi cally related to 
reviews of public health interventions which researchers need to consider in addition 
to the core principles presented in Chapter 1. A number of these key issues recur 
throughout the systematic review process, but to avoid repetition are only discussed 
in Section 3.2 The review question, scope and planning. As with all types of systematic 
review, the need to ensure a systematic approach remains paramount, with focus on 
critical thought, transparency, and explicitness about methods.
3.2 THE REVIEW QUESTION, SCOPE AND PLANNING
Determining the scope of the review and the subsequent question(s) to be addressed 
is a critical stage in the review process as decisions made in the early stages will 
determine both the protocol (see Chapter 1) and the subsequent review. A carefully 
selected advisory group with a range of experiences will help to ensure the questions 
addressed are those of importance to decision-makers. For reviews of public health 
interventions, authors might want to consider including practitioners, policy-makers 
(local or national), funders, and potential recipients or users of services.
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The development and use of a conceptual framework to guide the review process may 
offer a useful starting point. Although there are relatively few examples reported in the 
literature, one approach that offers particular promise is that developed by the Task 
Force on Community Preventive Services based in the USA.11 For each systematic review 
undertaken, the Task Force develop a logic framework, which is essentially a diagram 
mapping the hypothesised causal relationships between determinants (environmental, 
social, biological) and outcomes. The framework is then used to identify links between 
determinants, outcomes, possible interventions and strategic points to intervene. 
Once mapped in this way decisions can be made about which interventions to include. 
The approach has been used to review interventions ranging from early childhood 
development programmes such as Head Start12 to affordable family housing.13
Other approaches which researchers may fi nd useful are Realist synthesis14 and 
The Theory of Change.15 Realist synthesis, originally designed to work with complex 
social interventions, outlines the importance of using theory to drive the synthesis of 
evidence. The Theory of Change is currently used to guide health and social reform 
programmes in the UK, and is an approach to designing, implementing and evaluating 
complex interventions, involving multiple stakeholders who work together to map out 
the pathway for change.
3.2.1 Formulating different types of question
Public health questions are usually broad and multi-faceted, often seeking to address 
wide policy-based enquiries, where a range of specifi c interventions exist; examples 
being the promotion of walking16 and the reorganisation of shift-work.17 Specifi c 
examples of broad questions include ‘what is the evidence that national programmes of 
urban regeneration improve health?’18 and ‘which health promotion interventions reduce 
the risk of coronary heart disease in the general population?’19
Broad questions can be split to provide a more narrowly focussed enquiry, where 
immediate decisions of policy relevance are often required.5 Examples of narrowly 
focused questions include ‘what are the effects of water fl uoridation on the incidence of 
caries?’20 and ‘does over-the-counter nicotine replacement therapy increase abstinence 
rates?’21
3.2.2 Considerations when applying PICOS
The application of PICOS (Population, Interventions, Comparisons, Outcomes, Study 
Design, Chapter 1, Section 1.2 The review protocol) to the review question is relevant to 
reviews in public health, but adaptation may be required. For example, the importance 
of context within which the intervention is delivered has prompted the proposed 
inclusion of an additional C in the acronym (PICOCS).22
3.2.2.1 Population
The population of interest is often represented by groups of people, or entire 
communities, such as young people in schools, users of Healthy Living Centres or 
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particular geographical regions. This is in contrast to reviews of clinical topics where 
individuals are usually the focus, for example patients undergoing coronary artery 
bypass graft surgery or adults diagnosed with moderate to severe psoriasis.
Detail about participants is often lacking.22 Information about initial and fi nal study 
populations is not always easy to distinguish, and studies often fail to report levels of 
engagement, along with the characteristics of those that do and do not participate in 
the interventions of interest.
Researchers may be especially interested in the effects of interventions on 
disadvantaged groups in order to investigate the potential for reducing inequalities (see 
Section 3.2.2.4 Context).
3.2.2.2 Complex packages of interventions (and comparators)
Public health interventions are often characterised as a package of components, for 
example, the inclusion of diet, exercise, and counselling in weight loss programmes or 
education, community events, and access to nicotine replacement therapy to promote 
smoking cessation. This type of intervention is often referred to as ‘complex’, due to the 
fact that the constituent parts may act both independently and inter-dependently,1, 2 and 
defi ning the ‘active ingredient’ can be less straightforward than in other topic areas. 
Where research questions apply specifi cally to interventions that are part of a multi-
component package, it is important to decide on the usefulness of separating the 
component parts for evaluation. To do so may mean that the essence of the intervention 
is lost.23
The use of theory in guiding the development of complex interventions is considered 
good practice, due to its potential to predict success and also to explain failure. Theories 
can explain behaviour and behaviour change at the individual level such as the Theory 
of Planned Behaviour24-26 and the Health Belief Model.27 Theory can also explain change 
at the organisational or community level. Researchers might decide to only include 
interventions based on one particular theory, as in a review that focused on Stages 
of Change,28 or to include interventions based on different theories and record their 
theoretical underpinning as part of the description of the intervention, as in a review of 
HIV prevention.29 Theory can also be used to group interventions and explore potential 
differences in effect.
As with populations, interventions (and comparators) are often poorly described. A 
variety of possible interpretations and terminology is commonplace in the literature 
(see later in Section 3.3 Identifying research evidence). For example, in a systematic 
review of workplace exercise interventions, the words exercise and physical activity 
were interpreted differently by researchers and practitioners in terms of the activity 
being promoted, and there was no standardisation of use in the literature.30 With 
the help of the advisory group (see Chapter 1), researchers will need to spend 
time agreeing defi nitions for the interventions of interest. How the intervention is 
defi ned (e.g. in terms of intensity, frequency, duration), delivered, and whether it is 
sustainable are important indicators in determining effectiveness and these aspects 
should be considered at the protocol development stage and again later during quality 
assessment.
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It is also important to specify comparators, which might be no intervention, standard 
practice (or care) or another intervention. Choice of comparator is important, as it will 
have implications for the interpretation of results.
When framing the review question it may be appropriate to consider broad comparisons, 
for example the effectiveness of any community intervention for preventing the uptake 
of smoking versus no intervention, or the effectiveness of any community intervention 
versus any single component intervention,31 or all programmes aimed at preventing and 
treating childhood obesity.32 This represents a departure from the often well-defi ned 
interventions specifi ed in questions about the effects of clinical interventions such as 
efalizumab for the treatment of psoriasis.
3.2.2.3 Outcomes, surrogates for health and sustainability
Public health interventions often have a range of impacts on those receiving them, 
some of which will be considered more important than others. Questions about which 
outcomes to prioritise can be usefully discussed with the advisory group and often it will 
be necessary to assess a number of different outcomes (or groups of outcomes). In a 
review focusing on the prevention of smoking in young people,31 outcomes included the 
number of cigarettes purchased, membership of anti-smoking clubs, media reach, and 
level of implementation or exposure to each component of the intervention. Examining 
why and how the intervention works will require the development of questions 
addressing process or implementation.22, 33, 34 (See Section 3.5 Quality assessment, 
and Chapter 6). These questions might refer to critical success factors including 
communication, infrastructure, staff behaviour, and organisational fl exibility. As in other 
types of review, unintended outcomes should also be considered. For example, smoking 
cessation interventions might reduce the number of cigarettes smoked, but contribute 
to weight gain.
Although public health interventions have the potential to improve population 
health overall, improvements (in terms of the total number who benefi t from the 
intervention) may mask differences between groups. For example a review of healthy 
eating interventions in schoolchildren found differences between males and females 
in knowledge and consumption of healthy foods.35 It is possible that a strategy that 
improves population health, might actually widen inequalities between social groups if 
benefi ts are concentrated among the better off.36 Researchers might want to consider 
investigating differential outcomes according to varying levels of disadvantage, as 
in a recent review of school feeding programmes,37 or programmes that focus solely 
on disadvantaged populations (for example, the current UK Sure Start initiative). 
Information on differential outcomes is vital to the development of policy guidance, but 
is often ignored.
One set of criteria for measuring disadvantage is PROGRESS, which stands for place of 
residence, race/ethnicity, occupation, gender, religion, education, socioeconomic status 
and social capital.38 These criteria have been used in a small number of systematic 
reviews, including one on population tobacco control interventions,39 and a modifi ed and 
extended version (including items on disability, sexual orientation, and age) in a review 
of school-based cognitive behavioural therapy programmes for preventing/reducing 
depression.40, 41 The feasibility, usability and usefulness of the PROGRESS criteria 
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are being further investigated.42 The Cochrane Health Equity Field and The Campbell 
Equity Methods Group have identifi ed other examples of equity relevant reviews, which 
may be of interest to researchers considering investigating the differential impact of 
interventions.42
Given that many public health interventions involve long-term investment and have 
long-term outcomes, follow-up assessment is important. Indeed, the degree to which 
the intervention and its outcomes are sustainable may ultimately tip the balance 
for decision-makers. Despite this, long-term follow-up is often lacking or simply not 
feasible. As a consequence, there may be no other option than to work with interim or 
surrogate outcomes, for example, maximum oxygen uptake (VO2 Max) as an indicator 
of cardiovascular health; or measures of attitude and intention as markers for behaviour 
change). However, researchers should pay particular attention to the validity and 
reliability of such measures, and to the extent to which they can actually predict the 
primary outcome(s) of interest.43
3.2.2.4 Context
Consideration of the context (e.g. social and political, environmental, and seasonal)6, 44 
in which the intervention is introduced is important. If an intervention is found to be 
effective it is useful to be able to assess whether context was a contributor. However, 
boundaries between a particular intervention and the context in which it is delivered are 
not always easy to identify.
3.2.2.5 Study designs to assess effects, processes and implementation
The choice of study design should be guided by the review question and the needs of 
the end users. The traditional hierarchy of evidence discussed in Chapter 1, Sections 
1.2 The review protocol and 1.3.4. Quality Assessment is relevant to reviews of public 
health.
Given the greater diversity in conditions and settings, planning to evaluate the 
effectiveness of public health interventions requires consideration of the infl uences that 
might impact upon the success of the intervention. Public health questions often require 
consolidation of effi cacy (does the intervention work under ideal conditions?) and 
effectiveness (does the intervention work in everyday life?) criteria in the form of ‘does 
the intervention work’, in conjunction with ‘when, why, and how does it work’ (taking 
account of differences in context, setting or delivery formats) and for ‘whom does it 
work’ (with exploration of differential effects amongst groups).
The appropriateness of different study designs for answering a wide range of questions 
has been summarised.22 Although the RCT is considered to be the gold standard in 
establishing whether the intervention works, there are likely to be fewer conducted in 
public health, especially where policy questions are being addressed and the limitations 
of sole reliance on data from RCTs has been discussed.45 Restricting reviews to RCTs 
and controlled trials may also skew the fi ndings towards particular types of intervention. 
For example a review of interventions promoting a population shift from using cars 
to walking or cycling found that RCTs had been used to evaluate only two types of 
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intervention. Evidence about transport service developments, fi nancial incentives and 
population wide health promotion activities would have been missed, if other types of 
study design had been excluded.46
The cluster randomised trial design47 offers promise, however, methodological diffi culties 
with this design (such as the need for a suffi cient number of randomised units to ensure 
even distribution of confounders) suggest that further developments may be required. 
Others have commented on the diffi culties of low power, secular trends and small effect 
sizes in community-based designs.48 However, a small effect at the community level 
may have more practical signifi cance than an effect of comparable size at the individual 
level.47 Therefore, small measures of change should not routinely be ignored.
Other designs such as before-and-after, interrupted time series and uncontrolled are 
often used and should be considered. Regression-discontinuity and matched controlled 
designs have also been proposed.49
The inclusion of other types of study, such as qualitative research and surveys 
should also be considered as they can help to shape questions of importance to end 
users, help to understand the mechanisms behind effectiveness or ineffectiveness, 
contribute to understanding heterogeneous results, identify factors that impact on the 
implementation of an intervention, describe the experience of people receiving the 
interventions, and provide participants’ subjective evaluations of outcomes. Examples 
of systematic reviews in public health which have considered a range of evidence in 
the context of evaluating effectiveness include those focussing on healthy eating,35, 50 
HIV health promotion,51 and breastfeeding.52 The inclusion of qualitative evidence is 
discussed in Chapter 6.
The concept of using the best available evidence,22, 53 similar to the idea of best evidence 
synthesis,54 where the desire to include the ‘best’ evidence does not stand in the way 
of using the best available evidence, may be the preferred strategy. However, it is 
important to note that the choice of study designs will impact on the level of complexity 
in subsequent stages of the review, including searching, quality assessment, and 
especially synthesis.
3.3 IDENTIFYING RESEARCH EVIDENCE
3.3.1 Database searching
3.3.1.1 Exploring beyond health-related databases
Reviews of public health interventions tend to cut across a number of topic and 
disciplinary areas, meaning that relevant studies are scattered widely and are unlikely 
to be identifi ed if only health databases are searched. Databases should be selected 
according to the question(s) being addressed. In a review of water fl uoridation20 a 
wide range of databases were searched, including EI Compendex (Engineering Index), 
PAIS (Public Affairs Information Service), Water Resources Abstracts, and Agricola 
(Agriculture Online access). Other examples of specialist (non-health) databases are 
those relating to housing or architecture, such as ICONDA, Waternet, and Enviroline; 
to modes of transport such as the TRANSPORT database; to education, such as ERIC; 
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and to geographical data, such as GEOBASE. In an analysis of the sources of studies 
for a systematic review of interventions to promote walking and cycling, only four of 
69 relevant studies were identifi ed from a health database with a signifi cant proportion 
identifi ed by searching the TRANSPORT database.55
Many of the core databases used in medicine are readily available via the Internet, 
at university and college libraries, or as a result of national agreements between the 
NHS and database suppliers. Details of how and where to identify relevant databases 
are given in Chapter 1, Section 1.3.1 Identifying research evidence for systematic 
reviews. Access to some specialist databases such as SportDiscus may be restricted to 
subscribers or organisational members. Researchers need to consider carefully which 
databases are appropriate for identifying studies relevant to their specifi ed question, 
along with any cost implications.
3.3.1.2 Dealing with poor terminology and indexing of studies
In the databases that cover medicine, namely MEDLINE and EMBASE, there are 
structured and well-recognised thesauri (MeSH and EMTREE) that help to create a 
focused search strategy. The use of thesaurus terms to index an international literature 
can compensate for the use of different terms across countries and for variations in 
spelling. Although the settings of public health interventions are important, for example 
‘community-based’ or ‘neighbourhood level’ there are no MeSH terms for these specifi c 
concepts so the more general heading ‘residence characteristics’ has to be used.56 
To address this problem the UK Health Development Agency (now part of NICE) and 
England’s Public Health Observatories (PHO’s) have developed a unifi ed Public Health 
Language (PHL) to facilitate interoperability. The thesaurus (available from the Public 
Health Language website (www.nphl.nhs.uk/uk/default.aspx)) provides a detailed set of 
terms for indexing documents and records related to public health.
Searching for studies will be greatly enhanced when the use of this language becomes 
more widespread and especially when it is mapped to MeSH. While the PHL is still being 
developed, differences in terminology need to be compensated for by using free text 
terms and synonyms when constructing strategies.
Many of the available databases are poorly indexed or abstracted, and some, such as 
Midwifery & Infant Care, and PAIS International, do not have a thesaurus. This means 
there is a greater reliance on using free text terms, which impacts on the sensitivity and 
specifi city of the search.
The greater the number of databases searched the more likely it becomes that different 
search interfaces will need to be used, with strategies being translated to take account 
of differing search operators (e.g. the symbols used to indicate truncation of search 
terms or the adjacency of search terms).
Smaller databases or web-based databases do not routinely allow sophisticated 
searches to be undertaken so broad strategies need to be used to ensure completeness. 
Again, this results in a lower precision rate for the search.
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3.3.2 Acknowledging wider data sources and searching techniques
Extensive database searching is only part of the solution to identifying relevant 
research. Studies may appear as books, book chapters, working papers, policy 
documents or departmental reports, and traditional database searching may not be 
suffi cient to identify these sources. To identify studies published in these formats it is 
important to supplement database searches with Internet searching, scanning relevant 
organisational websites (for example, in the UK The Centre for Public Health Excellence, 
NICE; the EPPI-Centre, University of London; CRD, University of York), contacting 
experts in the fi eld, and reference checking to minimize publication bias.57 Searching 
grey literature sources for unpublished material is a vital part of any search strategy. 
Handsearching selected journals is helpful in keeping abreast of literature not yet loaded 
on electronic databases. A technique known as snowballing (citation tracking using the 
citation databases Science Citation Index, Social Sciences Citation Index, and Arts and 
Humanities Citation Index) might also be considered.
3.3.3 Managing document acquisition
Retrieval of a large number of articles is likely and this has consequences in terms 
of resources. For example, a review of tobacco control interventions58 identifi ed over 
17,000 citations of potential relevance. It may be diffi cult to acquire the identifi ed 
studies, especially if published as reports or working papers. Individuals and 
organisations often need to be contacted, so the whole process may take longer than 
when accessing journal publications.
3.4 DATA EXTRACTION
3.4.1 Incorporating diversity in the data extraction form
As indicated in Chapter 1, Section 1.3.3 Data Extraction, the data extraction form 
should always be designed in line with the research protocol and with the desired output 
in mind. In general, the form should follow the broad format according to PICOCS, 
taking account of any necessary adaptations. Given the potential variety and extent 
of information to be extracted, the design, content and completion of data extraction 
forms may be more time consuming than in most other types of review. For example, 
more information may be required on intervention characteristics including theoretical 
underpinning. It is also important to identify where theoretical information is absent 
from the primary studies. It is likely that all data on differential effects will be relevant, 
so adequate detail relating to the population is important.
Examples of potentially relevant data extraction forms are presented in Box 3.1. Whilst 
these can provide a foundation for data extraction, forms should always be developed 
according to the requirements of the individual review.
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Box 3.1: Data extraction forms
• A tool for data collection relating to studies of community prevention services59
• The Cochrane Effective Practice and Organisation of Care Review Group 
(EPOC) data collection checklist (including quality assessment for multiple 
study designs)60
• The Cochrane Non Randomised Studies Methods Group (NRSMG) checklist 
(to include data extraction and quality assessment of nonrandomised studies  
www.cochrane.dk/nrsmg/guidelines.html)
• EPPI-Centre data extraction and quality assessment guidelines for health 
promotion outcome and process evaluations61
• The RE-AIM framework to document data on intervention reach, effi cacy, 
adoption, implementation and maintenance62
3.4.2 Dealing with inadequate information
Given the potential reporting problems in many primary studies, researchers may need 
to allow extra time (at the study selection and/or data extraction stage) to make contact 
with study authors. It is important to record the potential impact of missing data for 
later discussion on review fi ndings and a designated area of the form is useful for this 
purpose.
3.5 QUALITY ASSESSMENT
3.5.1 Addressing the quality of the intervention and implementation
The importance of intervention and implementation quality in relation to systematic 
reviews of complex interventions is raised in Chapter 1, Section 1.3.4 Quality 
Assessment, and the discussion is expanded here. A distinction should also be made 
between the quality of the intervention and quality of the evaluation, the latter being 
extensively covered in Chapter 1 and therefore not discussed further here.
The quality of an intervention can be conceptualised as having two main aspects 
(i) whether the intervention has been appropriately defi ned, and (ii) whether the 
intervention was delivered as planned (integrity, or fi delity of the intervention).
3.5.1.1 Has the intervention been appropriately defi ned?
Theoretical underpinning, use of qualitative research and exploratory studies are 
important in developing a fully defi ned intervention. This includes outlining the most 
likely mechanism of action, and the most appropriate duration and timing of the 
intervention.2, 63 Developing the intervention from a needs assessment or piloting 
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exercise is also likely to be integral to effectiveness.64 However, in reality, complex 
interventions are not always developed in this way.
While this aspect of intervention quality is relevant to the appraisal of a primary study, 
and the subsequent synthesis of studies, it is often not formally assessed. A checklist 
is available to aid researchers with this task, although further developments have been 
recommended.65 Where there is evidence that aspects of an intervention should be 
administered in a particular way, it is important that this is assessed systematically. 
As a minimum, this should include the extraction of appropriate information describing 
the intervention and this information should be considered in the synthesis and 
interpretation as a possible source of heterogeneity.
3.5.1.2 Was the intervention delivered as planned?
The integrity or fi delity of an intervention refers to the extent to which the intervention 
has been delivered (or implemented) as planned.66 If an intervention is not delivered 
as planned a positive effect is less likely to be found. It is therefore important to 
distinguish between a failure of implementation and an ineffective intervention.5, 6 
It has been argued that fi ve dimensions – adherence, exposure, quality of delivery, 
participant responsiveness and programme differentiation – need to be measured 
to provide a comprehensive picture of integrity/fi delity.66 In practice however, these 
aspects are often not assessed and/or reported in primary studies,6, 33, 66, 67 and this has 
led to a recommendation for their inclusion in reporting statements such as CONSORT 
and TREND.68 A new conceptual framework has also recently been developed to aid 
understanding of the concept and for measuring the process.69
There are few assessment tools available for use in systematic reviews that include 
items on intervention integrity. However, one such tool recommended by The Cochrane 
Public Health Review Group10 is the Effective Public Health Practice Project Quality 
Assessment Tool for Quantitative Studies (www.city.hamilton.on.ca/PHCS/EPHPP). The 
Oxford Implementation Index is a new tool to help researchers extract, appraise and 
use implementation data in systematic reviews. Its applicability to Cochrane reviews of 
HIV prevention and psychosocial interventions has been demonstrated.70
Consideration of whether an intervention was implemented as planned overlaps 
with the concept of process evaluation, though the latter covers a wider range of 
activities. Process evaluation (within trials) has been described as an exploration of 
the implementation, receipt, and setting of an intervention, and helps to interpret the 
outcome results.33 It is of particular relevance to public health interventions though it 
is often not conducted in a formalised way.6 The methodology for process evaluations 
embedded within RCTs requires further development,33 but as knowledge develops it is 
likely to impact on how such studies are assessed in systematic reviews.
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3.6 DATA SYNTHESIS
3.6.1 Developing an appropriate strategy
The choice of synthesis method will ultimately depend on the question(s) addressed 
and the type of data included. Researchers should refer to Chapter 1, Section 1.3.5 
Data synthesis, for general guidance on data synthesis. Where the review question 
relates to whether interventions work in different groups, and centres around 
dimensions of inequality such as race or ethnic origin, occupation, education, gender 
and socioeconomic status, synthesis poses particular challenges. Researchers might 
want to consider a method71 devised for use in a review of population level tobacco 
control interventions on social inequalities in smoking.39 The method combines aspects 
of the graphical directness of a forest plot (see Chapter 1, Section 1.3.5.2 Quantitative 
synthesis of comparative studies) with a narrative account of what can be learned from 
a group of very diverse studies. The results from each category of intervention are 
weighted according to certain methodological criteria and plotted on a matrix (harvest 
plot). The harvest plot allows best use of all available evidence and provides a visual 
display, which aids the process of synthesis and the assimilation of fi ndings.71
In addition a comprehensive review of approaches to synthesis is available which 
outlines a range of options, including methods for qualitative evidence, for quantitative 
data and for both types of evidence. Readers interested in comparing the options 
available are advised to consult this text.72
3.6.2 Handling heterogeneity
Careful judgement is needed when integrating different types of evidence.73 Indeed, 
differences in study design, participants, context, and in processes/methods of 
implementation, theoretical underpinnings, outcomes and outcome measures are 
major contributions to the complexity, and thus heterogeneity at the synthesis 
stage.5 Exploring heterogeneity may be more complex in public health reviews due 
to mechanisms and interactions being less well developed and not always possible to 
determine a priori.5 Subgroup analysis can aid the evaluation of differential impacts 
across groups and in assessing inequalities. Importantly, subgroup analysis can also 
be used to explore interactions between effects and the quality of the intervention.74 
Available techniques are described in Chapter 1, Section 1.3.5.2 Quantitative synthesis 
of comparative studies.
3.6.3 Applicability
The extent to which public health interventions are expected to work in other contexts 
can be less predictable than for some clinical interventions. Therefore, it is usually 
necessary to examine the details of process and context (for example, the mechanics 
of the intervention and implementation process in relation to the study population, 
location, and wider environmental infl uences) before extrapolating the fi ndings from 
individual studies and any subsequent synthesis.6 Summarising the results of several 
studies carried out in different settings and with different populations is in itself a 
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test of the applicability of fi ndings.75 If study fi ndings are similar across a range of 
circumstances then confi dence that the fi ndings are transferable is increased. Where 
effects vary according to setting, population or intervention characteristics, this 
information is useful for understanding in which circumstances the evidence is likely 
to be applicable. Although not frequently reported in systematic reviews, applicability 
(often referred to as external validity or generalisability) is included in some checklists.76 
A tool for assessing applicability and transferability (another term with similar meaning) 
has been proposed.77
3.7 REPORTING
The guidance for report writing discussed in Chapter 1, Section 1.3.6 Report writing, 
is relevant to reviews of public health. However, given the diversity of public health 
research, and its concern with what works, for whom, why, when, and at what cost, 
there are likely to be additional reporting requirements, in particular factors impacting 
on applicability. These include context, development and rationale, implementation 
process, and sustainability.
Summary: Systematic reviews of public health interventions
• Public health interventions represent a set of activities aiming to protect, 
promote, and restore the health of all people.
• The evaluation of public health interventions is usually complex.
• Traditional criteria for producing systematic reviews only partially fulfi l the 
requirements for public health interventions.
• Unique challenges to reviewing in this topic area require consideration. These 
include:
• Applying an extended version of PICOS, with attention to context and to 
equity and inequalities
• Embracing a wider range of data sources and searching techniques
• Attention to quality assessment beyond traditional measures of 
methodological adequacy
• Dealing with diverse data and choosing appropriate methods of synthesis
• Reporting with additional focus on applicability
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4.1 INTRODUCTION
Therapeutic interventions can have negative (adverse) as well as benefi cial effects. 
Many adverse effects can be explained by the mode of action of the intervention and 
can therefore be anticipated and explained. Others may be unexpected, occurring only 
where unique combinations of genetic factors or personality and environment combine. 
Some adverse effects may be extensions of the expected response to an intervention; 
for example severe constipation following the use of an anti-diarrhoeal (loperamide). 
Others may occur where the response to an intervention is unexpectedly negative; for 
example phocomelia (limb abnormalities) following the use of thalidomide for pregnancy 
induced nausea.
Health care professionals and patients need information about both intended and 
unintended effects of an intervention in order to make an informed decision about its 
adoption.1-3 Even in the presence of reliable information regarding benefi t and harm, 
decision-making is seldom straightforward.4
Most reviews focus on the benefi cial effect or clinical effectiveness of an intervention 
without adequately addressing adverse effects.5-7 This imbalance may lead to 
interventions being prescribed or used inappropriately, or patients being harmed by 
potentially avoidable adverse consequences. Systematic review of adverse effects and 
consideration of adverse effects within reviews of effectiveness therefore needs to be 
encouraged. However, this is a relatively new area and methods are still evolving.8, 9
Some of the methodological issues have been reported10, 11 and a survey of 256 reviews 
of adverse effects identifi ed particular diffi culties with search strategies and the 
evaluation of diverse data sources.12 One issue of particular importance is that reviews 
focusing on adverse effects often include studies where harms were of secondary 
interest. Another issue is the selection of adverse effects on which to focus. Many 
systematic reviews have attempted to review all adverse effects of an intervention,10 
but this can be problematic given the often large numbers of different associated 
adverse effects/events some of which may be poorly documented. It is important 
to balance comprehensiveness against clinical relevance and in practical terms the 
outcomes chosen should be those that are important in guiding decisions related to the 
intervention.
The basic principles for carrying out a systematic review, as described in Chapter 1 
also apply to reviews of adverse effects. This chapter focuses on the differences in 
approach and specifi c issues related to assessment of the safety and tolerability of an 
intervention. Given that, to date, much development has been around adverse effects 
of pharmacological interventions, this chapter refl ects this emphasis. However, the 
principles also apply to other types of intervention, such as surgical procedures and 
medical devices.
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4.2 DEFINING THE REVIEW QUESTION
4.2.1 Population
Interventions are sometimes used to treat a number of different conditions. Any 
resulting adverse effects may be experienced across conditions or may be population 
specifi c. Decisions will need to be made about whether the review will focus on a 
specifi c population with a particular diagnosis or whether all patient populations who 
have received the intervention will be included. For example, a review assessing the 
effect of statins on cancer risk did not specify why the patients in the studies were 
taking statins.19 This was probably not important in this context, but might have been 
for other adverse effects.
Overall, broader inclusion criteria make the fi ndings more generalisable, whereas 
narrower inclusion criteria are likely to produce more homogenous results. It is 
important to consider the trade-off between the two approaches.
4.2.2 Intervention
For pharmacological interventions, reviews may focus on a single drug, all drugs in a 
class, or even include similar classes of drug. Boundaries will in part depend on the 
type of intervention and the type of adverse effects being investigated. However it is 
important to recognise that there can be problems with grouping drugs together in a 
class; even within a class there can be differences between drugs, and assumptions 
should be avoided. For example, arising from the clinical problem that selective COX2 
inhibitor drugs were suspected of causing cardiovascular adverse effects, a systematic 
review considered all drugs of this class, together with some nonselective COX2 
inhibitors.13 Importantly, drugs were not all treated as a single intervention. The review 
found that of the selective COX2 inhibitors, only rofecoxib was associated with an 
increased risk of cardiovascular events and that one of the older nonselective COX2 
inhibitors, diclofenac, may also increase risk.13 This highlights two important points. 
Firstly, if all selective COX2 inhibitors had been treated as a single intervention, then 
differences between the specifi c drugs would have been missed. Secondly, if only 
one selective COX2 inhibitor had been included (making the assumption that it was 
representative of its class) then the wrong conclusions would have been reached.
As for reviews of effectiveness, defi ning nonpharmacological interventions can be 
diffi cult. Surgical procedures and medical devices are frequently modifi ed by surgeons/
manufacturers and the researcher has to decide when such modifi cations might 
constitute a separate intervention.14 With surgical techniques, there is the added 
complexity that even a standardised technique can be performed differently by different 
surgeons or even by the same surgeon as his/her experience of the technique increases. 
Complex interventions may be even more diffi cult to defi ne in the context of potential 
adverse effects.
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4.2.3 Comparators
The appropriate comparator will ideally be placebo or no treatment in order to 
identify and evaluate those effects which are truly related to the intervention. 
However, sometimes it is important to explore differences between active treatments. 
This applies to pharmacological interventions such as selective COX2s or statins 
and to nonpharmacological treatments such as catheter ablation with or without 
anticoagulation. A reliable investigation of the differences between active treatments 
can only be undertaken for specifi c adverse effects within well-defi ned populations.
4.2.4 Outcomes
There is sometimes an assumption that all adverse effects should be included. However, 
such a broad approach can be resource intensive. An analysis of three systematic 
reviews indicated that two included a broad range of events, but generated a large 
volume of work and yielded little useful information for decision making.15 A fully 
comprehensive review will not always be necessary or feasible and narrowing the focus 
to a specifi c adverse effect or class of effects enables researchers to undertake analyses 
in a systematic, manageable and useful way.16 This can be achieved by investigating 
only those adverse effects that are defi ned by patients or clinicians as the most serious 
and/or severe and/or troublesome; or are commonly reported, or lead to participant 
withdrawal from treatment.16 The important point is that the scope of a particular review 
should be specifi ed and justifi ed in the protocol. It is also important to consider how to 
detect adverse effects (i.e. unwanted harms of the intervention) rather than adverse 
events that have been recorded in clinical studies, but which may not be causally 
related to the intervention of interest. This is considered further in Section 4.6 Data 
synthesis.
Primary studies that report on adverse events may differ, for example in the defi nitions 
of a specifi c adverse event, severity (or intensity); the reporting (or not) of events 
of differing degrees of severity; the terminology used to describe similar events (e.g. 
fatigue, tiredness, aesthenia and lethargy) and for continuous outcomes, the threshold 
for an ‘abnormal’ result. The review team will need to decide whether outcomes from 
different studies are similar enough to group together in the review. If outcomes are 
grouped it is important to justify the decision.
Attempts have been made to standardise terminology used to describe adverse events 
by for example, the National Cancer Institute and the World Health Organisation (WHO). 
The WHO criteria (WHO Adverse Reaction Terminology or WHO-ART; see MedDRA 
www.umc-products.com) have been widely adopted by regulatory bodies and the 
pharmaceutical industry. Serious adverse events are defi ned by the WHO as those that 
lead to signifi cant medical consequences such as death, disability or hospitalisation. 
However, primary studies may defi ne serious adverse events differently, for example 
those that the investigator (or the patient) considers serious. An adverse event may be 
severe in intensity (as opposed to mild or moderate) without necessarily being serious.17 
Different adverse events may be grouped under a broader classifi cation and it may not 
be clear which adverse effects are included, for example the term ‘minor haemorrhage’ 
recorded in studies of anticoagulants includes nose bleeds, bruises, gum bleeding, and 
other forms of minor bleeding.
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The identifi cation of rare effects can be specifi ed as an objective.18 However, causality 
and incidence are unlikely to be adequately addressed by reviewing the published 
literature. Rare events almost never occur in controlled trials, with their limited 
participant numbers and follow-up duration. A rate may be estimated from cohort 
studies, and, if the population is unselected, the rate may be a better estimate than 
that arising from an RCT on a highly selected population. However, even published 
observational studies are seldom large enough to provide defi nitive estimates of 
incidence. The lack of evidence of a rare adverse effect is therefore not proof that such 
an adverse effect is not associated with the intervention of interest.
It may be helpful when formulating the review question to think in terms of ‘hypothesis 
generating’ or ‘hypothesis testing’. Taking a broad approach in specifying the review 
question, for example by including all adverse effects, could be considered hypothesis 
generating, whereas hypothesis testing should seek to clarify the statistical nature of 
the risk, and/or better defi ne the characteristics of the adverse effect by having a more 
focussed question.
4.2.5 Study design
A range of different study designs can provide useful adverse effects data. For example, 
RCTs may be appropriate for common, anticipated adverse effects, observational studies 
may be particularly useful for long-term or rare adverse effects, and post-marketing 
monitoring data may be useful in detecting previously unknown adverse effects.
4.2.5.1 RCTs
It is generally recognised that RCTs have major limitations as sources of adverse 
effects/adverse events data. They may not be generalisable having excluded patients 
at high or even medium risk of experiencing certain adverse effects, or may have only 
short-term follow-up and relatively small sample sizes.
The way that adverse effects data are collected in RCTs and how they are reported is 
also a limitation to their usefulness in systematic reviews. A survey found that of 185 
RCTs of drug therapy, 14% made no mention of adverse effects, and data in a further 
32% could not be fully evaluated.20
4.2.5.2 Observational studies
Observational studies, such as controlled or uncontrolled cohort studies or case-control 
studies or large case series, are likely to provide more participants, longer follow-up and 
more generalisable data than RCTs. For example, a meta-analysis of RCTs identifi ed only 
340 cardiovascular events related to Cox 2 inhibitors,21 while a review of observational 
studies identifi ed 60,251 cardiovascular events in nine case-control studies.13 In another 
review of the incidence of thrombotic thrombocytopaenic purpura associated with 
ticlopidine plus aspirin, the only data found were in a single large observational study 
of 43,322 participants.7 Post-marketing surveillance studies may be useful sources of 
adverse events/effects data for pharmaceuticals.
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4.2.5.3 Case reports
Published case reports (reports of individual spontaneous occurrences of an adverse 
effect in clinical practice), may be a useful source as information about adverse effects 
are frequently reported.6,22,23 However, just because case reports are abundant and 
widely used, does not necessarily render them good sources of evidence.
Published case reports have signifi cant limitations,24 for example they frequently fail to 
provide important information, including an assessment of likely causal relationship to 
the intervention being evaluated, and some investigations have concluded that stricter 
criteria and guidelines for reporting are required.25, 26 Importantly, case reports cannot 
provide conclusive evidence; they cannot provide an estimate of incidence, and are 
usually only hypothesis generating. Although any indication that a treatment might have 
a signifi cant harmful effect should not be ignored, a balance has to be struck between 
responding to each report of an adverse effect and trying to eliminate uncertainty 
before acting.
4.2.5.4 Databases
Arguments have been made for reports of adverse events from drug surveillance 
databases, hospital databases or general practice databases to be incorporated 
into systematic reviews.8 However, it should be noted that analysis of this type of 
information is more akin to primary research than systematic review; using such 
sources will require a properly designed study to yield information, see for example the 
study on the role of paroxitine in suicide.27
4.3 IDENTIFYING ADVERSE EFFECTS EVIDENCE
Search methods may vary depending on whether the review focuses on the adverse 
effects of an intervention or focuses primarily on effectiveness but also addresses 
adverse effects.
If adverse effects are a secondary outcome, then the way that searches are conducted 
will depend largely on how the effectiveness searches were carried out. For example, 
if a search for effectiveness studies included only terms for the population and 
intervention with no search fi lters for study design, no terms for the outcomes, and 
the defi nition of the population has not changed, then it may be suffi cient to scan the 
results of the effectiveness searches for information on adverse effects. Only a few 
additional searches may be required in additional specialist sources.
If, for example, the effectiveness searches were limited to RCTs and the adverse effects 
sought are long-term, rare or unanticipated, then additional searches will be required. 
These searches would be carried out in the sources already searched, as well as in 
additional sources specifi c to adverse effects.
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4.3.1 Search strategy
If information on a specifi c named adverse effect is required, the approach used will 
be similar to that for a systematic review of effectiveness, using adverse effects as 
the outcome (see Appendix 4: Searching for specifi c adverse effects). It should be 
noted, however, that due to the poor reporting and poor indexing of adverse effect 
data this method will not necessarily retrieve all the relevant papers.28-30 Alternatively, 
if all adverse effects for a given intervention are required then a different approach is 
needed. This is outlined in Appendix 4: Searching with generic adverse effects terms. 
Consideration should be given to whether the adverse effect(s) of interest are common 
or rare, short or long-term, known or unknown as this will have implications for the 
choice of study design and therefore the most relevant sources of information and 
search fi lters.
4.3.2 Potentially useful sources
Textbooks and bulletins can be a useful starting point when searching for information on 
adverse effects, particularly of pharmaceuticals. The European Public Assessment Report 
(EPAR) provides a useful summary of adverse effects of drugs licensed by the European 
Medicine’s Agency (EMEA) as does the Summary of Product Characteristics. The 
Physician’s Desk Reference, Meyler’s Side Effects of Drugs, Martindale: The Complete 
Drug Reference and AHFS (American Hospital Formulary Service) Drug Information. 
Problems in Pharmacovigilance the Australian Adverse Drug Reactions Bulletin, or 
Reactions Weekly (via PharmaNewsFeed) are also useful sources.
The main electronic sources for adverse effects data are listed in Table 4.1. Potential 
sources of unpublished information on adverse effects are listed in Table 4.2.
Very few evaluations have been carried out of the comparative usefulness of these 
sources in terms of yield of relevant information. The available evaluations focus on 
case studies of drug interventions,30-33 and all indicate that EMBASE retrieves more 
relevant references than MEDLINE. Some studies suggest there is potential value in 
searching databases such as Derwent Drug File, 32, 34, 35 and TOXLINE. 30, 31, 36 Searching 
full-text articles may be particularly advantageous in identifying adverse effects due to 
the poor reporting of adverse effects in the title and abstracts of articles and therefore 
the indexing.28, 37-39 Full-text databases provide access to the full-text of articles and 
some enable searches of full-text articles.
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Table 4.1: Summary of information sources
Electronic sources Examples
Full-text databases Iowa Drug Information Service (IDIS), 
Content varies from generic coverage to  PharmaNewsFeed
specialisation in adverse effects or drug 
information
Bibliographic databases
These can be divided into:
• those specifi cally related to adverse effects • TOXLINE
• those containing a large section of adverse • Derwent Drug File, International 
 effects information  Pharmaceutical Abstracts (IPA), Pharmline
• generic databases that contain information  • MEDLINE, EMBASE
 on adverse effects
Referenced summary databases Drugdex, Reprorisk, Poisindex, XPharm
Most specialise in drug information
Internet reference collections Organization of Teratology Information
Most are topic related, and contain useful  Specialists, Motherisk (safety of drugs during
bibliographies or reference lists pregnancy)
Spontaneous reporting systems Canada’s Adverse Drug Reaction Database, UK
Some information is free on the internet,  Drug Analysis Prints (DAPS),
most useful data are available for a fee through  DIOGENES, Vigibase Services
databases or requests services
Table 4.2: Unpublished data sources
Unpublished information Examples
Authors Trialists, researchers
May be authors of effi cacy studies or adverse 
effects studies
Industry GlaxoSmithKline www.gsk-clinicalstudyregister.
Drug companies or manufacturers of medical  com/
devices International Federation of Pharmaceutical
 Manufacturers and Associations (IFPMA) 
In many countries, manufacturers of drugs  clinical trials portal (http://clinicaltrials.ifpma.
have a regulatory requirement to monitor  org/no_cashe/en/myportal/index.htm)
the adverse effects of their drugs. However  Food and Drug Administration (FDA) 
such data may be classed as commercially  www.fda.gov/ 40
sensitive and therefore not accessible, and 
even if obtained, can be extremely detailed  Comprehensive clinical trials reports (CCTRs)  
and diffi cult to navigate produced by or for manufacturers
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4.4 DATA EXTRACTION
Data extraction should include frequency, severity, seriousness of the event and 
withdrawals from treatment because of adverse events.
The way in which adverse events were monitored or recorded may affect the reported 
frequency and so should also, if possible, be extracted. For example, noting whether the 
data were collected at follow-up (and if so how frequently), and whether collected by 
patient diary or checklist, or relied on spontaneous reporting. In studies using patient 
diaries, adverse effects were found to be signifi cantly more common in the active 
treatment than control groups.41 However, when adverse effects were assessed by direct 
questioning, spontaneous reporting, or where the method was not reported, there were 
no signifi cant differences between groups or methods of assessment.
Withdrawals and drop-outs should be extracted where possible, together with the 
reason if known. However, withdrawals and drop-outs are not reliable surrogates for 
safety or tolerability; withdrawals may be for other reasons than adverse events, for 
example unpleasant or inconvenient study procedures, lack of improvement or earlier 
than expected recovery.42 Alternatively, investigators often make considerable efforts to 
keep withdrawals low43 and this can result in withdrawal rates lower than the ‘true’ rate 
that would be seen in clinical practice.
Data extraction is frequently complicated by poor reporting. For example, some studies 
only report the number of adverse events, not the number of patients with adverse 
events. This can lead to problems at the data synthesis stage. It is possible to derive 
the number of patients from the number of adverse events or use the number of 
adverse events.44 However this is controversial as it may over or underestimate the rate 
of adverse events.45
4.5 QUALITY ASSESSMENT
In studies assessing both effectiveness and adverse effects it is important to recognise 
that there might be differences in the quality of data relating to each type of outcome. 
Such differences are commonly related to the sample size and study duration, which 
may be adequate for the primary effi cacy/effectiveness variable but not for adverse 
effects.15, 42 Also the collection of data may be different: for example the effi cacy of an 
intervention may be studied in a placebo controlled RCT but the adverse effects data 
may be collected retrospectively when the assigned treatment is known.46
4.5.1 Quality assessment criteria
Criteria for assessing the quality of adverse effects data are being developed8, 11 and 
some checklists already exist such as the checklist for assessing quality of RCTs, cohort 
studies and uncontrolled surgical series that reported adverse effects.68 The majority of 
these have not been validated11, 42, 49, 59 and none are suitable for all purposes. However, 
different criteria should be used for different study designs, and the criteria should have 
been validated by empirical evidence wherever possible.11
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Efforts have been made to develop a standard scale for assessing the quality of different 
types of study design,69-72 but there is currently no consensus on how to incorporate 
information about quality from a range of study designs within a systematic review.15 
Researchers need to be clear about what they require from quality assessment and 
perform the assessment accordingly.15
4.5.1.1 Is there an adequate explanation of how adverse effects were 
identifi ed?
A variety of measurement instruments may be used to identify adverse effects. 
Examples include active or passive surveillance, questionnaire derived data, clinical 
laboratory and pharmacokinetic and pharmacodynamic data. The choice of instrument 
can signifi cantly affect the identifi cation, measurement and reporting of adverse 
effects.22, 47 For example, active surveillance may provide more reliable estimates than 
passive surveillance and even with active surveillance, a prospective method may yield 
more accurate information than a retrospective method.48 The strengths and limitations 
of these methods have been described elsewhere.11, 49 In assessing study quality, it is 
important to consider how adverse effects were identifi ed and reported for each data 
source used. For example, were the adverse effects assessed independently by someone 
other than the surgeon performing the procedure? Are the measurement instruments 
described? Is the timing and duration of follow-up reported?
4.5.1.2 Was a standardised or validated measurement instrument used?
There are a number of standardised instruments for reporting adverse effects.50-58 
For example the National Cancer Institute54 and the National Institute of Allergy and 
Infectious Diseases59 have introduced guidance on assessing the severity of adverse 
effects. Similarly, the Brighton Collaboration has developed guidelines for reporting 
adverse effects following immunisation.52 The use of nonstandardised and nonvalidated 
scales is also very common,42 and it is important to specify whether included studies 
used a standardised or validated scale to report adverse effects.
4.5.1.3 How was the adverse effect(s) attributed to the intervention?
Studies should make clear how they identifi ed that the harm was related to the 
intervention, who made the attribution (e.g. investigators, participants, sponsors or a 
combination of these) and whether the process was blinded to assigned treatment.42 
Establishing the causal link between the intervention and harms may be particularly 
diffi cult in case reports, and the following criteria may be helpful for establishing 
causality: temporal relationship, lack of alternative causes, and for interventions that 
are given repeatedly over time, response to discontinuation (dechallenge), dose-
response relationship and response to repeat exposure (rechallenge).11 For drug 
interventions the presence of toxic concentrations of a drug may also indicate a causal 
relationship.
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4.5.1.4 Are the terms clearly explained?
A variety of terms are used to identify adverse effects, with some of the terms 
remaining ill-defi ned and the boundaries between them not clearly described.42, 49 The 
lack of standard and well-constructed terms and a set of defi nitions has led to real 
diffi culties in comparing adverse effects between studies.20 To make accurate and 
reliable comparisons between, or synthesis of, studies it is important that clear and well-
constructed terms and defi nitions are used. In particular the severity of adverse effects 
should be adequately defi ned by either detailed description of severity or reference to a 
known scale of severity.60
4.5.2 The quality of the reporting of adverse effects in primary studies
Currently there is no agreed standard about what and how information is recorded 
and reported,61 and hence no consistency in the data available for extraction.62 The 
CONSORT statement has been extended in an effort to improve reporting of harms 
from RCTs,42 but this is likely to be of limited value as data on adverse events are 
often derived from studies other than RCTs. Some of the criteria in the extension to 
the CONSORT statement are relevant to absolute quality and others are important for 
enabling adverse effects information to be synthesised and compared across studies.
Ideally, study results should be reported according to the methods section of the study 
protocol.63 The number of each type of adverse effect should be reported for each 
study arm. The timing of events should also be reported, particularly when the follow-
up period is prolonged. Many RCTs are large enough to evaluate the benefi cial effects 
of the intervention, but the majority are not adequately powered to detect statistically 
signifi cant differences for most adverse effects, except very common ones.6, 48 This may 
lead to overinterpreting the absence of adverse effects especially when the sample size 
is small.48 Serious and life-threatening adverse effects in particular should be described 
separately for each type of event.48 If no adverse effect of a specifi c type or severity 
occurred this should be stated.
The report should specify the number of patients withdrawn from the study because 
of adverse effects by study arm and by type of adverse effects and detail who decided 
to withdraw (participant or physician) and whether attribution was blinded to the 
assigned treatment.42, 48 Such information is often not well reported. A systematic 
review of published RCTs on treatments for HIV infection found that although 82% 
of trials reported how many patients discontinued the study treatment, reasons were 
stated in only 38%.64 A further systematic review found that 75% of trials in seven 
medical areas reported the number of discontinuations due to toxicity per study arm, 
but specifi c reasons were given in only 46%.60 Studies with prolonged follow-up should 
report the timing of withdrawals as the causes of early withdrawals may differ from late 
withdrawals.
Sometimes more than one adverse effect may occur in a patient but this is not always 
reported clearly. It is most helpful when both the number of affected participants and 
the total number of adverse effects are reported, with the denominators and incidence 
or prevalence rates.42
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Intention-to-treat is usually the recommended method of analysis (see Chapter 1 
Section 1.3.5 Data synthesis). It may however, underestimate adverse effects 
particularly when there is a high rate of nonadherence with allocated treatment.42 ‘On 
treatment’ or ‘per protocol’ analysis, in which adverse effects are only considered in 
those patients who have received the intervention, are probably more appropriate.
There are a number of factors associated with bias in the reporting of adverse effects 
data. It is important to be clear about whether a paper includes all adverse effects that 
occurred or just a selected sample.42 If a subset is reported it should be clear how, why 
and who made the selection. It should also be clear whether the selection was made 
on the basis of frequency (e.g. common events), severity, seriousness, or biological 
relevance to the intervention.65 Clinical trials have been found to report adverse effects 
without distinction of severity and this may hinder accurate comparison of adverse 
effects between studies.60 If severity and seriousness are not considered then the 
synthesis may be fl awed. Where critical or otherwise signifi cant adverse effects have 
been reported they should ideally have been investigated and the fi ndings included in 
the report.8
Which adverse effects are critical or important is a clinical judgement and depends on 
the purpose of the study. For example if the study is of healthy individuals and the main 
focus is prevention, even minor harms might be important in the balance of harms 
and benefi ts. Alternatively, if the main study outcome is survival, only major or life-
threatening harms might be relevant.42
Some studies with poor reporting of adverse effects may be methodologically sound 
and contact with authors may retrieve additional information.66 However, contact with 
authors may retrieve little information, even when studies are recently completed and 
targeting a very common condition.67
4.5.3 Generalisability
A combination of factors such as patient characteristics (e.g. age), type and severity of 
disease, co-morbidities and clinical setting may contribute to the occurrence of adverse 
effects. Likely effects of confounding factors should be considered, particularly when 
using data from case series and observational studies. Interpreting adverse effects data 
from RCTs can also be problematic; in clinical trials most participants have the disease 
of interest but are otherwise healthy, but once the intervention is licensed it is often 
used in individuals with co-morbidities who are taking several other drugs.42 These 
confounding factors may affect the generalisability of the study and should be clearly 
described.
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4.6 DATA SYNTHESIS
4.6.1 Consideration of potential sources of heterogeneity
Systematic reviews of adverse effects often include evidence from a variety of 
sources including RCTs, observational studies, case reports and case series. There are 
diffi culties in synthesising disparate data sets and differences between studies have 
to be considered as a source of heterogeneity (whether narrative or quantitative). 
In observational studies the extent of drug exposure is not as certain as in RCTs. For 
example, in cohort studies many patients might have received an incomplete course 
of medication which may lead to the underestimation of the true rate or severity of 
adverse effects. Patients in the control group may have procured the medication during 
a generally prolonged follow-up period and this may lead to overestimation of the rate 
of adverse effects in the control group.73
4.6.2 Methods of data synthesis
Whether narrative or quantitative synthesis is used, researchers should try to explore 
any patterns identifi ed across the results and discuss the possible factors that might 
explain variations in study fi ndings (e.g. rate and severity of adverse effects). Attempts 
should be made to explore possible relationships between characteristics of included 
studies and their reported fi ndings and also between the fi ndings of different studies. 
Researchers should clearly indicate the populations addressed by the included studies 
and carefully assess the applicability to other populations.11
Exploring heterogeneity in study fi ndings is especially important.74 Variations may 
be due to methodological differences and/or differences in the characteristics of the 
included studies. The possible effects of individual study quality indicators (e.g. follow-
up period, methods used to identify adverse effects), study design, study size and 
funding sources in the analysis should be investigated and discussed.11 Subgroup, 
sensitivity or regression analyses may be helpful for explaining some of these variations 
and generating functional hypotheses.
Researchers should provide a detailed description of cases of unusual or not previously 
recorded adverse effects.48
4.6.2.1 Meta-analysis techniques
There is little guidance about when and how to perform meta-analysis of adverse effects 
data. It is important, but not always easy to determine when and what data from 
multiple studies should be combined.75 No standard technique is available for meta-
analysis of diverse and heterogeneous data, and selection of techniques depends on 
different factors including the aim of the review, characteristics of selected studies and 
type of outcomes.73 Although data from both observational studies and RCTs has been 
combined, for example to present a single estimate of mortality associated with chronic 
usage of non-steroidal anti-infl ammatory drugs (NSAIDs),73 in some reviews it may 
only be appropriate to quantitatively combine results from one or some study designs 
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(e.g. RCTs and cohort studies) and synthesise data from other types of studies (e.g. 
case series and case reports) using a narrative approach. As with effi cacy data it may 
be appropriate to conduct subgroup analyses or, where data allow, use meta-regression 
to further explore the risk of adverse effects. For example the risk of bowel perforation 
with the cancer drug bevacizumab is thought to be higher in patients with ovarian 
cancer than in other cancers.76
Various Bayesian approaches to meta-analysis have been used77-80 and when and how 
to use Bayesian approaches in reviews of adverse effects is a developing fi eld. For 
example, a Bayesian approach has been used to combine evidence from case-control 
and prospective studies to estimate the absolute risk of developing ovarian cancer.81
4.7 REPORTING
The guidance for report writing presented in Chapter 1, Section 1.3.6 Report writing, 
is relevant to reviews of adverse effects. However, when reporting reviews of adverse 
effects it is important that detailed cross referencing to related reviews of the intended 
effects of the intervention are provided for the reader.
Summary: Systematic reviews of adverse effects
• The number of different reported adverse effects/events can be large and 
comprehensiveness needs to be balanced against clinical relevance. The 
outcomes selected should be those that are important in guiding decisions 
related to the intervention.
• Observational studies, such as controlled or uncontrolled cohort studies or 
case-control studies or large case series, are likely to provide more patients, 
longer follow-up and more generalisable data than RCTs.
• Search methods may vary depending on whether adverse effects are the main 
focus of the review or a secondary focus.
• Both the quality of the primary studies and the quality of the reporting of 
adverse events within the primary studies should be considered.
• Meta-analysis may be more challenging and problematic than when applied to 
effectiveness data. Whatever the method of synthesis, researchers should try 
to illustrate the patterns identifi ed across the results and discuss the possible 
factors that might explain variations in study fi ndings.
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5.1 INTRODUCTION
Where resources are limited, decision-makers need to consider not only whether an 
intervention is effective but whether it is also cost-effective. If a new intervention 
requires more resource than current practice, then this will have to be found from 
elsewhere within the health system, and adoption may displace other treatments 
or services. Considering economic aspects alongside clinical effectiveness can make 
reviews more useful to health care decision-makers.1 There are three main options for 
addressing economic issues within or alongside a systematic review of effectiveness.
First, at a basic level any cost or resource information reported in the effectiveness 
studies can be extracted and presented as an additional outcome (see Chapter 1 Section 
1.2.2.2 Review question and inclusion criteria). Although this may not constitute a 
formal economic evaluation, it can provide useful additional information that may be of 
value in a decision-making context.
The second option involves undertaking two mutually dependent components: a 
review of all available evidence and an economic evaluation, which is often achieved 
through the use of decision modelling.2 The fi ndings of the review are used to help 
develop and populate a decision model. This is a common approach, used primarily in 
health technology assessment. Many such examples have been undertaken for NICE.3-5 
However, decision modelling is outside the remit of this chapter as it involves specialist 
skills, but good introductory texts are available.6
The third option is to carry out a systematic review of existing economic evaluation 
studies that have focused on the intervention in question. This is often done alongside 
the clinical effectiveness review. However, the exact role for this type of review is 
unclear and questions remain as to whether it is actually useful to undertake reviews 
of existing economic evaluations.7 A fundamental reason for undertaking a review of 
any kind is that the collation and synthesis of evidence will be more useful than that 
available from any individual study. But, given the disparity in methods used across 
existing economic evaluations it is extremely diffi cult to synthesise such studies into 
a coherent whole. Studies need to be adjusted to achieve standardised results, but in 
reality this is rarely achievable given the diverse nature of the elements considered, 
including differences in perspectives, health care systems (which use different 
resources) and time horizons.
Although some health economists have expressed concerns about the value of 
systematic reviews of economic evaluation7, 8 methods are available to guide their 
conduct9 and a large number have been undertaken.10, 11 Reasons for undertaking this 
type of review include i) to inform development of a decision model; ii) to identify the 
most relevant economic evaluation to inform a particular question; and iii) to identify 
the key economic trade-offs implicit in a particular treatment choice.8 Whether or 
not these are the only viable reasons is still open to debate, but when considering 
undertaking such a review it is important to have a clear rationale for doing so and that 
the objectives set are attainable.
This chapter assumes that, for whatever reason, a systematic review of economic 
evaluation is appropriate. The aim of the chapter is to guide non-health economists 
through some of the main issues to be considered when undertaking a systematic 
review of economic evaluation, and should be read in conjunction with the general 
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guidance presented in Chapter 1. The same basic principles apply and only issues 
specifi c to reviews of economic evaluation are described here.
5.1.1 What is an economic evaluation?
An economic evaluation is essentially a tool to allow comparative health interventions 
to be evaluated in order to address the issue of effi cient resource allocation. It is widely 
accepted that on their own, economic evaluations are not suffi cient to inform decision-
making, but that they are a necessary component of the decision-making process.
An economic evaluation is a study in which both the cost and health outcomes of 
comparative technologies or interventions have been assessed. The aim is to identify, 
measure, value and compare the cost and consequences of the alternative interventions 
being considered. Primary economic evaluation can either be undertaken as an integral 
part of a single clinical study, often a trial, or can be based on more than one source 
of effectiveness data derived from expert opinion, authors’ assumptions or reviews of 
clinical effectiveness - in this way economic evaluations can both use and be used in 
systematic review. Either approach may employ modelling techniques.
Full economic evaluation provides a framework for structuring specifi c decision problems 
and considers both the effectiveness and cost data for two or more interventions being 
compared within the analysis. A partial economic evaluation makes no comparison 
and simply describes a single intervention or service through consideration of costs or 
consequences alone.12 There are three generic types of full economic evaluation, each 
defi ned on the basis of the outcomes measured. See Box 5.1.
Box 5.1  Generic types of full economic evaluation
Cost-effectiveness analysis (CEA)
A single clinical outcome expressed in natural units (e.g. postoperative infections 
prevented or life years gained) is used. If multiple clinical outcomes are used, 
cost-consequences analysis (CCA) may be reported which includes all clinical 
outcomes and costs for each alternative. Clinical outcomes may vary in direction 
and magnitude of effect.
Cost-utility analysis (CUA)
Clinical outcomes (health states) are converted into utility scores using a utility 
measurement instrument such as the SF-6D or the EuroQol (EQ-5D) to estimate 
quality-adjusted-life-years (QALYs). Alternatively other utility measures such as 
healthy-years-equivalent (HYE) may be used.
Cost-benefi t analysis (CBA)
Clinical outcomes are converted into monetary units so that a net benefi t (or cost) 
can be estimated. Methods used to convert health benefi ts to monetary values 
include willingness to pay (WTP) and the human capital approach (HCA).
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As with other types of evaluation, a wide range of methods are used in economic 
evaluation, and therefore the methodological rigour of studies can vary; methods can 
be used inappropriately and decisions about the appropriateness of methods can impact 
on the quality and validity of a review. It is therefore important that the researcher 
understands at least some basic methodological concepts prior to undertaking a review 
of economic evaluations. More complex issues can be dealt with in consultation with the 
health economist that should be included in the review team.
5.2 CONDUCTING A REVIEW OF ECONOMIC EVALUATIONS
A protocol for a review of economic evaluations should be developed as for a review of 
effectiveness (see Chapter 1, Section 1.2 The review protocol) and be used to establish 
in advance the methods that will be used throughout. Early discussion with a health 
economist is recommended.
5.2.1 The review question
An economic review may consider questions relating to the cost-effectiveness of 
differing interventions, outcomes, populations and settings, or may explore the effect 
of other factors, such as change in patient adherence, on the cost-effectiveness of 
interventions.
The scope may need to be broader than that set for clinical effectiveness to capture all 
relevant costs and consequences. For example, resources such as further treatments 
consumed or avoided downstream of the intervention will need to be included in the 
economic evaluation. Working through the care pathway for relevant interventions 
may be helpful in identifying relevant costs and benefi ts, and in formulating the review 
question.
5.2.2 Inclusion criteria
As described in Chapter 1, Section 1.2 The review protocol, PICOS may be helpful in 
defi ning clear inclusion and exclusion criteria.
A basic consideration will be whether to include only full economic evaluations as 
under certain circumstances and for specifi c review questions, it might be appropriate 
to include partial economic evaluations. For example, if the review question involves 
incremental costs, then cost analyses may be relevant. Alternatively, if the question 
is about relative benefi ts (measured using methods such as QALYs or WTP) studies 
comparing these outcomes might be considered appropriate even if they are not full 
economic evaluations. Where partial evaluations are included, as for all reviews, a 
systematic and transparent approach must be taken.
Reviews of economic evaluations are more likely to require a time horizon of ‘till death’ 
which may necessitate including types of study that differ from the clinical review, and 
require additional inclusion criteria being specifi ed.
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The review may be limited to include only those economic studies that incorporated a 
high quality source of clinical evidence, from an RCT or a systematic review. 
Other considerations around the study type may include, for example, whether to 
restrict inclusion to economic evaluations from a societal perspective.
Outcomes may also differ from those of primary interest in the clinical review. For 
example, quality-adjusted-life-years are more likely to be relevant to economic 
evaluation.
5.3 IDENTIFYING ECONOMIC EVALUATIONS
Literature searches can utilise both the sources used routinely for effectiveness reviews 
(see Chapter 1, Section 1.3.1 Identifying research evidence for systematic reviews) and 
resources that focus on economic studies. These include specialised databases such as 
CRD’s NHS Economic Evaluation Database (NHS EED)13 which contains critical abstracts 
of full economic evaluations, alongside bibliographic details of partial evaluations, and 
the Health Economic Evaluations Database (HEED),14 produced by John Wiley and Sons, 
which contains summaries of economic evaluations (full and partial). As both NHS EED 
and HEED solely contain records of economic evaluation the strategy used to search 
these databases need only contain terms related to the subject area. In theory these 
databases should capture all health economic evaluations. However, if it is essential 
that results are as current as possible, additional searches of the most recent updates 
of MEDLINE and EMBASE could be carried out. If this is done the search strategy should 
contain terms for both the subject topic area as well as relevant economics terms. 
Similarly, if other subject specifi c databases are used, the search strategy should 
combine economic terms with subject terms.
Search fi lters are available for a range of study types including economic evaluations. 
The Hedges Project, based at McMaster University and funded by the US National 
Library of Medicine, develops search strategies (‘hedges’) to improve retrieval of study 
reports from large biomedical bibliographic databases such as MEDLINE, EMBASE, and 
CINAHL (http://hiru.mcmaster.ca/hiru/HIRU_Hedges_home.aspx). A range of fi lters, 
including economic and cost fi lters, is available, together with research papers providing 
information about how they were developed. The InterTASC Information Specialists’ 
Subgroup Search fi lter resource provides a comprehensive source of fi lters, including 
a section on economics (www.york.ac.uk/inst/crd/intertasc/econ.htm). The search 
strategies used for the NHS EED database can be found at www.crd.york.ac.uk/crdweb/
html/help.htm
5.4 DATA EXTRACTION
Data extraction should capture the key methodological elements that can impact on 
the results of an economic evaluation. These include: the perspective, the population, 
time horizon, outcomes, discounting, and the techniques employed in conducting the 
economic analysis. Consideration of the care pathway can be helpful in structuring data 
extraction.
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Data extraction requirements are specifi c to each review question but will need to 
include the following areas:
• Study question, included population, intervention, comparator and setting
• Modelling techniques
• Sources and quality of clinical data
• Sources and quality of cost data
• Study outcomes in terms of health benefi ts and costs, and the methods used to 
synthesise them
• Methods for dealing with uncertainty
• Study results, including results of analyses of uncertainty
Additional study-specifi c issues may also need to be included. For example, whether 
adverse effects were considered in the cost analysis or if certain health states were 
included in a Markov model.
If, following the systematic review of economic evaluations, a new primary economic 
analysis is planned, then additional data may need to be extracted to inform the design 
or conduct of that analysis.
An example data extraction form is presented in Box 5.2.
Box 5.2: Example data extraction template
Type of economic evaluation
Study Objective
Interventions
Location/Setting
Methods Analytical approach:
 Effectiveness data:
 Monetary benefi t and utility valuations:
 Measure of benefi t:
 Cost data:
 Analysis of uncertainty:
Results
Authors’ conclusions
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5.5 QUALITY ASSESSMENT
Quality assessment is likely to focus on the following elements of the economic 
evaluation, each of which can have an important impact on the validity of the overall 
results of that study:
• Methods of deriving the effectiveness data
• Measurement of resource data
• Valuation of resource data
• Measurement and valuation of health benefi ts (utilities)
• Method of synthesising the costs and effects
• Analysis of uncertainty
• Generalisability of the results
This is not an exhaustive list, but an understanding of these issues, which are discussed 
in more detail below, will provide insight into the quality assessment of economic 
evaluations. Quality assessment of decision models is not covered in detail here due to 
the technical nature of the material. It is recommended that more detailed information 
on good practice in decision modelling be consulted.15
5.5.1 Methods of deriving effectiveness data
There is a hierarchy of sources of evidence ranging from a formal systematic review to 
expert opinion and authors’ assumptions.16 Where possible economic evaluation should 
use effectiveness data obtained from a systematic review. However, non-systematic 
synthesis of effectiveness data may be justifi able when it is the only available source of 
evidence.
The type of effectiveness data included in an economic evaluation can vary from a 
single effi cacy parameter obtained from a meta-analysis of RCTs to epidemiological data 
mapping the natural history of disease. Quality assessment of the clinical effectiveness 
data incorporated in an economic evaluation will depend on the type of clinical data 
used; whether the data were obtained from a single study or from the literature or from 
expert opinion; and whether modelling techniques were used.
When the effectiveness data has been derived from a single study, quality assessment 
should be undertaken as described in Chapter 1. However, additional elements will 
also need to be assessed. For example, whether the study time horizon is adequate to 
capture all the relevant health outcomes required and, if statistical modelling techniques 
have been used to extrapolate the data, whether the extrapolation methods and 
assumptions used were appropriate.17
When the effectiveness data has been synthesised from a variety of sources assessment 
should focus on the quality of the literature review and the methods used to synthesise 
the data including:
• Whether a search strategy was used
• Which databases were searched
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• Whether there were clear inclusion and exclusion criteria
• Whether suffi cient information was given about the quality of the included studies
5.5.2 Cost analysis
Quality assessment of cost analysis should consider which costs were evaluated in the 
study, the measurement of the associated resource quantities, and the valuation (cost) 
of those resources. Some of the issues that need to be assessed are common to all 
economic evaluations, while others are specifi c to the type of approach used.
5.5.2.1 Cost categories
For any economic evaluation all costs relevant to the study question and the perspective 
adopted or viewpoint from which the analysis has been undertaken should have been 
included. For example patient travel costs are a cost from the patient’s perspective and 
a cost from society’s perspective, but not a cost from the hospital’s perspective.
Measurement of resources data
Resource use is measured in physical units such as equipment, staff, dressings and 
drugs. Issues to consider are as follows:
• The sources used to collect resource utilisation data should be reported clearly 
(e.g. clinical trials, administrative databases, clinical databases, medical records 
and published literature)
• Resource quantities should be reported independently from the costs, so that 
assessment of the measurement method is facilitated
• Any assumptions in the measurement of resources should be explicitly reported 
and justifi ed
• If an expert was consulted to estimate some of the resources, the methods used 
should be described
For trial-based economic evaluations, the most valid resource estimates are considered 
to be those collected prospectively alongside effectiveness data, utilising the robust 
infrastructure established for the trial.18
If resources utilized were identifi ed through a review of the literature, details of the 
process employed to identify and select the patterns of resource utilisation and the 
quantities used should have been given.
Valuation of resource data
For the valuation of resources, the relevant issues to consider are as follows:
• All the sources used to obtain unit costs should be reported and be relevant for 
the specifi c study setting
• All costs should be adjusted to a specifi c price year so that the effects of infl ation 
are removed from the cost estimation
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• If the time horizon for estimating costs was longer than one year, discounting 
should have been performed in order to refl ect time preferences19
• If prices were used instead of costs and cost-to-charge ratios calculated these 
should refl ect the true opportunity costs of the strategies compared20
5.5.3 Measurement and valuation of health benefi ts (utilities)
Utilities may be measured using either a generic valuation tool, such as the SF-6D 
or the EQ-5D, or a disease specifi c tool which may have been obtained using either 
standard gamble or time trade off techniques. Tools differ considerably (a full discussion 
is given in the books by Drummond12 and Brazier21) and choice of tool can impact on the 
results obtained and on their usefulness in priority setting. As a minimum assessment 
should consider who provided the scores (patients, clinicians, general public, etc.), 
which tool was used (EQ-5D, SF-6D, etc.) and when the scores were elicited (at 
baseline, during treatment, after treatment, etc.). A useful overview and comparison of 
the impact of different measures in rheumatoid arthritis is available.22
5.5.4 Methods of synthesising costs and effects
The true economic value of an intervention compared to another depends on the 
additional costs and benefi ts. Incremental cost-effectiveness ratios are the ratios 
that capture this relative value. Unless a treatment is clearly dominant (both cheaper 
and more effective), incremental cost-effectiveness ratios (ICERs) should have been 
calculated as this is the only appropriate way of capturing the true economic value.12 
A paper should report suffi cient data to ascertain dominance from the fi gures given, 
rather than relying on a statement from the authors which can be made in error and 
be potentially misleading. Cost-effectiveness results should have been reported in both 
a disaggregated and an aggregated way. That is, undiscounted and discounted health 
benefi t and cost results should have been reported both separately and as part of the 
ICERs. It is also appropriate to report the net benefi t statistic, which is sometimes used 
to overcome the statistical issues raised when dealing with a ratio, like the ICER.
5.5.5 Analysis of uncertainty
A well-conducted economic evaluation should investigate as thoroughly as possible, the 
following sources of uncertainty:
• Parameter uncertainty, which occurs because parameters are estimated from 
samples and their true value is unknown
• Methodological uncertainty, which arises from the analytical methods used in the 
evaluation, particularly where there is disagreement around the methods used 
(e.g. the inclusion of indirect costs, discounting of health benefi ts, discount rate)
• Modelling uncertainty which can arise due to the simplifying assumptions that are 
often required to facilitate modelling
CRD Systematic Reviews.indd   208 8/1/09   09:29:39
209
Systematic reviews of economic evaluations
Methods of evaluating uncertainty include statistical comparisons, bootstrapping, 
sensitivity analyses (one-way or multi-way sensitivity analyses, threshold analyses and 
analyses of extremes or worst/best case analysis) and probabilistic sensitivity analyses. 
The method(s) employed will vary depending on what is being assessed and the types 
of data that were used as input parameters in the economic evaluation.
5.5.5.1 Statistical comparisons
Statistical tests comparing effects, costs or cost-effectiveness are appropriate for 
studies that have derived their effectiveness and costs from patient level data. The 
quality assessment of the statistical comparisons performed should focus on the 
appropriateness of the type of tests used and the results reported (e.g. 95% confi dence 
intervals; p-values).
5.5.5.2 Bootstrapping
Bootstrapping is a statistical method that can be applied to capture uncertainty where 
patient level data are used.23 Due to the fact that the ICER is a ratio, normal parametric 
statistical methods based on the standard error cannot be used. Non-parametric 
bootstrapping is an alternative method which allows a comparison of the arithmetic 
means without making any assumptions about the sampling distribution. However, it 
should be noted that economic evaluations can use a net benefi t statistic rather than an 
ICER to overcome the statistical problems associated with a ratio.24
5.5.5.3 Sensitivity analysis - parameter uncertainty
Sensitivity analyses of parameter uncertainty are usual in economic evaluations that 
obtain their data from systematic or other reviews. The aim of the sensitivity analyses is 
to evaluate the sensitivity of the results to changes in the parameter estimates. N-way 
sensitivity analyses and threshold analysis can only vary a few parameters at the same 
time in practice. In contrast, probabilistic sensitivity analysis (PSA) (see below) can vary 
all parameters at the same time, subject to data availability.
The following issues should be assessed:
• Whether the parameters chosen were justifi ed
• Whether variations were performed across meaningful ranges of values
• Whether the robustness of the results was assessed according to a previously 
agreed level of ‘acceptable variation’
5.5.5.4 Sensitivity analysis - methodological uncertainty
Uncertainty around analytical methods is also assessed through the use of sensitivity 
analysis. For example, the impact of different discount rates and the use of discounting 
(or not) on health benefi ts should have been assessed in studies with a long time 
horizon.
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Box 5.3: Checklist for assessing economic evaluations
Study design
1. Was the research question stated?
2. Was the economic importance of the research question stated?
3. Was/were the viewpoint(s) of the analysis clearly stated and justifi ed?
4. Was a rationale reported for the choice of the alternative programmes or 
interventions compared?
5. Were the alternatives being compared clearly described?
6. Was the form of economic evaluation stated?
7. Was the choice of form of economic evaluation justifi ed in relation to the 
questions addressed?
Data collection
8. Was/were the source(s) of effectiveness estimates used stated?
9. Were details of the design and results of the effectiveness study given (if 
based on a single study)?
10. Were details of the methods of synthesis or meta-analysis of estimates given 
(if based on an overview of several effectiveness studies)?
11. Were the primary outcome measure(s) for the economic evaluation clearly 
stated?
12. Were the methods used to value health states and other benefi ts stated?
13. Were the details of the subjects from whom valuations were obtained given?
14. Were productivity changes (if included) reported separately?
15. Was the relevance of productivity changes to the study question discussed?
16. Were quantities of resources reported separately from their unit cost?
17. Were the methods for the estimation of quantities and unit costs described?
18. Were currency and price data recorded?
19. Were details of price adjustments for infl ation or currency conversion given?
20. Were details of any model used given?
21. Was there a justifi cation for the choice of model used and the key parameters 
on which it was based?
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Analysis and interpretation of results
22. Was time horizon of cost and benefi ts stated?
23. Was the discount rate stated?
24. Was the choice of rate justifi ed?
25. Was an explanation given if cost or benefi ts were not discounted?
26. Were the details of statistical test(s) and confi dence intervals given for 
stochastic data?
27. Was the approach to sensitivity analysis described?
28. Was the choice of variables for sensitivity analysis justifi ed?
29. Were the ranges over which the parameters were varied stated?
30. Were relevant alternatives compared? (i.e. Were appropriate comparisons 
made when conducting the incremental analysis?)
31. Was an incremental analysis reported?
32. Were major outcomes presented in a disaggregated as well as aggregated 
form?
33. Was the answer to the study question given?
34. Did conclusions follow from the data reported?
35. Were conclusions accompanied by the appropriate caveats?
36. Were generalisability issues addressed?
Based on Drummond’s checklist27
5.5.5.5 Probabilistic sensitivity analyses
This method can only be used to deal with parameter uncertainty in modelling-based 
economic evaluations. PSA, also referred to as second-order uncertainty, considers 
the uncertainty surrounding the value of a parameter. This is achieved by assigning 
a probability distribution rather than a point estimate to each parameter. The quality 
assessment in this case should focus on whether:
• Appropriate distributions were assigned to the model parameters6, 25
• Relevant assumptions were tested. For example, assumptions about model 
structure or interpretation of the available evidence12
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5.5.6 Generalisability of the results
Generalisability refers to the extent to which the results obtained can be applied to 
different settings. The relevance of the intervention, the patient population and the 
resources which have been included in the economic evaluation will determine whether 
the results can be generalised. Uncertainty regarding the generalisability of the results 
to the relevant study setting would usually be assessed through sensitivity analyses. A 
useful discussion on this issue is available.26
5.5.7 Use of checklists to assess the quality of economic evaluations
Several reliable, comprehensive, and easy to use checklists are available to guide 
the quality assessment of economic evaluations. The most widely used is the BMJ 
checklist.27 Both a 10-item version and an expanded 35-item version are available. In 
addition, a 36th item relating to generalisability may be added if it is relevant to the 
review (see Box 5.3). Although, this checklist does not provide detailed coverage of 
some issues relevant to modelling studies, it can be augmented using specifi c items 
such as model type, structural assumptions, time horizon, cycle length and health 
states. Alternatively, a checklist developed to assess the quality of the models used in 
economic evaluations can be used as a complement to the BMJ checklist.15
In some cases the validity of an economic evaluation may be diffi cult to assess due to 
limitations in reporting, an issue common to many studies and covered in Chapter 1.
5.5.8 Quality scoring systems
Several quality scoring systems have been devised for use in assessing the 
methodological quality of economic evaluations. These are generally based on 
completing checklists, assigning values to the different items considered, and summing 
these values to obtain a fi nal score, which is intended to refl ect the quality of the 
appraised study.
Six published quality scoring systems for economic evaluations have been identifi ed, but 
none of these are considered to be suffi ciently valid and reliable for use as a method of 
quality assessment.28 Given the limitations presented by quality scoring systems, their 
use is not recommended. Rather, it is preferable to present a checklist or a descriptive 
critical assessment based on appropriate guidelines or checklists, which should describe 
the methods and results, strengths and weaknesses and the implications of the 
strengths and weaknesses on the reliability of the conclusions.
5.6 DATA SYNTHESIS
Synthesis should begin with descriptive comparisons of the study question, methods 
and results. It may be useful to include summary tables which present key information 
relating to population, country, perspective, comparison of interventions, measure of 
benefi t and incremental cost-effectiveness ratios. An example is given in Table 5.1. The 
range of incremental cost-effectiveness ratios should be presented and the reliability 
CRD Systematic Reviews.indd   212 8/1/09   09:29:40
213
Systematic reviews of economic evaluations
Table 5.1: Example summary table
     Measure 
Author Population Country Perspective Interventions of benefi t Results
Bolin K.32 Smokers aged  Sweden Societal Bupropion QALY SEK23,400/
 35 or older   Nicotine   QALY gained
    replacement   for men for
    therapy  bupropion
      SEK16,600/
      QALY gained 
      for women 
      for bupropion
Cornuz J.33 Smokers aged  Canada Third-party Bupropion Life years CA$792/life
 45, 20 cigs   payer Counselling  year gained
 per day   Replacement  for men for
    therapies  bupropion
Nielsen K.34 Smokers in  USA Employer Sustained- Quit rate 30.3% quit rate
 cessation   release   and $163.49/
 programme   bupropion  person for
    Nicotine patch  bupropion
    Both  16.4% quit rate 
      and $245.22/
      person for 
      nicotine patch
      35.5% quit rate 
      and $408.71/
      person for both
SEK = Swedish Kroner       CA$ = Canadian Dollars       $ = US dollars
(internal validity) and relevance (generalisability) of the estimates should be explored. 
The analytical approaches used in the studies should be compared and their robustness 
discussed, for example, whether the studies used the same type of modelling technique 
and the same model structure.
This can be developed further and the results of the original cost-effectiveness studies 
adjusted to conform to standard methods specifi ed for a given setting, in order that 
study results can be compared more readily. In its simplest form, this may involve 
converting the currency of the cost estimates. However, if adequate detail is reported, 
local unit costs appropriate to the review could be substituted for the unit costs used 
in the individual studies.29 This would depend on the amount of disaggregated data 
reported in the individual economic evaluations and the heterogeneity across studies. 
The more disaggregated and homogenous the data, the easier and more feasible it 
would be to adjust the results. Theoretically, a meta-analysis of economic evaluations 
could be done. However, this is not straightforward and would require input from an 
experienced health economist.30, 31 In practice, economic evaluations addressing a 
particular question are often heterogeneous and published reports do not generally 
present suffi cient detail to permit such adjustments.
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Summary: Systematic reviews of economic evaluations
• The inclusion criteria for a review of effectiveness and a review of economic 
evaluations are likely to overlap, however, additional specifi c criteria may be 
needed ranging from the source of cost and clinical evidence to the use of a 
modelling approach.
• Preference based values of health outcomes as well as disease-specifi c 
measures should be considered when forming the inclusion criteria.
• Sources searched for economic evaluations should include specialised 
databases of economic evaluations such as NHS EED and HEED.
• The BMJ checklist is the most general quality assessment tool. However, the 
study question and inclusion criteria may well require a more specifi c quality 
assessment checklist.
• Identifi ed economic evaluations are usually too heterogeneous and are 
unlikely to report adequate details for a meta-analysis of results. A narrative 
synthesis is usual.
• Disaggregated results should be reported as well as incremental cost-
effectiveness ratios in order to facilitate the interpretation of the results.
5.7 REPORTING
Readers of the systematic review may well include non-economists so the results of the 
cost-effectiveness analyses need to be presented as clearly as possible. For example, it 
may be useful to report the absolute and incremental costs and effectiveness as well as 
the incremental cost-effectiveness ratios as these may be more readily understood. In 
Table 5.1, the absolute quit rates (where reported) are given alongside the incremental 
cost-effectiveness ratios.
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Incorporating qualitative evidence in or alongside systematic reviews of effect
6.1 INTRODUCTION
This chapter focuses on the identifi cation, assessment and synthesis of qualitative 
studies to help explain, interpret and implement the fi ndings from effectiveness 
reviews. There is growing recognition of the contribution that qualitative research 
can make to reviews of effectiveness, particularly in relation to understanding the 
what, how and why.1 This includes shaping questions of importance to end users, 
understanding the mechanisms behind effectiveness or ineffectiveness, understanding 
heterogeneous results, identifying factors that impact on the implementation of an 
intervention, describing the experience of people receiving the interventions, and 
providing participants’ subjective evaluations of outcomes. For example, what is it 
about the workings of a stroke unit that result in better survival rates? What elements 
of a community-based programme to prevent falls enable older people to retain their 
independence? How was the process of care perceived and what counts as a successful 
outcome for those receiving the intervention? An approach that uses qualitative 
research to address questions such as these helps to ensure that reviews are of 
maximum value in the decision-making process.
Despite recognition of the importance of qualitative research to effectiveness reviews, 
so far the number of available examples is relatively small. Poor availability may refl ect 
a relative lack of interest in applying review methods to qualitative research and/or lack 
of consensus about whether it is appropriate to do so. In recent years new approaches 
and techniques for reviewing qualitative studies have emerged, although debates about 
appropriateness continue. Because review methods are not well-developed or tested 
we outline various options for consideration, and provide references which should 
be consulted where more detailed information is required. We also include worked 
examples; where possible these have been selected because they are directly linked or 
related to reviews of effectiveness. But because these are few in number, other types of 
example are included, such as stand-alone reviews of qualitative research.
The process for reviewing qualitative studies has been argued to be an iterative 
one which might not proceed in a linear way.2, 3 So, although we have chosen to 
structure the chapter according to the recognised stages in a systematic review (study 
identifi cation, quality assessment and synthesis), in practice the process may deviate.
6.2 WHAT IS QUALITATIVE RESEARCH?
Qualitative research is concerned with the subjective world and offers insight into 
social, emotional, and experiential phenomena.4 The aim is to draw out understandings 
and perceptions, to explore the features of settings and culture and to understand 
the linkages between process and outcomes. Most qualitative studies are small 
scale, focusing on a single or small number of cases, and they provide depth and 
contextualised detail. Qualitative research is not a single method but includes a range 
of designs such as interviews, direct observation, analysis of texts/documents or of 
audio/video recorded speech or behaviour.2, 5 Choice of method is often determined by a 
particular theoretical perspective, such as phenomenology which provides a framework 
for the research.2
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More recently, the relevance of qualitative research to the assessment of health 
interventions, especially those that are complex, has been recognised. As a result 
qualitative and quantitative methods are increasingly being used together in primary 
evaluative research (mixed-method). For example qualitative methods have been used 
to understand participants’ experiences in a trial evaluating a computerised decision 
support tool for patients with atrial fi brillation being considered for anti-coagulation 
treatment.6 The main reason for the adoption of mixed-methods in primary research is 
to enhance relevance in the decision-making process.
Important to note is that some primarily quantitative studies provide information of a 
qualitative form such as observations or quotes, which are unlikely to be the result of a 
formal research process. Sometimes no detail is reported of how these ‘data’ have been 
collected or analysed and researchers need to be cautious if using such information. 
This issue has been discussed with respect to the implementation of community-based 
interventions to reduce unintentional injuries in children and young people.7
6.2.1 Options for utilising qualitative research
The approach to utilising qualitative research needs to be decided at an early stage, as 
it will impact on subsequent stages of the review, especially searching and synthesis. 
Outlined below are three options for including qualitative evidence in/alongside 
quantitative effectiveness reviews; the fi rst offers a more informal approach; the second 
involves a formal synthesis of the qualitative fi ndings. Both options treat qualitative 
and quantitative evidence as complementary with the qualitative evidence offering an 
explanation for, and interpretation of, the quantitative fi ndings; the third combines the 
fi ndings from the quantitative and qualitative syntheses. Used in this way the qualitative 
evidence does not contribute directly to the effectiveness data. If researchers are 
interested in including both quantitative and qualitative research to address questions 
of effectiveness they might consider using techniques or approaches capable of 
combining different types of research evidence such as Bayesian meta-analysis,8 critical 
interpretive synthesis9 or realist synthesis.10, 11 There are also a number of useful guides 
discussing various methods for synthesising complex bodies of evidence.2, 12
Option 1. Use the fi ndings from one or more qualitative studies in the discussion and 
interpretation of the results of the quantitative studies to help make sense 
of, or place the review fi ndings in context. Usually (although not always) 
the qualitative evidence will be linked to the quantitative studies included 
in the effectiveness review. Qualitative and quantitative evidence might be 
included in the same publication or in separate but associated publications.
Option 2. Undertake a review of qualitative studies alongside the review of 
quantitative studies and use the formal qualitative synthesis to interpret 
the fi ndings of the quantitative synthesis (sometimes referred to as 
parallel synthesis). Researchers might choose to include qualitative 
research embedded within the quantitative studies or stand-alone 
qualitative studies that address the question of interest.
Option 3. Where reviews of both quantitative and qualitative evidence are 
undertaken there is also the option to combine the results of the two 
syntheses. This approach is sometimes referred to as multi-level, 
sequenced, cross-design or meta-synthesis.2, 13
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6.3 IDENTIFICATION OF QUALITATIVE STUDIES
In line with the three options discussed in Section 6.2.1 Options for utilising qualitative 
research, researchers can choose to include qualitative evidence that is embedded 
within quantitative studies (i.e. mixed-method) or associated with the quantitative 
evaluation, or choose to include qualitative studies that address issues of direct 
relevance, but are not linked or associated with the quantitative evaluation.
A search for quantitative studies will often identify associated or linked studies using 
qualitative methods. However relying solely on this approach is questionable, as the 
studies are identifi ed by chance rather than in a structured systematic way.14 A very 
broad approach can be used, where the search strategy consists solely of subject 
and topic terms without specifying the study type(s) of interest. Both quantitative 
and qualitative studies would be identifi ed, but this method is likely to result in large 
numbers of records being retrieved. This approach is routinely used at the EPPI-Centre15 
when carrying out linked systematic reviews of qualitative and quantitative studies.
6.3.1 Using bibliographic databases
The methods and tools available to identify qualitative studies, especially from electronic 
databases are much less well developed than those available for identifying quantitative 
studies, especially RCTs.16 There are as yet no registers of qualitative studies, nor do 
existing RCT registers record whether qualitative data were also collected.
Qualitative research may be given a descriptive or creative title that makes retrieval 
using standard search techniques diffi cult. Database abstracts, where included, are 
often not structured and can have variable content, which further complicates their 
identifi cation.17 Many studies lack an abstract; for example a search for qualitative 
studies on support for breastfeeding found that 23 per cent of the records screened did 
not include an abstract.18 This means that many full papers will need to be retrieved to 
make decisions about inclusion, as in a review of adherence to tuberculosis treatment 
where over 600 full text articles were screened.19
There are differences in how qualitative research is, and has been, indexed in electronic 
databases that have implications for searching. While MEDLINE introduced the subject 
heading ‘qualitative research’ in 2003, CINAHL has had a wide range of detailed subject 
headings suitable for indexing qualitative research for much longer. For example, the 
headings ‘qualitative studies’ and ’grounded theory’ were both introduced in 1988. 
Assuming that the topic of interest falls within their scope, then searching both 
MEDLINE and CINAHL is likely to be important. For CINAHL using broad free text terms 
– ‘qualitative’, ‘fi ndings’, ‘interviews’ – in conjunction with topic specifi c thesaurus terms 
may be adequate to identify qualitative studies.20
When searching electronic databases it is important to be aware that uncertainty 
remains about how consistently the term ‘qualitative research’ is being used.21
The indexing of qualitative papers is generally viewed as less accurate than the indexing 
of quantitative studies, both in terms of whether suitable index terms are available and 
whether they have been applied correctly.22 In a comparison of three strategies across 
six databases – using thesaurus terms, free-text terms and broad-based terms – only 
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four per cent of records were actually relevant, and all three strategies had to be used 
in combination to avoid missing potentially relevant records.22 The identifi cation of a 
high proportion of irrelevant studies is likely to be due in part to poor indexing.
Search fi lters for identifying qualitative research are available for use in a number 
of electronic databases. For researchers wishing to use existing search fi lters, two 
resources are particularly helpful. The Hedges Project, based at McMaster University and 
funded by the US National Library of Medicine, develops search strategies (‘hedges’) 
to improve retrieval of study reports from large biomedical bibliographic databases 
such as MEDLINE, EMBASE, PsycINFO, and CINAHL. A range of fi lters is available for 
each database, together with information about the research papers underlying the 
development of the fi lter (http://hiru.mcmaster.ca/hiru/HIRU_Hedges_home.aspx). 
The webpages are arranged by database so, for example, on the pages about MEDLINE 
a number of qualitative fi lters of varying degrees of sensitivity, specifi city, accuracy 
and precision are presented in a tabular format. Where the aim is to comprehensively 
identify all papers on a topic, a fi lter with high sensitivity should be selected. If it is 
of less importance to identify all papers, a fi lter with high precision will usually be 
appropriate. Reading the accompanying research paper that describes the development 
of each fi lter can help researchers to choose the fi lter that is most appropriate.
The InterTASC Information Specialists’ Sub-Group (ISSG) Search Filter Resource offers 
another useful website (www.york.ac.uk/inst/crd/intertasc/). The ISSG is a group of 
information professionals supporting research groups within England and Scotland 
producing technology assessments for NICE. This resource includes a wider range of 
fi lters than the Hedges Project, but in some cases the fi lter is not displayed in full on the 
website, although details of where it is published are given.
6.3.2 Other sources
Given the identifi ed defi ciencies in the indexing of studies and in the study fi lters 
currently available, additional techniques such as Internet searching, personal contact 
with researchers, handsearching and reference checking are important (see Chapter 1).
6.3.3 Sampling methods
There is currently no consensus as to whether the searches undertaken to identify 
qualitative studies need to be as comprehensive in their coverage as those undertaken 
to identify quantitative studies, although they should be as systematic, explicit and 
reproducible as possible.23
Where the number of available studies may be simply too large to work through, 
researchers may decide to adopt a strategy for limiting the number of included studies. 
Options include purposive and/or theoretical sampling where papers are selected for 
inclusion on the basis of particular criteria such as rich description or conceptual clarity. 
Alternatively, random sampling can be used. Examples of purposive sampling are 
provided in reviews of caring24 and access to health care.9
The search strategy and, where used, the methods for sampling need to be documented 
clearly. It is important to outline the steps taken and discuss the potential impact of 
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any limitations. Proposed standards for reporting literature searches are available, and 
provide a useful resource.25
6.4 ASSESSMENT OF QUALITATIVE RESEARCH
The application of quality criteria to qualitative research is widely debated, although 
many accept the need for clear and transparent approaches for judging the quality or 
credibility of research. For example, it has been noted that the distinguishing mark of 
all ‘good’ research is the awareness and acknowledgement of error and, that what fl ows 
from this is the necessity of establishing procedures which will minimize the effect such 
errors may have on what counts as knowledge.26 It is less clear whether consensus can 
be reached over an agreed set of principles for judging quality. Qualitative researchers 
from different disciplines and from different theoretical backgrounds may have 
different criteria for assessing the quality of a study.27 Some argue that quality cannot 
be determined by following prescribed formulas28 or that it is fruitless to try to set 
standards for qualitative research as such.29 Others, accepting the need for structured 
procedures, argue for more rigorous use and reporting of analytical approaches which 
improve reliability and validity.30 Others have suggested there are general questions 
that can be asked to judge validity and reliability in qualitative research, but that these 
are not readily codifi ed.31 It has also been argued that quality assessment should take 
account of theory in the design of the research, analysis, and interpretation of the 
data.32
6.4.1 How should quality be assessed?
Despite lack of consensus about quality assessment a number of different tools 
and techniques are now available. Over one hundred sets of proposals on quality in 
qualitative research have been identifi ed,33 a subset of which have been reviewed,34 
including fi ve that were developed specifi cally for use in systematic reviews.35-39 The 
majority of tools available are generic, and to date there have been few attempts to 
develop method specifi c approaches. This is despite arguments that different qualitative 
methods need to be appraised in different ways.40
Some issues in using structured approaches were illustrated in a recent study.41 Two 
structured methods – the Critical Appraisal Skills Programme (CASP) tool,42 and the 
Quality Framework34 – were systematically compared with an approach based on 
unprompted judgement (where experienced qualitative researchers relied on their 
own expertise to make judgements of quality). Each approach was used to assess 
twelve qualitative studies investigating support for breastfeeding. Agreement between 
researchers and between methods was slight, and importantly researchers disagreed 
on the quality of the studies, whether papers were actually reporting qualitative 
research and whether the study was relevant to the review question. Because answering 
questions about quality is largely a subjective process involving judgement, it may lead 
to differences both between researchers and methods.
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In addition, the Quality Framework was criticised for its length and complexity, which is 
likely to impact on its use in future systematic reviews. The authors identifi ed a need for 
continued debate and empirical research into the use of quality assessment. Similarly, 
the authors of a recent review who attempted to apply two different quality frameworks, 
concluded that further methodological work is needed to produce clear guidance about 
how quality appraisal should be undertaken.32
An innovative approach, developed to appraise qualitative studies for inclusion in 
a set of reviews focusing on peoples’ experiences and perspectives, uses generic 
methodological quality criteria tailored to the specifi c review question.43 It is designed 
to help researchers assess to what extent studies may have distorted, misrepresented 
or simply missed people’s experiences and perspectives. The authors have published a 
series of reports that outline how the approach has been applied in practice.44, 45
Box 6.1: Appraisal tools
Popay, Rogers & Williams (1998)39 Primary question relates to the 
 appropriateness of the methods used. 
 This is followed by a detailed assessment 
 of methodological soundness.
Critical Appraisal Skills Programme 10 questions relating to rigour, credibility
(1998)42 and relevance.
Quality Framework (2003)34 18 questions relating to 9 key areas: 
 fi ndings; design; sample; data 
 collection; analysis; reporting; 
 refl exivity and neutrality; ethics and 
 auditability.
Prompts for appraising qualitative  Generic set of prompts relating to aspects
research (2004)33 of reporting and aspects of study design 
 and execution.
Long & Godfrey (2004)38 A tool to explore descriptive and evaluative 
 elements of a study. 34 questions across 
 4 key areas: phenomenon studied and 
 context; ethics; data collection, analysis and 
 potential researcher bias; policy and 
 practice implications.
Walsh & Downe (2006)48 Set of prompts relating to 8 key areas: 
 scope and purpose; design; sampling 
 strategy; analysis; interpretation; 
 refl exivity; ethical dimensions; relevance 
 and  transferability.
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A structured review of reports published between 1988 and 2004, appraising and 
synthesising qualitative studies in health and health care is available.46 The authors 
found that over 60% of the 42 reviews included either explicitly stated that quality 
appraisal was not carried out or failed to report any appraisal of studies. Interestingly 
where quality appraisal was used, in all but one case the instrument or criteria were 
modifi ed, suggesting that available methods are diffi cult to apply in practice. Others 
have opted to construct their own criteria for assessing rigor as part of the review 
process.47
Box 6.1 lists some of the different appraisal tools that have been developed explicitly 
for use in systematic reviews and/or have been used for that purpose (this is not a 
comprehensive list). Researchers interested in carrying out quality assessment, might 
consider using one or more of these tools.
6.4.2 How should quality assessment be used?
Quality assessment has been used to establish a quality threshold below which studies 
will be excluded, or to distinguish between studies in terms of overall contribution.32, 36, 49 
There is no consensus as to which approach is preferable. Quality assessment can also 
be used to gain an understanding of the relative strengths and weaknesses of the body 
of evidence and taken into account during the process of synthesis.
Some have reported that better quality studies appear to make stronger contributions to 
the synthesis19, 49 or that weaker studies contribute nothing substantially different from 
the stronger studies.32 Sensitivity analysis has been used to explore the relationship 
between the quality of qualitative studies and contribution to review fi ndings.50 The 
analysis was based on 62 primary studies from fi ve reviews, and suggested that 
studies judged to be of low quality contributed little to the overall review fi ndings. This 
appears to be the fi rst attempt to apply sensitivity analysis to the question of quality 
in qualitative research and further assessment is required. However, the fi ndings are 
consistent with the more descriptive accounts offered about study quality and overall 
contribution to synthesis.19, 32, 49
6.4.3 When should quality assessment be carried out?
The use of quality assessment is further complicated by debate around when it 
should be carried out. The need for appraisal of studies before the synthesis has been 
queried.51 The authors of one qualitative synthesis reported that the necessity of prior 
quality appraisal was a moot point.36 They did go on to comment however that the 
appraisal process was a useful prelude to the synthesis because it helped to screen 
out inappropriate and poor quality studies. Clearly, if quality assessment is to be used 
to establish a quality threshold then assessment will need to take place before the 
synthesis.
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6.5 SYNTHESIS OF QUALITATIVE RESEARCH
This section focuses on the formal synthesis of qualitative research. General debate 
about the appropriateness of combining qualitative studies continues, and more 
specifi cally whether different types of qualitative research, based on different theoretical 
assumptions and methods should be combined. Sometimes authors’ claims about 
the theoretical underpinnings of their work are not always closely related to the 
methods actually used. A recent investigation suggested it is very diffi cult to draw 
fi rm boundaries around what is, and is not, a particular type of qualitative research 
as many authors failed to give any defi nition.52 Despite these problems this same 
investigation also found that it is possible to synthesise across different traditions52 and 
indeed some review teams consider the combining of data from multiple theoretical and 
methodological traditions a strength of the review.24
(Continued)
Box 6.2: Methods proposed for the synthesis of qualitative evidence
Synthesis method Description
Meta-ethnography51 A set of techniques for synthesising qualitative studies. It 
 involves the selection, comparison and analysis of studies 
 to create new interpretations or concepts. Key stages include 
 the reading and re-reading of studies; determining how the 
 studies are related by listing key concepts and comparing 
 and contrasting them; translating the studies into one 
 another and synthesising the translations to identify concepts 
 which go beyond individual accounts and can be used to 
 produce a new interpretation.
 It has been used to address questions about the meanings of 
 medicines,54 55 the barriers and facilitators of adherence to TB 
 treatment,56 19 lay experiences of diabetes and diabetes 
 care,36 children’s perspectives of growing up in disadvantage57 
 and teenage mothers’ experiences of their lives.58
Thematic analysis/ The identifi cation of important or recurrent themes. Findings 
synthesis43 are summarised under thematic headings. Information 
 is tabulated allowing identifi cation of prominent themes and 
 offering structured ways of dealing with the data in each 
 theme. More recently the method has been refi ned, such that 
 a new method – thematic synthesis – has emerged.43, 59
 It has been used to address questions about barriers to 
 and facilitators of healthy eating amongst children;60 young 
 people, pregnancy and social exclusion44 and accidental 
 injury, risk taking behaviour and the social circumstances in 
 which young people live.61
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Synthesis method Description
Grounded theory (constant Grounded theory was originally developed for use with 
comparative method)62 primary studies and describes methods for sampling, data 
 collection and analysis. Its potential application to the 
 synthesis of multiple qualitative studies has recently been 
 reported.2, 63
 One particular element – the constant comparative method 
 – has received most attention as it offers a set of procedures 
 for analysing qualitative evidence.64
 It has been used to address questions about women’s 
 experiences of domestic violence,65 living with HIV infection66 
 and caring in nursing.24
Qualitative research A set of techniques for the interpretive integration of 
synthesis: Qualitative  qualitative research fi ndings.
meta-synthesis3
Content analysis67 A systematic technique for categorising data into themes and 
 counting frequency of themes.
Case survey68 Formal process for coding data from qualitative cases into a 
 quantitative form.
Qualitative comparative  A method for summarising and comparing data from case 
analysis69 studies using Boolean logic.
Qualitative research  A set of techniques for the quantitative aggregation of
synthesis: Qualitative  qualitative research fi ndings.
meta-summary3
Narrative synthesis70 A general framework and specifi c tools and techniques that 
 help to increase transparency and trustworthiness. Can be 
 applied to reviews of quantitative or qualitative research as 
 individual tools and techniques can be selected according to 
 the type of study design and data included in the review.
 The framework has been applied to questions relating to the 
 implementation of domestic smoke alarms.70
6.5.1 Methods of synthesis
A number of different methods have been proposed for the synthesis of qualitative 
fi ndings, many based on approaches used in primary research.2, 3, 12
Some of the methods maintain the qualitative form of the evidence such as meta-
ethnography and some involve converting qualitative fi ndings into a quantitative form 
such as content analysis. It has been argued that perhaps the least useful way of 
dealing with qualitative data is to turn them into quantitative data.53 Box 6.2 outlines 
some of the methods proposed. This is not a comprehensive list. Choice of method will 
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be infl uenced by a number of factors including the question posed, likely number of 
relevant studies and undoubtedly the knowledge and expertise of the team undertaking 
the review.
Many of the methods are still at a developmental stage and there are relatively few 
examples of their application. An overview of syntheses of qualitative research published 
between 1988 and 2004 identifi ed 42 such syntheses of which meta-ethnography was 
the method most commonly used.46 Consequently there is as yet little evaluation of the 
relative strengths and weaknesses of available methods and few guidelines exist for 
judging quality. However, the recent development of a comprehensive framework for 
good practice offers potential, both for researchers wanting to carry out a synthesis and 
for those wishing to use the fi ndings of a synthesis.52
It is important to note that there are many different terms used to describe the 
various methods, some of which have been applied inconsistently. Some terms such as 
‘qualitative meta-analysis’, ‘meta-study’ and ‘meta-synthesis’ appear to have been used 
in an over-arching way to describe any synthesis of qualitative research. The use of the 
term meta-synthesis to describe any synthesis of qualitative research has been criticised 
on the grounds that it is not specifi c to qualitative research, and is frequently technically 
incorrect, since what is being attempted is not at the meta-level of the synthesis but at 
the meta-level of the included studies (Mary Dixon-Woods, personal communication).
6.6 USING QUALITATIVE FINDINGS TO HELP EXPLAIN, 
INTERPRET AND IMPLEMENT FINDINGS FROM 
EFFECTIVENESS REVIEWS
The approach for integrating the fi ndings from qualitative studies with the effectiveness 
review will depend on which of the options outlined in Section 6.2.1 Options for utilising 
qualitative research is selected.
6.6.1 Findings from one or more qualitative studies
Using the fi ndings from one or more qualitative studies in the narrative discussion of the 
results of the quantitative studies is possibly the most straightforward approach, as it 
does not involve a separate synthesis of the qualitative studies. This method was used 
in a review of population tobacco control interventions.71 Relevant qualitative studies 
were searched for, identifi ed and quality assessed as part of the overall review process 
and used to help interpret the quantitative fi ndings. The qualitative fi ndings were 
helpful in understanding the experience of staff subjected to smoking restrictions in the 
workplace. Staff viewed restrictions as divisive, as they impacted differentially across 
staff grades.
6.6.2 Findings from a synthesis of qualitative studies
Findings from a synthesis of qualitative studies can be used to interpret the fi ndings of 
the quantitative synthesis. The best available examples are two reviews of qualitative 
studies, which address questions of adherence with tuberculosis treatment.32, 56 Both are 
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linked to a Cochrane review of directly observed therapy (DOT) for treating tuberculosis 
which found no evidence that direct observation of people taking their medication was 
better than self administered treatment.72 The reviews of qualitative studies aimed 
to help explain these fi ndings as well as helping to understand the factors infl uencing 
(negatively or positively) adherence with tuberculosis treatment. Both reviews identifi ed 
a number of factors that provide fresh insights into the reasons for poor adherence. In 
turn these factors can be used to inform the development of new interventions as well 
as inform the implementation of specifi c measures to improve adherence. With regard 
to interpreting the quantitative fi ndings, the qualitative synthesis offered huge insight. 
For example, in helping to understand that patient experience was frequently negative 
and dehumanizing in hospital or clinic based DOT where participants had less choice 
or fl exibility over treatment, often having to travel during work hours and not being 
in control of their drug supply. The authors suggest that costs to the patient in terms 
of time and resources and the dehumanizing nature of the intervention may help to 
explain why clinic based DOT tended to be less successful than the alternatives.32
6.6.3 Combining qualitative and quantitative syntheses
The synthesis of qualitative studies can be brought together in a formal way with the 
synthesis of quantitative studies. Because the model mixes methods at the review level, 
it preserves the integrity of the fi ndings from each study type. This approach developed 
by the EPPI-Centre has been used in a series of reviews focusing on young people and 
healthy eating73 as well as reviews in other topic areas such as HIV health promotion45 
and young people, pregnancy and social exclusion.44
The review focusing on promotion of healthy eating is used to illustrate the approach.73 
The fi ndings from each synthesis were juxtaposed. This was done by using a matrix that 
enabled the qualitative fi ndings relating to young peoples’ views about healthy eating 
(and implied recommendations) to be compared and contrasted against the actual 
interventions evaluated in the quantitative studies. The comparative analysis was guided 
by three questions, relating to which interventions matched the recommendations 
derived from young peoples’ views; which recommendations had yet to be evaluated 
using rigorous methods and whether interventions that matched recommendations 
demonstrated larger effects. One theme emerged relating to the promotion of fruit and 
vegetables as tasty rather than healthy, with minimal emphasis on health messages. 
Five evaluation studies matched this theme and subgroup analysis suggested that the 
biggest increase in vegetable consumption was in the studies with minimal focus on 
health messages. A research gap was identifi ed relating to the theme that fruit and 
vegetables should not be promoted in the same way.
In bringing together the results from the two sets of studies the review team were 
able to demonstrate added value both in helping to understand why certain types of 
intervention might be more effective than others, and in guiding recommendations 
for future research. This approach has the potential to involve any number of linked 
syntheses, addressing different questions that are important to the effectiveness of an 
intervention.
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6.7 FUTURE DEVELOPMENTS
Despite recognition of the importance of qualitative research to effectiveness reviews, 
the methods available are not fully developed or well established. Teams undertaking 
reviews of qualitative studies can usefully add to knowledge by publishing their own 
experiences of the process.
Summary: Incorporating qualitative evidence in or alongside 
systematic reviews of effect
• Qualitative research can enhance the utility of reviews of effectiveness in 
a variety of ways such as shaping questions of importance to end users, 
understanding the mechanisms behind effectiveness or ineffectiveness, 
understanding heterogeneous results, identifying factors that impact on 
the implementation of an intervention, describing the experience of people 
receiving the interventions, and providing participants’ subjective evaluations 
of outcomes.
• Qualitative research is not a single method but includes a range of designs 
such as interviews, direct observation, analysis of texts/documents or 
of audio/video recorded speech or behaviour. Choice of method is often 
determined by a particular theoretical perspective, such as phenomenology. 
• Whichever approach guides the search for qualitative research, it is important 
to be transparent and to document clearly the steps taken and discuss the 
potential impact of any limitations.
• Despite lack of consensus over the value of quality assessment, structured 
approaches for judging validity and reliability in qualitative research have been 
developed, used in practice and compared empirically.
• A number of methods have been proposed for the synthesis of qualitative 
studies, but little evaluation undertaken. 
• There are three main approaches to integrating the fi ndings from qualitative 
studies within an effectiveness review. Use the fi ndings from one or more 
qualitative studies in the narrative discussion of the quantitative fi ndings; use 
the fi ndings from the synthesis of qualitative studies to interpret the fi ndings 
of the quantitative synthesis or bring together in a formal way the synthesis of 
qualitative studies with the synthesis of quantitative studies.
CRD Systematic Reviews.indd   232 8/1/09   09:29:45
233
Incorporating qualitative evidence in or alongside systematic reviews of effect
REFERENCES
1. Sheldon TA. Making evidence synthesis more useful for management and policy-
making. J Health Serv Res Policy 2005;10 Suppl 1:1-5.
2. Pope C, Mays N, Popay J. Synthesizing qualitative and quantitative health evidence: a 
guide to methods. Maidenhead: Open University Press; 2007.
3. Sandelowski M, Barroso J. Handbook for synthesizing qualitative research. New York, 
NY: Springer; 2006.
4. Giacomini MK, Cook DJ, for the Evidence-Based Medicine Working Group. Users’ guide 
to the medical literature. XXIII. Qualitative research in health care. A. Are the results of 
the study valid? JAMA 2000;284:357-62.
5. Pope C, Mays N, editors. Qualitative research in health care. 3rd ed. Oxford: 
Blackwell 2006.
6. Murtagh MJ, Thomson RG, May CR, Rapley T, Heaven BR, Graham RH, et al. 
Qualitative methods in a randomised controlled trial: the role of an integrated 
qualitative process evaluation in providing evidence to discontinue the intervention in 
one arm of a trial of a decision support tool. Qual Saf Health Care 2007;16:224-9.
7. Roen K, Arai L, Roberts H, Popay J. Extending systematic reviews to include evidence 
on implementation: methodological work on a review of community-based initiatives to 
prevent injuries. Soc Sci Med 2006;63:1060-71.
8. Roberts KA, Dixon-Woods M, Fitzpatrick R, Abrams KR, Jones DR. Factors affecting 
uptake of childhood immunisation: a Bayesian synthesis of qualitative and quantitative 
evidence. Lancet 2002;360 1596-9.
9. Dixon-Woods M, Cavers D, Agarwal S, Annandale E, Arthur A, Harvey J, et al. 
Conducting a critical interpretive synthesis of the literature on access to healthcare by 
vulnerable groups. BMC Med Res Methodol 2006;6:35.
10. Pawson R, Greenhalgh T, Harvey G, Walshe K. Realist synthesis: an introduction. 
Manchester: ESRC Research Methods Programme; 2004.
11. Pawson R, Greenhalgh T, Harvey G, Walshe K. Realist review: a new method of 
systematic review designed for complex policy interventions. J Health Serv Res Policy 
2005;10 Suppl 1:21-34.
12. Dixon-Woods M, Agarwal S, Young B, Jones D, Sutton A. Integrative approaches to 
qualitative and quantitative evidence. London: NHS Health Development Agency; 2004.
13. Oliver S, Harden A, Rees R, Shepherd J, Brunton G, Garcia J, et al. An emerging 
framework for including different types of evidence in systematic reviews for public 
policy. Evaluation 2005;11:428-46.
14. Higgins JPT, Green S, (editors). Cochrane Handbook for Systematic Reviews of 
Interventions. Version 5.0.0 [updated February 2008]: The Cochrane Collaboration; 
2008. Available from: www.cochrane-handbook.org
CRD Systematic Reviews.indd   233 8/1/09   09:29:45
234
Systematic Reviews
15. EPPI-Centre [Internet]. London: The Evidence for Policy and Practice Information, 
Social Science Research Unit, Institute of Education, University of London; c2008. [cited 
2008 Apr 17]. Available from: http://eppi.ioe.ac.uk/cms/
16. Dixon-Woods M, Fitzpatrick R. Qualitative research in systematic reviews. Has 
established a place for itself. BMJ 2001;323:765-6.
17. Evans D. Database searches for qualitative research. J Med Libr Assoc 
2002;90:290–3.
18. Dixon-Woods M, Bonas S, Booth A, Jones DR, Miller T, Sutton AJ, et al. How can 
systematic reviews incorporate qualitative research? A critical perspective. Qualitative 
Research 2006;6:27-44.
19. Atkins S, Lewin S, Smith H, Engel M, Fretheim A, Volmink J. Conducting a meta-
ethnography of qualitative literature: lessons learnt. BMC Med Res Methodol 2008;8:21
20. Flemming K, Briggs M. Electronic searching to locate qualitative research: evaluation 
of three strategies. J Adv Nurs 2007;57:95–100.
21. Grant MJ. How does your searching grow? A survey of search preferences and the 
use of optimal search strategies in the identifi cation of qualitative research. Health Info 
Libr J 2004;21:21-32.
22. Shaw RL, Booth A, Sutton AJ, Miller T, Smith JA, Young B, et al. Finding qualitative 
research: an evaluation of search strategies. BMC Med Res Methodol 2004;4:5.
23. Booth A. Cochrane or cock-eyed? How should we conduct systematic reviews of 
qualitative research? [monograph online]. In: Qualitative Evidence-Based Practice 
Conference; 2001 May 14-16; Coventry University.
24. Finfgeld-Connett D. Meta-synthesis of caring in nursing. J Clin Nurs 2008;17:196-
204.
25. Booth A. “Brimful of STARLITE”: toward standards for reporting literature searches. 
J Med Libr Assoc 2006;94:421-9.
26. Oakley A. Experiments in knowing: gender and method in social sciences. 
Cambridge: Policy Press; 2000.
27. Sandelowski M, Docherty S, Emden C. Focus on qualitative methods. Qualitative 
metasynthesis: issues and techniques. Res Nurs Health 1997;20:365-71.
28. Buchanan DR. An uneasy alliance: combining qualitative and quantitative research 
methods. Health Educ Q 1992;19:117-35.
29. Howe K, Eisenhart M. Standards for qualitative (and quantitative) research: a 
prolegomenon. Educational Researcher 1990;19:2-9.
30. Seale S, Silverman D. Ensuring rigour in qualitative research. Eur J Pub Health 
1997;7:389-4.
31. Murphy E, Dingwall R, Greatbatch D, Parker S, Watson P. Qualitative research 
methods in health technology assessment: a review of the literature. Health Technol 
Assess 1998;2:1-274.
CRD Systematic Reviews.indd   234 8/1/09   09:29:45
235
Incorporating qualitative evidence in or alongside systematic reviews of effect
32. Noyes J, Popay J. Directly observed therapy and tuberculosis: how can a systematic 
review of qualitative research contribute to improving services? A qualitative meta-
synthesis. J Adv Nurs 2007;57:227-43.
33. Dixon-Woods M, Shaw RL, Agarwal S, Smith JA. The problem of appraising 
qualitative research. Qual Saf Health Care 2004;13:223-5.
34. Spencer L, Ritchie J, Lewis J, Dillon L. Quality in qualitative evaluation: a framework 
for assessing research evidence [monograph online]. London: Cabinet Offi ce; 2003. 
Available from: www.gsr.gov.uk/evaluating_policy/era_papers/qual_eval.asp
35. Boulton M, Fitzpatrick R, Swinburn C. Qualitative research in health care: II. A 
structured review and evaluation of studies. J Eval Clin Pract 1996;2:171-9.
36. Campbell R, Pound P, Pope C, Britten N, Pill R, Morgan M, et al. Evaluating meta-
ethnography: a synthesis of qualitative research on lay experiences of diabetes and 
diabetes care. Soc Sci Med 2003;56:671-84.
37. Hoddinott P, Pill R. A review of recently published qualitative research in general 
practice. More methodological questions than answers? Fam Pract 1997;14:313-9.
38. Long AF, Godfrey M. An evaluation tool to assess the quality of qualitative research 
studies. Int J Soc Res Meth 2004;7:181-96.
39. Popay J, Rogers A, Williams G. Rationale and standards for the systematic review of 
qualitative literature in health services research. Qual Health Res 1998;8:341-51.
40. Kuper A, Reeves S, Levinson W. An introduction to reading and appraising 
qualitative research. BMJ 2008;337:a288.
41. Dixon-Woods M, Sutton A, Shaw R, Miller T, Smith J, Young B, et al. Appraising 
qualitative research for inclusion in systematic reviews: a quantitative and qualitative 
comparison of three methods. J Health Serv Res Policy 2007;12:42-7.
42. Critical Appraisal Skills Programme (CASP). Qualitative research: appraisal tool. 
10 questions to help you make sense of qualitative research. In. Oxford: Public Health 
Resource Unit; 2006. p. 1-4. Available from: www.phru.nhs.uk/Doc_Links/Qualitative 
Appraisal Tool.pdf
43. Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in 
systematic reviews. BMC Med Res Methodol 2008;8:45.
44. Harden A, Brunton G, Fletcher A, Oakley A. Young people, pregnancy and social 
exclusion: a systematic synthesis of research evidence to identify effective, appropriate 
and promising approaches for prevention and support. London: EPPI-Centre, Social 
Science Research Unit, Institute of Education, University of London; 2006.
45. Rees R, Kavanagh J, Burchett H, Shepherd J, Brunton G, Harden A, et al. HIV 
health promotion and men who have sex with men (MSM): a systematic review of 
research relevant to the development and implementation of effective and appropriate 
interventions. London EPPI-Centre, Social Science Research Unit, Institute of Education, 
University of London; 2004.
CRD Systematic Reviews.indd   235 8/1/09   09:29:46
236
Systematic Reviews
46. Dixon-Woods M, Booth A, Sutton AJ. Synthesizing qualitative research: a review of 
published reports. Qual Res 2007;7:375-422.
47. Nicholas DB, Globerman J, Antle BJ, McNeill T, Lach LM. Processes of metastudy: a 
study of psychosocial adaptation to childhood chronic health conditions. International 
Journal of Qualitative Methods 2006;5:Article 5. Available from: www.ualberta.ca/
~iiqm/backissues/5_1/pdf/nicholas.pdf
48. Walsh D, Downe S. Appraising the quality of qualitative research. Midwifery 
2006;22:108-19.
49. Miller T, Bonas S, Dixon Woods M. Qualitative research on breastfeeding in the UK: a 
narrative review and methodological refl ection. Evidence & Policy 2007;3:197-230.
50. Harden A. Critical appraisal and qualitative research: exploring sensitivity analysis 
[abstract]. In: ESRC Research Methods Festival; 2008 Jun 30-Jul 3; St Catherine’s 
College, Oxford.
51. Noblit GW, Hare RD. Meta-ethnography: synthesizing qualitative studies. London: 
Sage; 1988.
52. Garside R. A comparison of methods for the systematic review of qualitative 
research: two examples using meta-ethnography and meta-study [PhD]. Exeter: 
Peninsula Postgraduate Health Institute, Universities of Exeter and Plymouth; 2008.
53. Petticrew M, Roberts H. Systematic reviews in the social sciences: a practical guide. 
Malden, MA: Blackwell Publishing; 2006.
54. Britten N, Campbell R, Pope C, Donovan J, Morgan M, Pill R. Using meta 
ethnography to synthesise qualitative research: a worked example. J Health Serv Res 
Policy 2002;7:209-15.
55. Pound P, Britten N, Morgan M, Yardley L, Pope C, Daker-White G, et al. Resisting 
medicines: a synthesis of qualitative studies of medicine taking. Soc Sci Med 
2005;61:133-55.
56. Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J. Patient adherence 
to tuberculosis treatment: a systematic review of qualitative research. PLoS Med 
2007;4:e238.
57. Attree P. Growing up in disadvantage: a systematic review of the qualitative 
evidence. Child Care Health Dev 2004;30:679-89.
58. Graham H, McDermott E. Qualitative research and the evidence base of policy: 
insights from studies of teenage mothers in the UK. J Soc Policy 2005;35:21-37.
59. Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in 
systematic reviews. London: ESRC National Centre for Research Methods; 2007. Report 
No.: NCRM Working Paper Series Number (10/07).
60. Thomas J, Sutcliffe K, Harden A, Oakley A, Oliver S, Rees R, et al. Children and 
healthy eating: a systematic review of barriers and facilitators. London: EPPI-Centre, 
Social Science Research Unit, Institute of Education, University of London; 2003.
CRD Systematic Reviews.indd   236 8/1/09   09:29:46
237
Incorporating qualitative evidence in or alongside systematic reviews of effect
61. Thomas J, Kavanagh J, Tucker H, Burchett H, Tripney J, Oakley A. Accidental 
injury, risk-taking behaviour and the social circumstances in which young people live: 
a systematic review. London: EPPI-Centre, Social Science Research Unit, Institute of 
Education, University of London; 2007.
62. Glaser BG, Strauss AL. The discovery of grounded theory. Chicago, IL: Aldine; 1967.
63. Dixon-Woods M, Agarwal S, Jones D, Young B, Sutton A. Synthesising qualitative 
and quantitative evidence: a review of possible methods. J Health Serv Res Policy 
2005;10:45-53.
64. Strauss A, Corbin J. Basics of qualitative research: techniques and procedures for 
developing grounded theory. 2nd ed. Thousand Oaks, CA: Sage; 1998.
65. Kearney MH. Enduring love: a grounded formal theory of women’s experience of 
domestic violence. Res Nurs Health 2001;24:270-82.
66. Barroso J, Powell-Cope GM. Metasynthesis of qualitative research on living with HIV 
infection. Qual Health Res 2000;10:340-53.
67. Hodson R. Analyzing documentary accounts. London: Sage; 1999.
68. Yin RK. Case study research: design and methods. 2nd ed. Thousand Oaks, CA: 
Sage; 1994.
69. Ragin CC. The comparative method: moving beyond qualitative and quantitative 
strategies. Berkeley, CA: University of California Press; 1987.
70. Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al. Guidance on 
the conduct of narrative synthesis in systematic reviews. Lancaster: ESRC Research 
Methods Programme; 2006.
71. Thomas S, Fayter D, Misso K, Ogilvie D, Petticrew M, Sowden A, et al. Population 
tobacco control interventions and their effects on social inequalities in smoking: 
systematic review. Tob Control 2008;17:230-7.
72. Volmink J, Garner P. Directly observed therapy for treating tuberculosis 
Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD003343. DOI: 
10.1002/14651858.CD003343.pub3.
73. Thomas J, Harden A, Oakley A, Oliver S, Sutcliffe K, Rees R, et al. Integrating 
qualitative research with trials in systematic reviews. BMJ 2004;328:1010-2.
CRD Systematic Reviews.indd   237 8/1/09   09:29:46
238
CRD Systematic Reviews.indd   238 8/1/09   09:29:46
239
APPENDIX 1: OTHER REVIEW APPROACHES
This guide describes the process of conducting a systematic review of the effectiveness 
of a health intervention using aggregate data presented in reports and publications. 
Issues specifi c to undertaking reviews of clinical tests, adverse events, public health 
interventions, economic evaluations and the identifi cation, assessment and synthesis 
of qualitative studies to help explain, interpret and implement the fi ndings from 
effectiveness reviews are also covered. However, different types of evidence synthesis 
have emerged in order to meet objectives not met by standard systematic review 
methods. These approaches are beyond the scope of this guide but are described briefl y 
here.
INDIVIDUAL PATIENT DATA (IPD) META-ANALYSIS
Individual patient data (IPD) meta-analysis is a specifi c method of systematic review. 
Instead of extracting data from study publications, the original research data for each 
participant is obtained directly from the researchers responsible for each included 
study. These data can then be collated and re-analysed centrally and, if appropriate, 
combined in meta-analyses. The approach has been used extensively in cancer1 and 
cardiovascular disease and is becoming used more frequently in many other areas of 
health.2
Although IPD meta-analysis usually takes longer and costs more than conventional 
systematic reviews of published aggregate data, they offer a number of benefi ts, related 
particularly to the quality of data and the type of analyses that can be done.3, 4 The IPD 
provided can be checked in detail and analyses carried out in a consistent way across 
studies. The reviewer does not have to interpret information or analyses presented 
in published reports, or have to consider combining differing outcome measures or 
summary statistics. If outcomes or patient characteristics have been measured, scored 
or defi ned differently, it is often possible to use the data supplied to redefi ne these 
according to an agreed review defi nition.5 Problems with the original analyses can also 
often be avoided, for example if data are obtained from all randomised patients then 
intention to treat (ITT) analyses (see Chapter 1 Section 1.3.5 Data synthesis) may 
be possible even if the original study analyses failed to use ITT methods.6 The IPD 
approach to systematic review can also be helpful in circumventing publication and 
associated biases.7 IPD reviews should therefore be considered in circumstances where 
the published information does not permit a good quality review, or where particular 
types of analyses are required that are not feasible using standard approaches. 
Although obtaining IPD can help avoid problems associated with the analyses and 
reporting of studies, as with other types of systematic review, it cannot, generally, help 
avoid bias associated with study design or conduct.
IPD reviews are usually carried out as collaborative projects whereby all researchers 
contributing information from their studies, together with those managing or providing 
expert advice to the project, become part of an active collaboration. Detailed discussion 
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of how such projects are operationalised is outside the scope of this report. However, 
the rationale for IPD meta-analysis is the same as for any other systematic review, and 
many of the approaches and methods used are the same, with substantial differences 
occurring only with respect to data collection, checking and analysis. Some aspects 
of analysis, relating particularly to time-to-event analysis and sub-group analysis are 
discussed briefl y in the synthesis section of Chapter 1. Their relevance to systematic 
reviews of clinical tests is briefl y discussed in Chapter 2. Further details on organisation 
of IPD meta-analysis and data collection and checking can be found elsewhere.3, 8
PROSPECTIVE META-ANALYSIS
Prospective meta-analysis involves selecting a group of studies for inclusion in a meta-
analysis before the results of those studies are known. Because decisions about relevant 
outcomes and subgroups are made in advance, there is no opportunity for selecting 
studies on the basis of their fi ndings, thereby preventing publication and selection 
biases. It may also mean that investigators can agree on consistent study methods and 
data structures that will facilitate the subsequent meta-analysis. Analyses are generally 
done using IPD. However, as with IPD meta-analysis, prospective meta-analyses may 
require the close collaboration of several independent research groups, which can 
present various logistical challenges.
REVIEWS OF REVIEWS
This describes a systematic review that includes only other systematic reviews. In 
theory the systematic reviews included in the review should have covered most of 
the primary studies available. Reviews of reviews are likely to be helpful when a 
review question is very broad and a number of systematic reviews have already been 
conducted in the topic area. However, the different inclusion criteria adopted by the 
various reviews can make synthesis and interpretation problematic.
SCOPING REVIEWS
A scoping review determines the size and nature of the evidence base for a particular 
topic area, which can in turn be used to identify gaps in the literature and make 
recommendations for future primary research. The literature search should be as 
extensive as possible, including a range of relevant databases, handsearching and 
attempts to identify unpublished literature. Scoping reviews differ from standard 
systematic reviews in that they do not attempt to synthesise the evidence. A scoping 
review might be useful to research bodies that are planning a primary study, or to 
assess the feasibility of a full systematic review. It is not appropriate to use a scoping 
review to answer a clinical question.
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RAPID EVIDENCE ASSESSMENTS
Rapid evidence assessments are used to summarise the available research evidence 
within the constraints of a given timetable, typically three months or less. Rapid 
evidence assessments differ from full systematic reviews in terms of the time 
constraints and consequently there are limitations on the extent of the literature 
searches and other review activities. Whilst attempting to be as comprehensive as 
possible, rapid evidence assessments usually make compromises to meet their tight 
deadlines; therefore they may fail to identify potentially relevant studies. They are 
useful to policy-makers who need to make decisions quickly, but should be viewed as 
provisional appraisals, rather than full systematic reviews.
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APPENDIX 2: EXAMPLE SEARCH STRATEGY TO 
IDENTIFY STUDIES FROM ELECTRONIC DATABASES
The development of a search strategy is an iterative process: one attempt will rarely 
produce the fi nal strategy. Strategies are usually built up from a series of test searches 
and discussions of the results of those searches among the review team.
The fi rst step is to break down the review question to help guide the development of 
search terms, using a structure such as PICOS.
For example:
Population(s)/Patient(s) Patients undergoing hip replacement
Intervention(s)/Treatment(s) Antimicrobial prophylaxis
Comparator(s) No prophylaxis
Outcome(s) Postoperative infection
Study Design Any type of study design
It is not necessary to include all of the PICOS concepts in the search strategy. It is 
preferable to search for those concepts that can be clearly defi ned and translated into 
search terms. Concepts that are poorly defi ned, not likely to be included in journal 
abstracts, or not indexed in a consistent way will be diffi cult to identify from database 
searches. If this is the case, using a broader search and then sifting through the 
identifi ed studies may be preferable. This may apply particularly to the outcome(s) 
of studies as these are frequently not referred to in either the title or abstract of a 
database record.
Search fi lters are tested and in some cases validated strategies that can be used in a 
named database to identify specifi c types of study. They usually consist of a series of 
database index terms relating to study type combined with free text terms describing 
the methods used in conducting that type of research. There are fi lters available that 
will, for example, reliably identify RCTs in MEDLINE and in EMBASE, but fi lters for use 
in other databases or to identify other study types are limited. The development and 
validation of fi lters to identify other study types, such as diagnostic accuracy studies and 
qualitative research, is ongoing.1-4 A useful source of information about search fi lters is 
the website maintained by the InterTASC Information Specialists’ Subgroup 
www.york.ac.uk/inst/crd/intertasc/ which lists both published search fi lters and research 
on their development and use.
Once the concepts of the search have been determined, the next stage is to produce 
a list of synonyms, abbreviations and spelling variants which may be used by authors. 
Similar research is often described using very different terms. To refl ect this variation, 
a search strategy will usually comprise both indexing terms (if the database has 
a thesaurus or controlled vocabulary) and ‘free text’ terms and synonyms (from 
the database record’s title and abstract) to ensure that as many relevant papers 
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are retrieved as possible. For example, when searching MEDLINE for studies about 
myocardial infarction, the free text term “heart attack” should be used as well as the 
Medical Subject Heading (MeSH) term “Myocardial Infarction”. Identifying appropriate 
indexing terms can be done by searching for key papers and checking how they have 
been indexed, consulting clinical experts in the review team and advisory group, as well 
as by scanning the thesaurus for relevant terms.
When selecting free text terms to use in the strategy it is important to take account 
of alternative spellings (including US and British English variants), abbreviations, 
synonyms, geographical variation, and changes in terminology over time. Sometimes it 
can also be useful to search for common mis-spellings, for example “asprin” when you 
want to retrieve studies of aspirin.
It is important to compile imaginatively and to check the indexing terms used in known 
relevant publications. Once a list of potential search terms has been compiled for each 
of the concepts, the next stage is to identify relevant subject headings which have 
been used to describe the topic in the databases you plan to search. For example with 
postoperative infection the following Medical Subject Headings (MeSH) are available for 
use in MEDLINE:
• Bacterial Infections
• Postoperative Complications
• Surgical Wound Infection
• Prosthesis-Related Infections
• Sepsis
• Infection Control.
Some of these terms are “high level” that encompass narrower or more specifi c 
terms. To capture these narrower terms, in those databases that offer the facility, it 
is possible to ‘explode’ the high level term and so search for many terms at once. The 
explosion facility within a database makes use of the hierarchical thesaurus. Using the 
command “exp Bacterial Infections/” in the OvidSP interface to MEDLINE will retrieve 
papers indexed with that term but will also automatically retrieve papers indexed with 
the narrower terms Bacteramia, Hemorrhagic Septicaemia, Central Nervous System 
Bacterial Infections, etc. as displayed in the section of the MeSH below.
Bacterial Infections/
• Bacteraemia
• Hemorrhagic Septicaemia
• Central Nervous System Bacterial Infections
• Endocarditis, Bacterial
• Eye Infections, Bacterial
• Fournier Gangrene
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The subject headings should be added to the concept list relating to the postoperative 
infection concept so that a fi rst test search strategy for MEDLINE includes a mixture of 
text terms and MeSH headings.
bacterial adj infect$.ti,ab.
(postoperative adj complication$ or post adj operative adj complication$).ti,ab.
surgical adj wound adj infection$.ti,ab.
prosthesis-related adj infection$.ti,ab.
hip adj replacement adj3 infection$.ti,ab.
sepsis.ti,ab.
Septic?emia.ti,ab.
infection adj control.ti,ab.
bacterial adj contamination.ti,ab.
Exp Bacterial Infections/
Exp Postoperative Complications/
Surgical Wound Infection/
Prosthesis-Related Infections/
Sepsis/
Exp Infection Control/
The search has been written for the OvidSP search interface to MEDLINE and has 
commands specifi c to that interface:
adj Words have to appear next to each other. Also retrieves hyphenated words.
adj3 Words have to appear within 3 words of each other. Other numbers can be 
used as required.
$ Truncation symbol, for example ‘complication$’ retrieves ‘complications’ as 
well as ‘complication’.
.ti,ab Restricts the search to title and abstract fi elds, to avoid retrieving 
unexpected results from the subject headings.
EXP Explode the subject heading, to retrieve more specifi c terms
/ MeSH heading.
? Optional wild card character used within, or at the end of, a search term 
to substitute for one or no characters. Useful for retrieving documents with 
British and American word variants.
Each database interface has its own unique set of commands and, information about 
these will be on the database help pages.
Once a series of concepts that refl ect the PICOS elements have been compiled they 
are then combined using Boolean logic (AND, OR, NOT) to create a set of results which 
should contain articles relating to the topic in question. The AND operator is used to 
ensure that all the search terms must appear in the record, for example searching for 
“prostate AND cancer” retrieves all records which contain both the term prostate and 
the term cancer. AND is used to narrow down or focus a search.
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OR is used to accumulate similar search terms and thus makes searches larger. 
Searching for “heparin OR warfarin” retrieves all records where either heparin or 
warfarin or both are found. It is best to use the OR operator to combine terms relating 
to the same concept (e.g. all the postoperative infection terms in the example above) 
before narrowing down a search using the AND operator with another set of terms.
NOT is used to exclude records from a search. For example, “acupuncture NOT asthma” 
will retrieve all records which contain the term acupuncture, but not those which also 
contain the word asthma. NOT should be used with great care because it may have a 
larger effect than anticipated; a record may well discuss both the concept of interest 
and the one to be excluded.
The combination of concepts using the Boolean operators might develop as follows (for 
MEDLINE using the OVIDSP interface):
1 Hip Joint/
2 Hip Prosthesis/
3 Acetabulum/
4 hip replacement$.ti,ab.
5 total-hip replacement$.ti,ab.
6 total joint replacement$.ti,ab.
7 hip surgery.ti,ab.
8 hip operation$.ti,ab.
9 (hip adj3 prosthe$).ti,ab.
10 (hip adj3 arthroplasty).ti,ab.
11 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10
12 exp Bacterial Infections/
13 exp Postoperative Complications/
14 Surgical Wound Infection/
14 Prosthesis-Related Infections/
16 Sepsis/
17 exp Anti-Infective Agents/
18 exp Infection Control/
19 exp Antibiotics/
20 Antibiotic Prophylaxis/
21 ((bacteri$ or wound$) adj2 (infect$ or contamin$)).ti,ab.
22 sepsis.ti,ab.
23 antibiotic$.ti,ab.
24 antimicrobial$.ti,ab.
25 anti-microbial$.ti,ab.
26 (anti$ adj infect$).ti,ab.
27 ultraclean.ti,ab.
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28 hypersterile.ti,ab.
29 or/12-28
30 11 and 29
Sets 1 to 10 capture the concepts of hip replacement or hip surgery and are combined 
using OR to produce result set 11. Sets 12 to 28 capture the concepts of infection and 
infection prevention and are combined using OR to produce result set 29. The two sets 
of concepts are then combined to fi nd the records which contain both concepts using 
AND to produce set 30.
The draft strategy can be tested on one database and the results checked by whether 
it retrieves papers that are already known to the team but were not used to develop 
the draft strategy. In addition, a small sample of the results of the test or scoping 
search can be examined by the review team to identify additional search terms (text 
words and indexing) or highlight potential limitations. The sample records need to be 
representative so bear in mind that the search results as output from the database 
will be listed in either alphabetical order by authors name, or by publication date or 
by date added to the database. Depending upon the complexity of the review topic, 
and consequently the search to be undertaken, this process may need to be repeated 
several times until an agreed strategy is formulated. If at all possible, the fi nal search 
strategy should be peer reviewed to check for errors (spelling mistakes, incorrect use of 
operators, or failure to include relevant MeSH) that could reduce the recall of papers.5
At this point, the searches using other databases and resources can begin. However, 
this does not mean that search iterations should necessarily stop. If new search terms 
are identifi ed during the review process they should be incorporated into the strategy or 
supplementary searches should be carried out.
Converting a fi nal strategy for use in other databases requires care. While free text 
terms can usually be re-used in other databases you will need to identify one or possibly 
more matching relevant thesaurus terms used by the other databases. Each database 
thesaurus is unique so this procedure should be undertaken for each database being 
searched. For example, if you are searching MEDLINE for papers about “pressure sores” 
you would use the MeSH term “pressure ulcer” while if you were searching EMBASE you 
would need to use the EMTREE term “decubitus”.
If the search interface is also different you will need to make appropriate changes to the 
search operators used in the strategy. For example, some database providers use ‘$’ as 
the truncation symbol, while other database providers use ‘*’.
Not all databases include an abstract in the record. Where this is the case the search 
strategy can be made more sensitive given the reliance solely upon terms being 
identifi ed in the title (and any indexing fi elds). This can be achieved by using more 
synonyms and broader terms.
In some cases databases with web interfaces have a restricted range of search options 
and if this is the case searchers need to adopt pragmatic approaches and use very 
simple searches. For example, if there are limited options for combining terms using 
Boolean operators such as AND an alternative approach may be to run a number of 
separate searches on the database in place of one longer search.
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The search should be described briefl y in the methods section of the review. The 
detailed description can be made available as a web document or as an appendix in a 
report, where space allows.
DESCRIBING ELECTRONIC DATABASE SEARCHES
The description should include:
• The name of the database searched
• The name of the database provider/system used
• The date when the search was run
• The years covered by the search
• The full strategy used. It is preferable to reproduce the strategy with the 
minimum of editing. Removing the number of hits identifi ed, for example, can 
introduce errors and hide genuine mistakes.
For example:
MEDLINE was searched using the Ovid interface on 06/11/07 for the period 1996 to 
October Week 4 2007
1 (smoking or antismoking or anti-smoking).ti,ab. (53347)
2 Smoking/(39157)
3 (smoker or smokers or tobacco or nicotine or cigar$).ti,ab. (53978)
4 Tobacco/or Tobacco, Smokeless/(9039)
5 “Tobacco Use Disorder”/(3192)
6 Nicotine/(6990)
7 or/1-6 (91596)
8 exp Mass Media/or Cellular Phone/(13165)
9 Electronic Mail/or Radio/or Television/or Telephone/(6855)
10 Advertising/or Hotlines/or Nonverbal Communication/(6927)
11 Multimedia/or Communications Media/or Pamphlets/(2296)
12 Health Education/or Internet/or Health Promotion/(55884)
13 Telecommunications/(1517)
14 (mass adj media).ti,ab. (949)
15 ((advert$ or campaign$ or program$) adj3 (tv or television or cable or cinema 
or cinemas or theatre or theatres or theater or theaters or movies or media or 
newspaper$ or journal$ or magazine$)).ti,ab. (1466)
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16 ((advert$ or campaign$ or program$) adj3 (broadcast$ or televised)).ti,ab. (67)
17 (internet adj3 (advert$ or campaign$ or information or program$)).ti,ab. (1349)
18 (sms or text messag$ or texting).ti,ab. (754)
19 ((pod adj cast$) or podcast$).ti,ab. (28)
20 (smoking adj day$).ti,ab. (22)
21 (selfhelp or (self adj help) or (counter adj marketing) or (consumer adj 
advocacy)).ti,ab. (1495)
22 ((quit adj3 win) or smokeout or (smoke adj out)).ti,ab. (54)
23 ((advert$ or campaign$ or program$ or intervention$) adj3 (nationwide or 
statewide or countrywide or citywide or national or nation wide or state wide or 
country wide or city wide)).ti,ab. (7031)
24 or/8-23 (88367)
25 7 and 24 (5364)
DESCRIBING JOURNAL HANDSEARCHES
Provide a list of journal full titles in alphabetical order. State the earliest month and year 
searched, together with the latest month and year searched, and any missing journal 
issues which were not searched.
DESCRIBING SEARCHES OF CONFERENCE PROCEEDINGS
Provide details of the conference proceedings searched, for example:
Proceedings with a title in addition to the conference name:
 Substance use: individual behaviour, social interactions, markets, and politics. 
24th Arne Ryde Symposium; 2004, Aug 13-14; Lund.
Proceedings without a separate title:
 International Meeting on the Economic, Social, and Health Issues in Tobacco 
Control; 2001 Dec 3-4; Kobe City
Proceedings in a language other than English:
 Arrêt de la consommation du tabac: Conférence de consensus [Consensus 
conference on smoking cessation]; 1998 Oct 8-9; Charcot.
Proceedings also published as part of a journal:
 Proceedings of the 6th Scientifi c Conference: Tobacco or health, eternal problem, 
new challenges; 2005 Nov 17-18; Poznan. (Przeglad Lekarski. 2005;62(10):947-
1226)
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DESCRIBING THE METHODS USED TO SEARCH RELEVANT INTERNET 
SOURCES
Report the website, the URL, the date searched, any specifi c sections searched and the 
search terms used. For example:
 The Action for Smoking and Health website (www.ash.org.uk/) was searched 
on 12/10/2006 using the on-site search engine with single search terms: ‘mass 
media’, ‘radio’, ‘television’, ‘fi lm’, ‘advertising’. The section of the website labelled 
‘Tobacco Industry Documents’ was scanned in detail.
DESCRIBING OTHER SEARCHES
Provide a brief summary of other sources searched, for example:
 The reference lists of studies selected for inclusion were scanned for relevant 
studies.
 The manufacturing company United Tobacco Substitutes International was 
contacted for further information (15/11/06).
 Citation searches in Science Citation Index (15/11/06) were carried out for 
papers citing the recent key paper: Smith P and Jones L. Innovative mass media 
smoking campaigns. Journal of Tobacco Control Innovation, 2004;23:560-569.
DESCRIBING THE SEARCH PROCESS
The following example shows how a search can be described briefl y in a fi nal report 
when it is possible to put the full searches in an appendix.
 The following databases were searched for relevant studies: ASSIA (via CSA 
1990 to 06/March/06); CENTRAL (via Cochrane Library issue 2/2006, 12/
April/06, 12/April/06); CINAHL (via WebSPIRS 1990 to 2006 wk 4, 01/April/06); 
DH-Data (via Datastar 1994 to 14/March/06, 14/March/06); EMBASE (via Dialog 
1974 to 2006 week 8, 16/March/06); MEDLINE (via Ovid, 1966 to week 10 2006, 
15/March/06); PsycINFO (via Datastar 1806 to 2006 week 2, 17/March/06). The 
search strategies used text words and relevant indexing to capture the concept 
of preventing the uptake of smoking in young people. The full strategies are 
shown in the appendix. The reference lists of included papers were assessed for 
additional relevant studies and the journal Tobacco Control was handsearched 
for the period January 2000-June 2006. The following websites were searched: 
National Guideline Clearinghouse (www.guideline.gov/15/Oct/06) and Action on 
Smoking and Health (ASH) (www.ash.org.uk/16/Oct/06).
The following example shows how a search can be described briefl y for a journal article 
where high levels of detail may not be permitted in the body of the paper:
 The following databases were searched from inception to March/April 2006 
for relevant studies: ASSIA, CENTRAL, CINAHL, DH-Data, EMBASE, MEDLINE, 
PsycINFO. The literature search used the following terms (with synonyms and 
CRD Systematic Reviews.indd   251 8/1/09   09:29:49
252
Systematic Reviews
closely related words): “smoking” combined with “prevention” and “young 
people”. The searches were not limited by study design or language of 
publication. Further studies were identifi ed by examining the reference lists of all 
included articles, handsearching the journal Tobacco Control from 2000 to 2006, 
and searching relevant websites. The full list of sources and the search strategy 
are available from the authors.
A detailed search description included as an appendix to a report, or as a web 
document, or available from the authors should include the detail described above, plus 
all the search strategies for each database and resource, as shown in Q.1 to Q.5 above.
The following are examples of the use of appendices for search strategies in CRD 
Reports:
1. Prostate biopsy methods is an example of a narrow, well-defi ned topic where 
brief details of the search strategy are given in the report methods section 
(pages 23-4), then a clear, well set out and very detailed appendix itemises 
exactly what was done (pages 87-97).
 CRD Report 29 – Diagnostic value of systematic prostate biopsy methods in 
the investigation for prostate cancer: a systematic review. 2005. www.york.
ac.uk/inst/crd/pdf/report29.pdf
2. Fuller information about the searches is given in the methods section of this 
report (pages 4-5) with additional detail in the appendix (pages 25-30).
 CRD Report 32 – Systematic review of interventions to increase participation 
of cancer patients in randomised controlled trials. 2006. www.york.ac.uk/
inst/crd/pdf/report32.pdf
3. This is an example of how an updated search looking at a broad subject area has 
been presented. Brief details are given in the review methods section (page 1) 
and readers are referred to the full details in the appendix (pages 41-50).
 CRD Report 35 – The treatment and management of chronic fatigue 
syndrome (CFS)/myalgic encephalomyelitis (ME) in adults and children: 
update of CRD Report 22. 2007. www.york.ac.uk/inst/crd/pdf/report35.pdf
Please note that in the three examples above the search strategies have been reported 
without including the numbers of records identifi ed by individual search statements. 
As stated earlier in this section, CRD would now recommend the strategies being 
reproduced with a minimum of editing so there is less opportunity for errors to be 
introduced.
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APPENDIX 4: SEARCHING FOR ADVERSE EFFECTS
Named adverse effects can be searched for as both indexing terms and text words. 
For example in MEDLINE OvidSP sudden death can be searched using the following 
approach;
#1 exp Death, Sudden/
#2 (sudden adj2 death$).ti,ab.
#3 #1 or #2
KEY
exp denotes exploding the succeeding indexing term
adj is the proximity operator in OvidSP, and adj2 denotes within 2 words
$ is the truncation symbol in OvidSP
ti, ab denotes searching in the title and abstract
In some instances subheadings may be available to focus the search on the outcome as 
an adverse effect (rather than, for example, a consequence of the disease). For example 
in MEDLINE the subheading ‘chemically induced’ is available and a search for vision 
disorders as an adverse effect may be carried out as follows:
#1 exp Vision Disorders/ci [chemically induced]
It should be noted, however, that for truly sensitive searches suitable text words will 
need to be added (for example, vision disorder$.ti,ab), this could be in combination with 
adverse effects terms (for example, vision disorder$.ti,ab and complication$.ti,ab etc).
In addition to terms for named adverse effects it may also be appropriate (due to poor 
reporting in papers and indexing in databases) to add generic adverse effect search terms 
as for a general search for all adverse effects associated with an intervention (see below).
SEARCHING WITH GENERIC ADVERSE EFFECTS TERMS
If none of the adverse effects are known at the time of searching then a sensitive 
search strategy in MEDLINE OvidSP would include a combination of MeSH fl oating 
subheadings and text words for generic adverse effects terms for example;
#1 ae.fs. OR co.fs. OR de.fs.
#2 (safe OR safety OR side effect$ OR undesirable effect$ OR treatment emergent 
OR tolerability OR toxicity OR adrs OR (adverse adj2 (effect or effects or reaction or 
reactions or event or events or outcome or outcomes))).ti,ab
#1 OR #2
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KEY
ae denotes the subheading ‘adverse effects’
co denotes the subheading ‘complications’
de denotes the subheading ‘drug effects’
.fs denotes ‘fl oating’ the preceding subheading (ie searching for the subheading 
attached to any indexing term).
Many papers on adverse effects will not contain any generic adverse effects terms in 
the title, abstract or indexing. In instances where the adverse effects are unknown at 
the time of searching, it may be possible to identify potential adverse effects to use as 
search terms from tertiary sources such as the BNF and Meyler’s Side Effects of Drugs.
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Abbreviations and acronyms
AcroMine Text mining tool dealing with term extraction and variation
AgeInfo Bibliographic database (specifi c population group)
Ageline Bibliographic database (specifi c population group)
Agricola Bibliographic database (agriculture)
AHRQ Agency for Healthcare Research and Quality
AMED Bibliographic database (complementary medicine)
ASSIA Bibliographic database (Applied Social Sciences Index & 
Abstracts)
AUC Area Under the Curve
BIOSIS Previews Bibliographic database (life sciences)
CASP Critical Appraisal Skills Programme
CBA Cost-benefi t Analysis
CCA Cost-consequences Analysis
CCTRs Comprehensive Clinical Trials Reports
CDSR Cochrane Database of Systematic Reviews
CEA Cost-effectiveness Analysis
CENTRAL Cochrane Central Register of Controlled Trials
ChildData Bibliographic database (specifi c population group)
CI Confi dence Interval
CINAHL Bibliographic database (nursing and allied health)
CONSORT A set of recommendations for the reporting of RCTs
CRD Centre for Reviews and Dissemination
CSA Bibliographic database (sociological & social services abstracts)
CUA Cost-utility Analysis
DAPS Drug Analysis Prints
DARE Database of Abstracts of Reviews of Effects
DE Design Effect
DFS Disease free survival
DH Department of Health
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Dialog Database provider
DoPHER Database of Promoting Health Effectiveness Reviews
DOR Diagnostic Odds Ratio
DOT Directly Observed Therapy
DSA Digital Subtraction Angiography
DUETs Database of Uncertainties about the Effects of Treatments
EE Effect Estimates
EI Compendex Bibliographic database (engineering)
EMBASE Bibliographic database (biomedicine)
EMTREE Thesaurus used in EMBASE database
Enviroline Bibliographic database (environment)
EPAR European Public Assessment Report
EPICOT Evidence, Population(s), Intervention(s), Comparison(s), 
Outcome(s), Time stamp
EPOC Cochrane Effective Practice and Organisation of Care Group
EPPI Evidence for Policy and Practice Information
EQUATOR Enhancing the QUAlity and Transparency Of health Research
EQ-5D An instrument for measuring utility in economic evaluations
ERIC Bibliographic database (education)
ESRC Economic and Social Research Council
FACTA Text mining tool that fi nds associated concepts using text 
analysis
FDA Federal Drug Administration
FN False Negative
FP False Positive
GEOBASE Bibliographic database (earth sciences and human geography)
HCA Human Capital Approach
HEED Health Economic Evaluations Database
HMIC Health Management Information Consortium. A bibliographic 
database
HR Hazard Ratio
HSROC Hierachical SROC
HTA Health Technology Assessment
HYE Healthy-years-equivalent
ICC Intracluster Correlation Coeffi cient
CRD Systematic Reviews.indd   256 8/1/09   09:29:50
257
Abbreviations and acronyms
ICER Incremental Cost-effectiveness Ratios
ICMJE International Committee of Medical Journal Editors
ICONDA Bibliographic database (housing and architecture)
IDIS Iowa Drug Information Service
InterTASC Inter Technology Assessment Services Collaboration
IPA International Pharmaceutical Abstracts. A bibliographic database
IPD Individual Patient Data
ISSG Information Specialists’ Sub-Group of InterTASC
ITT Intention To Treat
KLEIO Text mining tool that provides advanced searching facilities 
across Medline
LILACS Bibliographic database (Latin American and Caribbean Health 
Sciences Literature)
LMWH Low-molecular-weight heparin
MANTIS Bibliographic database (osteopathy and chiropractic)
MCUG Micturating cystourethrography
MD Mean Difference
MEDLINE Bibliographic database (medicine)
MeSH Medical Subject Headings used in MEDLINE database
MMR Measles Mumps and Rubella
MRA Magnetic Resonance Angiography
MTC Mixed Treatment Comparisons
NGC National Guidelines Clearinghouse
NHS National Health Service
NHS EED NHS Economic Evaluation Database
NICE National Institute for Health and Clinical Excellence
NIHR National Institute for Health Research
NRSMG Cochrane Non Randomised Studies Methods Group
NSAIDs Non-Steroidal Anti-Infl ammatory Drugs
NTIS National Technical Information Service
NTT Number Needed To Treat
O – E Observed–Expected
OR Odds Ratio
PAIS Public Affairs Information Service. A bibliographic database
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PDR Physician’s Desk Reference
PHL Public Health Language
PHO Public Health Observatories
PICOCS Population, Interventions, Comparators, Outcomes, Context, 
Study design
PICOS Population, Interventions, Comparators, Outcomes and Study 
Designs
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-
Analyses
PROGRESS Place of Residence, Race/ethnicity, Occupation, Gender, Religion, 
Education, Socioeconomic status and Social capital.
PSA Probabilistic Sensitivity Analysis
PsycINFO Bibliographic database (psychology and psychiatry)
QALYs Quality-Adjusted-Life-Years
QUADAS Quality Assessment of Diagnostic Accuracy Studies included in 
Systematic Reviews
QUOROM Quality of Reporting of Meta-analyses
RCT Randomised Controlled Trial
REMARK REporting recommendations for tumour MARKer prognostic 
studies
ROC Receiver Operating Characteristic
RR Risk Ratios
RRR Relative Risk Reduction
RSS Really Simple Syndication
SAS Data analysis and statistical software
SD Standard Deviation
SE Standard Error
SF-6D An instrument for measuring utility in economic evaluations
SIGN Scottish Intercollegiate Guidelines Network
SMD Standardised Mean Difference
SportDiscus Bibliographic database (sport, health, fi tness & sports medicine)
SROC Summary ROC
STARD Standards For The Reporting Of Diagnostic Accuracy Studies
STATA Data analysis and statistical software
STROBE An initiative to improve reporting of observational studies
TB Tuberculosis
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TerMine Text mining tool dealing with term extraction and variation
TN True Negative
TP True Positive
TRANSPORT Bibliographic database (transport)
TREND Guidelines for the reporting of nonrandomized evaluations of 
behavioural and public health interventions
SRS Systematic review software
TSH Thyroid Stimulating Hormone
UTI Urinary Tract Infection
VUR Vesicoureteric Refl ux
Wolters Kluwer Database provider
Waternet Bibliographic database (water supply)
WHO World Health Organisation
WHO-ART WHO Adverse Reaction Terminology
WINBUGS Data analysis and statistical software
WTP Willingness To Pay
ZETOC Database of journal contents pages provided by the British 
Library and the Mimas servic
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Term Defi nition
Absolute risk reduction See Risk difference.
Ad hoc A solution designed for a specifi c problem or task that is not 
generalisable to other situations (Latin).
Adverse effect An adverse event for which the causal relation between the 
drug/intervention and the event is at least a reasonable 
possibility.
Adverse event An adverse outcome that occurs during or after exposure to a 
drug or other intervention and which may or may not be caused 
by the intervention.
Allocation bias Bias resulting from a systematic difference (other than the 
intervention) between experimental and control groups in a 
clinical trial. Allocation bias can be avoided by randomisation.
Allocation concealment See Concealment of allocation.
A priori Formed or conceived beforehand (Latin).
Archive Collection of material made at the end of a project and 
preserved to assist in answering queries about the review and to 
facilitate any update.
Area under the curve (AUC) A graphical summary of overall diagnostic accuracy; the closer 
the curve is to the upper left hand corner of the graph, the 
better the diagnostic performance. The AUC ranges from 0 to 1, 
with 0.5 indicating a poor test where the accuracy is equivalent 
to chance.
Attrition bias Bias resulting from systematic differences between comparison 
groups as a result of differential withdrawals or exclusions of 
participants.
Bayesian analysis An approach to statistical analysis that can be used in single 
studies or meta-analysis. A prior probability distribution based 
on objective evidence and subjective opinion is defi ned at 
the outset. Bayes’ theorem is then used to update the prior 
distribution in light of the results of a study, producing a 
posterior distribution from which point estimates of effect and 
credible intervals (equivalent to confi dence intervals) can be 
defi ned.
Baseline characteristics Participant characteristics that are collected at the beginning 
of a study prior to receiving the intervention. Characteristics 
may include demographic details such as age and gender and 
clinical characteristics such as stage of disease or presence of 
co-morbidites.
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Before-and-after study A study design where a group is studied before and after an 
intervention.
Bias A systematic error or deviation in results or inferences from the 
underlying ‘truth’. See also selection bias; performance bias; 
attrition bias; detection bias and reporting bias.
Bibliographic databases Databases that provide descriptive records of items such as 
books and articles.
Bibliographic software Computer software that assists with the organisation of 
bibliographic references. There are many different packages 
(e.g. EndNote, Reference Manager), but most will allow for 
the import of references from bibliographic databases and the 
automated production of reference lists.
Blinding Keeping knowledge of which comparison group a participant 
belongs (e.g. to intervention or control) from the study 
participants, investigators or outcome assessors. This reduces 
the risk of bias.
Boolean operator Boolean operators are used to combine terms when conducting 
electronic searches. Examples include “AND” (used to narrow a 
search), “OR” (used to broaden a search) and “NOT” (used to 
exclude terms from a search).
Bootstrapping A statistical approach for examining the uncertainty in cost-
effectiveness analysis. It involves drawing many random sub-
samples from the original data set and computing the statistic 
of interest from each in the same way. After sampling, each sub-
sample is returned to the data set, a process known as sampling 
with replacement.
Case-control study An observational study that compares people with a specifi c 
disease or outcome of interest (cases) with a suitable control 
group of people without that disease or outcome, and which 
seeks to fi nd associations between the outcome and prior 
exposure to particular risk factors.
Case series A study reporting observations on a series of individuals, usually 
all receiving the same intervention, with no control group.
Case survey Formal process for coding data from qualitative cases into a 
quantitative form for statistical analysis.
Clinical heterogeneity See Heterogeneity.
Cluster randomised trial A trial where randomisation is of clusters of people (e.g. general 
practices, schools) rather than individuals themselves.
Cochrane Collaboration An international organisation that aims to help people make 
well-informed decisions about health care by preparing, 
maintaining, updating and ensuring the accessibility of 
systematic reviews of the effects of healthcare interventions.
Cohort study An observational study in which a defi ned group of participants 
is observed over time and a comparison made between those 
who did and those who did not receive the intervention.
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Co-intervention An additional diagnostic or therapeutic procedure given to 
people receiving a particular intervention.
Commissioning brief Information provided by an organisation wishing to commission 
a systematic review to assist researchers in preparing proposals 
to undertake the work.
Communication channel Any medium used to convey a message to an audience or 
audiences.
Co-morbidity The presence of one or more diseases or conditions other than 
those of primary interest.
Comparator In a controlled trial, the intervention (which could include 
placebo, usual care, another intervention or no treatment) with 
which the intervention of interest is compared.
Complex intervention An intervention involving a number of separate elements that 
seem essential to the proper functioning of the intervention 
although the active ingredient of the intervention that is 
effective is diffi cult to specify.
Concealment of allocation The process used to prevent foreknowledge of which comparison 
group an individual will be assigned to in a randomised 
controlled trial. Inadequate concealment of allocation may lead 
to selection bias.
Conceptual mapping In narrative synthesis, the use of visual methods to help to 
construct groupings of, and relationships between, ideas and/or 
concepts. Closely related to idea webbing.
Conceptual triangulation In narrative synthesis, the use of a combination of different 
perspectives and/or methods to study a particular concept.
Confi dence interval A measure of uncertainty around the results of a statistical 
analysis that describes the range of values within which we can 
be reasonably sure that the true effect lies.
 For example a 95% confi dence interval is based on the notion 
that if a study were repeated many times in other samples from 
the same population, 95% of the confi dence intervals from 
those studies would include the true value of the effect being 
measured.
 Wider intervals indicate lower precision; narrow intervals, 
greater precision.
Confounding A situation in which a measure of the effect is distorted because 
of an association between the intervention (or exposure) with 
other factor(s) that infl uence the outcome under investigation. 
For example, if the control group includes patients with more 
advanced stages of cancer than in the intervention group, then 
an analysis of survival will be confounded by tumour stage.
Content analysis A set of procedures for collecting and organizing non-structured 
information. This approach makes it easier to systematically 
and objectively analyze the data and make inferences about the 
population of interest.
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Continuous outcomes Outcomes related to variables with a potentially infi nite number 
of possible values within a given range, for example weight and 
blood pressure.
Contributorship A system of publication credit in which all those who contributed 
to a publication are listed with details of their contribution, 
including those who did not meet the standard criteria to be 
listed as authors.
Control group The group that acts as a comparator for one or more 
experimental interventions in a controlled trial.
 The group without the disease or outcome of interest in a case 
control study.
Controlled trial A clinical trial with a control group.
Cost-effectiveness analysis An economic analysis that converts effects into health terms and 
describes the costs for some additional health gain (e.g. cost per 
additional stroke prevented).
Cost-to-charge ratios In economic analyses, an adjustment applied to charges in 
order to better refl ect the true costs of the technology being 
evaluated.
Critical interpretive synthesis A form of review which, while sensitive to the issues involved 
in conducting reviews that conventional systematic review 
methodology has identifi ed, draws on a distinctive tradition of 
qualitative inquiry, including interpretive approaches to review, 
enabling the generation of theory with strong explanatory 
power.
Cross-over trial A type of clinical trial comparing two or more interventions in 
which all the participants receive all the interventions but the 
order of receipt is determined by randomisation.
Cross-sectional study A study that examines the relationship between diseases (or 
other health related characteristics) and other variables of 
interest as they exist in a defi ned population at a particular 
time.
Custom fi eld In bibliographic software, a fi eld for which the type of content 
is not pre-specifi ed by the software and which can therefore be 
customised by the individual. Often used in systematic reviews 
for keeping track of decisions or articles ordered.
Cutpoint The threshold or value at which continuous data are divided into 
dichotomous categories. If used it is important that the cutpoint 
is not determined by a data dependent process.
Database provider The specifi c platform through which a database is accessed. 
Examples include OVID and Dialog. Many databases are 
available via more than one provider. See also Search interface.
Decision modelling A theoretical construct (often using a mathematical framework) 
that allows the comparison of the relationship between costs 
and outcomes of alternative health care interventions by 
incorporating evidence from a variety of sources.
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Detection bias Bias caused by systematic differences between comparison 
groups in how outcomes are ascertained, diagnosed or verifi ed.
Diagnostic odds ratio An overall indicator of diagnostic performance, calculated as 
the odds of a positive test result among those with the target 
condition, divided by the odds of a positive test result among 
those without the condition.
Diagnostic threshold Point at which diagnostic test results are classifi ed as positive or 
negative.
Dichotomous data Data that can take one of two possible values for example dead 
or alive, myocardial infarction or no myocardial infarction. Also 
known as binary data.
Differential verifi cation bias A type of bias that occurs when a diagnosis is verifi ed using 
different reference standards, depending upon the result of the 
index test.
Discounting In health economics, a reduction applied to future costs and 
benefi ts to refl ect the fact that costs and benefi ts available today 
have a higher value than those occurring in the future.
Double-blind In a controlled trial, this is the process by which the participants 
and the investigators (outcome assessors) are prevented from 
knowing which intervention the participants have been given. 
See also Blinding.
Effectiveness The extent to which a specifi c intervention, applied under usual 
circumstances, does what it is intended to do.
Effi cacy The extent to which an intervention produces a benefi cial effect 
under ideal conditions.
Estimate of effect The observed relationship between an intervention and an 
outcome expressed as, for example odds ratio, risk difference, 
risk ratio, hazard ratio, standardised mean difference, weighted 
mean difference, number needed to treat.
Evidence-based practice An approach to the practice of medicine that involves integrating 
individual clinical expertise with the best available external 
clinical evidence from systematic research.
Experimental intervention An intervention under evaluation.
Experimental study A study in which investigators determine (by randomisation or 
another method) to which intervention group an individual will 
be allocated.
External validity The degree to which the results of a study hold true in other 
settings (generalisability). See also Validity.
Fixed-effect model A method of calculating a pooled effect that assumes all 
variation of estimates of effect between studies is assumed to 
be due to random error (the play of chance). See also Random-
effects model.
CRD Systematic Reviews.indd   265 8/1/09   09:29:52
266
Systematic Reviews
Forest plot A graphical representation of the individual results of each 
study included in a meta-analysis together with or without the 
pooled meta-analysis result. The plot provides an ‘at a glance’ 
indication of the variability between studies and highlights any 
studies with outlying results.
 Each study is shown as squares centred on its estimate of 
effect with a horizontal line indicating the confi dence interval. 
A vertical line is drawn through the value that indicates no 
difference between the interventions being compared (e.g. 
1.0 for an odds ratio). If shown, the overall pooled estimate is 
represented as a diamond at the bottom of the plot. The centre 
of the diamond represents the pooled point estimate, and its 
horizontal extremities represent the confi dence interval.
Free text terms In literature searching, the use of everyday words and phrases, 
as opposed to index terms, to search bibliographic databases.
Funnel plot A graphical display of study precision such as the standard error 
plotted against effect size that can be used to investigate biases 
associated with small trials (including publication bias).
Generalisability See External validity.
Grey literature A general term for the kind of material that is not published 
in an easily accessible form or listed in standard bibliographic 
databases, for example conference proceedings, internal 
reports, theses and some books.
Grounded theory A set of methods for sampling, data collection and analysis.
Handsearching The process of searching a journal page by page to identify 
relevant articles.
Hazard ratio A measure of effect calculated by time-to-event analyses that 
represents how many times more or less one group is likely to 
experience the outcome of interest.
Health technology A broad term that covers any method used by health 
professionals to promote health, to prevent and treat disease, or 
to foster and improve rehabilitation and long-term care.
Heterogeneity In systematic reviews heterogeneity refers to variability or 
differences between studies. A distinction is sometimes made 
between:
 statistical heterogeneity – differences in the effect estimates
 methodological heterogeneity – differences in study design
 clinical heterogeneity – differences in participants, 
interventions or outcome measures
 See also Homogeneity.
Hierarchy of evidence A hierarchy of study designs based on their internal validity, 
or risk of bias, with well-designed systematic reviews and 
randomised trials at the top and observational studies and case 
series lower down.
Homogeneous The degree of similarity between the studies included in a 
review.
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Idea webbing In narrative synthesis, the use of visual methods to help to 
construct groupings of, and relationships between, ideas and/or 
concepts. Closely related to Conceptual mapping.
Incorporation bias A type of bias that occurs when the result of the index test is 
used in establishing the fi nal diagnosis (i.e. it forms part of the 
reference standard).
Incremental cost-effectiveness  The difference in the mean costs of two interventions in the 
ratio (ICER) population of interest divided by the difference in the mean 
 outcomes in the population of interest.
Index test The test whose performance is being evaluated.
Indexing term(s) A word or words used to describe the subject of, for example, 
a journal article. They are designed to make searching easier 
and more effective. Ideally these terms will be assigned from a 
controlled vocabulary, for example MeSH. See also MeSH.
Individual patient data (IPD) A specifi c type of systematic review that uses the original 
meta-analysis  individual participant data obtained from those responsible for 
 included studies. Data are centrally collected, checked and 
 re-analysed.
Intention to treat (ITT) analysis True intention to treat analysis captures two criteria: (i) 
participants should be analysed irrespective of whether or not 
they received their allocated intervention and irrespective of 
what occurred subsequently, for example, participants with 
protocol violations or those subsequently judged ineligible 
should be included in the analysis; (ii) all participants should 
be included irrespective of whether outcomes were collected. 
Although the fi rst criterion is generally accepted, there is 
no clear consensus on the second as it involves including 
participants in the analyses whose outcomes are unknown, and 
therefore requires imputation of data. Many authors describe 
their analyses as ITT when only the fi rst criterion has been met.
Internal validity See Validity.
Inter-rater agreement The degree of agreement exhibited when a measurement is 
repeated under identical conditions by different raters.
Interrupted time series A quasi-experimental study design involving multiple 
observations over time that are ‘interrupted’, usually by an 
intervention, to permit separation of real intervention effects 
from other long-term trends.
Intervention group A group of participants in a study receiving a particular 
intervention.
Inverse variance method A widely used and easy to implement method of pooling study 
results which is very fl exible and can be used to combine 
any type of effect measure provided that standard errors 
are available. A fi xed effect meta-analysis using the generic 
inverse variance method calculates a weighted average of study 
effect estimates by summating individual effect estimates and 
weighting these by the reciprocal of their squared standard 
errors.
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Investigator triangulation In narrative synthesis, a method of exploring the extent to 
which heterogeneity in study results may be attributable to the 
diverse approaches taken by different researchers.
Kappa statistic A measure of inter-rater agreement.
Knowledge transfer Interactions between decision-makers and researchers through 
the process of planning, disseminating and applying existing or 
new research in decision-making.
L’Abbé plot A scatter plot of the risk in the experimental group against the 
risk in the control group, used to explore possible heterogeneity 
in systematic reviews.
Language bias Bias in a systematic review resulting from limiting inclusion to 
the exclusion of items not written in a particular language or 
languages.
Language restrictions The deliberate restriction of search results to particular 
languages. Results in language bias.
Likelihood ratio (LR) A measure of accuracy of a diagnostic test. The likelihood ratio 
expresses the odds that a diagnostic test will give the correct 
result in a patient with the target disorder.
Linkage and exchange Two way communications and partnerships between producers 
and users of research.
Literature search For a systematic review this should be a systematic search 
for information on a given topic. Can include searches of 
bibliographic databases, websites, handsearching of journals 
and books, citation searching and reference checking.
Mantel-Haenszel A method for combining studies that uses an alternative 
weighting scheme to the inverse variance method. It has better 
statistical properties than the inverse variance method when 
events are few.
Markov model An analytical method particularly suited to modelling repeated 
events (e.g. headache) or the progression of a chronic disease 
(e.g. dementia) over time.
Masking See Blinding.
Mean difference A standard statistic that measures the absolute difference 
between the mean value of two groups, estimating the amount 
by which on average the intervention changes the outcome 
compared to the control.
Medical Subject Heading (MeSH) MeSH is the controlled vocabulary indexing system used by the 
National Library of Medicine for indexing articles on Medline. It is 
also used in some other electronic bibliographic databases.
 See also Indexing term; Keyword.
Meta-analysis Statistical techniques used to combine the results of two or 
more studies and obtain a combined estimate of effect.
Meta-ethnography A set of techniques for synthesising qualitative studies. It 
involves the selection, comparison and analysis of studies to 
create new interpretations or concepts.
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Meta-regression A statistical technique used to explore the relationship between 
study characteristics and study results in a systematic review.
Meta-synthesis See Multi-level synthesis.
Mixed-method The use of qualitative and quantitative methods together.
Moderator variable A variable that alters the effect of an explanatory variable on a 
dependent variable.
Multivariable prediction  A method of quantifying the contribution of each of a series of 
modelling tests to the diagnostic process by modelling the occurrence of 
 the target condition as a function of the different test results.
Multi-level synthesis Where a review of qualitative studies is undertaken alongside 
a review of quantitative studies and the results of the two 
syntheses are combined. (Also referred to as meta-synthesis, 
sequenced, or cross-design synthesis).
Narrative synthesis Predominantly a textual approach that provides an analysis of 
the relationships within and between studies and an overall 
assessment of the robustness of the evidence.
Negative predictive value The probability of non-disease among persons with a negative 
test result.
Number needed to treat/harm  An estimate of how many people need to receive an intevention 
(NNT/NNH) before one more person would experience a benefi cial or a 
 harmful outcome, respectively. Also referred to as number 
 needed to treat for benefi t (NNTB) and number needed to treat 
 for harm (NNTH).
Observational study A study in which the investigators observe and measure but do 
not seek to intervene.
Odds Odds describe the ratio of the probability that an event will 
happen to the probability that it will not happen.
Odds ratio The ratio of the odds of an event in one group (e.g. the 
experimental (intervention) group) to the odds of an event in 
another (e.g. the control group).
One-way or multi-way  In economic evaluations, one-way simple sensitivity analysis 
sensitivity analyses  varies each parameter individually in order to isolate the 
 consequences of each parameter on the results of the study. 
 Multi-way simple sensitivity analysis varies two or more 
 parameters at the same time and the overall effect on the 
 results is evaluated.
Opportunity costs The cost of foregone outcomes that could have been achieved 
through alternative investments.
Outcome An aspect of a participant’s clinical or functional status that 
we seek to change through intervention, for example survival, 
tumour recurrence, conception, live birth, level of anxiety, 
frequency of asthma attacks. See also Primary outcome and 
Secondary outcome.
Overall accuracy The proportion of people correctly classifi ed by the test.
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Parallel synthesis Where a review of qualitative studies is undertaken alongside 
a review of quantitative studies and the formal qualitative 
synthesis is used to interpret the fi ndings of the quantitative 
synthesis.
Partial verifi cation bias A type of bias that occurs when only a selected sample of 
participants undergoing the index test also receive the reference 
standard (e.g. only those who had a positive index test result).
Per protocol analysis An analysis restricted to those participants in a study who 
followed the trial protocol closely enough to ensure that 
their data would be likely to show an effect of treatment if it 
existed. Per protocol analysis may be subject to bias because 
the reasons for not following the protocol may be related to 
treatment.
Performance bias Bias resulting from systematic differences in care provided to 
those in each intervention group (other than the intervention 
being evaluated) that arise because carers or participants 
act differently because they know which intervention is being 
delivered.
Peto odds ratio Calculates odds based on the difference between the observed 
number of events and the number of events that would be 
expected if there was no difference between experimental 
and control interventions. The method performs better than 
alternative approaches when events are very rare. It can also 
be used to combine time to event data by pooling log rank 
observed–expected (O – E) events and associated variance. It 
can give biased estimates when treatment effects are very large, 
or where there is a lack of balance in treatment allocation within 
the individual studies.
Piloting The process of testing a procedure on a small scale before 
introducing it into practice, e.g. testing a data extraction form 
on a small sample of studies to identify any problems and 
inconsistencies between reviewers.
Placebo An intervention without specifi c biological activity in the 
condition being treated, usually administered to compare its 
effects with those of an active intervention. Placebos are used 
because the act of intervention (rather than the intervention 
itself) may bring about some benefi t for psychological or other 
reasons.
Pooling See Meta-analysis.
Positive predictive value The probability of disease among persons with a positive test 
result.
Precision A measure of the likelihood of random errors in the results of a 
study, meta-analysis or measurement.
 The proportion of articles identifi ed by a search strategy that are 
relevant.
Primary outcome The main or outcome of greatest importance. See also Outcome 
and Secondary outcome.
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Primary study The original study in which data were collected. The term is 
sometimes used to distinguish such studies from secondary 
studies that re-examine previously collected data (e.g. 
systematic reviews).
Probabilistic sensitivity analyses In economic evaluations, probabilistic sensitivity analysis 
attributes distributions of probabilities to the uncertain variables 
which are incorporated into evaluation models based on decision 
analytical techniques (e.g. Monte-Carlo simulation). This method 
can only be used to deal with uncertainty in data input.
Prognostic markers (biomarkers) Characteristics that help to identify or categorise people with 
different risks of specifi c future outcomes. They may be simple 
clinical measures such as body mass index, but are more often 
pathological, biochemical, molecular or genetic measures or 
attributes.
Prognostic tests Tests conducted to assess a patient’s risk of a particular 
outcome.
Prospective study A study in which participants are identifi ed and then followed 
forward in time to observe whether particular outcomes do or do 
not occur.
Publication bias Bias arising from the fact that studies with statistically 
signifi cant results are more likely to be published than those 
with inconclusive results. As a result, systematic reviews 
that fail to include unpublished studies may omit relevant 
research and are likely to be biased towards the positive and 
overestimate the effect of an intervention.
Pull strategy Facilitating demand (user)-led access to research fi ndings.
Push strategy Researcher-led distribution of new research fi ndings.
p-value The probability of obtaining the observed effect (or larger) under 
the null hypothesis which for systematic reviews will commonly 
be the assumption that there is no effect of the experimental 
intervention. A very small p-value means that it is very unlikely 
that the observed effect has arisen purely by chance and 
provides evidence against the null hypothesis.
Q* The point on the ROC curve that intersects with the line of 
symmetry (where sensitivity is equal to specifi city). Sometimes 
used as an indicator of overall test performance where there 
is no clinical preference for maximising either sensitivity or 
specifi city.
Qualitative comparative analysis A method for summarising and comparing data from case 
studies using Boolean logic.
Qualitative meta-summary A set of techniques for aggregating qualitative research fi ndings.
Qualitative meta-synthesis A set of techniques for the interpretive integration of qualitative 
fi ndings.
Qualitative research Research that adopts an interpretive, naturalistic approach and 
studies things in their natural settings.
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Quality of life An individual’s emotional, social, and physical well-being, and 
their ability to function in the ordinary tasks of living.
Quality threshold In systematic reviews, restricting inclusion to studies that meet 
predefi ned criteria related to quality (validity).
Quality-adjusted life year (QALY) In economic evaluations, a measure of health gain in which 
survival duration is weighted or adjusted by the patient’s 
(health-related) quality of life during the survival period.
Quantitative research Research that concentrates on describing and analysing 
phenomena by using numerical data and empirical models.
Quantitative synthesis See Meta-analysis
Randomisation The process of allocating participants to one of the groups of a 
randomised controlled trial using (i) a means of generating a 
random sequence and (ii) a means of concealing the sequence, 
such that those entering participants to a trial are unaware of 
which intervention a participant will receive. This should ensure 
that intervention groups are balanced for both known and 
unknown factors.
Randomised controlled trial  An experiment in which investigators use randomisation to 
(RCT)  allocate participants into the groups that are being compared. 
 Usually allocation is made at the level of individuals, but 
 sometimes it is done at group level e.g. by schools or clinics.
Receiver Operating A graph used to display the trade-offs between sensitivity and 
Characteristic (ROC) curve  specifi city as a result of varying the diagnostic threshold.
Reference standard The best currently available diagnostic test, against which the 
index test is compared.
Regression analysis A statistical modelling technique used to estimate or predict the 
infl uence of one or more independent variables on a dependent 
variable e.g. the infl uence of stage of disease and tumour size 
on survival.
Regression to the mean A statistical phenomenon by which extreme examples from any 
set of data are likely to be followed by examples which are less 
extreme; a tendency towards the average of any sample. For 
example, the offspring of two very tall individuals tend to be tall, 
but closer to the average (mean) than either of their parents.
Relationship marketing Developing long-term relationships with customers in order 
to retain them; relationship marketing techniques focus on 
customer retention and satisfaction.
Relative risk See Risk ratio.
Reporting bias A bias caused by only a subset of all relevant data being 
available for inclusion. For example through not all trials being 
published or not all outcomes being reported.
Research synthesis The combination and evaluation of separate studies to provide a 
coherent overall understanding to a research question.
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Resources A general term covering the staff, time, money, equipment 
and consumables required to, for example, implement an 
intervention or conduct a systematic review.
Retrospective study A study in which the outcomes have occurred to the 
participants before the study commenced.
Risk The probability with which an outcome (usually adverse) 
will occur. For example, if out of 100 participants 20 have a 
myocardial infarction, the risk of infarction is 0.2.
Risk difference The difference in size of risk between two groups. For example, 
if the control group has a 30% risk of experiencing a particular 
event and the intervention group has a 20% risk of experiencing 
the event, the risk different is 10%. Also known as Absolute risk 
reduction.
Risk factor An aspect of an individual’s genetic, physiological, 
environmental, or socioeconomic state that affects the 
probability of them experiencing a particular disease or 
outcome. For example people with high body mass index are at 
increased risk of developing diabetes.
Risk ratio The ratio of the risk of an event in one group (e.g. the 
experimental (intervention) group) to the risk of an event in 
another (e.g. the control group).
Sample size calculation A calculation performed when planning a clinical study to 
determine the number of participants needed to ensure a given 
probability of detecting an effect of a given magnitude if it 
exists.
Screening test A test used to detect possible disease in people without 
symptoms.
Search interface The means by which a user can interrogate a database. 
Interfaces vary in complexity. Some consist merely of a text 
box in which a limited number of words can be entered. Others 
are more complex and allow the searcher to create complex 
searches. See also Database host.
Search operator A term used to combine words within a search. For example, 
many search interfaces allow searches for terms occurring within 
so many words of each other (known as adjacency searching). 
See also Boolean operator.
Search strategy The exact terms and their combinations used to search a 
bibliographic database.
Secondary outcome An outcome of lesser importance than the primary outcome. See 
also Outcome and Primary outcome.
Secular trend A relatively long-term trend in a community or country.
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Selection bias 1. Bias caused by systematic differences between comparison 
groups in prognosis or responsiveness to treatment.
 2. Bias caused by systematic differences between those who 
are selected for a study and those who are not. This affects 
the generalisability (external validity) of a study but not its 
(internal) validity or risk of bias.
 3. Bias arising from the way in which studies were selected for 
inclusion in a systematic review, for example, publication bias.
Sensitivity In diagnostic/screening tests, a measure of a test’s ability to 
correctly identify people with the disease or condition of interest.
 In literature searching, the proportion of relevant articles that 
are retrieved using a specifi c search strategy.
Sensitivity analysis An analysis used to test the robustness of fi ndings and 
determine how sensitive results are to the data that were 
included and/or the way that analyses were done.
Sham (surgery/device) An activity that makes the recipient believe they have received 
the actual intervention when they have not; e.g. sham surgery 
involves an anaesthetic, an incision and suturing, but without 
the actual surgical intervention being performed.
Specifi city In diagnostic/screening tests, a measure of a test’s ability 
to correctly identify people who do not have the disease or 
condition of interest.
 In literature searching, the proportion of non relevant articles 
that are not retrieved.
Stakeholder In systematic reviews a person or group with an interest in or 
potentially affected by the results of the review.
Standardised mean difference The difference between two estimated means divided by an 
estimate of the within-group standard deviation. It is used to 
standardise and combine results from studies that have used 
different ways of measuring the same concept, e.g. mental 
health.
Statistical heterogeneity See Heterogeneity.
Statistical power The probability of rejecting the null hypothesis when a specifi c 
alternative hypothesis is true. In comparative studies the chance 
of detecting a real effect as statistically signifi cant, given that 
the effect actually exists. For a given size of effect, studies with 
more participants have greater power. Studies with a given 
number of participants have more power to detect large effects 
than to detect small effect.
Stochastic An adjective describing a random or probabilistic event or 
process.
Sub-group analysis In a clinical study or systematic review, an analysis in which 
the effect of the intervention is evaluated in a defi ned subset or 
subsets of participants.
Summary data Data that have been aggregated for presentation or analysis, for 
example numbers of events in each group in a clinical trial.
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Surrogate outcome An outcome measure that is not of direct practical importance 
but is believed to be an indicator or predictor of outcomes 
that are clinically important. These are often physiological or 
biochemical markers that can be obtained much more quickly 
compared to the clinical outcome of interest. To be valid, a 
surrogate outcome must have been shown to correlate with and 
accurately predict the outcome of interest.
Test accuracy study A one-sided comparison between the results of an index test 
and those of a reference standard. Any discrepancy is assumed 
to arise from error in the index test.
Thematic analysis/synthesis A method used in the analysis of qualitative data to 
systematically identify the main, recurrent and/or most 
important themes and/or concepts across multiple responses.
Threshold analyses In economic evaluations, threshold analysis identifi es the critical 
values of the parameters above or below which the results of 
a study vary. This method is usually used together with simple 
sensitivity analysis.
Time horizon The time span that refl ects the period over which the main 
differences between interventions in health effects and use of 
health care resources are expected to be experienced.
Time preferences The predilection of an individual (or a society) for the use of 
resources in the present rather than in the future.
Time-to-event data Data that refl ect not just whether an event occurs but the time 
at which it happens. For example time to death or survival 
analysis. Each data item is represented by a state variable 
indicating whether or not an event has occurred and an elapsed 
time at which the state was assessed. Individuals who have not 
(yet) experienced the event at a particular point in time are 
censored and contribute their event-free time to the analysis.
Treatment received analysis See Per-protocol analysis.
Triangulation A research strategy in which the researcher observes the same 
variable or phenomenon with multiple sources, measures, 
and methods.
Truncation symbol A symbol used when searching electronic databases to retrieve 
all words that begin with a particular stem. For example, a 
search for ‘child$’ on Ovid MEDLINE will fi nd any words that 
begin with ‘child’, including ‘child’, ‘children’ and ‘childhood’.
Undiscounted See Discounting.
Update searching The re-running of a literature search to capture material that 
has become available since the original search was conducted. 
May involve re-writing search strategies to take account of 
changes in terminology and database indexing.
Validity (of a measurement) The degree to which a measurement truly measures what it 
purports to measure.
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Validity (of a study) The degree to which a result of a study is likely to be true 
and free of bias (systematic errors), and hence the degree to 
which inferences drawn from the study are likely to be justifi ed. 
Validity in this sense is synonymous with internal validity. See 
also External validity.
Weighting In meta-analysis, the relative contribution of each individual 
study to the overall result and/or the method used to determine 
this. Studies are often weighted by the inverse of the variance 
of their measure of effect so that studies with more statistical 
information make a relatively greater contribution.
Worst/best case analysis  In economic evaluations, a sensitivity analysis using extreme 
  values for the input data to investigate the outcome of the 
 economic evaluation in the extreme case. A pessimistic or 
 optimistic outcome is generated. Also known as Analysis of 
 extremes.
2x2 contingency table A table presenting the results of a test accuracy study, showing 
the number of true positive, false positive, false negative and 
true negative results.
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